



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— Without international search report and to be republished upon receipt of that report.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)



**(19) World Intellectual Property Organization
International Bureau**

International Bureau

(43) International Publication Date
5 April 2001 (05.04.2001)

(10) International Publication Number
WO 01/22972 A2

(51) International Patent Classification's: A61K 31/7088, 39/59, 41/00, 3/072, A61L 1/20, A61B 3/708, 7/0616, 31/7088, 31/000, A61K 31/7088, 38/000, A61K 31/7088, 39/595

(21) International Application Number: PCT/US2002/03193

Inventors: KRUEG, Arthur M.; University of Iowa, Dept. of Internal Medicine, 540 EM Res. Bldg, Iowa City, IA 52242, US; SCHETTER, Candace; Quigen GmbH, Quigen Pharmaceuticals Group GmbH, Quigen GmbH, Mas-Volmer Strube 4, D-40724 Hilden (DE); VOLLMER, Jörg; Quigen Pharmaceuticals Group GmbH, Quigen GmbH, Mas-Volmer Strube 4, D-40724 Hilden (DE).

(21) International Application Number PCT/US00/26383

(22) International Filing Date **23 September 2000 (25.09.2000)**

(25) Filling Law (1992):


26) Publication Languages

(30)	Priority Dates			
	60/156,113	25 September 1999 (25.09.1999)	US	
	60/156,135	27 September 1999 (27.09.1999)	US	
	60/227,436	23 August 2000 (23.08.2000)	US	

(71) Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION (USURF); 214 Technology Innovation Center, Outdoor Research Campus, Iowa City, IA 52242 (US); COLVY PHARMACEUTICAL GMBH (DSUR); Elisabeth-Schober-Strasse 9, D-40764 Langenfeld (DS).

[Continued on next page]

(50) Title: IMMUNOSTIMULATORY NUCLEIC ACIDS



(97) A bracket: The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The 1'-thioid nucleic acids contain poly T sequences and have greater than 25% T nucleotides within. The TG nucleic acids have TG dinucleotides. The TG nucleic acids have at least one poly-C region and/or greater than 50% C nucleotides. These immunostimulatory nucleic acid functions to a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.

IMMUNOSTIMULATORY NUCLEIC ACIDS

BACKGROUND OF THE INVENTION

Bacterial DNA has immune stimulatory effects to activate B cells and natural killer cells, but vertebrate DNA does not (Tokuwaga, T., et al., 1988, *Jpn. J. Cancer Res.* 79:682-686; Tokumaga, T., et al., 1984, *JNCI* 72:955-962; Manning, J.P., et al., 1991, *J. Immunol.* 147:1759-1764; and reviewed in Kriegl, 1998, *Int. Applied Oligonucleotide Technology*, C.A. Stein and A.M. Kriegl, (Eds.), John Wiley and Sons, Inc., New York, NY, pp. 431-449). It is now understood that these immune stimulatory effects of bacterial DNA are a result of the presence of unmethylated CpG dinucleotides in particular base contexts (CpG motifs), which are common in bacterial DNA, but methylated and underrepresented in vertebrate DNA (Kriegl et al., 1995 *Nature* 374:346-349; Kriegl, 1999 *Biochim. Biophys. Acta* 932:1-10). The immune stimulatory effects of bacterial DNA can be mimicked with synthetic oligodeoxynucleotides (ODN) containing these CpG motifs. Such CpG ODN have highly stimulatory effects on human and murine leukocytes, inducing B cell proliferation, cytokine and immunoglobulin secretion, natural killer (NK) cell lytic activity and IFN- γ secretion, and activation of dendritic cells (DCs) and other antigen presenting cells to express costimulatory molecules and secrete cytokines, especially the Th1-like cytokines that are important in promoting the development of Th1-like T cell responses. These immune stimulatory effects of native phosphodiester backbone CpG ODN are highly CpG specific in that the effects are essentially abolished if the CpG motif is methylated, changed to a CpC, or otherwise eliminated or altered (Kriegl et al., 1995 *Nature* 374:346-349; Hartmann et al., 1999 *Proc. Natl. Acad. Sci. USA* 96:9305-10). Phosphodiester CpG ODN can be formulated in lipids, alum, or other types of vehicles with depot properties or improved cell uptake in order to enhance the immune stimulatory effects (Yamanoto et al., 1994 *Microbiol. Immunol.* 38:831-836; Granuzinski et al., 1998 *Mol. Med.* 4:109-118).

In early studies, it was thought that the immune stimulatory CpG motif followed the formula purine-purine-CpG-pyrimidine-pyrimidine (Kriegl et al., 1995 *Nature* 374:346-349; Fliselsky, 1996 *J. Immunol.* 156:421-423; Backer et al., 1998 *EMBO J.* 17:6230-6240; Lifjard et al., 1998 *Trends in Microbiol.* 6:496-500). However, it is now clear that mouse lymphocytes respond quite well to phosphodiester CpG motifs that do

-2-

not follow this "formula" (Yi et al., 1998 *J. Immunol.* 160:5898-5900) and the issue is true of human B cells and dendritic cells (Hartmann et al., 1999 *Proc. Natl. Acad. Sci. USA* 96:9305-10; Liang, 1996 *J. Clin. Invest.* 98:1119-1129).

Several past investigators have looked at whether the nucleotide content of ODN may have effects independently of the sequence of the ODN. Interestingly, antisense ODN have been found to be generally enriched in the content of GG, CCC, CC, CAC, and CG sequences, while having reduced frequency of TT or TCC nucleotide sequences compared to what would be expected if base usage were random (Sniderman et al., 1996 *Antisense Nucleic Acid Drug Develop.* 6:63-67). This raised the possibility that the over-represented sequences may comprise preferred targeting elements for antisense oligonucleotides or *vis a versa*. One reason to avoid the use of thymidine-rich ODN for antisense experiments is that degradation of the ODN by nucleases present in cells releases free thymidine which competes with 3H-thymidine which is frequently used in experiments to assess cell proliferation (Matson et al., 1992 *Antisense Research and Development* 2:325-330).

SUMMARY OF THE INVENTION

The present invention relates in part to pyrimidine rich (Py-rich) and in some embodiments thymidine (T) rich immunostimulatory nucleic acids which do not require the presence of a CpG motif. The present invention also relates in part to the discovery that nucleic acids which contain a TG dinucleotide motif are also immunostimulatory. The invention is based in part on the unexpected finding that nucleic acid sequences which do not contain CpG motifs are immunostimulatory. It was discovered upon analysis of the immune stimulation properties of many nucleic acid sequences that these sequences may be Py-rich e.g., T-rich or that they may contain TG motifs. It was also discovered that these sequences preferentially activate non-rodent immune cells. The Py-rich and TG sequences are only minimally immunostimulatory with respect to rodent immune cells, compared to non-rodent immune cells. Thus, it is possible according to the methods of the invention to induce an immune response in a non-rodent subject by administering Py-rich or TG immunostimulatory nucleic acids. The Py-rich and TG immunostimulatory nucleic acids of the invention may optionally include CpG motifs. These findings have important implications for the clinical development of immunostimulatory CpG containing and non-CpG containing nucleic acids.

In one aspect the invention is a pharmaceutical composition comprising an effective amount for stimulating an immune response of isolated Py-rich or TG immunostimulatory nucleic acids, and a pharmaceutically acceptable carrier. In other aspects the invention is a composition of matter, comprising an isolated Py-rich or TG immunostimulatory nucleic acid. In other embodiments, the immunostimulatory nucleic acid may be T-rich. In still other embodiments, the immunostimulatory nucleic acid may be T-rich and also have at least one TG motif.

Preferably the Py-rich nucleic acid is a T-rich nucleic acid. In some embodiments the T-rich immunostimulatory nucleic acid is a poly T nucleic acid comprising 5' TTTT 3'. In yet other embodiments the poly T nucleic acid comprises 5' X₁ X₂ TTTT X₃ X₄ 3' wherein X₁, X₂, X₃ and X₄ are nucleotides. In some embodiments X₁ X₂ is TT and/or X₃ X₄ is TT. In other embodiments X₁ X₂ is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC; and/or X₃ X₄ is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, CG, GT, GG, GA, and GC.

The T-rich immunostimulatory nucleic acid may have only a single poly T motif or it may have a plurality of poly T nucleic acid motifs. In some embodiments the T-rich immunostimulatory nucleic acid comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 T motifs. In other embodiments it comprises at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 CpG motifs. In preferred embodiments the plurality of CpG motifs and poly T motifs are interspersed.

In yet other embodiments at least one of the plurality of poly T motifs comprises at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, or at least 9 contiguous T nucleotide residues. In other embodiments the plurality of poly T motifs is at least 3 motifs and wherein at least 3 motifs each comprises at least 3 contiguous T nucleotide residues or the plurality of poly T motifs is at least 4 motifs and wherein the at least 4 motifs each comprises at least 3 contiguous T nucleotide residues.

In some cases the T-rich immunostimulatory nucleic acid may be five of poly T motifs but may rather comprise a nucleotide composition of greater than 25% T. In other embodiments the T-rich immunostimulatory nucleic acids have poly T motifs and also comprise a nucleotide composition of greater than 25% T. In preferred embodiments the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater

than 35% T, greater than 40% T, greater than 50% T, greater than 60% T, greater than 80% T, or greater than 90% T nucleotide residues. In important embodiments, the nucleic acid is at least 50% T.

The T-rich and TG immunostimulatory nucleic acids can have any length greater than 7 nucleotides, but in some embodiments can be between 8 and 100 nucleotides residues in length. In preferred embodiments the T-rich immunostimulatory nucleic acid comprises at least 20 nucleotides, at least 24 nucleotides, at least 27, nucleotides, or at least 30 nucleotides. In preferred embodiments, the TG immunostimulatory nucleic acid is between 15 and 25 nucleotides in length. The T-rich and TG immunostimulatory nucleic acids may be single stranded or double stranded.

In one preferred embodiment, the immunostimulatory nucleic acid has a T-rich region located in the middle of its length (i.e., an approximately equal number of nucleotides flank the T-rich region on the 5' and 3' ends).

The T rich nucleic acid in some embodiments is selected from the group consisting of SEQ ID NO: 59-63, 73-75, 142, 215, 226, 241, 267-269, 282, 301, 304, 330, 342, 358, 370-372, 393, 433, 471, 479, 486, 491, 497, 503, 556-558, 567, 694, 793-794, 797, 833, 852, 861, 867, 868, 882, 886, 905, 907, 908, and 910-913. In other embodiments the T rich nucleic acids are sequence selected from the group consisting of SEQ ID NO: 64, 98, 112, 146, 185, 204, 208, 214, 224, 233, 244, 246, 247, 258, 262, 263, 265, 270-273, 300, 305, 316, 317, 343, 344, 350, 352, 354, 374, 376, 392, 407, 411-413, 429-432, 434, 435, 443, 474, 475, 498-501, 518, 687, 692, 693, 804, 862, 883, 884, 888, 890, and 891.

In other embodiments the Py-rich immunostimulatory nucleic acid is a C-rich nucleic acid. An immunostimulatory C-rich nucleic acid is a nucleic acid including at least one and preferably at least 2 poly-C regions or which includes 50% or greater C nucleotides.

The Py-rich and TG immunostimulatory nucleic acids may include one or more CpG motifs. The motifs may be methylated or unmethylated. In other embodiments the Py-rich and TG immunostimulatory nucleic acids are free of one or more CpG dinucleotides.

In other embodiments the Py-rich and TG immunostimulatory nucleic acids also include poly-A, poly G, and/or poly C motifs. In yet other embodiments the Py-rich or

- 5 -

5 TG immunostimulatory nucleic acid is free of two poly C sequences of at least 3
 contiguous C nucleotide residues or is free of two poly A sequences of at least 3
 contiguous A nucleotide residues. In other embodiments the Py-rich or TG
 immunostimulatory nucleic acid comprises a nucleotide composition of greater than 25%
 10 C or greater than 25% A. In yet other embodiments the Py-rich or TG
 immunostimulatory nucleic acid is free of poly-C sequences, poly-G sequences or poly-
 A sequences.

A poly G nucleic acid in some embodiments is selected from the group consisting
 of SEQ ID NO: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 335, 339, 386, 387, 444,
 476, 531, 537-539, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938. In other
 15 embodiments the poly G nucleic acid includes a sequence selected from the group
 consisting of SEQ ID NO: 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264,
 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661,
 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937.

20 According to another aspect of the invention, the immunostimulatory nucleic
 acids may be defined as those which possess a TG motif, herein referred to as TG
 immunostimulatory nucleic acids. The TG nucleic acid in one embodiment contains at
 least one TG dinucleotide having a sequence including at least the following formula:
 5'N₁X₁TGX₂N₂3'. In related embodiments, N₁ is a nucleic acid sequence composed of a
 number of nucleotides ranging from (1-N₁) to (21-N₁) and N₂ is a nucleic acid sequence
 composed of a number of nucleotides ranging from (1-N₂) to (21-N₂). In a preferred
 embodiment, X₂ is thymidine.

In other embodiments, the TG nucleic acid has at least the following formula: 5'
 X₁X₂TGX₃X₄3'. In yet another embodiment, the TG nucleic acid comprises the
 25 following sequence: 5'N₁X₁X₂TGX₃X₄N₂3'. In a related embodiment, N₁ is a nucleic
 acid sequence composed of a number of nucleotides ranging from (3-N₁) to (19-N₁) and
 N₂ is a nucleic acid sequence composed of a number of nucleotides ranging from (3-N₂)
 to (19-N₂). In one preferred embodiment, X₃ is thymidine. X₁X₂ are nucleotides which
 may be selected from the group consisting of GT, GG, GA, AA, AT, AG, CT, CA, CG,
 30 TA and TT, and X₄ are nucleotides which may be selected from the group consisting
 of TT, CT, AT, AG, CG, TC, AC, CC, TA, AA, and CA. In some preferred
 embodiments, X₃ is a thymidine. In important embodiments, X₃X₄ are nucleotides

- 6 -

selected from the group consisting of TT, TC, TA and TG. In other embodiments X₁X₂
 are GA or GT and X₃X₄ are TT. In yet other embodiments X₁ or X₂ or both are purines
 and X₃ or X₄ or both are pyrimidines or X₁X₂ are GpA and X₃ or X₄ or both are
 5 pyrimidines. In one embodiment X₃ is a T and X₄ is a pyrimidine.
 In one embodiment the 5' X₁X₂TGX₃X₄3' sequence of the TG nucleic acid or
 the entire length or some fragment thereof of the TG nucleic acid is a non-palindromic
 sequence, and in other embodiments it is a palindromic sequence.

In some preferred embodiments, the TG nucleic acid is also T-rich.

10 The Py-rich and TG immunostimulatory nucleic acids in some embodiments have
 a nucleotide backbone which includes at least one backbone modification, such as a
 phosphorothioate modification. The nucleotide backbone may be chlorine, or preferably
 the nucleotide backbone is entirely modified. In one preferred embodiment, the
 immunostimulatory nucleic acid has a poly T motif and a phosphorothioate backbone.

In another aspect, the invention is a composition of an immunostimulatory
 15 nucleic acid, in the form of a Py-rich or a TG nucleic acid, and an antigen, wherein the
 nucleic acid is free of unmodified CpG motifs.

Another composition of the invention is a Py-rich or TG immunostimulatory
 nucleic acid and an anti-microbial agent, wherein the Py-rich or TG nucleic acid is free
 of unmodified CpG motifs. Preferably the anti-microbial agent is selected from the
 20 group consisting of an anti-viral agent, an anti-parasitic agent, an anti-bacterial agent
 and an anti-fungal agent.

A composition of a sustained release device including a Py-rich and/or TG
 immunostimulatory nucleic acid, wherein the Py-rich and/or TG nucleic acid is free of
 unmodified CpG motifs, is provided according to another aspect of the invention.

25 The invention also includes nutritional supplements of a Py-rich or TG
 immunostimulatory nucleic acid in a delivery device selected from the group consisting
 of a capsule, a pill, and a sublingual tablet, wherein the Py-rich or TG nucleic acid is free
 of unmodified CpG motifs.

30 It should be understood that when it is useful to administer a Py-rich e.g., poly T,
 T-rich, C-rich, or TG oligonucleotide and a CpG oligonucleotide, it may also be
 desirable to co-administer a Py-rich or a TG oligonucleotide together with a physically
 separate CpG, Py-rich or TG oligonucleotide. Alternatively, the CpG, Py-rich or TG

motif may be present on the same contiguous nucleic acid as the Py-rich or TG oligonucleotide. In yet a further embodiment, all or some combination of Py-rich, TG and CpG nucleic acids may be co-administered either on separate nucleic acids or in same nucleic acid molecule. By co-administer it is intended that the nucleic acids be administered close enough in time to one another to achieve a combined benefit of both oligonucleotides, preferably more than the benefit achieved by administering each of the oligonucleotides alone at the same dose.

CpG oligonucleotides have, in general, the formula $5'X_1X_2CX_3X_43'$, wherein X_1 , X_2 , X_3 and X_4 are nucleotides and wherein at least the C of CpG is unmethylated. Preferred CpG oligonucleotides are 8-100 nucleotides in length and have modified back bones. Particular structures are detailed in the published PCT applications, U.S. applications and references cited herein, the disclosures of which are incorporated herein in their entirety. In one embodiment, the CpG oligonucleotide is free of poly T and TG motifs and is not T-rich.

In other embodiments, the CpG oligonucleotide has a sequence selected from the group consisting of SEQ ID NO: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58, 64-67, 69, 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133, 136-141, 146-150, 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302, 305-307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365, 367-369, 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-437, 439, 441-443, 445, 447, 448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478, 480, 483-485, 488, 489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541, 543-555, 564-566, 568-576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622, 625-646, 648-650, 653-664, 666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737, 739-744, 746, 747, 749-761, 763, 766-767, 769, 772-779, 781-783, 785-786, 790-792, 798-799, 804-808, 810, 815, 817, 818, 820-832, 835-846, 849-850, 855-859, 862, 865, 872, 874-877, 879-881, 883-885, 888-904, and 909-913.

In another embodiment, the Py-rich or TG oligonucleotide is free of a CpG motif. This embodiment of the invention also involves pharmaceutical compositions and kits which contain both a CpG oligonucleotide (which can be free of poly T and TG motifs and not be T-rich) and a Py-rich and/or TG oligonucleotide physically separate

from the CpG oligonucleotide. The pharmaceutical preparations are in effective amounts and typically include pharmaceutically acceptable carriers, all as set forth in detail herein with respect to Py-rich and TG oligonucleotides. The kits include at least one container containing an oligonucleotide which is a Py-rich or TG oligonucleotide (or some combination thereof). The same container, or in other embodiments, a second container, may contain an oligonucleotide with a CpG motif, which may be free of Py-rich and/or TG motifs. The kit also contains instructions for administering the oligonucleotides to a subject. The kits also may include a container containing a solvent or a diluent.

In summary, as if fully recited herein, a CpG oligonucleotide physically separates from the Py-rich or TG oligonucleotide can be used together with the Py-rich or TG oligonucleotides in the methods, compositions and products described above.

The invention relates in other aspects to immunostimulatory oligonucleotides which have chimeric backbones and which do not require the presence of a CpG motif. The invention is based in part on the discovery that nucleic acid sequences which did not contain CpG motifs were immunostimulatory, and that those which have chimeric backbones have unexpectedly enhanced immune stimulating properties. Thus the invention in one aspect relates to a composition of an oligonucleotide having a formula: $5'Y_1N_1ZN_2Y_23'$, wherein Y_1 and Y_2 are, independent of one another, nucleic acid molecules having between 1 and 10 nucleotides, wherein Y_1 includes at least one modified internucleotide linkage and Y_2 includes at least one modified internucleotide linkage and wherein N_1 and N_2 are nucleic acid molecules, each independent of one another, having between 0 and 5 nucleotides, but wherein N_1ZN_2 has at least 6 nucleotides in total and wherein the nucleotides of N_1ZN_2 have a phosphodiester backbone, and wherein Z is an immunostimulatory nucleic acid motif but does not include a CG. In one embodiment Z is a nucleic acid sequence selected from the group consisting of TTTT, TG, and a sequence wherein at least 50% of the bases of the sequence are Ts.

In some embodiments Y_1 and/or Y_2 have between 3 and 8 nucleotides. In other embodiments Y_1 and/or Y_2 are comprised of at least three Cs, at least four Cs, least seven Cs, or all Cs. In other embodiments Y_1 and/or Y_2 are selected from the group consisting of TCGTCG, TCGTCGT, and TCGTCGTT (SEQ ID NO:1145). In yet other

-9-

embodiments Y_1 and/or Y_2 include at least one, two, three, four, or five poly-A, poly-T, or poly-C sequences.

The center nucleotides (N_1ZN_2) of the formula $Y_1N_1ZN_2Y_2$ have phosphodiester internucleotide linkages and Y_1 and Y_2 have at least one modified internucleotide linkage. In some embodiments Y_1 and/or Y_2 have at least two modified internucleotide linkages. In other embodiments Y_1 and/or Y_2 have between two and five modified internucleotide linkages. In yet other embodiments Y_1 has two modified internucleotide linkages and Y_2 has five modified internucleotide linkages or Y_1 has five modified internucleotide linkages and Y_2 has two modified internucleotide linkages. The modified internucleotide linkage in some embodiments is a phosphorothioate modified linkage, a phosphonodithioate modified linkage or a P-ethoxy modified linkage.

Portions of the formula $Y_1N_1ZN_2Y_2$ may optionally form a palindromic. Thus, in some embodiments the nucleotides of N_1ZN_2 form a palindromic. In some embodiments the palindromic is not a direct repeat. In yet other embodiments the nucleotides of N_1ZN_2 do not form a palindromic.

According to other embodiments N_1ZN_2 has a sequence of nucleotides selected from the group consisting of GATTTCATCGTC (SEQ ID NO: 1098),

TCGATTTTTCGA (SEQ ID NO: 1099), TCAATTTTATGA (SEQ ID NO: 1100),
GTTTTCACGAC (SEQ ID NO: 1101), TCAATTTTTCGA (SEQ ID NO: 1102),
ACGTTTTCACGT (SEQ ID NO: 1103), TCGTTTTCACGA (SEQ ID NO: 1104),
TCGATTTTCACGTCA (SEQ ID NO: 1105), AATTTTTCACGTT (SEQ ID NO:
1106), TCGTTTTCACGA (SEQ ID NO: 1107), ACGTTTTCACGT (SEQ ID
NO: 1108), GATTTTATCGTC (SEQ ID NO: 1109), GACGATTTTCGTC (SEQ ID
NO: 1110), GATTTTACGTCGTC (SEQ ID NO: 1111), GATTTTTCACGT (SEQ ID
NO: 1112), AATTTATCGT (SEQ ID NO: 1113), AACGATTTTCGTT (SEQ ID NO:
1114), TCACTTTTCGTA (SEQ ID NO: 1115), TCGTATTTTA (SEQ ID NO: 1116),
ACTTTTTCACCGGT (SEQ ID NO: 1117), TCGATTTTTCGACGTCA (SEQ ID
NO: 1118), ACGATTTTTCGT (SEQ ID NO: 1119), GATGATCGTC (SEQ ID NO:
1120), TCGATGTCGA (SEQ ID NO: 1121), TCAATGTCGA (SEQ ID NO: 1122),
GTGTTTACGAC (SEQ ID NO: 1123), TCAATGTCGA (SEQ ID NO: 1124),
ACGTGACGT (SEQ ID NO: 1125), TCGTTCACGA (SEQ ID NO: 1126),
TCGATGTCACGTCA (SEQ ID NO: 1127), AATGTTTACGTT (SEQ ID NO: 1128),

-10-

TCGTTGTTACGA (SEQ ID NO: 1129), ACGTTTACGT (SEQ ID NO: 1130),
GATGATTCGTC (SEQ ID NO: 1131), GACGATGTCGTC (SEQ ID NO: 1132),
GATGACGTCGTC (SEQ ID NO: 1133), GATGATTCGTC (SEQ ID NO: 1134),
ATGATCGT (SEQ ID NO: 1135), AACGATGTCGTT (SEQ ID NO: 1136),
TCAGTGGTGA (SEQ ID NO: 1137), TCGTATGA (SEQ ID NO: 1138),
ACTGATACCGGT (SEQ ID NO: 1139), TCGATGTCGACGTCA (SEQ ID NO:
1140), and ACGATGTCGT (SEQ ID NO: 1141).

The composition may optionally include a pharmaceutical carrier and/or be formulated in a delivery device. In some embodiments the delivery device is selected from the group consisting of cationic lipids, cell permeating proteins, and sustained release devices. In one preferred embodiment the sustained release device is a biodegradable polymer. In another embodiment the sustained release device is a microparticle.

In another aspect the invention is a composition of an immunostimulatory oligonucleotide having the formula $Y_1N_1ZN_2Y_2$, and an antigen.

Another composition of the invention is an immunostimulatory oligonucleotide having the formula $Y_1N_1ZN_2Y_2$, and an anti-microbial therapeutic agent. Preferably the anti-microbial therapeutic agent is selected from the group consisting of an anti-viral agent, an anti-parasitic agent, an anti-bacterial agent, or an anti-fungal agent.

A composition of a sustained release device including an immunostimulatory oligonucleotide having the formula $Y_1N_1ZN_2Y_2$, is provided according to another aspect of the invention.

The invention also includes nutritional supplements of an immunostimulatory oligonucleotide having the formula $Y_1N_1ZN_2Y_2$, in a delivery device selected from the group consisting of a capsule, a sublingual tablet, and a pill.

In another aspect the compositions described above also include an immunostimulatory nucleic acid having an unmethylated CG dinucleotide, a TG dinucleotide, or a Py-rich sequence wherein the immunostimulatory nucleic acid having an unmethylated CG dinucleotide, a TG dinucleotide or a Py-rich sequence has a different sequence than the oligonucleotide comprising 5' $Y_1N_1ZN_2Y_2$ 3'.

In some embodiments the immunostimulatory nucleic acid having an unmethylated CG dinucleotide, a TG dinucleotide or a Py-rich sequence has a

completely phosphodiester backbone and in other embodiments the immunostimulatory nucleic acid having an unmodified CG dinucleotide, a TG dinucleotide or a Py-rich sequence has a modified backbone, which optionally may have internucleotide linkages selected from the group consisting of phosphorothioate, phosphorodithioate, and p-ethoxy.

In one embodiment immunostimulatory nucleic acid having an unmodified CG dinucleotide has a formula comprising: $5' X_1 X_2 COX_3 X_4 3'$ wherein X_1 , X_2 , X_3 and X_4 are nucleotides. In other embodiments the immunostimulatory nucleic acid sequence includes at least the following formula: $5' TCNTX_1 X_2 COX_3 X_4 3'$ wherein N is a nucleic acid sequence composed of from about 0-25 nucleotides, wherein at least one nucleotide has a modified internucleotide linkage, and wherein the nucleic acid has less than or equal to 100 nucleotides. According to some embodiments $X_1 X_2$ are nucleotides selected from the group consisting of GT, GG, GA and AA and $X_3 X_4$ are nucleotides selected from the group consisting of TT, CT or GT. In a preferred embodiment $X_1 X_2$ are GA and $X_3 X_4$ are TT.

In another embodiment the immunostimulatory nucleic acid sequence having an unmodified CG dinucleotide includes at least one of the following sequences:

ATCGACTCTCGAGCGTTTC (SEQ ID No. 15); TCCATGTCGGTCTCTGCTGAT
(SEQ ID No. 32); TCCATGTCGGTCTGATGCT (SEQ ID No. 31);
ATCGACTCTCGAGCGTTTC (SEQ ID No. 18); TCCATGTCGGTCTCTGATGCT
(SEQ ID No. 28); GCGGGG (SEQ ID No. 12); TCCATGACGGTCTCTGATGCT (SEQ
ID No. 35); TCCATGCGCGTCTCTGATGCT (SEQ ID No. 34);
TCCATGACGGTCTCTGATGCT (SEQ ID No. 7); TCCATGTCGGTCTCTGATGCT
(SEQ ID No. 38); GCGGTCACTCTGACGGGG (SEQ ID No. 41);
TCCATGTCGGTCTCTGATGCT (SEQ ID No. 37); TCCATGTCGGTCTCTGATGCT
(SEQ ID No. 36); TCCATGCGGTCTCTGATGCT (SEQ ID No. 33);
TCCATGACGGTCTCTGATGCT (SEQ ID No. 3); TCCATGACGGTCTCTGATGCT
(SEQ ID No. 7); TCCATGACGGTCTCTGATGCT (SEQ ID No. 39);
TCCATGACGGTCTCTGATGCT (SEQ ID No. 48); TCCATGACGGTCTCTGATGCT
(SEQ ID No. 10); ATGACGTTCTCTGACGGT (SEQ ID No. 70);
TCTCCACGCGCGCCAT (SEQ ID No. 72); TCCATGTCGGTCTCTGATGCT (SEQ
ID No. 73); TCCATGCGGTCTCTGATGCT (SEQ ID No. 74);

TCCATGACGGTCTCTGATGCT (SEQ ID No. 76); TCCATGTCGGTCTCTGATGCT (SEQ
ID No. 77); TCCATGTCGGTCTCTGATGCT (SEQ ID No. 52);

TCCATGTCGGTCTCTGATGCT (SEQ ID No. 121); TCCATGTCGGTCTCTGATGCT
(SEQ ID No. 208); TCCATGTCGGTCTCTGATGCT (SEQ ID No. 120);

TCCATGTCGGTCTCTGATGCT (SEQ ID No. 81); TCCATGACGGTCTCTGATGCT
(SEQ ID No. 82); TCCATGTCGGTCTCTGATGCT (SEQ ID No. 47);

TCCATGTCGGTCTCTGATGCT (SEQ ID No. 46);

TCCATGTCGGTCTCTGATGCT (SEQ ID No. 49);

GCATGTCGGTCTCTGATGCT (SEQ ID No. 56); TCCATGTCGGTCTCTGATGCT
(SEQ ID No. 48); TCCATGTCGGTCTCTGATGCT (SEQ ID No. 84);

TCCATGTCGGTCTCTGATGCT (SEQ ID No. 50); TCCATGTCGGTCTCTGATGCT (SEQ ID No.
51); and TCCATGTCGGTCTCTGATGCT (SEQ ID No. 85). In another embodiment the

immunostimulatory nucleic acid having a Py-rich or TG sequence is a nucleic acid as described above.

In another aspect the invention relates to pharmaceutical compositions and kits which contain both an oligonucleotide having the formula $Y_1 N_1 ZN_2 Y_2$ and a CpG oligonucleotide (which optionally may be free of poly T and TG motifs and not be Py-rich), a Py-rich and/or TG oligonucleotide physically separate from the oligonucleotide having the formula $Y_1 N_1 ZN_2 Y_2$. The pharmaceutical preparations are in effective

amounts and typically include pharmaceutically acceptable carriers, all as set forth in detail herein. The kits include at least one container containing an oligonucleotide having the formula $Y_1 N_1 ZN_2 Y_2$. The same container, or in other embodiments, a second container, may contain an oligonucleotide with a CpG motif, which optionally may be free of Py-rich and/or TG motifs and/or a Py-rich or TG oligonucleotide (or some combination thereof). The kit also contains instructions for administering the oligonucleotides to a subject. The kits also may include a container containing a solvent or a diluent.

In summary, as is fully recited herein, an oligonucleotide having the formula $Y_1 N_1 ZN_2 Y_2$, which is physically separate from the CpG, Py-rich or TG oligonucleotide can be used together with the CpG, Py-rich, TG oligonucleotide, in the methods, compositions and products described herein.

- 13 -

In another aspect the invention relates to a pharmaceutical composition including at least two oligonucleotides of the invention, wherein the at least two oligonucleotides have different sequences from one another and a pharmaceutically acceptable carrier.

A vaccine formulation is provided according to another aspect of the invention.

5 The vaccine includes any of the compositions of the invention in combination with an antigen.

According to another aspect of the invention a method of stimulating an immune response is provided. The method involves administering a Py-rich or a TG

10 immunostimulatory nucleic acid to a non-todent subject in an amount effective to induce an immune response in the non-todent subject. Preferably the Py-rich or TG immunostimulatory nucleic acid is administered orally, locally, in a sustained release device, mucosally to a mucosal surface, systemically, parenterally, or intramuscularly.

When the Py-rich or TG immunostimulatory nucleic acid is administered to the mucosal surface it may be delivered in an amount effective for inducing a mucosal immune

15 response or a systemic immune response. In preferred embodiments the mucosal surface is selected from the group consisting of an oral, nasal, rectal, vaginal, and ocular surface.

In some embodiments the method includes exposing the subject to an antigen wherein the immune response is an antigen-specific immune response. The antigen may be encoded by a nucleic acid vector which can be delivered to the subject. In some 20 embodiments the antigen is selected from the group consisting of a tumor antigen, a viral antigen, a bacterial antigen, a parasitic antigen and a peptide antigen.

Py-rich and TG immunostimulatory nucleic acids are capable of providing a broad spectrum of immune response. For instance these immunostimulatory nucleic acids can be used to redirect a Th2 to a Th1 immune response. Py-rich and TG nucleic acids may also be used to activate an immune cell, such as a leukocyte, a dendritic cell, 25 and an NK cell. The activation can be performed *in vivo*, *in vitro*, or *ex vivo*, i.e., by isolating an immune cell from the subject, contacting the immune cell with an effective amount to activate the immune cell of the Py-rich or TG immunostimulatory nucleic acid and re-administering the activated immune cell to the subject. In some embodiments the dendritic cell expresses a cancer antigen. The dendritic cell can be exposed to the cancer antigen *ex vivo*. 30

- 14 -

The immune response produced by Py-rich or TG nucleic acids may also result in induction of cytokine production, e.g., production of IL-6, IL-12, IL-18 TNF, IFN- α and IFN- γ .

5 In still another embodiment, the Py-rich and TG nucleic acids are useful for treating cancer. The Py-rich and TG nucleic acids are also useful according to other aspects of the invention in preventing cancer (e.g., reducing a risk of developing cancer) in a subject at risk of developing a cancer. The cancer may be selected from the group

10 consisting of biliary tract cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, gastric cancer, intraepithelial neoplasia, lymphoma, liver cancer, lung cancer (e.g. small cell and non-small cell), melanoma, neuroblastomas, oral cancer, ovarian cancer, pancreas cancer, prostate cancer, rectal cancer, sarcoma, thyroid cancer, and renal cancer, as well as other carcinomas and sarcomas. In some important embodiments, the cancer is selected from the group consisting of bone cancer, brain and CNS cancer, connective tissue cancer, esophageal cancer, eye cancer, Hodgkin's lymphoma, larynx cancer, oral cavity cancer, skin cancer, and testicular cancer.

15 Py-rich and TG nucleic acids may also be used for increasing the responsiveness of a cancer cell to a cancer therapy (e.g., an anti-cancer therapy), optionally when the Py-rich or TG immunostimulatory nucleic acid is administered in conjunction with an anti-cancer therapy. The anti-cancer therapy may be a chemotherapy, a vaccine (e.g., an *in vitro* primed dendritic cell vaccine or a cancer antigen vaccine) or an antibody based therapy. This latter therapy may also involve administering an antibody specific for a cell surface antigen of, for example, a cancer cell, wherein the immune response results in antigen dependent cellular cytotoxicity (ADCC). In one embodiment, the antibody 20 may be selected from the group consisting of Rituximab, Herceptin, Quadrant, Panorex, IDBC-Y238, BEC2, C223, Oncozym, SMART M193, ATRAGEN, Ovener, Becara, LDP-03, for 16, MDX-210, MDX-11, MDX-22, OVI03, 362W94, anti-VBGR, Zampira, MDX-220, MDX-447, MELIMADUNE-2, MELIMADUNE-1, CEACDIB, Preanger, NovoMAb-G2, TMT, Glucanab-H, GNI-250, RMD-72000, LymphoCide, CMA 676, Monopharm-C, 4B5, for egf4, for c5, BABS, anti-FLK-2, MDX-260, ANA AB, SMART ID10 Ab, SMART ABL 364 Ab and ImmALIT-CEA. 30

Thus, according to some aspects of the invention, a subject having cancer or at risk of having a cancer is administered an immunostimulatory nucleic acid and an anti-

cancer therapy. In some embodiments, the anti-cancer therapy is selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent and a cancer vaccine. The chemotherapeutic agent may be selected from the group consisting of methotrexate, vincristine, adriamycin, cisplatin, non-sugar containing

- 5 chloroethyl/nitrosourea, 5-fluorouracil, mitomycin C, bleomycin, doxorubicin, decarbazine, taxol, fruguline, Meglumine GLA, valrubicin, carmustine and polifeposum, MM1270, BAY 12-9366, RAS farnesyl transferase inhibitor, farnesyl transferase inhibitor, MMP, MTAL/Y231514, LY2646181/omeclizol, Glumolec, CI-994, TNP-470, Hyacinth/Topotecan, PKC412, Valopodar/PSC833,
- 10 Novotrans/Mitoxantrene, Meines/Sunamin, Bufimastat, E7070, BCH-4556, CS-682, 9-AC, AG3340, AG3433, Inocel/VX-710, VX-853, ZD0101, ISI641, ODN 698, TA 2516/Marmistat, BB2516/Marmistat, CDP 845, D2163, PD183805, DX8951f, Lemonal DP 2202, FK 317, Pielbani/OK-432, AD 32/Valrubicin, Menastoru/stromium derivative, Temodal/Temozolomide, Evance/liposomal doxorubicin, Yewtuxan/Paclitaxel,
- 15 Taxol/Paclitaxel, Xeloda/Capecitabine, Furtulow/Doxifluridine, Cyclopaex/oral paclitaxel, Oral Taxoid, SP-077/Cisplatin, HMR 1275/Fluoropyridol, CP-358 (774)EGFR, CP-609 (754)/RAS oncogene inhibitor, BMS-182731/oral platinum, UFT(Tegafur/Uracil), Eganisole/Levamisole, Eaulunell/776C85/5FU enhancer, Camptio/Levamisole, Campozar/Triptocan, Tumodex/Ralirexed, Leustatin/Cladribine, Poxez/Paclitaxel, Doxil/liposomal doxorubicin, Caelys/liposomal doxorubicin, Fludaur/Fludauridine, Pharmurubicin/Epirubicin, DepoCyt, ZD1839, LU 79553/Bis-Naphthalimide, LU 103793/Dolanidin, Caelys/liposomal doxorubicin, Genazur/Gemcitabine, ZD 0473/Axonmed, YM 116, Iodine seeds, CDK4 and CDK2 inhibitors, PARP inhibitors,
- 20 D4809/Dactinosamide, Ifex/Mesenz/Isoamide, Vunon/Teniposide, ZD 9331, Pamplatin/Carboplatin, Platinol/cisplatin, Vepeside/Etoposide, ZD 9331, Taxotere/Docetaxel, prodrug of guanine arabinoside, Taxane Analog, nitrosourea, alkylating agents such as melphalan and cyclophosphamide, Aminoglutathimide, Aspergillase, Busulfan, Carboplatin, Chlorambucil, Cytarabine HCl, Daunomycin, Daunorubicin HCl, Benaruridine phosphate sodium, Etoposide (VP16-213), Flouxuridine,
- 25 Fluorouracil (5-FU), Flutamide, Hydroxyurea (hydroxyureamide), Ifosfamide, Interferon Alfa-2a, Alfa-2b, Leuprolide acetate (LHRH-releasing factor analogue), Lomustine (CCNU), Mechlorethamine HCl (nitrogen mustard), Mercaptopurine, Mesna,
- 30

Mitomine (6-p-DDD), Mitoxantrene HCl, Oestrone, Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate, Thiotepa, Vinblastine sulfate, Anastroline (m-AMSA), Anastroline, Eribopitacin, Hexamethylmelamine (HMM), Interleukin 2, Mitoguanzone (methyI-GAG; methyl glyoxal bis-guanyldreazone; MGBG), Pentostatin (2'-deoxycobfurycin), Semustine (methyI-CCNU), Teniposide (VM-26) and Vinorelbine sulfate, but it is not so limited.

The immunotherapeutic agent may be selected from the group consisting of Ribavirin, Herceptin, Quaramet, Penicex, IDEC-Y2B8, BEC2, C225, Oncoblyn, SMART M195, ATRAQEN, Ovarax, Bexser, LDP-03, for 16, MDX-210, MDX-11, MDX-22, OV103, 362ZW94, anti-VEGF, Zenasex, MDX-220, MDX-447,

MELIMMUNE-2, MELIMMUNE-1, CEACIDE, Preterget, NovoMAB-G2, TNT, Gliomab-H, GNI-250, EMD-72000, LymphoCide, CMA 676, Monopharm-C, 4B5, for egf-3, for c5, BABS, anti-FLK-2, MDX-260, ANA Ab, SMART ID10 Ab, SMART ABL 364 Ab and ImmunRAIT-CEA, but it is not so limited.

The cancer vaccine may be selected from the group consisting of EGF, Anti-idiotypic cancer vaccines, Op75 antigen, GMK melanoma vaccine, MOV ganglioside conjugate vaccine, Hec2/here, Ovarax, M-Vax, O-Vax, L-Vax, STb-KHEL theratope, BLP25 (MUC-1), liposomal idiotypic vaccine, Melacine, peptide antigen vaccines, toxin/antigen vaccines, MVA-based vaccine, PACIS, BC3 vaccine, TA-HPV, TA-CIN, DISC-virus and ImmunCys/TheraCys, but it is not so limited.

In still another embodiment of the methods directed to preventing or treating cancer, the subject may be further administered interferon- α .

The invention in other aspects relates to methods for preventing disease in a subject. The method involves administering to the subject a Py-dib or a TG immunostimulatory nucleic acid on a regular basis to promote immune system responsiveness to prevent disease in the subject. Examples of diseases or conditions sought to be prevented using the prophylactic methods of the invention include microbial infections (e.g., sexually transmitted diseases) and anaphylactic shock from food allergies.

In other aspects, the invention is a method for inducing an innate immune response by administering to the subject a Py-dib or a TG immunostimulatory nucleic acid in an amount effective for activating an innate immune response.

- 17 -

According to another aspect of the invention a method for treating or preventing a viral or retroviral infection is provided. The method involves administering to a subject having or at risk of having a viral or retroviral infection, an effective amount for treating or preventing the viral or retroviral infection of any of the compositions of the invention.

In some embodiments the virus is caused by a hepatitis virus, HIV, hepatitis B, hepatitis C, herpes virus, or papillomavirus.

A method for treating or preventing a bacterial infection is provided according to another aspect of the invention. The method involves administering to a subject having or at risk of having a bacterial infection, an effective amount for treating or preventing the bacterial infection of any of the compositions of the invention. In one embodiment the bacterial infection is due to an intracellular bacteria.

In another aspect the invention is a method for treating or preventing a parasitic infection by administering to a subject having or at risk of having a parasitic infection, an effective amount for treating or preventing the parasitic infection of any of the compositions of the invention. In one embodiment the parasitic infection is due to an intracellular parasite. In another embodiment the parasitic infection is due to a non-intracellular parasite.

In some embodiments the subject is a human and in other embodiments the subject is a non-human vertebrate selected from the group consisting of a dog, cat, horse, cow, pig, goat, fish, monkey, chicken, and sheep.

In yet another aspect, the invention is a method for treating or preventing asthma, by administering to a subject having or at risk of having asthma, an effective amount for treating or preventing the asthma of any of the compositions of the invention. In one embodiment the asthma is allergic asthma.

In another aspect the invention relates to a method for treating or preventing allergy. The method involves administering to a subject having or at risk of having allergy, an effective amount for treating or preventing the allergy of any of the compositions of the invention.

A method for treating or preventing an immune deficiency is provided according to another aspect of the invention. The method involves administering to a subject having or at risk of an immune deficiency, an effective amount for treating or preventing the immune deficiency of any of the compositions of the invention.

- 18 -

In another aspect the invention relates to a method for inducing a TH1 immune response by administering to a subject any of the compositions of the invention in an effective amount to produce a TH1 immune response.

In one embodiment the methods of the invention involve administering an oligonucleotide of formula $5' \text{Y(N)}_2\text{N}_3\text{Y}_3 3'$ and an immunostimulatory nucleic acid having an unmethylated CG dinucleotide a TG dinucleotide or a T-rich sequence. In an embodiment the oligonucleotide comprising $5' \text{Y(N)}_2\text{N}_3\text{Y}_3 3'$ is administered separately from the immunostimulatory nucleic acid. In some embodiments the oligonucleotide comprising $5' \text{Y(N)}_2\text{N}_3\text{Y}_3 3'$ and the immunostimulatory nucleic acid are administered on an alternating weekly schedule and in other embodiments the oligonucleotide comprising $5' \text{Y(N)}_2\text{N}_3\text{Y}_3 3'$ and the immunostimulatory nucleic acid are administered on an alternating biweekly schedule.

The invention provides in another aspect a composition, comprising an immunostimulatory nucleic acid and an anti-cancer therapy, formulated in a pharmaceutically-acceptable carrier and in an effective amount to treat a cancer or to reduce the risk of developing a cancer. In important embodiments, the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid, a TG nucleic acid and a C-rich nucleic acid.

The invention further provides a kit comprising a first container housing an immunostimulatory nucleic acid and at least one other container (e.g., a second container) housing an anti-cancer therapy, and instructions for use. In one embodiment, the kit further comprises interferon- α , which may be separately housed in yet another container (e.g., a third container). In an important embodiment, the kit comprises a sustained-release vehicle combining an immunostimulatory nucleic acid, and at least one container housing an anti-cancer therapy, and instructions for timing of administration of the anti-cancer therapy. The immunostimulatory nucleic acid may be selected from the group consisting of a T-rich nucleic acid, a TG nucleic acid and a C-rich nucleic acid, wherein the C-rich nucleic acid has a nucleotide sequence comprising SEQ ID NO: 246.

The invention further provides a method for preventing or treating asthma or allergy, comprising administering an immunostimulatory nucleic acid and an asthma/allergy medicament in an effective amount to treat or prevent the asthma or

allergy. In important embodiments, the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid, a TG nucleic acid and a C-rich nucleic acid.

In one embodiment the immunostimulatory nucleic acid is a T-rich nucleic acid.

In a related embodiment, the T-rich nucleic acid has a nucleotide sequence selected from the group consisting of SEQ ID NO: 59-63, 73-75, 142, 215, 226, 241, 267-269, 282, 301, 304, 330, 342, 358, 370-372, 393, 433, 471, 479, 486, 491, 497, 503, 556-558, 567, 694, 793-794, 797, 833, 852, 861, 867, 868, 882, 886, 905, 907, 908, and 910-913. In other embodiments the T-rich nucleic acids are sequence selected from the group

consisting of SEQ ID NO: 64, 98, 112, 146, 185, 204, 208, 214, 224, 233, 244, 246, 247, 258, 262, 263, 265, 270-273, 300, 305, 316, 317, 343, 344, 350, 352, 354, 374, 376, 392, 407, 411-413, 429-432, 434, 435, 443, 474, 475, 498-501, 518, 687, 692, 693, 804, 862, 883, 884, 888, 890, and 891.

In yet a further related embodiment, the T-rich nucleic acid is not a TG nucleic acid. In yet still another embodiment, the T-rich nucleic acid is not a CpG nucleic acid.

In one embodiment, the immunostimulatory nucleic acid is a TG nucleic acid. In a further related embodiment, the TG nucleic acid is not a T-rich nucleic acid. In another related embodiment, the TG nucleic acid is not a CpG nucleic acid.

In one embodiment, the immunostimulatory nucleic acid is a CpG nucleic acid, wherein the CpG nucleic acid has a nucleotide sequence comprising SEQ ID NO: 246.

In another embodiment, the asthma/allergy medicament is a medicament selected from the group consisting of PDE-4 inhibitor, Bronchodilator/beta-2 agonist, K⁺ channel opener, VLA-4 antagonist, Neurexin antagonist, TXA2 synthesis inhibitor, Xanthine, Arachidonic acid antagonist, 5 lipooxygenase inhibitor, Thromboxan A2 receptor antagonist, Thromboxane A2 antagonist, Inhibitor of 5-lipoxygenase activation protein, and Protease inhibitor, but is not so limited. In some important embodiments, the asthma/allergy medicament is a Bronchodilator/beta-2 agonist selected from the group consisting of salmeterol, albuterol, terbutaline, D15722/formoterol, fenoterol, and oriprenaline.

In another embodiment, the asthma/allergy medicament is a medicament selected from the group consisting of Anti-histamines and Prostaglandin inducers. In one embodiment, the anti-histamines is selected from the group consisting of loratadine, cetirizine, buclizine, ceterizine analogues, fenofenadine, terfenadine, desloratadine,

nonsteroidal, epinastine, ebastine, ebastine, astemizole, levocabastine, azelastine, triamterol, terfenadine, mizolastine, betastine, CS 560, and HSR 609. In another embodiment, the Prostaglandin inducer is S-5751.

In yet another embodiment, the asthma/allergy medicament is selected from the group consisting of Steroids and Immunomodulators. The immunomodulators may be selected from the group consisting of anti-inflammatory agents, leukotriene antagonists, IL4 inhibitors, Soluble IL-4 receptors, Immunosuppressants, anti-IL-4 antibodies, IL-4 antagonists, anti-IL-5 antibodies, soluble IL-13 receptor-Fe fusion proteins, anti-IL-9 antibodies, CCR3 antagonists, CCR5 antagonists, VLA-4 inhibitors, and Downregulators of IgE, but are not so limited. In one embodiment, the downregulator of IgE is an anti-IgE.

In another embodiment, the Steroid is selected from the group consisting of beclomethasone, fluticasone, triamcinolone, budesonide, and budesonide. In still a further embodiment, the Immunosuppressant is a Tolerizing peptide vaccine.

In one embodiment, the immunostimulatory nucleic acid is administered concurrently with the asthma/allergy medicament. In another embodiment, the subject is an immunocompromised subject.

The immunostimulatory nucleic acid to be administered to a subject in the methods disclosed herein relating to the prevention and treatment of asthma/allergy are as described for other method aspects of the invention.

In another aspect, the invention provides a kit comprising a first container housing an immunostimulatory nucleic acid, and at least another container (e.g., a second container) housing an asthma/allergy medicament, and instructions for use. The immunostimulatory nucleic acid useful in the kit is as described herein. In important embodiments, the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid, a TG nucleic acid and a C-rich nucleic acid. In another important embodiment, the kit comprises a sustained-release vehicle containing an immunostimulatory nucleic acid, and at least one container housing an asthma/allergy medicament, and instructions for timing of administration of the asthma/allergy medicament. The asthma/allergy medicament may be selected from the group of asthma/allergy medicaments described in the foregoing methods directed towards the prevention or treatment of asthma/allergy.

In yet another aspect, the invention provides a composition, comprising an immunostimulatory nucleic acid and an asthma/allergy medicament, formulated in a pharmaceutically-acceptable carrier and in an effective amount for preventing or treating an immune response associated with exposure to a mediator of asthma or allergy. The immunostimulatory nucleic acid may be selected from the group of immunostimulatory nucleic acids described for the foregoing methods and compositions. In important embodiments, the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid, a TG nucleic acid and a C-rich nucleic acid. The asthma/allergy medicament may be selected from the group consisting of asthma medicaments and allergy medicaments as described in the foregoing methods and compositions.

In still a further aspect, the invention provides a composition comprising an immunostimulatory nucleic acid selected from the group consisting of SEQ ID NO: 95-136, SEQ ID NO: 138-152, SEQ ID NO: 154-222, SEQ ID NO: 224-245, SEQ ID NO: 247-261, SEQ ID NO: 263-299, SEQ ID NO: 301, SEQ ID NO: 303-4109, SEQ ID NO: 414-420, SEQ ID NO: 424, SEQ ID NO: 426-947, SEQ ID NO: 959-1022, SEQ ID NO: 1024-1093, and a pharmaceutically acceptable carrier. Preferably the immunostimulatory nucleic acid is present in the composition in an effective amount. In one embodiment, the immunostimulatory nucleic acid is present in an effective amount to induce an immune response. In another embodiment, the immunostimulatory nucleic acid is present in an effective amount to prevent or treat cancer. In yet a further embodiment, the immunostimulatory nucleic acid is present in an effective amount to prevent or treat asthma/allergy. The invention also provides kits comprising any of the foregoing immunostimulatory nucleic acid compositions, and instructions for use.

In another aspect the invention includes a composition of an immunostimulatory nucleic acid consisting essentially of: 5' M₁TCGTCGTTM₂ 3' wherein at least one of the C_s is unmethylated, wherein M₁ is a nucleic acid having at least one nucleotide, wherein M₂ is a nucleic acid having between 0 and 50 nucleotides, and wherein the immunostimulatory nucleic acid has less than 100 nucleotides.

In yet other aspects the invention relates to a pharmaceutical composition of an immunostimulatory nucleic acid comprising: 5' TCGTCGTT 3' wherein at least one of the C_s is unmethylated, wherein the immunostimulatory nucleic acid has less than 100 nucleotides and a phosphodiester backbone, and a sustained release device. In some

embodiments the sustained release device is a microparticle. In other embodiments the composition includes an antigen.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A is a histogram of the expression of CD86 (Y-axis) by CD19+ cells following exposure of these cells to the oligonucleotides shown on the X-axis at a concentration of 0.15 µg/ml.

Figure 1B is a histogram of the expression of CD86 (Y-axis) by CD19+ cells following exposure of these cells to the oligonucleotides shown on the X-axis at a concentration of 0.30 µg/ml.

Figure 2 is a graph comparing the abilities of ODN 2137, ODN 2177, ODN 2200 and ODN 2202 to stimulate B cell proliferation at concentrations ranging from 0.2 µg/ml to 20 µg/ml.

Figure 3 is a graph comparing the abilities of ODN 2188, ODN 2189, ODN 2190 and ODN 2182 to stimulate B cell proliferation at concentrations ranging from 0.2 µg/ml to 20 µg/ml.

Fig. 4 is a bar graph depicting dose-dependent B cell activation induced by non-CpG ODN. PBMC of a blood donor were incubated with the indicated concentrations of ODNs 2006 (SEQ ID NO: 246), 2117 (SEQ ID NO: 358), 2137 (SEQ ID NO: 886), 5126 (SEQ ID NO: 1058) and 5162 (SEQ ID NO: 1094) and stained with mAb for CD19 (B cell marker) and CD86 (B cell activation marker, B7-2). Expression was measured by flow cytometry.

Fig. 5 is a bar graph depicting stimulation of B cells by a diverse set of non-CpG ODNs. PBMC of one representative donor were stimulated by 0.4 µg/ml, 1.0 µg/ml or 10.0 µg/ml of the following ODNs: 2006 (SEQ ID NO: 246), 2196 (SEQ ID NO: 913), 2194 (SEQ ID NO: 911), 5162 (SEQ ID NO: 1094), 5163 (SEQ ID NO: 1095), 5168 (SEQ ID NO: 1096) and 5169 (SEQ ID NO: 1097) and expression of the activation marker CD86 (B7-2) on CD19-positive B cells was measured by flow cytometry.

Fig 6 is a bar graph depicting B cell activation by non-CpG ODNs 1982 and 2041. PBMC were incubated with the indicated concentrations of ODN 2006 (SEQ ID NO.: 246), 1982 (SEQ ID NO.: 225) and 2041 (SEQ ID NO.: 282) and B cell activation (expression of the activation marker CD86) was measured by flow cytometry.

Fig. 7 is a bar graph depicting NK cells are activated by non-CpG ODNs. PBMC were incubated with 6 μ g/ml of the following ODNs: 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 911) and 5126 (SEQ ID NO.: 1058) and stained with mAb for CD3 (T cell marker), CD56 (NK cell marker) and CD69 (early activation marker). Expression of CD69 on CD56-positive NK cells was measured by flow cytometry.

Fig. 8 is a bar graph depicting NK-mediated cytotoxicity is enhanced by non-CpG ODN. NK-mediated lysis of K-562 target cells was measured after overnight incubation of PBMC with 6 μ g/ml of the ODN 2006 (SEQ ID NO.: 246), 2194 (SEQ ID NO.: 911) and 5126 (SEQ ID NO.: 1058).

Fig. 9 is a bar graph depicting NKT cells can be activated by non-CpG ODN. PBMC of one representative donor were incubated with 6 μ g/ml ODN 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 911) and 5126 (SEQ ID NO.: 1058) for 24h and activation of NKT cells was measured by flow cytometry after staining of cells with mAb for CD3 (T cell marker), CD56 (NK cell marker) and CD69 (early activation marker).

Fig. 10 is a bar graph depicting stimulation of monocytes by different CpG and non-CpG ODN. PBMC were incubated with 6 μ g/ml 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2178 (SEQ ID NO.: 428), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 911), 5126 (SEQ ID NO.: 1058) and 5163 (SEQ ID NO.: 1095) and stained for CD14 (monocyte marker) and CD80 (B7-1, activation marker). Expression was measured by flow cytometry.

Fig. 11 is a bar graph depicting release of TNF α upon culture of human cells with non-CpG ODN. PBMC were cultured for 24h with or without 6 μ g/ml of the indicated ODNs or 1 μ g/ml LPS as positive control and TNF α measured by ELISA.

Fig. 12 is a bar graph depicting release of IL-6 after culture with non-CpG ODNs above the same pattern as for TNF α . PBMC were cultured with the indicated ODNs (1.0 μ g/ml) and IL-6 was measured in the supernatants by ELISA.

DETAILED DESCRIPTION

The invention in one aspect involves the finding that pyrimidine (Py) rich and preferably thymidine (T) rich nucleic acids as well as nucleic acids that contain TG dinucleotide motifs are effective in mediating immune stimulatory effects. It was known in the prior art that CpG containing nucleic acids are therapeutic and prophylactic compositions that stimulate the immune system to treat cancer, infectious diseases, allergy, asthma and other disorders and to help protect against opportunistic infections following cancer chemotherapies. The strong yet balanced, cellular and humoral immune responses that result from CpG stimulation reflect the body's own natural defense system against invading pathogens and cancerous cells. CpG sequences, while relatively rare in human DNA are commonly found in the DNA of infectious organisms such as bacteria. The human immune system has apparently evolved to recognize CpG sequences as an early warning sign of infection, and to initiate an immediate and powerful immune response against invading pathogens without causing adverse reactions frequently seen with other immune stimulatory agents. Thus CpG containing nucleic acids, relying on this innate immune defense mechanism, can utilize a unique and natural pathway for immune therapy. The effects of CpG nucleic acids on immune modulation were discovered by the inventor of the instant patent application and have been described extensively in co-pending patent applications, such as U.S. Patent Application Serial Nos: 08/386,063 filed on 02/07/95 (and related PCT US95/01570); 08/738,652 filed on 10/30/96; 08/960,774 filed on 10/30/97 (and related PCT/US97/19791, WO 98/18810); 09/191,170 filed on 11/13/98; 09/030,701 filed on 02/25/98 (and related PCT/US98/03678; 09/082,649 filed on 05/20/98 (and related PCT/US98/10409); 09/325,193 filed on 06/03/99 (and related PCT/US98/04703); 09/286,098 filed on 04/02/99 (and related PCT/US99/07335); 09/306,281 filed on 05/06/99 (and related PCT/US99/09863). The entire contents of each of these patents and patent applications is hereby incorporated by reference.

The findings of the instant invention are applicable to all of the above described uses of CpG containing nucleic acids as well as any other known use for CpG nucleic acids. The invention involves, in one aspect, the discovery that Py-rich and preferably T-rich and TG nucleic acids have similar immune stimulatory properties to CpG oligonucleotides regardless of whether a CpG motif is present. Thus the invention is

useful for any method for stimulating the immune system using Pyrinin or T_H molecule acids. It was also discovered surprisingly according to the invention that chimeric oligonucleotides which lack a CpG motif are immune stimulatory and have many of the same prophylactic and therapeutic activities as a CpG oligonucleotide.

5 A *P*-rich nucleic acid is a *T*-rich or *C*-rich immunostimulatory nucleic acid. In some embodiments *T*-rich nucleic acids are preferred. A *T*-rich nucleic acid is a nucleic acid which includes at least one poly *T* sequence and/or which has a nucleotide composition of greater than 25% *T* nucleotide residues. A nucleic acid having a poly-*T* sequence includes at least four *T*s in a row, such as 5'TTTTT3'. Preferably the *T*-rich nucleic acid includes more than one poly *T* sequence. In preferred embodiments the *T*-rich nucleic acid may have 2, 3, 4, etc poly *T* sequences, such as oligonucleotide #2006 (SEQ ID NO246). One of the most highly immunostimulatory *T*-rich oligonucleotides discovered according to the invention is a nucleic acid composed entirely of *T* nucleotide residues, e.g., oligonucleotide #2183 (SEQ ID NO433). Other *T*-rich nucleic acids according to the invention have a nucleotide composition of greater than 25% *T* nucleotide residues, but do not necessarily include a poly *T* sequence. In these *T*-rich nucleic acids the *T* nucleotide residues may be separated from one another by other types of nucleotide residues, i.e., *G*, *C*, and *A*. In some embodiments the *T*-rich nucleic acids have a nucleotide composition of greater than 33%, 40%, 50%, 60%, 70%, 80%, 90%, and 99%, *T* nucleotide residues and every integer % in between. Preferably the *T*-rich nucleic acids have at least one poly *T* sequence and a nucleotide composition of greater than 25% *T* nucleotide residues.

It was discovered according to the invention that the T content of an ODN has a dramatic effect on the immune stimulatory effect of the ODN and that T-rich ODN can activate multiple human immune cell types in the absence of any CpG motifs. An oligonucleotide having a 3' poly-T region and 2 5' C's e.g., ODN 2181 (SEQ ID NO:431) is highly immune stimulatory. An oligonucleotide of similar length, ODN 2116 (SEQ ID NO:357) which contains two CG dinucleotides at the 5' and a poly-C region at the 3' end was also immune stimulatory but to a lesser extent than the T-rich oligonucleotide using standard experimental conditions. Thus, although C and T have almost identical structures, their effects on the immune properties of an ODN are varied. They both are capable of inducing an immune response but to different extents. Thus

both T-rich and C-rich oligonucleotides are useful according to the invention, but T-rich oligonucleotides are preferred. Furthermore, if the T content of the ODN is reduced by incorporating other bases such as G, A, or C, then the immune stimulatory effect is reduced (ODN #2,88 (SEQ ID NO:905), 2190 (SEQ ID NO:907), 2191 (SEQ ID NO:908), and 2193 (SEQ ID NO:910)).

A C-rich nucleic acid is a nucleic acid molecule having at least one or preferably at least two poly-C region or which is composed of at least 50% C nucleotides. A poly-C region is at least four C residues in a row. Thus a poly-C region is encompassed by the formula 5'CCCC 3'. In some embodiments it is preferred that the poly-C region have the formula 5'CCCCCCC 3'. Other C-rich nucleic acids according to the invention have a nucleotide composition of greater than 50% C nucleotide residues, but do not necessarily include a poly C sequence. In these C-rich nucleic acids the C nucleotide residues may be separated from one another by other types of nucleotide residues, i.e., G, T, and A. In some embodiments the C-rich nucleic acids have a nucleotide composition of greater than 60%, 70%, 80%, 90%, and 99%, C nucleotide residues and every integer % in between. Preferably the C-rich nucleic acids have at least one poly C sequence and a nucleotide composition of greater than 50% C nucleotide residues, and in some embodiments are also T-rich.


As shown in the Examples, several ODN previously believed to be non-immunostimulatory, including two ODNs SEQ ID NO.: 225 and SEQ ID NO.: 282 previously described to be non-stimulatory and mainly used as control ODNs (Takahashi, T et al 2000, *J Immunol* 164:4436) were found to be immunostimulatory. Our experiments demonstrated that these ODNs can stimulate B cells, although at higher concentrations compared to CpG ODNs (Fig. 6). A long Poly T ODN (30mers) incubated, at least in some experiments, comparably strong activation of B cells to one of the strongest CpG ODN activators of B cells. These experiments also revealed the surprising finding that even Poly C ODNs can lead to stimulation of B cells.

Immunostimulation by these ODNs, however, was not limited to human B cells. Differential experimental assays clearly demonstrated that monocytes, NK cells and even NK1 cells can be activated by such non-CpG ODNs (Fig. 7–10). In contrast to Poly I and Poly C sequences, immunostimulation by Poly A sequences (at least for monocytes, B and NK cells) was not achieved. Interestingly it was found that the

introduction of a CpG motif into SEQ ID NO.: 225 enhanced the immunostimulatory activity whereas the elongation with a Poly T stretch did not enhance immunostimulation. This suggests that CpG and T-rich ODN may operate through different mechanisms or pathways. It is also possible that insertion of a poly-T motif into a different position of SEQ ID NO.: 225 may result in a change in immunostimulatory properties.

A "TG nucleic acid" or a "TG immunostimulatory nucleic acid" as used herein is a nucleic acid containing at least one TpG dinucleotide (thymidine-guanine dinucleotide sequence, i.e. "TG DNA" or DNA containing a 5' thymidine followed by 3' guanosine and linked by a phosphate bond) and activates a component of the immune system.

In one embodiment the invention provides a TG nucleic acid represented by at least the formula:



wherein X_1 and X_2 are nucleotides and N is any nucleotide and N_1 and N_3 are nucleic acid sequences composed of any number of N provided that the sum total of N_1 and N_3 is in the range of 11 to 21. As an example, if N_1 is 5, then N_3 may be 6 (leading to a total length for the oligonucleotide of 15 nucleotides). The TG may be located anywhere within the oligonucleotide stretch, including the 5' end, the center and the 3' end. Thus, N_1 may be zero through to 21, inclusive, provided that N_3 is appropriately chosen to give a sum of N_2 and N_1 equal to 11 through to 21, inclusive. Similarly, N_3 may be zero through to 21, inclusive, provided that the sum total of N_1 and N_3 equals 11 to 21, inclusive. In some embodiments X_1 is adenine, guanine, or thymidine and X_2 is cytosine, adenine, or thymidine. In one preferred embodiment, X_2 is thymidine. In other embodiments X_1 is cytosine and/or X_2 is guanine. In other embodiments, as discussed herein, the nucleic acid may encompass other motifs, provided it is long enough to do so.

In other embodiments the TG nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides. In some embodiments, X_1X_2 are nucleotides selected from the group consisting of GpT, GpG, GpA, ApA, ApT, ApG, CpT, CpA, TpA and TpT; and X_3X_4 are nucleotides selected from the group consisting of: TpT, CpT, ApT, ApG, TpC, ApC, TpA, ApA, and CpA; N is any nucleotide and N_1 and N_3 are nucleic acid sequences composed of any number of nucleotides

provide that the sum total of N_1 and N_3 is in the range of 9 to 19. In some embodiments, X_1X_2 are GpA or GpT and X_3X_4 are TpT. In other embodiments X_1 or X_2 or both are purines and X_3 or X_4 or both are pyrimidines or X_1X_2 are CpA and X_3 or X_4 or both are pyrimidines. In one preferred embodiment, X_3X_4 are nucleotides selected from the group consisting of: TpT, TpC and TpA.

The immunostimulatory nucleic acid may be any size (i.e., length) provided it is at least 4 nucleotides. In important embodiments, the immunostimulatory nucleic acids have a length in the range of between 6 and 100. In still other embodiments, the length is in the range of between 8 and 35 nucleotides. Preferably, the TG oligonucleotides range in size from 15 to 25 nucleotides.

The size (i.e., the number of nucleotide residues along the length of the nucleic acid) of the immunostimulatory nucleic acid may also contribute to the stimulatory activity of the nucleic acid. It has been discovered, surprisingly that even for highly immune stimulating immunostimulatory nucleic acids, the length of the nucleic acid influences the extent of immunostimulation that can be achieved. It has been

demonstrated that increasing the length of a T-rich nucleic acid up to 24 nucleotides causes increased immune stimulation. The experiments presented in the examples demonstrate that when the length of the T-rich nucleic acid is increased from 18 to 27 nucleotides the ability of the nucleic acid to stimulate an immune response is increased significantly (compare ODN #2194, 2183, 2195, and 2196 decreasing in size from 27-18 nucleotides). Increasing the length of the nucleic acid up to 30 nucleotides had a dramatic impact on the biological properties of the nucleic acid but increasing the length beyond 30 nucleotides did not appear to further influence the immune stimulatory effect (e.g., compare ODN 2179 to 2006).

It has been shown that TG nucleic acids ranging in length from 15 to 25 nucleotides in length may exhibit an increased immune stimulation. Thus, in one aspect, the invention provides an oligonucleotide that is 15-27 nucleotides in length (i.e., an oligonucleotide that is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27 nucleotides in length) that may be a T-rich nucleic acid or may be a TG nucleic acid, or may be both a T-rich and a TG nucleic acid. In one embodiment, the oligonucleotide is not a T-rich nucleic acid nor is it a TG nucleic acid. In other embodiments, the oligonucleotide does not have a CG motif. The invention similarly provides oligonucleotides that are 15-27

nucleotides in length, oligonucleotides that are 18-25 nucleotides in length, oligonucleotides that are 20-23 nucleotides in length, and oligonucleotides that are 23-25 nucleotides in length. Any of the foregoing embodiments relating to oligonucleotides 15-27 in length also relate to the oligonucleotides of these differing lengths. The invention further embraces the use of any of these foregoing oligonucleotides in the methods recited herein.

Although a maximal level of immune stimulation is achieved with some T-rich nucleic acids when the nucleic acid is 24-30 nucleotide residues in length, as well as with some TG nucleic acids that range from 15 to 25 nucleotides in length, shorter or longer immunostimulatory nucleic acids can also be used according to the methods of the invention. For facilitating uptake into cells immunostimulatory nucleic acids preferably have a minimum length of 6 nucleotide residues. Nucleic acids of any size greater than 6 nucleotides (even many kb long) are capable of inducing an immune response according to the invention if sufficient immunostimulatory motifs are present, since larger nucleic acids are degraded inside of cells. Preferably the immunostimulatory nucleic acids are in the range of between 8 and 100 and in some embodiments T-rich containing immunostimulatory nucleic acids are between 24 and 40 nucleotides in length and TG containing immunostimulatory nucleic acids are between 15 and 25 nucleotides in length.

In one embodiment the T-rich nucleic acid is represented by at least the formula:



wherein X_1 , X_2 , X_3 , and X_4 are nucleotides. In one embodiment X_1X_2 is TT and/or X_3X_4 is TT. In another embodiment X_1X_2 are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, GT, GG, GA, and GC, and X_3X_4 are any one of the following nucleotides TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, GT, GG, GA, and GC.

In some embodiments it is preferred that the immunostimulatory nucleic acids do not contain poly-G (CCCC), or poly-A (AAAA). In other embodiments it is preferred that the immunostimulatory nucleic acid include poly-C, poly-A, poly-G (GCGG) or multiple GAs. In particular poly-G or multiple GA motifs have dramatic effects on some immunostimulatory nucleic acids. The effect of these runs-T sequences depends in part on the status of the nucleic acid backbone. For instance, if the nucleic acid has a

phosphodiester backbone or a chimeric backbone the inclusion of these sequences in the nucleic acid will only have minimal if any effect on the biological activity of the nucleic acid. If the backbone is completely phosphorothioate (or other phosphate modification) or significantly phosphorothioate then the inclusion of these sequences may have more influence on the biological activity or the kinetics of the biological activity, causing a decrease in potency of the T-rich and TG immunostimulatory nucleic acids.

Although C-rich nucleic acids have been demonstrated to have immune stimulating properties, insertion of Poly-C sequences into a T-rich nucleic acid in a manner that would reduce the relative proportion of T nucleotides in the nucleic acid can have a negative impact on the nucleic acid. Although applicants are not bound by a proposed mechanism, it is believed that the immune system has developed a mechanism for distinguishing nucleic acids having different nucleotide properties, possibly resulting from different sets of binding proteins which recognize different sequences or specific binding proteins which recognize all the immunostimulatory sequences but with different affinities. In general nucleic acids including unmethylated CpG motifs are the most immunostimulatory, followed by T-rich nucleic acids, TG nucleic acids and C-rich nucleic acids. This generalization, however, has many exceptions. For instance a strong T-rich nucleic acid like SEQ ID NO.: 886 is more immune stimulatory in some assays than some CpG containing nucleic acids (e.g., a phosphorothioate CpG nucleic acid containing a single CpG motif).

It has also been discovered that the addition of a poly-A tail to an immunostimulatory nucleic acid can enhance the activity of the nucleic acid. It was discovered that when a highly immune stimulatory CpG nucleic acid (SEQ ID NO.: 246) was modified with the addition of a poly-A tail (AAAAAA) or a poly-T tail (TTTTTT), the resultant oligonucleotides increased in immune stimulatory activity. The ability of the poly-A tail and the poly-T tail to increase the immunostimulating properties of the oligonucleotide was very similar. SEQ ID NO.: 246 is a T-rich oligonucleotide. It is likely that if poly-A and poly-T tails are added to a nucleic acid which is not T-rich, it would have a bigger impact on the immune stimulating capability of the nucleic acid. Since the poly-T tail was added to a nucleic acid that was already highly T-rich the immune stimulating properties of the poly-T addition was diluted somewhat, although not completely. This finding has important implications for the use of poly-A regions.

Thus in some embodiments the immunostimulatory nucleic acids include a poly-A region and in other embodiments they do not.

Some of the immunostimulatory nucleic acids of the invention include one or more CG motifs. The presence of CG motifs in the immunostimulatory nucleic acids also has an influence on the biological activity of the nucleic acids. If the total length of an immunostimulatory nucleic acid is 20 nucleotide residues or less, then CpG motifs are important in determining the immune effect of the nucleic acid, and methylation of these motifs reduces the potency of the immune stimulatory effects of the nucleic acid. If the length of the immunostimulatory nucleic acid is increased to 24, then the immune stimulatory effects of the nucleic acid become less dependent on the CpG motifs, and are no longer abolished by methylation of the CpG motifs or by their inversion to GC dinucleotides, provided the other immune-stimulatory properties described herein are present.

For example, ODN 2006 (SEQ ID NO:246) is a highly immune stimulatory T-rich nucleic acid of 24 nucleotide residues in length with four CpG dinucleotides.

However, ODN 2117 (SEQ ID NO:358), in which the CpG motifs are methylated is also highly immune stimulatory. ODN 2137 (SEQ ID NO:886), in which the CpG motifs of ODN 2006 are inverted to CpC, and which as a result possesses six TG dinucleotides is also immune stimulatory. The immune stimulatory effects of nucleic acids such as ODN

2117 and 2137 are regulated by their T and TG content. Each of these three nucleic acids is T-rich and ODN 2137 is additionally TG rich. If their T content is reduced by inserting other bases such as A (ODN 2117 (SEQ ID NO:358)) or if their TG content is reduced by substituting TG with AG, then the immune stimulatory effects are somewhat reduced. In another example, a nucleic acid 24 nucleotides in length in which all of the positions are randomized has only a modest immune stimulatory effect (ODN 2182 (SEQ ID NO:432)). Likewise, a nucleic acid 24 nucleotides in length with other nucleotide compositions have variable immune stimulatory effects, depending on their T content (ODN 2188 (SEQ ID NO:905), 2189 (SEQ ID NO:906), 2190 (SEQ ID

NO:907), 2191 (SEQ ID NO:908), 2193 (SEQ ID NO:910), 2183 (SEQ ID NO:433), and 2178 (SEQ ID NO:428)). ODN 2190 which contains TGT motifs is more immune stimulatory than ODN 2202 which possesses TGG motifs. Thus, in some embodiments, TGT motifs are preferred. In still other embodiments, the number of TG motifs is

important in that an increase in the number of TG motifs leads to an increase in immune stimulation. Some preferred TG nucleic acids contain at least three TG motifs.

Examples of CpG nucleic acids include but are not limited to those listed in Table A, such as SEQ ID NO: 1, 3, 4, 14-16, 18-24, 28, 29, 33-46, 49, 50, 52-56, 58, 64-67, 69, 71, 72, 76-87, 90, 91, 93, 94, 96, 98, 102-124, 126-128, 131-133, 136-141, 146-150, 152-153, 155-171, 173-178, 180-186, 188-198, 201, 203-214, 216-220, 223, 224, 227-240, 242-256, 258, 260-265, 270-273, 275, 277-281, 286-287, 292, 295-296, 300, 302, 305-307, 309-312, 314-317, 320-327, 329, 335, 337-341, 343-352, 354, 357, 361-365, 367-369, 373-376, 378-385, 388-392, 394, 395, 399, 401-404, 406-426, 429-433, 434-437, 439, 441-443, 445, 447, 448, 450, 453-456, 460-464, 466-469, 472-475, 477, 478, 480, 483-485, 488, 489, 492, 493, 495-502, 504-505, 507-509, 511, 513-529, 532-541, 543-555, 564-566, 568-576, 578, 580, 599, 601-605, 607-611, 613-615, 617, 619-622, 625-646, 648-650, 653-664, 666-697, 699-706, 708, 709, 711-716, 718-732, 736, 737, 739-744, 746, 747, 749-761, 763, 766-767, 769, 772-779, 781-783, 785-786, 790-792, 798-799, 804-808, 810, 815, 817, 818, 820-832, 835-846, 849-850, 855-859, 862, 865, 872, 874-877, 879-881, 883-885, 888-904, and 909-913.

In some embodiments of the invention the immunostimulatory nucleic acids include CpG dinucleotides and in other embodiments the immunostimulatory nucleic acids are free of CpG dinucleotides. The CpG dinucleotides may be methylated or unmethylated. A nucleic acid containing at least one unmethylated CpG dinucleotide is a nucleic acid molecule which contains an unmethylated cytosine-guanine dinucleotide sequence (i.e. "CpG DNA" or DNA containing an unmethylated 5' cytosine followed by 3' guanine and linked by a phosphate bond) and activates the immune system. A

nucleic acid containing at least one methylated CpG dinucleotide is a nucleic acid which contains a methylated cytosine-guanine dinucleotide sequence (i.e., a methylated 5' cytosine followed by a 3' guanine and linked by a phosphate bond).

Examples of T rich nucleic acids that are free of CpG nucleic acids include but are not limited to those listed in Table A, such as SEQ ID NO: 59-63, 73-75, 142, 215, 226, 241, 267-269, 282, 301, 304, 330, 342, 358, 370-372, 393, 433, 471, 479, 486, 491, 497, 503, 556-558, 567, 694, 793-794, 797, 833, 852, 861, 867, 868, 882, 886, 905, 907, 908, and 910-913. Examples of T rich nucleic acids that include CpG nucleic acids include but are not limited to those listed in Table A, such as SEQ ID NO: 64, 98, 112,

- 33 -


146, 183, 204, 208, 214, 224, 233, 244, 246, 247, 258, 262, 263, 265, 270-273, 300, 305, 316, 317, 343, 344, 350, 352, 354, 374, 376, 392, 407, 411-413, 429-432, 434, 435, 443, 474, 475, 498-501, 518, 587, 692, 693, 804, 862, 883, 884, 888, 890, and 891.

5 The immunostimulatory nucleic acids can be double-stranded or single-stranded. Generally, double-stranded molecules are more stable *in vivo*, while single-stranded molecules have increased immuno activity. Thus in some aspects of the invention it is preferred that the nucleic acid be single stranded and in other aspects it is preferred that the nucleic acid be double stranded.

10 The term T-rich nucleic acid and TG nucleic acid, as used herein, refers to an immunostimulatory T-rich nucleic acid and an immunostimulatory TG nucleic acid, respectively, unless otherwise indicated. The T-rich nucleic acid sequences of the invention are those broadly described above as well as the nucleic acids shown in Table A that have at least one poly T motif and/or have a composition of greater than 25% T or preferably 35% nucleotide residues. The C-rich nucleic acids are those having at least one and preferably at least two poly-C regions. The TG nucleic acids of the invention are those broadly described above as well as the specific nucleic acids shown in Table A that have at least one TG motif.

20 The nucleic acids of the invention may, but need not, also include a poly G motif. Poly G containing nucleic acids are also immunostimulatory. A variety of references, including Plavitsky and Reich, 1993 *Mol. Biol. Reports*, 18:217-221; Krieger and Herz, 1994, *Ann. Rev. Biochem.*, 63:601-637; Maseya et al., 1993, *PNAS*, 90:3745-3749; Wyatt et al., 1994, *PNAS*, 91:1356-1360; Rando and Hogen, 1998, in *Applied Antisense Oligonucleotide Technology*, ed. Krieger and Stein, p. 335-352; and Kimura et al., 1994, *J. Biochem.*, 116, 991-994 also describe the immunostimulatory properties of poly G nucleic acids.

Poly G nucleic acids preferably are nucleic acids having the following formula:



30 wherein X_1 , X_2 , X_3 , and X_4 are nucleotides. In preferred embodiments at least one of X_3 and X_4 are a G. In other embodiments both of X_3 and X_4 are a G. In yet other embodiments the preferred formula is 5' GGGNGGG 3', or 5' GGGNGGGNGGG 3' wherein N represents between 0 and 20 nucleotides. In other embodiments the poly G nucleic acid is free of unmodified CG dinucleotides, such as, for example, the nucleic

- 34 -

acids listed below as SEQ ID NO: 5, 6, 73, 215, 267-269, 276, 282, 288, 297-299, 355, 359, 386, 387, 444, 476, 531, 557-559, 733, 768, 795, 796, 914-925, 928-931, 933-936, and 938. In other embodiments the poly G nucleic acid includes at least one unmodified CG dinucleotide, such as, for example, the nucleic acids listed above as SEQ ID NO: 67, 80-82, 141, 147, 148, 173, 178, 183, 185, 214, 224, 264, 265, 315, 329, 434, 435, 475, 519, 521-524, 526, 527, 535, 554, 565, 609, 628, 660, 661, 662, 725, 767, 825, 856, 857, 876, 892, 909, 926, 927, 932, and 937.

10 The terms "nucleic acid" and "oligonucleotide" are used interchangeably to mean multiple nucleotides (i.e. molecules comprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymidine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G)). As used herein, the terms refer to oligonucleotides as well as oligodeoxyribonucleotides. The terms shall also include polynucleotides (i.e. a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably synthetic (e.g., produced by nucleic acid synthesis).

20 The terms nucleic acid and oligonucleotide also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars. For example, they include nucleic acids having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby combining any possible combination of polymer units linked together such as peptide- nucleic acids (which have amino acid backbone with nucleic acid bases). In some embodiments, the nucleic acids are homogeneous in backbone composition. Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne modified bases (Meyers et al., *Nature Biotechnology* 14:840-844, 1996). Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymidine, 5-methylcytosine, 2-aminoguanine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and

non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties. Other such modifications are well known to those of skill in the art.

For use in the instant invention, the nucleic acids of the invention can be synthesized *de novo* using any of a number of procedures well known in the art. For example, the b-cyanoethyl phosphoramidite method (Beauregard, S.L., and Caruthers, M.H., *Tet. Let.* 22:1859, 1981); nucleoside H-phosphonate method (Garegg *et al.*, *Tet. Let.* 27:4031-4054, 1986; Froehner *et al.*, *Nucl. Acid. Res.* 14:5399-5407, 1986; Garegg *et al.*, *Tet. Let.* 27:4055-4058, 1986; Garffney *et al.*, *Tet. Let.* 22:2619-2622, 1988).

These chemistries can be performed by a variety of automated nucleic acid synthesizers available in the market. These nucleic acids are referred to as synthetic nucleic acids.

Alternatively, T-rich and/or TG dinucleotides can be produced on a large scale in plasmids, (see Sambrook, T., *et al.*, "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory Press, New York, 1989) and separated into smaller pieces or administered whole. Nucleic acids can be prepared from existing nucleic acid sequences (e.g., genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases. Nucleic acids prepared in this manner are referred to as isolated nucleic acid. An isolated nucleic acid generally refers to a nucleic acid which is separated from components which it is normally associated with in nature. As an example, an isolated nucleic acid may be one which is separated from a cell, from a nucleus, from mitochondria or from chromatin. The terms Py-rich nucleic acids and TG nucleic acids encompasses both synthetic and isolated Py-rich nucleic acids and TG nucleic acids.

For use *in vivo*, the Py-rich and TG nucleic acids may optionally be relatively resistant to degradation (e.g., are stabilized). A "stabilized nucleic acid molecule" shall mean a nucleic acid molecule that is relatively resistant to *in vivo* degradation (e.g. via an *exo- or endo-nuclease*). Stabilization can be a function of length or secondary structure. Nucleic acids that are tens to hundreds of kbs long are relatively resistant to *in vivo* degradation. For shorter nucleic acids, secondary structure can stabilize and increase their effect. For example, if the 3' end of a nucleic acid has self-complementarity to an upstream region, so that it can fold back and form a sort of stem loop structure, then the nucleic acid becomes stabilized and therefore exhibits more activity.

Alternatively, nucleic acid stabilization can be accomplished via phosphate backbone modifications. Preferred stabilized nucleic acids of the instant invention have a modified backbone. It has been demonstrated that modification of the nucleic acid backbone provides enhanced activity of the Py-rich and TG nucleic acids when administered *in vivo*. These stabilized structures are preferred because the Py-rich and TG molecules of the invention have at least a partial modified backbone. Py-rich and TG constructs having phosphorothioate linkages provide maximal activity and protect the nucleic acid from degradation by intracellular *exo- and endo-nucleases*. Other modified nucleic acids include phosphodiester modified nucleic acids, combinations of phosphodiester and phosphorothioate nucleic acid, methylphosphonate, methylphosphorothioate, phosphorodithioate, p-ethoxy, and combinations thereof. Each of these combinations and their particular effects on immune cells is discussed in more detail with respect to CpG nucleic acids in PCT Published Patent Applications PCT/US95/01570 (WO 96/02555) and PCT/US97/19791 (WO 98/18810) claiming priority to U.S. Serial Nos. 08/386,063 and 08/960,774, filed on February 7, 1995 and October 30, 1997 respectively, the entire contents of which are hereby incorporated by reference. It is believed that these modified nucleic acids may show more stimulatory activity due to enhanced nuclease resistance, increased cellular uptake, increased protein binding, and/or altered intracellular localization.

The compositions of the invention may optionally be chimeric oligonucleotides. The chimeric oligonucleotides are oligonucleotides having a formula: 5' Y₁NZ_NY₂ 3', Y₁ and Y₂ are nucleic acid molecules having between 1 and 10 nucleotides. Y₁ and Y₂ each include at least one modified internucleotide linkage. Since at least 2 nucleotides of the chimeric oligonucleotides include backbone modifications these nucleic acids are an example of one type of "stabilized immunostimulatory nucleic acids."

With respect to the chimeric oligonucleotides, Y₁ and Y₂ are considered independent of one another. This means that each of Y₁ and Y₂ may or may not have different sequences and different backbone linkages from one another in the same molecule. The sequences vary, but in some cases Y₁ and Y₂ have a poly-G sequence. A poly-G sequence refers to at least 3 Gs in a row. In other embodiments the poly-G sequence refers to at least 4, 5, 6, 7, or 8 Gs in a row. In other embodiments Y₁ and Y₂ may be TCGTCG, TCGTCGT, or TCGTCGTT (SEQ ID NO:1145). Y₁ and Y₂ may also

have a poly-C, poly-T, or poly-A sequence. In some embodiments Y₁ and/or Y₂ have between 3 and 8 nucleotides.

N₁ and N₂ are nucleic acid molecules having between 0 and 5 nucleotides as long as N₁ZN₂ has at least 6 nucleotides in total. The nucleotides of N₁ZN₂ have a phosphodiester backbone and do not include nucleic acids having a modified backbone.

Z is an immunostimulatory nucleic acid motif but does not include a CG. For instance, Z may be a nucleic acid a T-rich sequence, e.g. including a TTTT motif or a sequence wherein at least 50% of the bases of the sequence are Ts or Z may be a TG sequence.

The center nucleotides (N₁ZN₂) of the formula Y₁N₁ZN₂Y₂ have phosphodiester internucleotide linkages and Y₁ and Y₂ have at least one, but may have more than one or even may have all modified internucleotide linkages. In preferred embodiments Y₁ and/or Y₂ have at least two or between two and five modified internucleotide linkages or Y₁ has two modified internucleotide linkages and Y₂ has five modified internucleotide linkages or Y₁ has five modified internucleotide linkages and Y₂ has two modified internucleotide linkages. The modified internucleotide linkages, in some embodiments is a phosphorothioate modified linkage, a phosphorodithioate modified linkage or a p-ethoxy modified linkage.

Modified backbones such as phosphorothioates may be synthesized using automated techniques employing either phosphoramidates or H-phosphonate chemistries. Aryl- and alkyl-phosphonates can be made, e.g., as described in U.S. Patent No. 4,469,863; and alkylphosphorothioates (in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents.

Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, R. and Peyman, A., *Chem. Rev.* 80:544, 1990; Goodchild, J., *Bioconjugate Chem.* 1:165, 1990).

Other stabilized nucleic acids include: ionomic DNA analogs, such as alkyl- and aryl-phosphates (in which the charged phosphonate oxygen is replaced by an alkyl or aryl group), phosphodiester and alkylphosphorothioates, in which the charged oxygen moiety is alkylated. Nucleic acids which contain diol, such as tetraethylammonium or

hexaethylammonium, at either or both termini have also been shown to be substantially resistant to nuclease degradation.

In the case when the Py-rich or TG nucleic acid is administered in conjunction with an antigen which is encoded in a nucleic acid vector, it is preferred that the backbone of the Py-rich or TG nucleic acid be a chimeric combination of phosphodiester and phosphorothioate (or other phosphate modification). The cell may have a problem taking up a plasmid vector in the presence of completely phosphorothioate nucleic acid. Thus when both a vector and a nucleic acid are delivered to a subject, it is preferred that the nucleic acid have a chimeric backbone or have a phosphorothioate backbone but that the plasmid be associated with a vehicle that delivers it directly into the cell, thus avoiding the need for cellular uptake. Such vehicles are known in the art and include, for example, liposomes and gene guns.

The nucleic acids described herein as well as various control nucleic acids are presented below in Table A.

15

Table A

SEQ ID NO:	DNB SEQUENCE	BACKBONE
1	ttctccagcgtgcgcac	a
2	ataatccagcttgacacag	a
3	ataatcgagcttcaagacag	a
4	taacgcgtgcgcacctct	a
5	gggttgaggt	a
6	gggttgaggt	a
7	gggttgaggt	a
8	ttcatggtgttctcgtact	a
9	ttcatggtgttctcgtact	a
10	ttcatggtgttctcgtact	a
11	ttcatggtgttctcgtact	a
12	gcttgaagttgttctgt	a
13	agcttcagttgttctgt	a
14	gcagcttcagcttcagctga	a
15	gcagcttcagcttcagctga	a
16	ttcatggtgttctcgtact	a
17	gttgcgttcaggttcagctgttg	a
18	gttgcgttcaggttcagctgttg	a
19	gttgcgttcaggttcagctgttg	a
20	acccatggaagagctgttccctc	a
21	acccatggaagagctgttccctc	a
22	acccatggaagagctgttccctc	a
23	acccatggaagagctgttccctc	a
24	acccatggaagagctgttccctc	a
25	ccacttcagctgtgttcacacag	a
26	actttctatgttcactttgttcacag	a

27	tcactgaggttcctgagtt	0
28	gaggaagtgagagagtt	0
29	gttaattctcttcgagtt	0
30	ataata	0
31	cccccc	0
32	ctctta	0
33	tcctag	0
34	tcctgg	0
35	tcctgg	0
36	tcactgaggttcctgagtt	0
37	tcactgaggttcctgagtt	0
38	tcactgaggttcctgagtt	0
39	tcactgaggttcctgagtt	0
40	tcactgaggttcctgagtt	0
41	tcactgaggttcctgagtt	0
42	tcactgaggttcctgagtt	0
43	tcactgaggttcctgagtt	0
44	tcactgaggttcctgagtt	0
45	tcactgaggttcctgagtt	0
46	tcactgaggttcctgagtt	0
47	tcactgaggttcctgagtt	0
48	tcactgaggttcctgagtt	0
49	tcactgaggttcctgagtt	0
50	tcactgaggttcctgagtt	0
51	tcactgaggttcctgagtt	0
52	tcactgaggttcctgagtt	0
53	tcactgaggttcctgagtt	0
54	tcactgaggttcctgagtt	0
55	tcactgaggttcctgagtt	0
56	tcactgaggttcctgagtt	0
57	tcactgaggttcctgagtt	0
58	tcactgaggttcctgagtt	0
59	tcactgaggttcctgagtt	0
60	tcactgaggttcctgagtt	0
61	tcactgaggttcctgagtt	0
62	tcactgaggttcctgagtt	0
63	tcactgaggttcctgagtt	0
64	tcactgaggttcctgagtt	0
65	tcactgaggttcctgagtt	0
66	tcactgaggttcctgagtt	0
67	tcactgaggttcctgagtt	0
68	tcactgaggttcctgagtt	0
69	tcactgaggttcctgagtt	0
70	tcactgaggttcctgagtt	0
71	tcactgaggttcctgagtt	0
72	tcactgaggttcctgagtt	0
73	tcactgaggttcctgagtt	0
74	tcactgaggttcctgagtt	0
75	tcactgaggttcctgagtt	0
76	tcactgaggttcctgagtt	0
77	tcactgaggttcctgagtt	0

78	tcactgaggttcctgagtt	0
79	tcactgaggttcctgagtt	0
80	tcactgaggttcctgagtt	0
81	tcactgaggttcctgagtt	0
82	tcactgaggttcctgagtt	0
83	tcactgaggttcctgagtt	0
84	tcactgaggttcctgagtt	0
85	tcactgaggttcctgagtt	0
86	tcactgaggttcctgagtt	0
87	tcactgaggttcctgagtt	0
88	tcactgaggttcctgagtt	0
89	tcactgaggttcctgagtt	0
90	tcactgaggttcctgagtt	0
91	tcactgaggttcctgagtt	0
92	tcactgaggttcctgagtt	0
93	tcactgaggttcctgagtt	0
94	tcactgaggttcctgagtt	0
95	tcactgaggttcctgagtt	0
96	tcactgaggttcctgagtt	0
97	tcactgaggttcctgagtt	0
98	tcactgaggttcctgagtt	0
99	tcactgaggttcctgagtt	0
100	tcactgaggttcctgagtt	0
101	tcactgaggttcctgagtt	0
102	tcactgaggttcctgagtt	0
103	tcactgaggttcctgagtt	0
104	tcactgaggttcctgagtt	0
105	tcactgaggttcctgagtt	0
106	tcactgaggttcctgagtt	0
107	tcactgaggttcctgagtt	0
108	tcactgaggttcctgagtt	0
109	tcactgaggttcctgagtt	0
110	tcactgaggttcctgagtt	0
111	tcactgaggttcctgagtt	0
112	tcactgaggttcctgagtt	0
113	tcactgaggttcctgagtt	0
114	tcactgaggttcctgagtt	0
115	tcactgaggttcctgagtt	0
116	tcactgaggttcctgagtt	0
117	tcactgaggttcctgagtt	0
118	tcactgaggttcctgagtt	0
119	tcactgaggttcctgagtt	0
120	tcactgaggttcctgagtt	0
121	tcactgaggttcctgagtt	0
122	tcactgaggttcctgagtt	0
123	tcactgaggttcctgagtt	0
124	tcactgaggttcctgagtt	0
125	tcactgaggttcctgagtt	0
126	tcactgaggttcctgagtt	0
127	tcactgaggttcctgagtt	0
128	tcactgaggttcctgagtt	0

[illegible]

180	tccttaagcttgaagt	0
181	tccttagagctgaagt	0
182	tccttagagcttgaagt	0
183	tccttagagcttgaagt	0
184	tccttagagcttgaagt	0
185	ggtctccgagagaggaattttgtctat	0
186	atcgagaaaattccctcccggagaa	0
187	tcctatgagcttctcttgaagct	ma
188	tcgtccggtctctccgcttctt	aa
189	tcgtccggtctctccgcttctt	gzo
190	tcgtccggtctctccgcttctt	0
191	tcgtccggtctctccgcttctt	0
192	tcgtccggtctctccgcttctt	0
193	tcgtccggtctctccgcttctt	0
194	tcgtccggtctctccgcttctt	0
195	tcgtccggtctctccgcttctt	0
196	tcgtccggtctctccgcttctt	0
197	tcgtccggtctctccgcttctt	0
198	ggtccggtctctccgcttctt	0
199	atccgagagctctccgcttctt	0
200	tccttaagcttccgcttctt	p-thioxy
201	tccttaagcttccgcttctt	p-thioxy
202	tccttaagcttccgcttctt	p-thioxy
203	tccttaagcttccgcttctt	p-thioxy
204	tccttaagcttccgcttctt	p-thioxy
205	tccttaagcttccgcttctt	p-thioxy
206	tccttaagcttccgcttctt	p-thioxy
207	tccttaagcttccgcttctt	p-thioxy
208	tccttaagcttccgcttctt	p-thioxy
209	tccttaagcttccgcttctt	p-thioxy
210	tccttaagcttccgcttctt	p-thioxy
211	tccttaagcttccgcttctt	p-thioxy
212	tccttaagcttccgcttctt	p-thioxy
213	tccttaagcttccgcttctt	p-thioxy
214	tccttaagcttccgcttctt	p-thioxy
215	tccttaagcttccgcttctt	p-thioxy
216	tccttaagcttccgcttctt	p-thioxy
217	tccttaagcttccgcttctt	p-thioxy
218	tccttaagcttccgcttctt	p-thioxy
219	tccttaagcttccgcttctt	p-thioxy
220	tccttaagcttccgcttctt	p-thioxy
221	tccttaagcttccgcttctt	p-thioxy
222	tccttaagcttccgcttctt	p-thioxy
223	tccttaagcttccgcttctt	p-thioxy
224	tccttaagcttccgcttctt	p-thioxy
225	tccttaagcttccgcttctt	p-thioxy
226	tccttaagcttccgcttctt	p-thioxy
227	tccttaagcttccgcttctt	p-thioxy
228	tccttaagcttccgcttctt	p-thioxy
229	tccttaagcttccgcttctt	p-thioxy
230	tccttaagcttccgcttctt	p-thioxy

231	tcaatgagcttactgctgtt	a
232	tcaatgagcttactgctgtt	a
233	tcaatgagcttactgctgtt	a
234	tcaatgagcttactgctgtt	a
235	tcaatgagcttactgctgtt	a
236	tcaatgagcttactgctgtt	a
237	tcaatgagcttactgctgtt	a
238	tcaatgagcttactgctgtt	a
239	tcaatgagcttactgctgtt	a
240	tcaatgagcttactgctgtt	a
241	tcaatgagcttactgctgtt	a
242	tcaatgagcttactgctgtt	a
243	tcaatgagcttactgctgtt	a
244	tcaatgagcttactgctgtt	a
245	tcaatgagcttactgctgtt	a
246	tcaatgagcttactgctgtt	a
247	tcaatgagcttactgctgtt	a
248	tcaatgagcttactgctgtt	a
249	tcaatgagcttactgctgtt	a
250	tcaatgagcttactgctgtt	a
251	tcaatgagcttactgctgtt	a
252	tcaatgagcttactgctgtt	a
253	tcaatgagcttactgctgtt	a
254	tcaatgagcttactgctgtt	a
255	tcaatgagcttactgctgtt	a
256	tcaatgagcttactgctgtt	a
257	tcaatgagcttactgctgtt	a
258	tcaatgagcttactgctgtt	a
259	tcaatgagcttactgctgtt	a
260	tcaatgagcttactgctgtt	a
261	tcaatgagcttactgctgtt	a
262	tcaatgagcttactgctgtt	a
263	tcaatgagcttactgctgtt	a
264	tcaatgagcttactgctgtt	a
265	tcaatgagcttactgctgtt	a
266	tcaatgagcttactgctgtt	a
267	tcaatgagcttactgctgtt	a
268	tcaatgagcttactgctgtt	a
269	tcaatgagcttactgctgtt	a
270	tcaatgagcttactgctgtt	a
271	tcaatgagcttactgctgtt	a
272	tcaatgagcttactgctgtt	a
273	tcaatgagcttactgctgtt	a
274	tcaatgagcttactgctgtt	a
275	tcaatgagcttactgctgtt	a
276	tcaatgagcttactgctgtt	a
277	tcaatgagcttactgctgtt	a
278	tcaatgagcttactgctgtt	a
279	tcaatgagcttactgctgtt	a
280	tcaatgagcttactgctgtt	a
281	tcaatgagcttactgctgtt	a

282	tcaatgagcttactgctgtt	a
283	tcaatgagcttactgctgtt	a
284	tcaatgagcttactgctgtt	a
285	tcaatgagcttactgctgtt	a
286	tcaatgagcttactgctgtt	a
287	tcaatgagcttactgctgtt	a
288	tcaatgagcttactgctgtt	a
289	tcaatgagcttactgctgtt	a
290	tcaatgagcttactgctgtt	a
291	tcaatgagcttactgctgtt	a
292	tcaatgagcttactgctgtt	a
293	tcaatgagcttactgctgtt	a
294	tcaatgagcttactgctgtt	a
295	tcaatgagcttactgctgtt	a
296	tcaatgagcttactgctgtt	a
297	tcaatgagcttactgctgtt	a
298	tcaatgagcttactgctgtt	a
299	tcaatgagcttactgctgtt	a
300	tcaatgagcttactgctgtt	a
301	tcaatgagcttactgctgtt	a
302	tcaatgagcttactgctgtt	a
303	tcaatgagcttactgctgtt	a
304	tcaatgagcttactgctgtt	a
305	tcaatgagcttactgctgtt	a
306	tcaatgagcttactgctgtt	a
307	tcaatgagcttactgctgtt	a
308	tcaatgagcttactgctgtt	a
309	tcaatgagcttactgctgtt	a
310	tcaatgagcttactgctgtt	a
311	tcaatgagcttactgctgtt	a
312	tcaatgagcttactgctgtt	a
313	tcaatgagcttactgctgtt	a
314	tcaatgagcttactgctgtt	a
315	tcaatgagcttactgctgtt	a
316	tcaatgagcttactgctgtt	a
317	tcaatgagcttactgctgtt	a
318	tcaatgagcttactgctgtt	a
319	tcaatgagcttactgctgtt	a
320	tcaatgagcttactgctgtt	a
321	tcaatgagcttactgctgtt	a
322	tcaatgagcttactgctgtt	a
323	tcaatgagcttactgctgtt	a
324	tcaatgagcttactgctgtt	a
325	tcaatgagcttactgctgtt	a
326	tcaatgagcttactgctgtt	a
327	tcaatgagcttactgctgtt	a
328	tcaatgagcttactgctgtt	a
329	tcaatgagcttactgctgtt	a
330	tcaatgagcttactgctgtt	a
331	tcaatgagcttactgctgtt	a
332	tcaatgagcttactgctgtt	a

333	gacgcagtcacagcgatccacgaagatctcgtt	0
334	gatccacgatctctgtagtgatccattcgatccgttt	0
335	tccgttcctcccccaccaccca	0
336	tactggtctcccccaccaccca	0
337	tactggtctcccccaccaccca	0
338	tccgttcctcccccaccaccca	0
339	tccgttcctcccccaccaccca	0
340	tccgttcctcccccaccaccca	0
341	tccgttcctcccccaccaccca	0
342	ggatctctcccccaccaccca	0
343	tccgttcctcccccaccaccca	0
344	tccgttcctcccccaccaccca	0
345	cagtccgttcctcccccaccaccca	0
346	ggatccgttcctcccccaccaccca	0
347	tccgttcctcccccaccaccca	0
348	aggcttcctcccccaccaccca	0
349	cctgcatctcccccaccaccca	0
350	btatttcgttcgttcctcccccaccaccca	08
351	tccgttcctcccccaccaccca	0
352	tccgttcctcccccaccaccca	0
353	tccgttcctcccccaccaccca	0
354	tccgttcctcccccaccaccca	0
355	tccgttcctcccccaccaccca	0
356	tccgttcctcccccaccaccca	0
357	tccgttcctcccccaccaccca	0
358	tccgttcctcccccaccaccca	0
359	gggttcacagcttcgagtgaggg	808
360	tccgttcctcccccaccaccca	0
361	tccgttcctcccccaccaccca	0
362	tccgttcctcccccaccaccca	0
363	tccgttcctcccccaccaccca	0
364	tccgttcctcccccaccaccca	0
365	tccgttcctcccccaccaccca	0
366	tccgttcctcccccaccaccca	0
367	tccgttcctcccccaccaccca	0
368	tccgttcctcccccaccaccca	0
369	tccgttcctcccccaccaccca	0
370	tccgttcctcccccaccaccca	0
371	tccgttcctcccccaccaccca	0
372	tccgttcctcccccaccaccca	0
373	tccgttcctcccccaccaccca	0
374	tccgttcctcccccaccaccca	0
375	tccgttcctcccccaccaccca	0
376	tccgttcctcccccaccaccca	0
377	tccgttcctcccccaccaccca	0
378	tccgttcctcccccaccaccca	0
379	tccgttcctcccccaccaccca	0
380	tccgttcctcccccaccaccca	0
381	tccgttcctcccccaccaccca	0
382	tccgttcctcccccaccaccca	0
383	tccgttcctcccccaccaccca	0

[illegible]

537	gategtgcataatgctcg	808
538	gtcgtccatgctgttcc	808
539	tccgtccatgctgttcc	808
540	ctgacatccatgctgtcg	808
541	gtcgtccatgctgttcc	808
542	ctgacatccatgctgtcg	808
543	ctgacatccatgctgtcg	808
544	gtcgtccatgctgttcc	808
545	gtcgtccatgctgttcc	808
546	gtcgtccatgctgttcc	808
547	gtcgtccatgctgttcc	808
548	gtcgtccatgctgttcc	808
549	gtcgtccatgctgttcc	808
550	gtcgtccatgctgttcc	808
551	gtcgtccatgctgttcc	808
552	gtcgtccatgctgttcc	808
553	gtcgtccatgctgttcc	808
554	gtcgtccatgctgttcc	808
555	gtcgtccatgctgttcc	808
556	gtcgtccatgctgttcc	808
557	gtcgtccatgctgttcc	808
558	gtcgtccatgctgttcc	808
559	gtcgtccatgctgttcc	808
560	gtcgtccatgctgttcc	808
561	gtcgtccatgctgttcc	808
562	gtcgtccatgctgttcc	808
563	gtcgtccatgctgttcc	808
564	gtcgtccatgctgttcc	808
565	gtcgtccatgctgttcc	808
566	gtcgtccatgctgttcc	808
567	gtcgtccatgctgttcc	808
568	gtcgtccatgctgttcc	808
569	gtcgtccatgctgttcc	808
570	gtcgtccatgctgttcc	808
571	gtcgtccatgctgttcc	808
572	gtcgtccatgctgttcc	808
573	gtcgtccatgctgttcc	808
574	gtcgtccatgctgttcc	808
575	gtcgtccatgctgttcc	808
576	gtcgtccatgctgttcc	808
577	gtcgtccatgctgttcc	808
578	gtcgtccatgctgttcc	808
579	gtcgtccatgctgttcc	808
580	gtcgtccatgctgttcc	808
581	gtcgtccatgctgttcc	808
582	gtcgtccatgctgttcc	808
583	gtcgtccatgctgttcc	808
584	gtcgtccatgctgttcc	808
585	gtcgtccatgctgttcc	808
586	gtcgtccatgctgttcc	808
587	gtcgtccatgctgttcc	808

588	gtcgtccatgctgttcc	808
589	gtcgtccatgctgttcc	808
590	gtcgtccatgctgttcc	808
591	gtcgtccatgctgttcc	808
592	gtcgtccatgctgttcc	808
593	gtcgtccatgctgttcc	808
594	gtcgtccatgctgttcc	808
595	gtcgtccatgctgttcc	808
596	gtcgtccatgctgttcc	808
597	gtcgtccatgctgttcc	808
598	gtcgtccatgctgttcc	808
599	gtcgtccatgctgttcc	808
600	gtcgtccatgctgttcc	808
601	gtcgtccatgctgttcc	808
602	gtcgtccatgctgttcc	808
603	gtcgtccatgctgttcc	808
604	gtcgtccatgctgttcc	808
605	gtcgtccatgctgttcc	808
606	gtcgtccatgctgttcc	808
607	gtcgtccatgctgttcc	808
608	gtcgtccatgctgttcc	808
609	gtcgtccatgctgttcc	808
610	gtcgtccatgctgttcc	808
611	gtcgtccatgctgttcc	808
612	gtcgtccatgctgttcc	808
613	gtcgtccatgctgttcc	808
614	gtcgtccatgctgttcc	808
615	gtcgtccatgctgttcc	808
616	gtcgtccatgctgttcc	808
617	gtcgtccatgctgttcc	808
618	gtcgtccatgctgttcc	808
619	gtcgtccatgctgttcc	808
620	gtcgtccatgctgttcc	808
621	gtcgtccatgctgttcc	808
622	gtcgtccatgctgttcc	808
623	gtcgtccatgctgttcc	808
624	gtcgtccatgctgttcc	808
625	gtcgtccatgctgttcc	808
626	gtcgtccatgctgttcc	808
627	gtcgtccatgctgttcc	808
628	gtcgtccatgctgttcc	808
629	gtcgtccatgctgttcc	808
630	gtcgtccatgctgttcc	808
631	gtcgtccatgctgttcc	808
632	gtcgtccatgctgttcc	808
633	gtcgtccatgctgttcc	808
634	gtcgtccatgctgttcc	808
635	gtcgtccatgctgttcc	808
636	gtcgtccatgctgttcc	808
637	gtcgtccatgctgttcc	808
638	gtcgtccatgctgttcc	808

639	taacggt		0
640	taacggt		0
641	taacggt		0
642	taacggt		0
643	taacggt		0
644	taacggt		0
645	taacggt		0
646	taacggt		0
647	taacggt		0
648	taacggt		0
649	taacggt		0
650	taacggt		0
651	taacggt		0
652	taacggt		0
653	taacggt		0
654	taacggt		0
655	taacggt		0
656	taacggt		0
657	taacggt		0
658	taacggt		0
659	taacggt		0
660	taacggt		0
661	taacggt		0
662	taacggt		0
663	taacggt		0
664	taacggt		0
665	taacggt		0
666	taacggt		0
667	taacggt		0
668	taacggt		0
669	taacggt		0
670	taacggt		0
671	taacggt		0
672	taacggt		0
673	taacggt		0
674	taacggt		0
675	taacggt		0
676	taacggt		0
677	taacggt		0
678	taacggt		0
679	taacggt		0
680	taacggt		0
681	taacggt		0
682	taacggt		0
683	taacggt		0
684	taacggt		0
685	taacggt		0
686	taacggt		0
687	taacggt		0
688	taacggt		0
689	taacggt		0

690	taacggt		0
691	taacggt		0
692	taacggt		0
693	taacggt		0
694	taacggt		0
695	taacggt		0
696	taacggt		0
697	taacggt		0
698	taacggt		0
699	taacggt		0
700	taacggt		0
701	taacggt		0
702	taacggt		0
703	taacggt		0
704	taacggt		0
705	taacggt		0
706	taacggt		0
707	taacggt		0
708	taacggt		0
709	taacggt		0
710	taacggt		0
711	taacggt		0
712	taacggt		0
713	taacggt		0
714	taacggt		0
715	taacggt		0
716	taacggt		0
717	taacggt		0
718	taacggt		0
719	taacggt		0
720	taacggt		0
721	taacggt		0
722	taacggt		0
723	taacggt		0
724	taacggt		0
725	taacggt		0
726	taacggt		0
727	taacggt		0
728	taacggt		0
729	taacggt		0
730	taacggt		0
731	taacggt		0
732	taacggt		0
733	taacggt		0
734	taacggt		0
735	taacggt		0
736	taacggt		0
737	taacggt		0
738	taacggt		0
739	taacggt		0
740	taacggt		0

741	atcgactccagatggtcttc	0
742	aaagtcagactccgat	0
743	ctcaagctggaactccat	0
744	atcgactccaggtcttc	0
745	gaagatgctggaactccat	0
746	tcagactccagactccat	0
747	baagaaagctccagactccat	0
748	baagaaagctggaactccat	0
749	agctgaggtttagctga	0
750	gctgaggtttagctga	0
751	atggaagctccagcttc	0
752	gctgaggtttagctga	0
753	gctgaggtttagctga	0
754	tcacatgagctccagactccat	0
755	tcacatgagctccagactccat	0
756	gctgaggtttagctga	0
757	gctgaggtttagctga	0
758	tcacatgagctccagactccat	0
759	tcacatgagctccagactccat	0
760	gctgaggtttagctga	0
761	gctgaggtttagctga	0
762	tcacatgagctccagactccat	0
763	tcacatgagctccagactccat	0
764	atggaagctccagcttc	0
765	atggaagctccagcttc	0
766	gctgaggtttagctga	0
767	gctgaggtttagctga	0
768	gctgaggtttagctga	0
769	gctgaggtttagctga	0
770	gctgaggtttagctga	0
771	gctgaggtttagctga	0
772	gctgaggtttagctga	0
773	gctgaggtttagctga	0
774	gctgaggtttagctga	0
775	gctgaggtttagctga	0
776	gctgaggtttagctga	0
777	gctgaggtttagctga	0
778	gctgaggtttagctga	0
779	gctgaggtttagctga	0
780	gctgaggtttagctga	0
781	gctgaggtttagctga	0
782	gctgaggtttagctga	0
783	gctgaggtttagctga	0
784	gctgaggtttagctga	0
785	gctgaggtttagctga	0
786	gctgaggtttagctga	0
787	gctgaggtttagctga	0
788	gctgaggtttagctga	0
789	gctgaggtttagctga	0
790	gctgaggtttagctga	0
791	gctgaggtttagctga	0

792	ccatgaggtttagctga	0
793	gctgaggtttagctga	0
794	gctgaggtttagctga	0
795	gctgaggtttagctga	0
796	gctgaggtttagctga	0
797	gctgaggtttagctga	0
798	gctgaggtttagctga	0
799	gctgaggtttagctga	0
800	gctgaggtttagctga	0
801	gctgaggtttagctga	0
802	gctgaggtttagctga	0
803	gctgaggtttagctga	0
804	gctgaggtttagctga	0
805	gctgaggtttagctga	0
806	gctgaggtttagctga	0
807	gctgaggtttagctga	0
808	gctgaggtttagctga	0
809	gctgaggtttagctga	0
810	gctgaggtttagctga	0
811	gctgaggtttagctga	0
812	gctgaggtttagctga	0
813	gctgaggtttagctga	0
814	gctgaggtttagctga	0
815	gctgaggtttagctga	0
816	gctgaggtttagctga	0
817	gctgaggtttagctga	0
818	gctgaggtttagctga	0
819	gctgaggtttagctga	0
820	gctgaggtttagctga	0
821	gctgaggtttagctga	0
822	gctgaggtttagctga	0
823	gctgaggtttagctga	0
824	gctgaggtttagctga	0
825	gctgaggtttagctga	0
826	gctgaggtttagctga	0
827	gctgaggtttagctga	0
828	gctgaggtttagctga	0
829	gctgaggtttagctga	0
830	gctgaggtttagctga	0
831	gctgaggtttagctga	0
832	gctgaggtttagctga	0
833	gctgaggtttagctga	0
834	gctgaggtttagctga	0
835	gctgaggtttagctga	0
836	gctgaggtttagctga	0
837	gctgaggtttagctga	0
838	gctgaggtttagctga	0
839	gctgaggtttagctga	0
840	gctgaggtttagctga	0
841	gctgaggtttagctga	0
842	gctgaggtttagctga	0

843	caagttgagcttgaag	o
844	caagcaagctggtcaggttctga	o
845	caagcaagctggtcaggttctga	o
846	caagcaagcttctga	o
847	caagcaagcttctga	o
848	caagcaagcttctga	o
849	caagcaagcttctga	o
850	caagcaagcttctga	o
851	caagcaagcttctga	o
852	caagcaagcttctga	o
853	caagcaagcttctga	o
854	caagcaagcttctga	o
855	caagcaagcttctga	o
856	caagcaagcttctga	o
857	caagcaagcttctga	o
858	caagcaagcttctga	o
859	caagcaagcttctga	o
860	caagcaagcttctga	o
861	caagcaagcttctga	o
862	caagcaagcttctga	o
863	caagcaagcttctga	o
864	caagcaagcttctga	o
865	caagcaagcttctga	o
866	caagcaagcttctga	o
867	caagcaagcttctga	o
868	caagcaagcttctga	o
869	caagcaagcttctga	o
870	caagcaagcttctga	o
871	caagcaagcttctga	o
872	caagcaagcttctga	o
873	caagcaagcttctga	o
874	caagcaagcttctga	o
875	caagcaagcttctga	o
876	caagcaagcttctga	o
877	caagcaagcttctga	o
878	caagcaagcttctga	o
879	caagcaagcttctga	o
880	caagcaagcttctga	o
881	caagcaagcttctga	o
882	caagcaagcttctga	o
883	caagcaagcttctga	o
884	caagcaagcttctga	o
885	caagcaagcttctga	o
886	caagcaagcttctga	o
887	caagcaagcttctga	o
888	caagcaagcttctga	o
889	caagcaagcttctga	o
890	caagcaagcttctga	o
891	caagcaagcttctga	o
892	caagcaagcttctga	o
893	caagcaagcttctga	o

894	caagcaagcttctga	o
895	caagcaagcttctga	o
896	caagcaagcttctga	o
897	caagcaagcttctga	o
898	caagcaagcttctga	o
899	caagcaagcttctga	o
900	caagcaagcttctga	o
901	caagcaagcttctga	o
902	caagcaagcttctga	o
903	caagcaagcttctga	o
904	caagcaagcttctga	o
905	caagcaagcttctga	o
906	caagcaagcttctga	o
907	caagcaagcttctga	o
908	caagcaagcttctga	o
909	caagcaagcttctga	o
910	caagcaagcttctga	o
911	caagcaagcttctga	o
912	caagcaagcttctga	o
913	caagcaagcttctga	o
914	caagcaagcttctga	o
915	caagcaagcttctga	o
916	caagcaagcttctga	o
917	caagcaagcttctga	o
918	caagcaagcttctga	o
919	caagcaagcttctga	o
920	caagcaagcttctga	o
921	caagcaagcttctga	o
922	caagcaagcttctga	o
923	caagcaagcttctga	o
924	caagcaagcttctga	o
925	caagcaagcttctga	o
926	caagcaagcttctga	o
927	caagcaagcttctga	o
928	caagcaagcttctga	o
929	caagcaagcttctga	o
930	caagcaagcttctga	o
931	caagcaagcttctga	o
932	caagcaagcttctga	o
933	caagcaagcttctga	o
934	caagcaagcttctga	o
935	caagcaagcttctga	o
936	caagcaagcttctga	o
937	caagcaagcttctga	o
938	caagcaagcttctga	o
939	caagcaagcttctga	o
940	caagcaagcttctga	o
941	caagcaagcttctga	o
942	caagcaagcttctga	o
943	caagcaagcttctga	o
944	caagcaagcttctga	o

945	ltghgtltltltghgtltltltltltltltltgt	8
946	lttccatttccatttccatttccatttccatttcc	8
947	ggggccatcgttccggggggg	8
948	tcattggagttccattccattccattccattcc	808
949	tcattggagttccattccattccattccattcc	
950	tcattggagttccattccattccattccattcc	
951	tcattggagttccattccattccattccattcc	
952	tcattggagttccattccattccattccattcc	
953	tcattggagttccattccattccattccattcc	
954	tcattggagttccattccattccattccattcc	
955	tcattggagttccattccattccattccattcc	
956	tcattggagttccattccattccattccattcc	
957	tcattggagttccattccattccattccattcc	
958	tcattggagttccattccattccattccattcc	
959	ggggggagagtcgtccggggggg	808
960	ggggggagagtcgtccggggggg	808
961	tttttttttttttttttttttttttttttttt	808
962	aaaaaaaaaaaaaaaaaaaaaaaaaaaaaa	po
963	cccccccccccccccccccccccccccc	po
964	tcgttcgttttgcgttttgcgttttgcgttt	po
965	tcgttcgttttgcgttttgcgttttgcgttt	
966	tcgttcgttttgcgttttgcgttttgcgttt	
967	tcgttcgttttgcgttttgcgttttgcgttt	
968	gggggtccagcttcgtggggggg	
969	gggggtccagcttcgtggggggg	
970	gggggtccagcttcgtggggggg	
971	tcgttcgtttccgttcgttcgttcgttcgttc	
972	gggggtccagcttcgtggggggg	808
973	gggggtccagcttcgtggggggg	808
974	gggggtccagcttcgtggggggg	808
975	gggggtccagcttcgtggggggg	808
976	gggggtccagcttcgtggggggg	808
977	gggggtccagcttcgtggggggg	808
978	gggggtccagcttcgtggggggg	808
979	gggggtccagcttcgtggggggg	808
980	gggggtccagcttcgtggggggg	808
981	gggggtccagcttcgtggggggg	808
982	tcatttcgttcgttcgttcgttcgttcgttc	8
983	tcatttcgttcgttcgttcgttcgttcgttc	8
984	tcatttcgttcgttcgttcgttcgttcgttc	8
985	tcatttcgttcgttcgttcgttcgttcgttc	8
986	gggggtccagcttcgtggggggg	808
987	gggggtccagcttcgtggggggg	808
988	gggggtccagcttcgtggggggg	808
989	gggggtccagcttcgtggggggg	808
990	gggggtccagcttcgtggggggg	808
991	gggggtccagcttcgtggggggg	808
992	tcatttcgttcgttcgttcgttcgttcgttc	808
993	tcatttcgttcgttcgttcgttcgttcgttc	808
994	tcatttcgttcgttcgttcgttcgttcgttc	8

995	995g9gaacgacatctcggggggg	808
996	gggggaacgacatctcggggggg	808
997	ggg ggg aag atc ggc ggg ggg	808
998	ggg ggg gga cga tgg tgg ggg ggg	808
999	aaa gaa ggt aaa	po
1000	aaagagctttaa	po
1001	aaagagctttaa	po
1002	aaattcgaaaa	po
1003	gggggctatcgatgaagggggg	808
1004	ggggggcagaatcgaaggggggg	808
1005	atgagctcttaataaagc	po
1006	ggatcccttgagttactct	po
1007	ccattccatctctgattcc	po
1008	tatgttatctatgttgagta	po
1009	agacctacgttatctaacccac	po
1010	tctactcgaaactctatctgta	po
1011	atagagggcctcaaacaggt	po
1012	ctaaacacgttctatggagagt	po
1013	ctaaacacgactaaagctcggg	po
1014	ctctagatttgatctggttag	po
1015	tctaaagctcgtccagctgag	po
1016	catgttcgaacagagagctta	po
1017	tgggtggttgggggaagagctc	po
1018	ggactcctccacccacacaa	po
1019	ggacttcgactctcgttgggga	po
1020	tgagatctctcttgcgcgtct	po
1021	atgcgtctatgcacggcaaaa	po
1022	accggaatcagcggaagagga	po
1023	tccatctacgttccgcgcgtct	po
1024	ggggaataaccatggagctatcgtg	po
1025	aacacagagacagagggcaaa	po
1026	ggagcgtgaacgtccggagaaa	po
1027	tcgggttaacatctggagcgagtt	po
1028	ctggagctccatccaaagagat	po
1029	ggcactccatcaccacagagat	po
1030	ccgaagagaggaagacagagctt	po
1031	ctgtgtctatctgaatacaaaa	po
1032	aattagactcagtgagatttggt	po
1033	aaatcgtctctactctaaagg	po
1034	ataagctaatctttgggacatc	po
1035	cccatctcaataagagctaat	po
1036	gggtgtcgtccagacggggggg	808
1037	gggtgttcctgaagagggggggg	808
1038	gggggaacgttcgaagagggggggg	808
1039	tctctggcgggggaagct	8
1040	gggggaacgagcgtcgtttgggggg	808
1041	gggggaacgagcgtcgtttgggggg	808
1042	gggggaacgagcgtcgtttgggggg	808
1043	gggggaacgagcgtcgtttgggggg	808

1044	ggagtcagacgtacgtcagggggg	808
1045	ggagtcagacgtacgtcagggggg	809
1046	ggagtcagacgtacgtcagggggg	810
1047	ggagtcagacgtacgtcagggggg	811
1048	ggagtcagacgtacgtcagggggg	812
1049	ggagtcagacgtacgtcagggggg	813
1050	ggagtcagacgtacgtcagggggg	814
1051	ggagtcagacgtacgtcagggggg	815
1052	ggagtcagacgtacgtcagggggg	816
1053	ggagtcagacgtacgtcagggggg	817
1054	ggagtcagacgtacgtcagggggg	818
1055	ggagtcagacgtacgtcagggggg	819
1056	ggagtcagacgtacgtcagggggg	820
1057	ggagtcagacgtacgtcagggggg	821
1058	ggagtcagacgtacgtcagggggg	822
1059	ggagtcagacgtacgtcagggggg	823
1060	ggagtcagacgtacgtcagggggg	824
1061	ggagtcagacgtacgtcagggggg	825
1062	ggagtcagacgtacgtcagggggg	826
1063	ggagtcagacgtacgtcagggggg	827
1064	ggagtcagacgtacgtcagggggg	828
1065	ggagtcagacgtacgtcagggggg	829
1066	ggagtcagacgtacgtcagggggg	830
1067	ggagtcagacgtacgtcagggggg	831
1068	ggagtcagacgtacgtcagggggg	832
1069	ggagtcagacgtacgtcagggggg	833
1070	ggagtcagacgtacgtcagggggg	834
1071	ggagtcagacgtacgtcagggggg	835
1072	ggagtcagacgtacgtcagggggg	836
1073	ggagtcagacgtacgtcagggggg	837
1074	ggagtcagacgtacgtcagggggg	838
1075	ggagtcagacgtacgtcagggggg	839
1076	ggagtcagacgtacgtcagggggg	840
1077	ggagtcagacgtacgtcagggggg	841
1078	ggagtcagacgtacgtcagggggg	842
1079	ggagtcagacgtacgtcagggggg	843
1080	ggagtcagacgtacgtcagggggg	844
1081	ggagtcagacgtacgtcagggggg	845
1082	ggagtcagacgtacgtcagggggg	846
1083	ggagtcagacgtacgtcagggggg	847
1084	ggagtcagacgtacgtcagggggg	848
1085	ggagtcagacgtacgtcagggggg	849
1086	ggagtcagacgtacgtcagggggg	850
1087	ggagtcagacgtacgtcagggggg	851
1088	ggagtcagacgtacgtcagggggg	852
1089	ggagtcagacgtacgtcagggggg	853
1090	ggagtcagacgtacgtcagggggg	854
1091	ggagtcagacgtacgtcagggggg	855
1092	ggagtcagacgtacgtcagggggg	856

1093	ggagtcagacgtacgtcagggggg	858
1094	ggagtcagacgtacgtcagggggg	859
1095	ggagtcagacgtacgtcagggggg	860
1096	ggagtcagacgtacgtcagggggg	861
1097	ggagtcagacgtacgtcagggggg	862

While CpG effects in mice are well characterized, information regarding the human system is limited. CpG phosphorothioate oligonucleotides with strong stimulatory activity in the mouse system show lower activity on human and other non-rodent immune cells. In the examples the development of a potent human CpG motif and the characterization of its effects and mechanisms of action on human primary B-cells is described. DNA containing this CpG motif strongly stimulated primary human B-cells to proliferate, to produce IL-6 and to express increased levels of CD86, CD40, CD34 and MHC II. It increased DNA binding activity of the transcription factors NFkB and AP-1, as well as phosphorylation of the stress activated protein kinases JNK and p38, and the transcription factor ATF-2. B-cell signalling pathways activated by CpG DNA were different from those activated by the B-cell receptor which activated ERK and a different isoform of JNK, but did not activate p38 and ATF-2. In general the data on CpG DNA-initiated signal transduction are consistent with those obtained in mice (Hoeker H, et al. 1998. *Embo J* 17:6230, Yi A. K., and Kleeg A. M. 1998. *J Immunol* 161:4493).

The preferred non-rodent motif is 5' TCGTCGTT 3'. Base exchanges within the most potent flanking CpG motif (5' TCGTCGTT 3') diminished the activity of the oligonucleotide. The thymidines at the 5' and the 3' position of this motif were more important than the thymidine at the middle position. An adenine or guanosine at the middle position produced a decrease in the activity.

Of note, our studies demonstrate that one human CpG motif within a phosphorothioate oligonucleotide (2080) is sufficient to produce the maximal effect, and that additional CpG motifs (2059) did not further enhance the activity. The oligonucleotide with the 8mer motif 5' TCG TCG TT 3' (2080) containing two CpG dinucleotides showed the highest activity in the studies. Replacement of the bases flanking the two CpG dinucleotides (5' position, middle position, 3' position) reduced the activity of this sequence. Both CpG dinucleotides within the 8mer CpG motif were required for the optimal activity (2108, 2106). Cytidine methylation of the CpG dinucleotides (2095) abolished the activity of 2080, while methylation of an unrelated

cytidine (2094) did not. The addition of two CpG motifs into the sequence of 2080 resulting in 2039 did not further increase the activity of the phosphodiester oligonucleotide. The sequence of 2080 with a phosphorothioate backbone (2116) demonstrated less activity, suggesting that additional CpG motifs are preferred for a potent phosphorothioate oligonucleotide.

It has been discovered according to the invention that the immunostimulatory nucleic acids have dramatic immune stimulatory effects on human cells such as NK cells, B cells, and DCs *in vitro*. It has been demonstrated that the *in vitro* assays used herein predict *in vivo* effectiveness as a vaccine adjuvant in non-rodent vertebrates (Example 13), suggesting that immunostimulatory nucleic acids are effective therapeutic agents for human vaccination, cancer immunotherapy, asthma immunotherapy, general enhancement of immune function, enhancement of hematopoietic recovery following radiation or chemotherapy, and other immune modulatory applications.

Thus the immunostimulatory nucleic acids are useful in some aspects of the invention as a prophylactic vaccine for the treatment of a subject at risk of developing an infection with an infectious organism or a cancer in which a specific cancer antigen has been identified or an allergy or asthma where the allergen or predisposition to asthma is known. The immunostimulatory nucleic acids can also be given without the antigen or allergen for shorter term protection against infection, allergy or cancer, and in this case repeated doses will allow longer term protection. A subject at risk as used herein is a subject who has any risk of exposure to an infection causing pathogen or a cancer or an allergen or a risk of developing cancer. For instance, a subject at risk may be a subject who is planning to travel to an area where a particular type of infectious agent is found or it may be a subject who through lifestyle or medical procedures is exposed to bodily fluids which may contain infectious organisms or directly to the organism or even any subject living in an area where an infectious organism or an allergen has been identified. Subjects at risk of developing infection also include general populations to which a medical agency recommends vaccination with a particular infectious organism antigen. If the antigen is an allergen and the subject develops allergic responses to that particular antigen and the subject may be exposed to the antigen, i.e., during pollen season, then that subject is at risk of exposure to the antigen. A subject at risk of developing an allergy to asthma includes those subjects that have been identified as having an allergy or

asthma but that don't have the active disease during the immunostimulatory nucleic acid treatment as well as subjects that are considered to be at risk of developing these diseases because of genetic or environmental factors.

A subject at risk of developing a cancer is one who is who has a high probability of developing cancer. These subjects include, for instance, subjects having a genetic abnormality, the presence of which has been demonstrated to have a correlative relation to a higher likelihood of developing a cancer and subjects exposed to cancer causing agents such as tobacco, asbestos, or other chemical toxins, or a subject who has previously been treated for cancer and is in apparent remission. When a subject at risk of developing a cancer is treated with an antigen specific for the type of cancer to which the subject is at risk of developing and a immunostimulatory nucleic acid, the subject may be able to kill the cancer cells as they develop. If a tumor begins to form in the subject, the subject will develop a specific immune response against the tumor antigen.

In addition to the use of the immunostimulatory nucleic acids for prophylactic treatment, the invention also encompasses the use of the immunostimulatory nucleic acids for the treatment of a subject having an infection, an allergy, asthma, or a cancer. A subject having an infection is a subject that has been exposed to an infectious pathogen and has acute or chronic detectable levels of the pathogen in the body. The immunostimulatory nucleic acids can be used with an antigen to mount an antigen specific systemic or mucosal immune response that is capable of reducing the level of or eradicating the infectious pathogen. An infectious disease, as used herein, is a disease arising from the presence of a foreign microorganism in the body. It is particularly important to develop effective vaccine strategies and treatments to protect the body's mucosal surfaces, which are the primary site of pathogenic entry.

A subject having an allergy is a subject that has or is at risk of developing an allergic reaction in response to an allergen. An allergy refers to acquired hypersensitivity to a substance (allergen). Allergic conditions include but are not limited to eczema, allergic rhinitis or hay fever, conjunctivitis, bronchial asthma, urticaria (hives) and food allergies, and other atopic conditions.

Currently, allergic diseases are generally treated by the injection of small doses of antigen followed by subsequent increasing dosage of antigen. It is believed that this procedure induces toleration to the allergen to prevent further allergic reactions. These

methods, however, can take several years to be effective and are associated with the risk of side effects such as anaphylactic shock. The methods of the invention avoid these problems.

Allergies are generally caused by IgE antibody generation against harmless allergens. The cytokines that are induced by systemic or mucosal administration of immunostimulatory nucleic acids are predominantly of a class called Th1 (examples are IL-12 and IFN- γ) and these induce both humoral and cellular immune responses. The types of antibodies associated with a Th1 response are generally more protective because they have high neutralization and opsonization capabilities. The other major type of immune response, which is associated with the production of IL-4, IL-5 and IL-10 cytokines, is termed a Th2 immune response. Th2 responses involve predominantly antibodies and these have less protective effect against infection and some Th2 isotypes (e.g., IgE) are associated with allergy. In general, it appears that allergic diseases are mediated by Th2 type immune responses while Th1 responses provide the best protection against infection, although excessive Th1 responses are associated with autoimmune disease. Based on the ability of the immunostimulatory nucleic acids to shift the immune response in a subject from a Th2 (which is associated with production of IgE antibodies and allergy) to a Th1 response (which is protective against allergic reactions), an effective dose for inducing an immune response of a immunostimulatory nucleic acid can be administered to a subject to treat or prevent an allergy.

Thus, the immunostimulatory nucleic acids have significant therapeutic utility in the treatment of allergic and non-allergic conditions such as asthma. Th2 cytokines, especially IL-4 and IL-5 are elevated in the airways of asthmatic subjects. These cytokines promote important aspects of the asthmatic inflammatory response, including IgE isotype switching, eosinophil chemotaxis and activation and mast cell growth. Th1 cytokines, especially IFN- γ and IL-12, can suppress the formation of Th2 clones and production of Th2 cytokines. Asthma refers to a disorder of the respiratory system characterized by inflammation, narrowing of the airways and increased reactivity of the airways to inhaled agents. Asthma is frequently, although not exclusively associated with atopic or allergic symptoms.

A subject having a cancer is a subject that has detectable cancerous cells. The cancer may be a malignant or non-malignant cancer. Cancers or tumors include but are

not limited to biliary tract cancer; brain cancer; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; intraepithelial neoplasias; lymphomas; liver cancer; lung cancer (e.g. small cell and non-small cell); melanoma; neuroblastomas; oral cancer; ovarian cancer; pancreas cancer; prostate cancer; rectal cancer; sarcomas; skin cancer; testicular cancer; thyroid cancer; renal cancer, as well as other carcinomas and sarcomas. In one embodiment the cancer is hairy cell leukemia, chronic myelogenous leukemia, cutaneous T-cell leukemia, multiple myeloma, follicular lymphoma, malignant melanoma, squamous cell carcinoma, renal cell carcinoma, prostate carcinoma, bladder cell carcinoma, or colon carcinoma.

A subject according to the invention is a non-rodent subject. A non-rodent subject shall mean a human or vertebrate animal including but not limited to a dog, cat, horse, cow, pig, sheep, goat, chicken, primate, e.g., monkey, and fish (aquaculture species), e.g. salmon, but specifically excluding rodents such as rats and mice.

Thus, the invention can also be used to treat cancer and tumors in non human subjects. Cancer is one of the leading causes of death in companion animals (i.e., cats and dogs). Cancer usually strikes older animals which, in the case of house pets, have become integrated into the family. Forty-five % of dogs older than 10 years of age, are likely to succumb to the disease. The most common treatment options include surgery, chemotherapy and radiation therapy. Other treatment modalities which have been used with some success are laser therapy, cryotherapy, hyperthermia and immunotherapy.

The choice of treatment depends on type of cancer and degree of dissemination. Unless the malignant growth is confined to a discrete area in the body, it is difficult to remove only malignant tissue without also affecting normal cells.

Malignant disorders commonly diagnosed in dogs and cats include but are not limited to lymphosarcoma, osteosarcoma, mammary tumors, mastocytoma, brain tumor, melanoma, adenocarcinoma carcinoma, carcinoid lung tumor, bronchial gland tumor, bronchiolar adenocarcinoma, fibrosarcoma, myxochondroma, pulmonary sarcoma, neurosarcoma, osteoma, papilloma, retinoblastoma, Ewing's sarcoma, Wilms' tumor, Burkitt's lymphoma, microglioma, neuroblastoma, osteoclastoma, oral neoplasia, fibrosarcoma, osteosarcoma and rhabdomyosarcoma. Other neoplasias in dogs include genital squamous cell carcinoma, transmissible venereal tumor, testicular tumor,

semiboma, Sertoli cell tumor, hemangioepithelioma, histiocytoma, ellipoma (granulocytic sarcoma), corneal papilloma, corneal squamous cell carcinoma, hemangiomasarcoma, pleural mesothelioma, basal cell tumor, thymoma, stomach tumor, adrenal gland carcinoma, oral papillomatosis, hemangioendothelioma and cystadenoma. Additional malignancies diagnosed in cats include follicular lymphoma, intestinal lymphosarcoma, fibrosarcoma and pulmonary squamous cell carcinoma. The ferret, an ever-more popular house pet is known to develop insulinoma, lymphoma, sarcoma, neurooma, pancreatic islet cell tumor, gastric MALT lymphoma and gastric adenocarcinoma.

Neoplasias affecting agricultural livestock include leukemias, hemangioepithelioma and bovine ocular neoplasia (in cattle); preputial fibrosarcoma, ulcerative squamous cell carcinoma, preputial carcinoma, connective tissue neoplasia and mastocytoma (in horses); hepatocellular carcinoma (in swine); lymphoma and pulmonary adenomatosis (in sheep); pulmonary sarcoma, lymphoma, Rous sarcoma, reticulendotheliosis, fibrosarcoma, osteoblastoma, B-cell lymphoma and lymphoid leukemia (in avian species); retinoblastoma, hepatic neoplasia, lymphosarcoma (lymphoblastic lymphoma), plasmacytoid leukemias and swimbladder sarcoma (in fish), caecum lymphadenitis (C.A.): diarrhea, infections, contagious disease of sheep and goats caused by the bacterium *Corynebacterium pseudotuberculosis*, and contagious lung tumor of sheep caused by *Jasgidiella*.

The subject is exposed to the antigen. As used herein, the term exposed to refers to either the active step of contacting the subject with an antigen or the passive exposure of the subject to the antigen *in vivo*. Methods for the active exposure of a subject to an antigen are well-known in the art. In general, an antigen is administered directly to the subject by any means such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal, or subcutaneous administration. The antigen can be administered systemically or locally. Methods for administering the antigen and the immunostimulatory nucleic acid are described in more detail below. A subject is passively exposed to an antigen if an antigen becomes available for exposure to the immune cells in the body. A subject may be passively exposed to an antigen, for instance, by entry of a foreign pathogen into the body or by the development of a tumor cell expressing a foreign antigen on its surface.

The methods in which a subject is passively exposed to an antigen can be particularly dependent on timing of administration of the immunostimulatory nucleic acid. For instance, in a subject at risk of developing a cancer or an infectious disease or an allergic or asthmatic response, the subject may be administered the immunostimulatory nucleic acid on a regular basis when that risk is greatest, i.e., during allergy season or after exposure to a cancer causing agent. Additionally the immunostimulatory nucleic acid may be administered to travelers before they travel to foreign lands where they are at risk of exposure to infectious agents. Likewise the immunostimulatory nucleic acid may be administered to soldiers or civilians at risk of exposure to bio warfare to induce a systemic or mucosal immune response to the antigen when and if the subject is exposed to it.

An antigen as used herein is a molecule capable of provoking an immune response. Antigens include but are not limited to cells, cell extracts, proteins, polypeptides, peptides, polysaccharides, polysaccharide conjugates, peptide and non-peptide mimics of polysaccharides and other molecules, small molecules, lipids, glycolipids, carbohydrates, viruses and viral extracts and multicellular organisms such as parasites and allergens. The term antigen broadly includes any type of molecule which is recognized by a host immune system as being foreign. Antigens include but are not limited to cancer antigens, microbial antigens, and allergens.

A cancer antigen as used herein is a compound, such as a peptide or protein, associated with a tumor or cancer cell surface and which is capable of provoking an immune response when expressed on the surface of an antigen presenting cell in the context of an MHC molecule. Cancer antigens can be prepared from cancer cells either by preparing crude extracts of cancer cells, for example, as described in Cohen, et al., 1994, *Cancer Research*, 54:1035, by partially purifying the antigens, by recombinant technology, or by *de novo* synthesis of known antigens. Cancer antigens include but are not limited to antigens that are recombinantly expressed, an immunogenic portion of, or a whole tumor or cancer. Such antigens can be isolated or prepared recombinantly or by any other means known in the art.

A microbial antigen as used herein is an antigen of a microorganism and includes but is not limited to virus, bacteria, parasites, and fungi. Such antigens include the intact microorganism as well as natural isolates and fragments or derivatives thereof and also

synthetic compounds which are identical to or similar to natural microorganism antigens and induce an immune response specific for that microorganism. A compound is similar to a natural microorganism antigen if it induces an immune response (humoral and/or cellular) to a natural microorganism antigen. Such antigens are used routinely in the art and are well known to those of ordinary skill in the art.

Examples of viruses that have been found in humans include but are not limited to: *Rotoviridae* (e.g. human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV-III/LAV, or HIV-III; and other isolates, such as HIV-LP; *Picornaviridae* (e.g. polio viruses, hepatitis A virus; enteroviruses, human Coxsackie viruses, rhinoviruses, echoviruses); *Calchiviridae* (e.g. strains that cause gastroenteritis); *Togaviridae* (e.g. equine encephalitis viruses, rubella viruses); *Flaviviridae* (e.g. dengue viruses, encephalitis viruses, yellow fever viruses); *Coronaviridae* (e.g. coronavirus); *Rhabdoviridae* (e.g. vesicular stomatitis viruses, rabies viruses); *Coronaviridae* (e.g. coronavirus); *Rhabdoviridae* (e.g. vesicular stomatitis viruses, rabies viruses); *Rotoviridae* (e.g. rotaviruses); *Flaviviridae* (e.g. ebola viruses); *Paramyxoviridae* (e.g. parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus); *Orthomyxoviridae* (e.g. influenza viruses); *Bunyaviridae* (e.g. Hantaan viruses, bunya viruses, phleboviruses and Nairo viruses); *Arna viridae* (hemorrhagic fever viruses); *Reoviridae* (e.g. reoviruses, orbiviruses and rotaviruses); *Birnaviridae*; *Hepadnaviridae* (Hepatitis B virus); *Parvoviridae* (parvoviruses); *Papovaviridae* (papilloma viruses, polyoma viruses); *Adenoviridae* (most adenoviruses); *Herpesviridae* (herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV), herpes virus; *Parriviridae* (varicella viruses, vaccinia viruses, pox viruses); and *Iridoviridae* (e.g. African swine fever virus); and unclassified viruses (e.g. the etiological agents of Spongiform encephalopathies, the agent of delta hepatitis (thought to be a defective satellite of hepatitis B virus), the agents of non-A, non-B hepatitis (class 1 = internally transmitted; class 2 = parenterally transmitted (i.e. Hepatitis C); Norwalk and related viruses, and astroviruses).

Both gram negative and gram positive bacteria serve as antigens in vertebrate animals. Such gram positive bacteria include, but are not limited to, *Pasteurella* species, *Staphylococci* species, and *Streptococcus* species. Gram negative bacteria include, but are not limited to, *Escherichia coli*, *Pseudomonas* species, and *Salmonella* species. Specific examples of infectious bacteria include but are not limited to, *Helicobacter*

plyoritis, *Borella burgdorferi*, *Legionella pneumophila*, *Mycobacterium* spp (e.g. *M. tuberculosis*, *M. avium*, *M. intracellulare*, *M. kansasii*, *M. goodii*), *Staphylococcus aureus*, *Neisseria gonorrhoea*, *Neisseria meningitidis*, *Listeria monocytogenes*, *Streptococcus pyogenes* (Group A Streptococcus), *Streptococcus agalactiae* (Group B Streptococcus), *Streptococcus* (viridans group), *Streptococcus faecalis*, *Streptococcus bovis*, *Streptococcus* (anaerobic spp.), *Streptococcus pneumoniae*, pathogenic *Campylobacter* spp., *Enterococcus* spp., *Haemophilus influenzae*, *Bacillus anthracis*, *Corynebacterium diphtheriae*, *Corynebacterium* spp., *Cryptosporidium parvum*, *Clostridium perfringens*, *Clostridium tetani*, *Enterobacter aerogenes*, *Klebsiella pneumoniae*, *Pasteurella multocida*, *Bacteroides* spp., *Fusobacterium nucleatum*, *Streptobacillus moniliformis*, *Treponema pallidum*, *Treponema pertenax*, *Leptospira*, *Rickettsia*, and *Actinomyces israelii*.

Examples of fungi include *Cryptococcus neoformans*, *Histoplasma capsulatum*, *Coccidioides immitis*, *Blastomycosis dermatitidis*, *Chlamydia trachomatis*, *Candida albicans*.

Other infectious organisms (i.e., protists) include *Plasmodium* spp. such as *Plasmodium falciparum*, *Plasmodium malariae*, *Plasmodium ovale*, and *Plasmodium vivax* and *Toxoplasma gondii*. Blood-borne and/or tissue parasites include *Plasmodium* spp., *Babesia microti*, *Babesia divergens*, *Leishmania tropica*, *Leishmania* spp., *Leishmania braziliensis*, *Leishmania donovani*, *Trypanosoma gambiense* and *Trypanosoma rhodesiense* (African sleeping sickness), *Trypanosoma cruzi* (Chagas' disease), and *Toxoplasma gondii*.

Other medically relevant microorganisms have been described extensively in the literature, e.g., see C.G.A. Thomas, *Medical Microbiology*, Bailliere Tindall, Great Britain 1983, the entire contents of which is hereby incorporated by reference.

Although many of the microbial antigens described above relate to human disorders, the invention is also useful for treating other nonhuman vertebrates.

Nonhuman vertebrates are also capable of developing infections which can be prevented or treated with the immunostimulatory nucleic acids disclosed herein. For instance, in addition to the treatment of infectious human diseases, the methods of the invention are useful for treating infections of animals.

As used herein, the term treat, treated, or treating when used with respect to an infectious disease refers to a prophylactic treatment which increases the resistance of a subject (a subject at risk of infection) to infection with a pathogen or, in other words, decreases the likelihood that the subject will become infected with the pathogen as well as a treatment after the subject (a subject who has been infected) has become infected in order to fight the infection, e.g., reduce or eliminate the infection or prevent it from becoming worse.

Many vaccines for the treatment of non-human vertebrates are disclosed in Bennett, K. *Compendium of Veterinary Products*, 3rd ed. North American

10 Compendium, Inc., 1995. As discussed above, antigens include infectious microbes such as virus, parasite, bacteria and fungi and fragments thereof, derived from natural sources or synthetically. Infectious viruses of both human and non-human vertebrates, include retroviruses, RNA viruses and DNA viruses. This group of retroviruses includes both simple retroviruses and complex retroviruses. The simple retroviruses include the

15 subgroup of B-type retroviruses, C-type retroviruses and D-type retroviruses. An example of a B-type retrovirus is mouse mammary tumor virus (MMTV). The C-type retroviruses include subgroups C-type group A (including Rous sarcoma virus (RSV), avian leukemia virus (ALV), and avian myeloblastosis virus (AMV)) and C-type group B (including feline leukemia virus (FeLV), gibbon ape leukemia virus (GALV), spleen necrosis virus (SNV), reticuloendotheliosis virus (REV) and simian sarcoma virus (SSV)).

20 The D-type retroviruses include Mason-Pfizer monkey virus (MFMV) and simian retrovirus type 1 (SRV-1). The complex retroviruses include the subgroups of lentiviruses, T-cell leukemia viruses and the foamy viruses. Lentiviruses include HIV-1, but also include HIV-2, STV, Visna virus, feline immunodeficiency virus (FIV), and equine infectious anemia virus (EIAV). The T-cell leukemia viruses include HTLV-1, HTLV-II, simian T-cell leukemia virus (STLV), and bovine leukemia virus (BLV). The foamy viruses include human foamy virus (HFV), simian foamy virus (SFV) and bovine foamy virus (BFV).

25 Examples of other RNA viruses that are antigens in vertebrate animals include, but are not limited to, members of the family Reoviridae, including the genus Orbivirus (Bluetongue virus, Bagdadungu virus, Kemerovo virus, African horse sickness

virus, and Colorado Tick Fever virus), the genus Rotavirus (human rotavirus, Nebraska calf diarrhea virus, simian rotavirus, bovine or ovine rotavirus, avian rotavirus); the family Picornaviridae, including the genus Enterovirus (poliovirus, Coxsackie virus A and B, enteric cytopathic human orphan (ECHO) viruses, hepatitis A virus, Simian enteroviruses, Murine encephalomyelitis (ME) viruses, Poliovirus muris, Bovine enteroviruses, Porcine enteroviruses, the genus Cardiovirus (Encephalomyocarditis virus (EMCV), Mengovirus), the genus Rhinovirus (human rhinoviruses including at least 113 subtypes; other rhinoviruses), the genus Astrovirus (Foot and Mouth disease (FMDV); the family Caliciviridae, including Vesicular exanthema of swine virus, San Miguel sea lion virus, Feline picornavirus and Norwalk virus; the family Togaviridae, including the

10 genus Alphavirus (Eastern equine encephalitis virus, Semliki forest virus, Sindbis virus, Chikungunya virus, O'Nyong-Nyong virus, Ross river virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus), the genus Flavivirus (Mosquito borne yellow fever virus, Dengue virus, Japanese encephalitis virus, St. Louis encephalitis virus, Murray Valley encephalitis virus, West Nile virus, Kunjin virus, Central European tick borne virus, Far Eastern tick borne virus, Kyasanur forest virus, Louping III virus, Powassan virus, Onkni hemorrhagic fever virus), the genus Rubivirus (Rubella virus), the genus Pestivirus (Mucosal disease virus, Hog cholera virus, Border disease virus); the family Bunyviridae, including the genus Bunyavirus (Bunyamwera and related viruses, California encephalitis group viruses), the genus Phlebovirus

20 (Sandfly fever Sicilian virus, Rift Valley fever virus), the genus Nairovirus (Crimean-Congo hemorrhagic fever virus, Nairobi sheep disease virus), and the genus Unkrivirus (Ukukuni and related viruses); the family Orthomyxoviridae, including the genus Influenza virus (Influenza virus type A, many human subtypes); Swine influenza virus, and Avian and Equine Influenza viruses; Influenza type B (many human subtypes), and Influenza type C (possible separate genus); the family Paramyxoviridae, including the genus Paramyxovirus (Parainfluenza virus type 1, Sendai virus, Hemadsorption virus, Parainfluenza viruses types 2 to 5, Newcastle Disease Virus, Mumps virus), the genus Morbillivirus (Measles virus, subacute sclerosing panencephalitis virus, distemper virus, Rinderpest virus), the genus Pneumovirus (respiratory syncytial virus (RSV), Bovine respiratory syncytial virus and Pseudomonia virus); the family Rhabdoviridae, including the genus Vesiculovirus (VSV), Chandelipya virus, Flinders-Hart Park virus), the genus

Lyssavirus (Rabies virus), fish Rhabdoviruses, and two probable Rhabdoviruses (Marburg virus and Ebola virus), the family Arenaviridae, including Lymphocytic choriomeningitis virus (LCM), Tacaribe virus complex, and Lassa virus; the family Coronaviridae, including Infectious Bronchitis Virus (IBV), Hepatitis virus, Human enteric corona virus, the genus *Coronavirinae* (Hepatitis virus, Human enteric corona virus).

Illustrative DNA viruses that are antigens in vertebrate animals include, but are not limited to, the family *Poxviridae*, including the genus *Orthopoxvirus* (*Varicella major*, *Varicella minor*, *Monkey pox* *Vaccinia*, *Cowpox*, *Buffalopox*, *Rabbitpox*, *Ectromelia*), the genus *Lepidopoxvirus* (*Myxoma*, *Filovirina*), the genus *Avipoxvirus* (*Fowlpox*, other avian poxvirus), the genus *Capripoxvirus* (*sheepox*, *goatpox*), the genus *Suipoxvirus* (*Swinepox*), the genus *Parapoxvirus* (contagious pustular dermatitis virus, pseudocowpox, bovine papular stomatitis virus); the family *Iridoviridae* (African swine fever virus, Frog viruses 2 and 3, *Lymphocystis* virus of fish); the family *Herpesviridae*, including the alpha-Herpesviruses (Herpes Simplex Types 1 and 2, *Varicella-Zoster*, Equine abortion virus, Equine herpes virus 2 and 3, pseudomoles virus, infectious bovine keratoconjunctivitis virus, infectious bovine rhinotracheitis virus, feline rhinotracheitis virus, infectious laryngotracheitis virus) the Beta-Herpesviruses (Human cytomegalovirus and cytomegaloviruses of swine and monkeys); the gamma-Herpesviruses (Epstein-Barr virus (EBV), *Murk's disease* virus, *Herpes salivari*, *Herpesvirus stiles*, *Herpesvirus* *syllagius*, *guinea pig herpes virus*, *Lucke tumor virus*); the family *Adenoviridae*, including the genus *Mastadenovirus* (Human subgroups A,B,C,D,E and ungrouped; alkanine adenoviruses (at least 23 serotypes), infectious canine hepatitis, and adenoviruses of cattle, pigs, sheep, frogs and many other species, the genus *Aviadenovirus* (Avian adenoviruses); and non-cultivable adenoviruses; the family *Papoviridae*, including the genus *Papillomavirus* (Human papilloma viruses, bovine papilloma viruses, Shope rabbit papilloma virus, and various pathogenic papilloma viruses of other species), the genus *Polyomavirus* (*Polyomavirus*, Simian vacuolating agent (SV-40), Rabbit vacuolating agent (RVK), K virus, BK virus, JC virus, and other primate polyoma viruses such as *Lymphotropic papilloma virus*); the family *Parvoviridae* including the genus *Adeno-associated viruses*, the genus *Parvovirus* (*Feline panleukopenia virus*, bovine parvovirus, canine parvovirus, Aleutian mink disease virus, etc). Finally, DNA viruses may include viruses which do not fit into the above families such as Kuru and

Creutzfeldt-Jacob disease viruses and chronic infectious neuropathic agents (CHINA virus).

Each of the foregoing lists is illustrative, and is not intended to be limiting.

In addition to the use of the immunostimulatory nucleic acids to induce an antigen specific immune response in humans, the methods of the preferred embodiments are particularly well suited for treatment of birds such as hens, chickens, turkeys, ducks, geese, quail, and pheasant. Birds are prime targets for many types of infections.

Hatching birds are exposed to pathogenic microorganisms shortly after birth. Although these birds are initially protected against pathogens by maternal derived antibodies, this protection is only temporary, and the bird's own immature immune system must begin to protect the bird against the pathogens. It is often desirable to prevent infection in young birds when they are most susceptible. It is also desirable to prevent against infection in older birds, especially when the birds are housed in closed quarters, leading to the rapid spread of disease. Thus, it is desirable to administer the immunostimulatory nucleic acid and the non-nucleic acid adjuvant of the invention to birds to enhance an antigen-specific immune response when antigen is present.

An example of a common infection in chickens is chicken infectious anemia virus (CIAV). CIAV was first isolated in Japan in 1979 during an investigation of a Marek's disease vaccination break (Yusaka et al., 1979, *Avian Dis.* 23:366-385). Since that time, CIAV has been detected in commercial poultry in all major poultry producing countries (van Bulow et al., 1991, pp. 690-699) in *Diseases of Poultry*, 9th edition, Iowa State University Press).

CIAV infection results in a clinical disease, characterized by anemia, hemorrhage and immunosuppression, in young susceptible chickens. Atrophy of the thymus and of the bone marrow and consistent lesions of CIAV-infected chickens are also characteristic of CIAV infection. Lymphocyte depletion in the thymus, and occasionally in the bursa of Fabricius, results in immunosuppression and increased susceptibility to secondary viral, bacterial, or fungal infections which then complicate the course of the disease. The immunosuppression may cause aggravated disease after infection with one or more of Marek's disease virus (MDV), infectious bursal disease virus, reticuloendotheliosis virus, adenovirus, or reovirus. It has been reported that pathogenesis of MDV is enhanced by CIAV (DeBoer et al., 1989, p. 28 In *Proceedings*

- 73 -

of the 36th Western Poultry Diseases Conference, Tampa, Aziz.). Further, it has been reported that CIAV agglutinates the signs of infectious bursal disease (Rosenberger et al., 1989, Avian Dis. 33:707-713). Chickens develop an age resistance to experimentally induced disease due to CAA. This is essentially completed by the age of 2 weeks, but older birds are still susceptible to infection (Yusa, N. et al., 1979 *supra*; Yusa, N. et al., Avian Diseases 24, 202-209, 1980). However, if chickens are dually infected with CAA and an immunosuppressive agent (IBDV, MDV etc.), age resistance against the disease is delayed (Yusa, N. et al., 1979 and 1980 *supra*; Bulow von V. et al., J. Veterinary Medicine 33, 93-116, 1986). Characteristics of CIAV that may potentiate disease transmission include high resistance to environmental inactivation and some common deficiencies. The economic impact of CIAV infection on the poultry industry is clear from the fact that 10% to 30% of infected birds in disease outbreaks die.

Vaccination of birds, like other vertebrate animals can be performed at any age. Normally, vaccinations are performed at up to 12 weeks of age for a live microorganism and between 14-18 weeks for an inactivated microorganism or other type of vaccine. For in ovo vaccination, vaccination can be performed in the last quarter of embryo development. The vaccine may be administered subcutaneously, by spray, orally, intracocularly, intratracheally, nasally, or by other mucosal delivery methods described herein. Thus, the immunomodulatory nucleic acids of the invention can be administered to birds and other non-human vertebrates using routine vaccination schedules and the antigen can be administered after an appropriate time period as described herein.

Cattle and livestock are also susceptible to infection. Diseases which affect these animals can produce severe economic losses, especially amongst cattle. The methods of the invention can be used to protect against infection in livestock, such as cows, horses, pigs, sheep, and goats.

Cows can be infected by bovine viruses. Bovine viral diarrhoea virus (BVDV) is a small enveloped positive-stranded RNA virus and is classified, along with hog cholera virus (HOCV) and sheep border disease virus (BDV), in the pestivirus genus. Although, Pestiviruses were previously classified in the Togaviridae family, some studies have suggested their reclassification within the Flaviviridae family along with the flavivirus and hepatitis C virus (HCV) groups (Petrocci, et al., 1991).

- 74 -

BVDV, which is an important pathogen of cattle can be distinguished, based on cell culture analysis, into cytopathogenic (CP) and noncytopathogenic (NCP) biotypes. The NCP biotype is more widespread although both biotypes can be found in cattle. If a pregnant cow becomes infected with an NCP strain, the cow can give birth to a persistently infected and specifically immunotolerant calf that will spread virus during its lifetime. The persistently infected cattle can succumb to mucosal disease and both biotypes can then be isolated from the animal. Clinical manifestations can include abortion, leucopenia, and respiratory problems, mucosal disease and mild diarrhea. In addition, severe thrombocytopenia, associated with herd epidemics, that may result in the death of the animal has been described and strains associated with this disease occur more virulent than the classical BVDV.

Equine herpes viruses (EHV) comprise a group of antigenically distinct biological agents which cause a variety of infections in horses ranging from subclinical to fatal diseases. These include Equine herpesvirus-1 (EHV-1), a ubiquitous pathogen in horses. EHV-1 is associated with epidemics of abortion, respiratory tract disease, and central nervous system disorders. Primary infection of upper respiratory tract of young horses results in a febrile illness which lasts for 8 to 10 days. Immunologically experienced mares may be re-infected via the respiratory tract without disease becoming apparent, so that abortion usually occurs without warning. The neurological syndrome is associated with respiratory disease or abortion and can affect animals of either sex at any age, leading to lack of co-ordination, weakness and posterior paralysis (Telford, E. A. R. et al., Virology 189, 304-316, 1992). Other EHV's include EHV-2, or equine cyromegalovirus, EHV-3, equine colic exanthema virus, and EHV-4, previously classified as EHV-1 subtype 2.

Sheep and goats can be infected by a variety of dangerous microorganisms including virus-maeel.

Primates such as monkeys, apes and manaqueas can be infected by simian immunodeficiency virus. Inactivated cell-virus and cell-free whole simian immunodeficiency vaccines have been reported to afford protection in manaqueas (Stott et al. (1990) Lancet 36:1538-1541; Destrotes et al. PNAS USA (1989) 86:6353-6357; Murphy-Corb et al. (1989) Science 246:1293-1297; and Carlson et al. (1990) AIDS Res. Human Retroviruses 6:1239-1246). A recombinant HIV gp120 vaccine has been

reported to afford protection in chimpanzees (Berman et al. (1990) Nature 345:622-625).

Cats, both domestic and wild, are susceptible to infection with a variety of microorganisms. For instance, feline infectious peritonitis is a disease which occurs in both domestic and wild cats, such as lions, leopards, cheetahs, and jaguars. When it is desirable to prevent infection with this and other types of pathogenic organisms in cats, the methods of the invention can be used to vaccinate cats to protect them against infection.

Domestic cats may become infected with several retroviruses, including but not limited to feline leukemia virus (FeLV), feline sarcoma virus (FeSV), endogenous type C coronavirus (RD-114), and feline syncytia-forming virus (FeSFV). Of these, FeLV is the most significant pathogen, causing diverse symptoms, including lymphoreticular and myeloid neoplasms, anemia, immune mediated disorders, and an immunodeficiency syndrome which is similar to human acquired immune deficiency syndrome (AIDS). Recently, a particular replication-defective FeLV mutant, designated FeLV-AIDS, has been more particularly associated with immunosuppressive properties.

The discovery of feline T-lymphotropic lentivirus (also referred to as feline immunodeficiency) was first reported in Pedersen et al. (1987) Science 235:790-793. Characteristics of FIV have been reported in Yamamoto et al. (1988) Leukemia, December Supplement 2:204S-215S; Yamamoto et al. (1988) Am. J. Vet. Res. 49:1246-1258; and Adley et al. (1990) J. Virol. 64:5652-5655. Cloning and sequence analysis of FIV have been reported in Olmsted et al. (1989) Proc. Natl. Acad. Sci. USA 86:2448-2452 and 86:4355-4360.

Feline infectious peritonitis (FIP) is a sporadic disease occurring unpredictably in domestic and wild Felidae. While FIP is primarily a disease of domestic cats, it has been diagnosed in lions, mountain lions, leopards, cheetahs, and the jaguar. Smaller wild cats that have been afflicted with FIP include the lynx and caracal, sand cat, and pallas cat. In domestic cats, the disease occurs predominantly in young animals, although cats of all ages are susceptible. A peak incidence occurs between 6 and 12 months of age. A decline in incidence is noted from 5 to 13 years of age, followed by an increased incidence in cats 14 to 15 years old.

Viral, bacterial, and parasitic diseases in fin-fish, shellfish or other aquatic life forms pose a serious problem for the aquaculture industry. Owing to the high density of animals in the hatchery tanks or enclosed marine farming areas, infectious diseases may eradicate a large proportion of the stock in, for example, a fin-fish, shellfish, or other aquatic life forms facility. Prevention of disease is a more desired remedy to these threats to fish than intervention once the disease is in progress. Vaccination of fish is the only preventative method which may offer long-term protection through immunity. Nucleic acid based vaccinations are described in US Patent No. 5,780,448 issued to Davis.

The fish immune system has many features similar to the mammalian immune system, such as the presence of B cells, T cells, lymphokines, complement, and immunoglobulins. Fish have lymphocyte subclasses with roles that appear similar in many respects to those of the B and T cells of mammals. Vaccines can be administered by immersion or orally.

Aquaculture species include but are not limited to fin-fish, shellfish, and other aquatic animals. Fin-fish include all vertebrate fish, which may be bony or cartilaginous fish, such as, for example, salmonids, carp, catfish, yellowtail, sea trout, and sea bass. Salmonids are a family of fin-fish which include trout (including rainbow trout), salmon, and Arctic char. Examples of shellfish include, but are not limited to, clams, lobster, shrimp, crab, and oysters. Other cultured aquatic animals include, but are not limited to, eels, squid, and octopi.

Polypeptides of viral aquaculture pathogens include but are not limited to glycoprotein (G) or nucleoprotein (N) of viral hemorrhagic septicemia virus (VHSV); G or N proteins of infectious hematopoietic necrosis virus (IHNV); VP1, VP2, VP3 or N structural proteins of infectious pancreatic necrosis virus (IPNV); G protein of spring viremia of carp (SVC); and a membrane-associated protein, tegument or capsid protein or glycoprotein of channel catfish virus (CCV).

Typical parasites infecting burses are *Gasterophilus* spp.; *Eimeria leuckarti*, *Glardia* spp.; *Trichostrongylus axei*; *Bobaria* spp. (RBC's); *Theileria equi*; *Trypanosoma* spp.; *Klebsiella equi*; *Sarcocystis* spp.

- 77 -

Typical parasites infecting swine include *Eimeria babielacki*, *Eimeria acabra*, *Isospora suis*, *Giardia* spp.; *Belontidium coli*, *Eximamoeba histolytica*, *Toxoplasma gondii* and *Sarcocystis* spp., and *Trichinella spiralis*.

The major parasites of dairy and beef cattle include *Eimeria* spp.

- 5 *Cryptosporidium* sp., *Giardia* spp.; *Toxoplasma gondii*, *Babesia bovis* (RBC), *Babesia biguttata* (RBC), *Trypanosoma* spp. (glasma), *Theileria* spp. (RBC), *Theileria parva* (lymphocytes), *Trichostrongylus flexus*, and *Sarcocystis* spp.

- 10 The major parasites of ruminants include *Trichostrongylus colubratus*, *Coccidia* (*Eimeria* spp.), *Plasmodium relictum*, *Leucocytozon danielwasyi* (ovine), *Haemonchus* spp., *Trypanosoma* spp.; *Histomonas*, *Cryptosporidium meleagridis*, *Cryptosporidium baileyi*, *Giardia*, *Eimeria*, *Toxoplasma*.

- 15 Typical parasites infecting sheep and goats include *Eimeria* spp., *Cryptosporidium* sp., *Giardia* sp.; *Toxoplasma gondii*, *Babesia* spp. (RBC), *Trypanosoma* spp. (glasma), *Theileria* spp. (RBC), and *Sarcocystis* spp.

- 20 Typical parasitic infections in poultry include coccidiosis caused by *Eimeria acervulina*, *E. necatrix*, *E. tenella*, *Isospora* spp. and *Eimeria brunetti*, histomoniasis, caused by *Histomonas meleagridis* and *Histomonas gallinarum*, trichomoniasis caused by *Trichomonas gallinarum*, and hexamitiasis caused by *Hexamita meleagridis*. Poultry can also be infected *Eimeria maxima*, *Eimeria meleagridis*, *Eimeria adenoviridis*, *Eimeria meleagridis*, *Cryptosporidium*, *Eimeria brunetti*, *Eimeria adenoviridis*, *Leucocytozon* spp., *Plasmodium* spp., *Haemonchus meleagridis*, *Toxoplasma gondii* and *Sarcocystis*.

- 25 The methods of the invention can also be applied to the treatment and/or prevention of parasitic infection in dogs, cats, birds, fish and fawns. Typical parasites of birds include *Trichostrongylus gallinarum*, *Eimeria* spp., *Isospora* spp., *Giardia*, *Cryptosporidium*, *Sarcocystis* spp., *Toxoplasma gondii*.

- 30 *Haemonchus/parabronchovirus*, *Plasmodium* spp., *Leucocytozon/Albica*, *Alveolaria*, *Trypanosoma* spp. Typical parasites infecting dogs include *Trichinella spiralis*, *Isospora* spp., *Sarcocystis* spp., *Cryptosporidium* spp., *Hammondi* spp., *Giardia duodenalis* (canine), *Belontidium coli*, *Eximamoeba histolytica*, *Hepatozon canis*; *Toxoplasma gondii*, *Trypanosoma cruzi*, *Babesia canis*, *Leishmania amastigotes*, *Neospora caninum*.

- 78 -

Typical parasites infecting feline species include *Isospora* spp., *Toxoplasma gondii*, *Sarcocystis* spp., *Hammondi hammondi*, *Bemisia* spp., *Giardia* spp.; *Eximamoeba histolytica*, *Hepatozon canis*, *Cyanozon* sp., *Cyanozon* sp., *Cyanozon* sp. (red cells, RE cells).

- 5 Typical parasites infecting fish include *Hexamita* spp., *Eimeria* spp.; *Cryptobia* spp., *Neosoma* spp., *Myxosoma* spp., *Chilodonella* spp., *Trichodin* spp.; *Platyphora* spp., *Myxosoma hemerythra*, *Costia* spp., *Ichthyophthirius* spp., and *Oodinium* spp.

- 10 Typical parasites of wild mammals include *Giardia* spp. (canine, bativores), *Isospora* spp. (canine, bativores), *Eimeria* spp. (canine, bativores), *Theileria* spp. (bativores), *Schistosoma* spp. (bativores), *Trypanosoma* spp. (canine, bativores), *Fasciola magna* (bativores), *Fasciola gigantica* (bativores), *Trichinella spiralis* (canine, bativores).

- 15 Parasitic infections in zoos can also pose serious problems. Typical parasites of the bovidae family (Gusobok, antelope, bonteng, eland, gazelle, hippopotamus, kudu, gazelle) include *Eimeria* spp. Typical parasites in the plinividae family (seal, sea lion) include *Eimeria phoca*. Typical parasites in the camelidae family (camels, llamas) include *Eimeria* spp. Typical parasites of the giraffidae family (giraffes) include *Eimeria* spp.

- 20 Typical parasites in the elephantidae family (African and Asian) include *Fasciola* spp. Typical parasites of lower primates (Chimpanzee, orangutan, gibbon, baboon, macaque, monkey) include *Giardia* sp.; *Belontidium coli*, *Eximamoeba histolytica*, *Sarcocystis* spp., *Toxoplasma gondii*, *Plasmodium* spp. (RBC), *Babesia* spp. (RBC), *Trypanosoma* spp. (glasma), *Leishmania* spp. (macrophages).

- 25 Polypeptides of bacterial pathogens include but are not limited to an iron-regulated outer membrane protein, (IROMP), an outer membrane protein (OMP), and an A-protein of *Aeromonas salmonicida* which causes furunculosis, p57 protein of *Renibacterium salmoninarum* which causes bacterial kidney disease (BKD), major surface associated antigen (msa), a surface expressed cytotoxin (mcp), a surface expressed hemolysin (shb), and a flagellar antigen of *Yersinia enterocolitica*, an extracellular protein (ECP), an iron-regulated outer membrane protein (IROMP), and a structural protein of *Pasteurella*, an OMP and a flagellar protein of *Vibrio anguillarum* and *V. ordalii*, a flagellar protein, an OMP protein, *swA*, and *purA* of *Edwardsiella ictaluri* and *E.*

tards, and surface antigen of Icthyophthirius; and a structural and regulatory protein of Cytophaga columnaris; and a structural and regulatory protein of Rickettsia.

Polypeptides of a parasitic pathogen include but are not limited to the surface antigens of Icthyophthirius.

- 5 An allergen refers to a substance (antigen) that can induce an allergic or autoimmune response in a susceptible subject. The list of allergens is enormous and can include pollens, insect venoms, animal dander dust, fungal spores and drugs (e.g. penicillins). Examples of natural, animal and plant allergens include but are not limited to proteins specific to the following genera: *Canine (Canis familiaris)*; *Dermatophagoides* (e.g. *Dermatophagoides farinae*); *Felis (Felis domesticus)*; *Ambrosia* (*Ambrosia artemisiifolia*; *Lolium* (e.g. *Lolium perenne* or *Lolium multiflorum*); *Cryptomeria* (*Cryptomeria japonica*); *Alternaria* (*Alternaria alternata*); *Alder*; *Alnus* (*Alnus gallica*); *Betula* (*Betula verrucosa*); *Quercus* (*Quercus alba*); *Olea* (*Olea europaea*); *Artemisia* (*Artemisia vulgaris*); *Plantago* (e.g. *Plantago lanceolata*); *Parietaria* (e.g. *Parietaria officinalis* or *Parietaria judaica*); *Blattella* (e.g. *Blattella germanica*); *Apis* (e.g. *Apis mellifera*); *Cyperus* (e.g. *Cyperus sempervirens*, *Cyperus arvensis* and *Cyperus macrocarpa*); *Juniperus* (e.g. *Juniperus sibirica*, *Juniperus virginiana*, *Juniperus communis* and *Juniperus aschii*); *Thuja* (e.g. *Thuja orientalis*); *Chamaecyparis* (e.g. *Chamaecyparis obtusa*); *Periplaneta* (e.g. *Periplaneta americana*); *Agropyron* (e.g. *Agropyron repens*); *Secale* (e.g. *Secale cereale*); *Triticum* (e.g. *Triticum aestivum*); *Dactylis* (e.g. *Dactylis glomerata*); *Festuca* (e.g. *Festuca elatior*); *Poa* (e.g. *Poa pratensis* or *Poa compressa*); *Avena* (e.g. *Avena sativa*); *Holcus* (e.g. *Holcus lanatus*); *Anthriscanthum* (e.g. *Anthriscanthum odoratum*); *Arrhenatherum* (e.g. *Arrhenatherum elatius*); *Agrostis* (e.g. *Agrostis alba*); *Phleum* (e.g. *Phleum pratense*); *Phalaris* (e.g. *Phalaris arundinacea*); *Paspalum* (e.g. *Paspalum notatum*); *Sorghum* (e.g. *Sorghum halepense*); and *Bromus* (e.g. *Bromus tectorum*).

The antigen may be an antigen that is encoded by a nucleic acid vector or it may be not encoded in a nucleic acid vector. In the former case the nucleic acid vector is administered to the subject and the antigen is expressed *in vivo*. In the latter case the antigen may be administered directly to the subject. An antigen not encoded in a nucleic acid vector as used herein refers to any type of antigen that is not a nucleic acid. For instance, in some aspects of the invention the antigen not encoded in a nucleic acid

vector is a polypeptide. Minor modifications of the primary amino acid sequences of polypeptide antigens may also result in a polypeptide which has substantially equivalent antigenic activity as compared to the unmodified counterpart polypeptide. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein as long as antigenicity still exists. The polypeptide may be, for example, a viral polypeptide.

The term substantially purified as used herein refers to a polypeptide which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. One skilled in the art can purify viral or bacterial polypeptides using standard techniques for protein purification. The substantially pure polypeptide will often yield a single major band on a non-reducing polyacrylamide gel. In the case of partially glycosylated polypeptides or those that have several start codons, there may be several bands on a non-reducing polyacrylamide gel, but these will form a distinctive pattern for that polypeptide. The purity of the viral or bacterial polypeptide can also be determined by amino-terminal amino acid sequence analysis. Other types of antigens not encoded by a nucleic acid vector such as polysaccharides, small molecules, mimics etc are described above, and included within the invention.

The invention also utilizes polynucleotides encoding the antigenic polypeptides. It is envisioned that the antigen may be delivered to the subject in a nucleic acid molecule which encodes for the antigen such that the antigen must be expressed *in vivo*. Such antigens delivered to the subject in a nucleic acid vector are referred to as antigens encoded by a nucleic acid vector. The nucleic acid encoding the antigen is operatively linked to a gene expression sequence which directs the expression of the antigen nucleic acid within a eukaryotic cell. The gene expression sequence is any regulatory nucleotide sequence, such as a promoter sequence or promoter-enhancer combination, which facilitates the efficient transcription and translation of the antigen nucleic acid to which it is operatively linked. The gene expression sequence may, for example, be a mammalian or viral promoter, such as a constitutive or inducible promoter. Constitutive mammalian promoters include, but are not limited to, the promoters for the following genes: hypoxanthine phosphoribosyl transferase (HPT), adenovirus deaminase, pyruvate kinase, b-actin promoter and other constitutive promoters. Exemplary viral promoters which function constitutively in eukaryotic cells include, for example, promoters from

the cytomegalovirus (CMV), simian virus (e.g., SV40), papilloma virus, adenovirus, human immunodeficiency virus (HIV), Rous sarcoma virus, cytomegalovirus, the long terminal repeats (LTR) of Moloney leukemia virus and other retroviruses, and the thymidine kinase promoter of herpes simplex virus. Other constitutive promoters are known to those of ordinary skill in the art. The promoters useful as gene expression sequences of the invention also include inducible promoters. Inducible promoters are expressed in the presence of an inducing agent. For example, the metallothionein promoter is induced to promote transcription and translation in the presence of certain metal ions. Other inducible promoters are known to those of ordinary skill in the art.

In general, the gene expression sequence shall include, as necessary, 5' non-transcribing and 3' non-transcribing sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAAT sequence, and the like. Especially, such 5' non-transcribing sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined antigen nucleic acid. The gene expression sequences optionally include enhancer sequences or upstream activator sequences as desired.

The antigen nucleic acid is operatively linked to the gene expression sequence. As used herein, the antigen nucleic acid sequence and the gene expression sequence are said to be operably linked when they are covalently linked in such a way as to place the expression or transcription and/or translation of the antigen coding sequence under the influence or control of the gene expression sequence. Two DNA sequences are said to be operably linked if induction of a promoter in the 5' gene expression sequence results in the transcription of the antigen sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the antigen sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a gene expression sequence would be operably linked to an antigen nucleic acid sequence if the gene expression sequence were capable of effecting transcription of that antigen nucleic acid sequence such that the resulting transcript is translated into the desired protein or polypeptide.

The antigen nucleic acid of the invention may be delivered to the immune system alone or in association with a vector. In its broadest sense, a vector is any vehicle

capable of facilitating the transfer of the antigen nucleic acid to the cells of the immune system so that the antigen can be expressed and presented on the surface of the immune cell. The vector generally transports the nucleic acid to the immune cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector. The vector optionally includes the above-described gene expression sequence to enhance expression of the antigen nucleic acid in immune cells. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagenda, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antigen nucleic acid sequences. Viral vectors are a preferred type of vector and include, but are not limited to, nucleic acid sequences from the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kiegle, M., Gene Transfer and Expression, A Laboratory Manual W.H. Freeman C.O., New York (1990) and Murry, E.J. Methods in Molecular Biology, vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

A preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication -deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, the adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression characteristic of retroviral infection. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells *in vivo* because of their inability to replicate within and integrate into a host genome. These plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid. Some commonly used plasmids include pBR322, pUC18, pUC19, pRCMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

It has recently been discovered that genes carrying plasmids can be delivered to the immune system using bacteria. Modified forms of bacteria such as *Salmonella* can be transfected with the plasmid and used as delivery vehicles. The bacterial delivery vehicles can be administered to a host subject orally or by other administration means. The bacteria deliver the plasmid to immune cells, e.g. B cells, dendritic cells, likely by passing through the gut barrier. High levels of immune protection have been established using this methodology. Such methods of delivery are useful for the aspects of the

invention utilizing systemic delivery of antigen, immunostimulatory nucleic acid and/or other therapeutic agent.

Thus, the immunostimulatory nucleic acids are useful as vaccine adjuvants. It was previously established that CpG oligonucleotides are excellent vaccine adjuvants. It was also demonstrated, however, that CpG ODN which are superb vaccine adjuvants in mice are not the preferred adjuvants in non-rodent animals. In order to identify the best immunostimulatory nucleic acids for use as a vaccine adjuvant in humans and other non-rodent animals, *in vivo* screening of different nucleic acids for this purpose was conducted. Several *in vitro* assays were evaluated in mice for their predictive value of adjuvant activity *in vivo* in mice. During the course of this study, an *in vitro* test that is predictive of *in vivo* efficacy was identified. It was discovered, rather surprisingly, that both B cell and NK cell activation correlated particularly well with the ability of an immunostimulatory nucleic acid to enhance an *in vivo* immune response against an antigen.

The good predictive value of B cell activation for *in vivo* vaccine adjuvant activity is most likely linked to the central role of B cells in the establishment of a specific immune response. Polyclonal proliferation of B cells (induced by immunostimulatory nucleic acids) increases the likelihood of an antigen specific B cell/T helper cell match. Furthermore, enhanced expression of the co-stimulatory molecule CD86 on polyclonally expanded B cells activates antigen specific T helper cells. B cells also increase their CD40 expression in response to immunostimulatory nucleic acids improving the capability of CD40L expressing activated T helper cells to stimulate B cells. Increased ICAM-1 synthesis on B cells facilitates the cell to cell contact. Thus, the activation status of polyclonal B cells plays a critical role during the initiation of a specific antibody response.

The contribution of NK cell activity for the establishment of specific antibodies was, however, surprising. NK cells are part of the innate immune system and as such are involved in the first line of defense against pathogens. Most likely the cytokine pattern produced by NK cells upon activation is closely related to the initiation of a specific immune response. Thus, in one aspect the invention relates to a method of identifying an adjuvant by detecting NK cell activation. The NK cell activation assay may be carried out as described in the Examples below or using other known NK cell activity assays. It

is preferred, however than a mixed cell population such as PBMAC be used because of the likelihood that NK cell activation is an indirect effect. The assay is preferably useful for identifying immunostimulatory nucleic acids which are useful as adjuvants in human and other non-primate animals.

Cytokine induction was also identified as an important predictor of *in vivo* adjuvant activity. As there is a 2 log higher endotoxin sensitivity of human than mouse primary monocytes, some caution, however, is required to avoid endotoxin contamination of immunostimulatory nucleic acids used for testing in the human system (Hartmann G. and Krieg A. M. 1999, *Gene Therapy* 6:893). Since TNF- α , IL-6 and IL-12 are produced by human monocytes in response to even low amounts of endotoxin, their value for high throughput *in vitro* screening assays is limited. On the other hand, human B cells and NK cells show only minor activation by endotoxin and thus are far more useful in testing for immunostimulatory activity.

Stimulation of cellular function in either NK or B cells (i.e., lytic activity, proliferation) requires a stronger immunostimulatory nucleic acid than the induction of activation markers at their surface (CD69, CD86). For both cell types, the use of cell surface activation markers showed a higher nonspecific background attributable to the phosphorothioate backbone compared to the functional assays. This high sensitivity of surface markers requires the use of low immunostimulatory nucleic acid concentrations for optimal discrimination between immunostimulatory nucleic acid of cellular activity. Thus, the use of surface markers allows the comparison of immunostimulatory nucleic acids with weak activity, while functional assays are preferred for comparing immunostimulatory nucleic acids with high activity. It is of note that the optimal immunostimulatory nucleic acid concentrations for stimulating B cells and NK cells differ. While 0.6 μ g/ml ODN is already maximal to stimulate B cells, optimal NK cell activation may require 6 μ g/ml ODN. Both B cell activation and NK cell functional activity were measured within freshly isolated PBMAC. It was previously found that highly purified human primary B cells are activated by CpG DNA. The existence of a direct effect of CpG DNA on NK cells is less clear, and a secondary mechanism mediated by another cell type within PBMAC might contribute to CpG-induced functional activity of NK cells.

The nucleic acids of the invention may be administered to a subject with an anti-microbial agent. An anti-microbial agent, as used herein, refers to a naturally-occurring or synthetic compound which is capable of killing or inhibiting infectious microorganisms. The type of anti-microbial agent useful according to the invention will depend upon the type of microorganism with which the subject is infected or at risk of becoming infected. Anti-microbial agents include but are not limited to anti-bacterial agents, anti-viral agents, anti-fungal agents and anti-parasitic agents. Phrases such as

"anti-infective agent", "anti-bacterial agent", "anti-viral agent", "anti-fungal agent", "anti-parasitic agent" and "parasiticide" have well-established meanings to those of ordinary skill in the art and are defined in standard medical texts. Briefly, anti-bacterial agents kill or inhibit bacteria, and include antibiotics as well as other synthetic or natural compounds having similar functions. Antibiotics are low molecular weight molecules which are produced as secondary metabolites by cells, such as microorganisms. In general, antibiotics interfere with one or more bacterial functions or structures which are specific for the microorganism and which are not present in host cells. Anti-viral agents can be isolated from natural sources or synthesized and are useful for killing or inhibiting viruses. Anti-fungal agents are used to treat superficial fungal infections as well as opportunistic and primary systemic fungal infections. Anti-parasitic agents kill or inhibit parasites.

Examples of anti-parasitic agents, also referred to as parasitocides useful for human administration include but are not limited to albendazole, amphotericin B, benzimidazole, bilhicol, chloroquine HCl, chloroquine phosphate, clindamycin, dehydroemetine, diethylcarbamazine, difloxamide fumarate, eflorentin, furozolidonum, glucocorticoids, halofantrine, iodoquinol, ivermectin, mebendazole, mefloquine, meglumine antimoniate, mefloquine, metronidazole, metronidazole, nifedipine, nifurtimox, oxamandiquin, paromomycin, pentamidine isethionate, piperazine, praziquantel, primaquine phosphate, proguanil, pyramel pamoate, pyrimethamine-sulfonamides, pyrimethamine-sulfadiazole, quinine HCl, quinine sulfate, quinidine gluconate, spinosyn, sibogluconate sodium (sodium antimony gluconate), suramin, tetrahydropyrim, thiabendazole, tinidazole, trimethoprim-sulfamethoxazole, and pyrazinamide some of which are used alone or in combination with others.

[illegible][illegible]

blocked or inhibited by antiviral agents. These stages include, attachment of the virus to the host cell (immunoglobulin or binding peptides), uncoating of the virus (e.g. amantadine), synthesis or translation of viral mRNA (e.g. interferon), replication of viral RNA or DNA (e.g. nucleoside analogues), maturation of new virus proteins (e.g. protease inhibitors), and budding and release of the virus.

Nucleoside analogues are synthetic compounds which are similar to nucleotides, but which have an incomplete or abnormal deoxyribose or ribose group. Once the nucleoside analogues are in the cell, they are phosphorylated, producing the triphosphate formed which competes with normal nucleotides for incorporation into the viral DNA or RNA. Once the triphosphate form of the nucleoside analogue is incorporated into the growing nucleic acid chain, it causes irreversible association with the viral polymerase and thus chain termination. Nucleoside analogues include, but are not limited to, acyclovir (used for the treatment of herpes simplex virus and varicella-zoster virus), ganciclovir (useful for the treatment of cytomegalovirus), idoxuridine, ribavirin (useful for the treatment of respiratory syncytial virus), dideoxyinosine, dideoxycytidine, and zidovudine (azidothymidine).

The interferons are cytokines which are secreted by virus-infected cells as well as immune cells. The interferons function by binding to specific receptors on cells adjacent to the infected cells, causing the change in the cell which protects it from infection by the virus. α and β -interferon also induce the expression of Class I and Class II MHC molecules on the surface of infected cells, resulting in increased antigen presentation for host immune cell recognition. α and β -interferons are available as recombinant forms and have been used for the treatment of chronic hepatitis B and C infection. At the dosages which are effective for anti-viral therapy, interferons have severe side effects such as fever, malaise and weight loss.

Immunoglobulin therapy is used for the prevention of viral infection.

Immunoglobulin therapy for viral infections is different than bacterial infections, because rather than being antigen-specific, the immunoglobulin therapy functions by binding to extracellular viruses and preventing them from attaching to and entering cells which are susceptible to the viral infection. The therapy is useful for the prevention of viral infection for the period of time that the antibodies are present in the host. In general there are two types of immunoglobulin therapies, normal immunoglobulin therapy and

hyper-immunoglobulin therapy. Normal immune globulin therapy utilizes an antibody product which is prepared from the serum of normal blood donors and pooled. This pooled product contains low titers of antibody to a wide range of human viruses, such as hepatitis A, parvovirus, enterovirus (especially in neonates). Hyper-immune globulin therapy utilizes antibodies which are prepared from the serum of individuals who have high titers of an antibody to a particular virus. Those antibodies are then used against a specific virus. Examples of hyper-immune globulins include zoster immune globulin (useful for the prevention of varicella in immuno-compromised children and neonates), human rabies immunoglobulin (useful in the post-exposure prophylaxis of a subject bitten by a rabid animal), hepatitis B immune globulin (useful in the prevention of hepatitis B virus, especially in a subject exposed to the virus), and RSV immune globulin (useful in the treatment of respiratory syncytial virus infections).

Another type of immunoglobulin therapy is active immunization. This involves the administration of antibodies or antibody fragments to viral surface proteins. Two types of vaccines which are available for active immunization of hepatitis B include serum-derived hepatitis B antibodies and recombinant hepatitis B antibodies. Both are prepared from HBsAg. The antibodies are administered in three doses to subjects at high risk of infection with hepatitis B virus, such as health care workers, sexual partners of chronic carriers, and infants.

Thus, anti-viral agents useful in the invention include but are not limited to immunoglobulins, amantadine, interferon, nucleoside analogues, and protease inhibitors. Specific examples of anti-virals include but are not limited to Acemannan; Acyclovir; Acyclovir Sodium; Adefovir; Alovudine; Alivrect Sulfoxide; Amantadine Hydrochloride; Amantadine; Arbidol; Atridol; Atridol Mesylate; Avridine; Cidofovir; Ciprofylline; Cytarabine Hydrochloride; Delavirdine Mesylate; Descidovir; Didanosine; Disoxathi; Edoxuridine; Efavirenz; Efavirenz; Foscarnet Sodium; Foscarnet Sodium Hydrochloride; Flactabine; Flactabine; Fosarnet Sodium; Fosfarnet Sodium; Ganciclovir; Ganciclovir Sodium; Idoxuridine; Koforal; Lamivudine; Lobucavir; Meroquin Hydrochloride; Methisazone; Nevirapine; Penciclovir; Pirodavir; Ribavirin; Rimantadine Hydrochloride; Sequinavir Mesylate; Somanadine Hydrochloride; Sorivudine; Stablon; Stavudine; Tilorone Hydrochloride; Trifluoridine; Valacyclovir

- 93 -

Hydrochlorides; Vidarabine; Vidarabine Phosphate; Vidarabine Sodium Phosphate; Viroxime; Zalcitabine; Zidovudine; and Ziviroxime.

- Anti-fungal agents are sometimes classified by their mechanism of action. Some anti-fungal agents are well water inhibitors by inhibiting glucose synthase. These include, but are not limited to, isavuconazole/ECB. Other anti-fungal agents function by destabilizing membrane integrity. These include, but are not limited to, micafungin, such as echinocandin, echinocandin, fluconazole, isavuconazole, isavuconazole, micafungin, and voriconazole, as well as FK 463, amphotericin B, BAY 38-9072, MK 991, predmichin, UK 292, butamifone, and terbinafine. Other anti-fungal agents function by breaking down chitin (e.g. chitinase) or immunosuppression (501 cretin). Some examples of commercially-available agents are shown in Table B
- 10

Table B

[illegible]

1 But, the anti-fungal agents useful in the invention include but are not limited to

15
imidazole, JK 463, empobornitron B, BA.V 38-9502, MK 991, pyrimidin, UK 292,
butenafin, citalinax, 501 cream, Aurocentin, Ambutimid, Aurofin, Ambobornitron B;
Azaacetonitril, Azaacetonitril, Bisthiazol, Biphenamine Hydrochloride;
Bispyrithione Magnesium; Butonacetonitril, Calcium Undecylenate, Caudalidin,

- 94 -

[illegible]

- 13 Immunostimulatory nucleic acids can be combined with other therapeutic agents such as adjuvants to enhance immune responses. The immunostimulatory nucleic acid and other therapeutic agent may be administered simultaneously or sequentially. When the other therapeutic agents are administered simultaneously they can be administered in the same or separate formulations, but are administered at the same time. The other therapeutic agents are administered sequentially with one another and with immunostimulatory nucleic acid, when the administration of the other therapeutic agents and the immunostimulatory nucleic acid is temporally separated. The separation in time between the administration of these compounds may be a matter of minutes or it may be longer. Other therapeutic agents include but are not limited to adjuvants, cytokines, antibodies, antigens, etc.
- 20

The immunostimulatory nucleic acids are useful as adjuvants for inducing a systemic immune response. Thus either can be delivered to a subject exposed to an antigen to produce an enhanced immune response to the antigen.

In addition to the immunostimulatory nucleic acids, the compositions of the invention may also be administered with non-nucleic acid adjuvants. A non-nucleic acid adjuvant is any molecule or compound except for the immunostimulatory nucleic acids described herein which can stimulate the humoral and/or cellular immune response.

Non-nucleic acid adjuvants include, for instance, adjuvants that create a depo effect, immune stimulating adjuvants, and adjuvants that create a depo effect and stimulate the immune system.

An adjuvant that creates a depo effect as used herein is an adjuvant that causes the antigen to be slowly released in the body, thus prolonging the exposure of immune cells to the antigen. This class of adjuvants includes but is not limited to alum (e.g., aluminum hydroxide, aluminum phosphate), or emulsion-based formulations including mineral oil, non-aqueous oil, water-in-oil or oil-in-water-in oil emulsion, oil-in-water emulsions such as Seppic ISA series of Montanide adjuvants (e.g., Montanide ISA 720, AltrAqualide, Paris, France); MF-59 (a squalene-in-water emulsion stabilized with Span 85 and Tween 80; Chiron Corporation, Emeryville, CA; and PROVAX (an oil-in-water emulsion containing a stabilizing detergent and a micelle-forming agent; IDEC, Pharmaceuticals Corporation, San Diego, CA).

An immune stimulating adjuvant is an adjuvant that causes activation of a cell of the immune system. It may, for instance, cause an immune cell to produce and secrete cytokines. This class of adjuvants includes but is not limited to saponins purified from the bark of the *Q. sapotaria* tree, such as QS21 (a glycolipid that elutes in the 21st peak with HPLC fractionation; Aquila Biopharmaceuticals, Inc., Worcester, MA); poly[di(carboxylatophenyl)phosphazene (PCPP polymer; Virus Research Institute, USA); derivatives of lipopolysaccharides such as monophosphoryl lipid A (MPL; Ribi ImmunoChem Research, Inc., Hamilton, MT), muramyl dipeptide (MDP; Ribi) and threonyl-carrumyl dipeptide (t-MDP; Ribi); OM-174 (a glucosamine disaccharide related to lipid A; OM Pharma SA, Meyrin, Switzerland); and Leishmanin elongation factor (a purified *Leishmania* protein; Corixa Corporation, Seattle, WA).

Adjuvants that create a depo effect and stimulate the immune system are those compounds which have both of the above-identified functions. This class of adjuvants includes but is not limited to ISCOMs (immunostimulating complexes which contain mixed saponins, lipids and form virus-sized particles with pores that can hold antigen; CSL, Melbourne, Australia); SB-AS2 (SmithKline Beecham adjuvant system #2 which is an oil-in-water emulsion containing MPL and QS21; SmithKline Beecham Biologicals [SBB], Rixensart, Belgium); SB-AS4 (SmithKline Beecham adjuvant system #4 which contains alum and MPL; SBB, Belgium); non-ionic block copolymers that form micelles

such as CRL 1005 (these contain a linear chain of hydrophobic polyoxypropylene flanked by chains of polyoxyethylene; Vaxcel, Inc., Norcross, GA); and Syntex Adjuvant Formulation (SAF, an oil-in-water emulsion containing Tween 80 and a nonionic block copolymer; Syntex Chemicals, Inc., Boulder, CO).

The immunostimulatory nucleic acids are also useful as mucosal adjuvants. It has previously been discovered that both systemic and mucosal immunity are induced by mucosal delivery of CpG nucleic acids. The systemic immunity induced in response to CpG nucleic acids included both humoral and cell-mediated responses to specific antigens that were not capable of inducing systemic immunity when administered alone to the mucosa. Furthermore, both CpG nucleic acids and cholera toxin (CT, a mucosal adjuvant that induces a Th2-like response) induced CTL. This was surprising since with systemic immunization, the presence of Th2-like antibodies is normally associated with a lack of CTL (Schirmbeck *et al.*, 1995). Based on the results presented herein it is expected that the immunostimulatory nucleic acids will function in a similar manner.

Additionally, the immunostimulatory nucleic acids induce a mucosal response at both local (e.g., lung) and remote (e.g., lower digestive tract) mucosal sites. Significant levels of IgA antibodies are induced at distant mucosal sites by the immunostimulatory nucleic acids. CT is generally considered to be a highly effective mucosal adjuvant. As has been previously reported (Snider 1995), CT induces predominantly IgG1 isotype of antibodies, which are indicative of Th2-type response. In contrast, the

immunostimulatory nucleic acids are more Th1 with predominantly IgG2a antibodies, especially after boost or when the two adjuvants are combined. Th1-type antibodies in general have better neutralizing capabilities, and furthermore, a Th2 response in the lung is highly undesirable because it is associated with asthma (Kag, 1996; Hogg, 1997).

Thus the use of immunostimulatory nucleic acids as a mucosal adjuvant has benefits that other mucosal adjuvants cannot achieve. The immunostimulatory nucleic acids of the invention also are useful as mucosal adjuvants for induction of both a systemic and a mucosal immune response.

Mucosal adjuvants referred to as non-nucleic acid mucosal adjuvants may also be administered with the immunostimulatory nucleic acids. A non-nucleic acid mucosal adjuvant as used herein is an adjuvant other than a immunostimulatory nucleic acid that is capable of inducing a mucosal immune response in a subject when administered to a

- mucosal surface in conjunction with an antigen. Mucosal adjuvants include but are not limited to Bacterial toxins e.g., Cholera toxin (CT), CT derivatives including but not limited to CT B subunit (CTB) (Wu et al., 1998, Teichko et al., 1998); CTB53 (Val to Arg) (Fontana et al., 1995); CTB37 (Val to Lys) (Fontana et al., 1995); CTB104 (Tyr to Lys) (Fontana et al., 1995); CTB53/K63 (Val to Arg, Ser to Lys) (Fontana et al., 1995); CTB54 (Arg to His) (Fontana et al., 1995); CTB112K (Gln to Lys) (Yamanoto et al., 1997a); CTB61P (Ser to Phe) (Yamanoto et al., 1997a, 1997b); CTB106 (Pro to Lys) (Douce et al., 1997, Fontana et al., 1995); and CTB63 (Ser to Lys) (Douce et al., 1997, Fontana et al., 1995). *Zonula occludens* toxin, zot, *Escherichia coli* heat-labile enterotoxin, Labile Toxin (LT), LT derivatives including but not limited to LT B subunit (LTB) (Verweij et al., 1998); LTTK (Arg to Lys) (Komase et al., 1998, Douce et al., 1995); LTI6P (Ser to Phe) (Komase et al., 1998); LTI12K (Gln to Lys) (Komase et al., 1998); LTI18E (Gly to Gln) (Komase et al., 1998); LTI46E (Arg to Gln) (Komase et al., 1998); LTI92G (Arg to Gly) (Komase et al., 1998); LTK63 (Ser to Lys) (Marchetti et al., 1998, Douce et al., 1997, 1999, Di Tommaso et al., 1996); and LTK72 (Ala to Arg) (Giuliani et al., 1998). Pertussis toxin, PT, (Lys to Leu), 1992, Spongel BD, 1992, Freytag and Clemmets, 1999, Roberts et al., 1995, Wilson et al., 1995) including PT-9K/129G (Roberts et al., 1995, Copley et al., 1995); Toxin derivatives (see below) (Holmgren et al., 1993, Verweij et al., 1998, Rappelli et al., 1995, Freytag and Clemmets, 1999); Lipid A derivatives (e.g., monophosphoryl lipid A, MPL) (Sasaki et al., 1998, Vanoot et al., 1998; Muramyl Dipeptide (MDP) derivatives (Fukushima et al., 1996, Ogawa et al., 1989, Michalek et al., 1983, Morisaki et al., 1983); Bacterial outer membrane proteins (e.g., outer surface protein A (OspA) lipoprotein of *Borrelia burgdorferi*, outer membrane proteins of *Neisseria meningitidis*) (Martino et al., 1999, Van de Vort et al., 1996); Oil-in-water emulsions (e.g., MF59) (Baruch et al., 1999, Verachior et al., 1999, O'Hagan, 1998); Aluminum salts (Saka et al., 1998, 1999); and Saponins (e.g., QS21) Aquila Biopharmaceuticals, Inc., Worcester, MA) (Sasaki et al., 1998, MacNeil et al., 1998), ISCOMS, MF-59 (a squalene-in-water emulsion stabilized with Span 85 and Tween 80; Chiron Corporation, Emeryville, CA); the Sargis ISA series of Monomelic adjuvants (e.g., Monomelic ISA 720; Afti Aquide, Paris, France); PROVAX (an oil-in-water emulsion containing a stabilizing detergent and a nucleic-

- forming agent, IDBC Pharmaceuticals Corporation, San Diego, CA); Syntex Adjuvant Formulation (SAF; Syntex Chemicals, Inc., Boulder, CO); poly(dicyclopentylphosphazene) (PCPP polymer; Virus Research Institute, USA) and Leishmanin elongation factor (Corixa Corporation, Seattle, WA).
- Immune responses can also be induced or augmented by the co-administration or co-linear expression of cytokines (Queller & Mulligan, 1996; Chow et al., 1997; Gishler et al., 1997; Iwasaki et al., 1997; Kim et al., 1997) or B-7 co-stimulatory molecules (Iwasaki et al., 1997; Tsuji et al., 1997) with the immunostimulatory nucleic acids. The cytokines can be administered directly with immunostimulatory nucleic acids or may be administered in the form of a nucleic acid vector that encodes the cytokine, such that the cytokine can be expressed *in vivo*. In one embodiment, the cytokine is administered in the form of a plasmid expression vector. The term cytokine is used as a generic name for a diverse group of soluble proteins and peptides which act as humoral regulators at nano- to picomolar concentrations and which, either under normal or pathological conditions, modulate the functional activities of individual cells and tissues. These proteins also mediate interactions between cells directly and regulate processes taking place in the extracellular environment. Examples of cytokines include, but are not limited to IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-18, granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interferon- γ (IFN- γ), IFN- α , tumor necrosis factor (TNF), TGF- β , FLT-3 ligand, and CD40 ligand.
- Cytokines play a role in directing the T cell response. Helper (CD4+) T cells orchestrate the immune response of mammals through production of soluble factors that act on other immune system cells, including other T cells. Most mature CD4+ T helper cells express one of two cytokine profiles: Th1 or Th2. The Th1 subset promotes delayed-type hypersensitivity, cell-mediated immunity, and immunoglobulin class switching to IgG_{2a}. The Th2 subset induces humoral immunity by activating B cells, promoting antibody production, and inducing class switching to IgG₁ and IgE. In some embodiments, it is preferred that the cytokine be a Th1 cytokine.
- The nucleic acids are also useful for redirecting an immune response from a Th2 immune response to a Th1 immune response. Redirection of an immune response from a Th2 to a Th1 immune response can be assessed by measuring the levels of cytokines produced in response to the nucleic acid (e.g., by inducing monocyte cells and other

cells to produce Th1 cytokines, including IL-12, IFN- γ and GM-CSF). The redirection or rebalance of the immune response from a Th2 to a Th1 response is particularly useful for the treatment or prevention of asthma. For instance, an effective amount for treating asthma can be that amount useful for redirecting a Th2 type of immune response that is associated with asthma to a Th1 type of response. Th2 cytokines, especially IL-4 and IL-5 are elevated in the airways of asthmatic subjects. These cytokines promote important aspects of the asthmatic inflammatory response, including IgE isotype switching, eosinophil chemotaxis and activation and mast cell growth. Th1 cytokines, especially IFN- γ and IL-12, can suppress the formation of Th2 clones and production of Th2 cytokines. The immunostimulatory nucleic acids of the invention cause an increase in Th1 cytokines which helps to rebalance the immune system, preventing or reducing the adverse effects associated with a predominantly Th2 immune response.

The nucleic acids are also useful for improving survival, differentiation, activation and maturation of dendritic cells. The immunostimulatory nucleic acids have the unique capability to promote cell survival, differentiation, activation and maturation of dendritic cells. Dendritic precursor cells isolated from blood by immunomagnetic cell sorting develop morphologic and functional characteristics of dendritic cells during a two day incubation with GM-CSF. Without GM-CSF these cells undergo apoptosis. The immunostimulatory nucleic acids are superior to GM-CSF in promoting survival and differentiation of dendritic cells (MHC II expression, cell size, granularity). The immunostimulatory nucleic acids also induce maturation of dendritic cells. Since dendritic cells form the link between the innate and the acquired immune system, by presenting antigens as well as through their expression of pattern recognition receptors which detect microbial molecules like LPS in their local environment, the ability to activate dendritic cells with immunostimulatory nucleic acids supports the use of these immunostimulatory nucleic acid based strategies for *in vivo* and *ex-vivo* immunotherapy against disorders such as cancer and allergic or infectious diseases. The immunostimulatory nucleic acids are also useful for activating and inducing maturation of dendritic cells.

Immunostimulatory nucleic acids also increase natural killer cell lytic activity and antibody dependent cellular cytotoxicity (ADCC). ADCC can be performed using a immunostimulatory nucleic acid in combination with an antibody specific for a cellular

target, such as a cancer cell. When the immunostimulatory nucleic acid is administered to a subject in conjunction with the antibody the subject's immune system is induced to kill the tumor cell. The antibodies useful in the ADCC procedure include antibodies which interact with a cell in the body. Many such antibodies specific for cellular targets have been described in the art and many are commercially available. Examples of these antibodies are listed below among the list of cancer immunotherapies.

The immunostimulatory nucleic acids may also be administered in conjunction with an anti-cancer therapy. Anti-cancer therapies include cancer medications, radiation and surgical procedures. As used herein, a "cancer medication" refers to a agent which is administered to a subject for the purpose of treating a cancer. As used herein, "treating cancer" includes preventing the development of a cancer, reducing the symptoms of cancer, and/or inhibiting the growth of an established cancer. In other aspects, the cancer medication is administered to a subject at risk of developing a cancer for the purpose of reducing the risk of developing the cancer. Various types of medications for the treatment of cancer are described herein. For the purpose of this specification, cancer medications are classified as chemotherapeutic agents, immunotherapeutic agents, cancer vaccines, hormone therapy, and biological response modifiers.

As used herein, a "cancer medication" refers to an agent which is administered to a subject for the purpose of treating a cancer. As used herein, "treating cancer" includes preventing the development of a cancer, reducing the symptoms of cancer, and/or inhibiting the growth of an established cancer. In other aspects, the cancer medication is administered to a subject at risk of developing a cancer for the purpose of reducing the risk of developing the cancer. Various types of medications for the treatment of cancer are described herein. For the purpose of this specification, cancer medications are classified as chemotherapeutic agents, immunotherapeutic agents, cancer vaccines, hormone therapy, and biological response modifiers. Additionally, the methods of the invention are intended to embrace the use of more than one cancer medication along with the immunostimulatory nucleic acids. As an example, where appropriate, the immunostimulatory nucleic acids may be administered with a both a chemotherapeutic agent and an immunotherapeutic agent. Alternatively, the cancer medication may embrace an immunotherapeutic agent and a cancer vaccine, or a

- 101 -

chemotherapeutic agent and a cancer vaccine, or a chemotherapeutic agent, an immunotherapeutic agent and a cancer vaccine all administered to one subject for the purpose of treating a subject having a cancer or at risk of developing a cancer.

Cancer medications function in a variety of ways. Some cancer medications work by targeting physiological mechanisms that are specific to tumor cells. Examples include the targeting of specific genes and their gene products (i.e., proteins primarily) which are mutated in cancers. Such genes include but are not limited to oncogenes (e.g., Ras, Her2, bcl-2), tumor suppressor genes (e.g., EGFR, p53, Rb), and cell cycle targets (e.g., CDK4, p21, telomerase). Cancer medications can alternatively target signal transduction pathways and molecular mechanisms which are altered in cancer cells. Targeting of cancer cells via the epitopes expressed on their cell surface is accomplished through the use of monoclonal antibodies. This latter type of cancer medication is generally referred to herein as immunotherapy.

Other cancer medications target cells other than cancer cells. For example, some medications prime the immune system to attack tumor cells (i.e., cancer vaccines). Still other medications, called angiogenesis inhibitors, function by attacking the blood supply of solid tumors. Since the most malignant cancers are able to metastasize (i.e., exit the primary tumor site and seed a distal tissue, thereby forming a secondary tumor), medications that impede this metastasis are also useful in the treatment of cancer. Angiogenic mediators include basic FGF, VEGF, angiotensin, angiotensin, endostatin, TNF α , TNF- β , thrombospondin-1, platelet factor 4, CAI, and certain members of the integrin family of proteins. One category of this type of medication is a metalloproteinase inhibitor, which inhibits the enzymes used by the cancer cells to exit the primary tumor site and extravasate into another tissue.

Some cancer cells are antigenic and thus can be targeted by the immune system. In one aspect, the combined administration of immunostimulatory nucleic acids and cancer medications, particularly those which are classified as cancer immunotherapies, is useful for stimulating a specific immune response against a cancer antigen. A "cancer antigen" as used herein is a compound, such as a peptide, associated with a tumor or cancer cell surface and which is capable of provoking an immune response when expressed on the surface of an antigen presenting cell in the context of an MHC molecule. Cancer antigens, such as those present in cancer vaccines or those used to

- 102 -

prepare cancer immunotherapies, can be prepared from crude cancer cell extracts, as described in Cohen, et al., 1994, *Cancer Research*, 54:1055, or by partially purifying the antigen, using recombinant technology, or de novo synthesis of known antigens. Cancer antigens can be used in the form of immunogenic portions of a particular antigen or in some instances a whole cell or a tumor mass can be used as the antigen. Such antigens can be isolated or prepared recombinantly or by any other means known in the art.

The theory of immune surveillance is that a prime function of the immune system is to detect and eliminate neoplastic cells before a tumor forms. A basic principle of this theory is that cancer cells are antigenically different from normal cells and thus elicit immune reactions that are similar to those that cause rejection of immunologically incompatible allografts. Studies have confirmed that tumor cells differ, either qualitatively or quantitatively, in their expression of antigens. For example, "tumor-specific antigens" are antigens that are specifically associated with tumor cells but not normal cells. Examples of tumor specific antigens are viral antigens in tumors induced by DNA or RNA viruses. "Tumor-associated" antigens are present in both tumor cells and normal cells but are present in a different quantity or a different form in tumor cells. Examples of such antigens are oncofetal antigens (e.g., carcinoembryonic antigen), differentiation antigens (e.g., T and Tr antigens), and oncogene products (e.g., HER/neu).

Different types of cells that can kill tumor targets *in vitro* and *in vivo* have been identified: natural killer cells (NK cells), cytolytic T lymphocytes (CTLs), lymphokine-activated killer cells (LAKs), and activated macrophages. NK cells can kill tumor cells without having been previously sensitized to specific antigens, and the activity does not require the presence of class I antigens encoded by the major histocompatibility complex (MHC) on target cells. NK cells are thought to participate in the control of nascent tumors and in the control of metastatic growth. In contrast to NK cells, CTLs can kill tumor cells only after they have been sensitized to tumor antigens and when the target antigen is expressed on the tumor cells that also express MHC class I. CTLs are thought to be effector cells in the rejection of transplanted tumors and of tumors caused by DNA viruses. LAK cells are a subset of null lymphocytes distinct from the NK and CTL populations. Activated macrophages can kill tumor cells in a manner that is not antigen

dependent nor MHC restricted once activated. Activated macrophages are through to decrease the growth rate of the tumors they infiltrate. *In vitro* assays have identified other immune mechanisms such as antibody-dependent, cell-mediated cytotoxic reactions and lysis by antibody plus complement. However, these immune effector mechanisms are thought to be less important *in vivo* than the function of NK, CTLA, LAK, and macrophages *in vivo* (for review see Pissessens, W.P., and David, J., "Tumor Immunology", in: *Scientific American Medicine*, Vol. 2, Scientific American Books, N.Y., pp. 1-13, 1996).

The goal of immunotherapy is to augment a patient's immune response to an established tumor. One method of immunotherapy includes the use of adjuvants. Adjuvant substances derived from microorganisms, such as bacillus Calmette-Guérin, heighten the immune response and enhance resistance to tumors in animals.

Immunotherapeutic agents are medicaments which derive from antibodies or antibody fragments which specifically bind or recognize a cancer antigen. As used herein a cancer antigen is broadly defined as an antigen expressed by a cancer cell. Preferably, the antigen is expressed at the cell surface of the cancer cell. Even more preferably, the antigen is one which is not expressed by normal cells, or at least not expressed to the same level as in cancer cells. Antibody-based immunotherapies may function by binding to the cell surface of a cancer cell and thereby stimulate the endogenous immune system to attack the cancer cell. Another way in which antibody-based therapy functions is as a delivery system for the specific targeting of toxic substances to cancer cells. Antibodies are usually conjugated to toxins such as ricin (e.g., from castor beans), colicistatinin and maytansinoids, to radioactive isotopes such as Iodine-131 and Yttrium-90, to chemotherapeutic agents (as described herein), or to biological response modifiers. In this way, the toxic substances can be concentrated in the region of the cancer and non-specific toxicity to normal cells can be minimized. In addition to the use of antibodies which are specific for cancer antigens, antibodies which bind to vasculature, such as those which bind to endothelial cells, are also useful in this invention. This is because generally solid tumors are dependent upon newly formed blood vessels to survive, and thus most tumors are capable of recruiting and stimulating the growth of new blood vessels. As a result, one strategy of many cancer medicaments

is to attack the blood vessels feeding a tumor and/or the connective tissues (or stroma) supporting such blood vessels.

The use of immunostimulatory nucleic acids in conjunction with immunotherapeutic agents such as monoclonal antibodies is able to increase long-term survival through a number of mechanisms including significant enhancement of ADCC (as discussed above), activation of natural killer (NK) cells and an increase in IFN γ levels. The nucleic acids when used in combination with monoclonal antibodies serve to reduce the dose of the antibody required to achieve a biological result.

Examples of cancer immunotherapies which are currently being used or which are in development are listed in Table C.

Table C

MARKET	BEING NAME (GENERIC NAME)	INDICATION
IDEC/Quantack, Inc./Hoffmann-La Roche (first monoclonal antibody licensed for the treatment of cancer in the U.S.)	Rituximab (Rituxan, Mabthera) (anti-CD20 MAb)	non-Hodgkin's lymphoma
Genentech/Hoffmann-La Roche	Herceptin, anti-H2T DMAS	breast cancer
Cytogen Corp.	Quadrant (CYP-205) radioimmunologic agent	B-cell neoplasms
Centocor/Ciba/Junon	Psorcet (P-1A) (murine monoclonal antibody)	Adjuvant therapy for colorectal (Duke-C)
Centocor/Junon	Psorcet (P-1A) (chimeric murine monoclonal antibody)	Pancreatic, lung, breast, ovary
IDEC	IDEC-Y2B (murine, anti-CD30 MAb) labeled with Yttrium-90	non-Hodgkin's lymphoma
ImClone Systems	BE23 (anti-epidermal MAb, reacts the CD3 epidermal growth factor receptor (EGFR)) (with B03)	Small cell lung
ImClone Systems	C225 (chimeric monoclonal antibody to epidermal growth factor receptor (EGFR))	Metastatic
Techniclon Immunotech/Alpha Therapeutics	Oncocept (anti-vascular endothelial growth factor receptor (VEGFR))	non-Hodgkin's lymphoma
Protein Design Labs	SMART M193 Ab, humanized	Acute myeloid leukemia
Techniclon Corporation/Cambridge Antibody Technology	anti-VEGFR (Camlymar)	non-Hodgkin's lymphoma
Amgen Pharmaceuticals, Inc.	ATRA (ATRA)	Acute promyelocytic leukemia
ImClone Systems	C225 (chimeric anti-EGFR monoclonal antibody) + epidermal radiation	Head & neck, non-small cell lung cancer

Abnova, Canada	Oncor (G43.13, anti-Hicotype CA125, mouse MAb)	Ovarian
Conley Pharma (clinical results have been positive, but the drug has been associated with significant bone marrow toxicity)	Bevac (anti-CD30 MAb labeled with ⁹⁰ Y)	non-Hodgkin's lymphoma
Abnova Pharmaceuticals, Inc.	ATRA-90	Kaposi's sarcoma
IDEC Pharmaceuticals Corp./Genentech	Rituxan [®] (MAb against CD20) plus B Ab in combo. with chemotherapy	B cell lymphoma
Leibniz-Institut Oncology	DP-401, hMAb to the leukocyte antigen CD45	Granulocytic leukemia (CLL)
Center of Molecular Immunology	her 16 (anti CD5, murine MAb) CTL	Cancer
Medarex/Novartis	MDX-210 (humanized anti-HER-2 bispecific antibody)	Breast, ovarian
Medarex/Novartis	MDX-210 (humanized anti-HER-2 bispecific antibody)	Prostate, non-small cell lung, pancreatic, breast
Medarex	MDX-11 (complement activating receptor (CAR) monoclonal antibody)	Acute myelogenous leukemia (AML)
Medarex/Novartis	MDX-210 (humanized anti-HER-2 bispecific antibody)	Renal and colon
Medarex	MDX-11 (complement activating receptor (CAR) monoclonal antibody)	Bx who have marrow purging to acute myelogenous leukemia (AML)
Medarex	MDX-11 (complement activating receptor (CAR) monoclonal antibody)	Acute myeloid leukemia
Medarex	MDX-22 (humanized bispecific antibody, MAb-conjugated) (complement cascade activator)	Acute myeloid leukemia
Cytogen	OV108 (Vincristine-90 labeled antibody)	Ovarian
Cytogen	OV108 (Vincristine-90 labeled antibody)	Prostate
Abnova Pharmaceuticals, Inc.	ATRA-90	non-Hodgkin's lymphoma
Glaxo Wellcome plc	3323Vp4 MAb that binds to ED940 (T _H 1A) presentation antigen on dendritic cells	non-small cell lung, prostate (defunct)
Genentech	Anti-Vβ6/β7, hMAb (MAb conjugated)	Lung, breast, prostate, colorectal
Protein Design Labs	Zenopex (BMAb Anti-Tie (T _H 2 receptor) Ab, humanized)	Leukemia, lymphoma
Protein Design Labs	BMAb M193 Ab, humanized	Acute promyelocytic leukemia
ImClone Systems	C225 (chimeric anti-EGF monoclonal antibody) + toxin	Breast
ImClone Systems (licensed from BPI)	C225 (chimeric anti-EGF monoclonal antibody) + docetaxel	Prostate
ImClone Systems	C225 (chimeric anti-EGF monoclonal antibody) + adriamycin	Prostate
ImClone Systems	B8C4 (anti-Hicotype MAb, similar to Gb3 epitope)	Melanoma
Medarex	MDX-210 (humanized anti-HER-2 bispecific antibody)	Cancer

Medarex	MDX-220 (bispecific for tumor that express TAC-7)	Lung, colon, prostate, ovarian, endometrial, pancreatic and gastric
Medarex/Novartis	MDX-210 (humanized anti-HER-2 bispecific antibody)	Prostate
Medarex/Merck KGaA	MDX-441 (humanized anti-EGF receptor bispecific antibody)	EGF receptor cancer (head & neck, prostate, lung, bladder, cervical, ovarian)
Medarex/Novartis	MDX-210 (humanized anti-HER-2 bispecific antibody)	Comb. Therapy with G-CSF for various cancers, esp. breast
IDEC	HE13040NE-2 (murine monoclonal antibody therapeutic vaccine)	Melanoma
IDEC	HE13040NE-1 (murine monoclonal antibody therapeutic vaccine)	Melanoma
Immunomedica, Inc.	CEACIDE [®] (1-31)	Colorectal and other
Norix	Protargel [®] radioactive antibodies	lymphoma
Novopharm Biotech, Inc.	NovoMAB-02 (pancreatic specific Ab)	Cancer
Techniclon Corporation/ Cambridge Antibody Technology	TNF (chimeric MAb to human antigen)	Brain
Techniclon Corporation/ Cambridge Antibody Technology	TNF (chimeric MAb to human antigen)	Brain
Techniclon International/ Cambridge Antibody Technology	TNF (chimeric MAb to human antigen)	Brain
Genentech/Amgen/AMP	QIN-230 MAb	Colorectal
Merck KGaA	BM0-72000 (chimeric-EGF antagonist)	Cancer
Immunomedica	LymphoCide (humanized IL2 antibody)	non-Hodgkin's B-cell lymphoma
Immunomedica	CMA 676 (monoclonal antibody conjugate)	Acute myelogenous leukemia
Novopharm Biotech, Inc.	Memoparin-C	Colon, lung, pancreatic
Novopharm Biotech, Inc.	4B3 anti-Hicotype Ab	Melanoma, small-cell lung
Center of Molecular Immunology	her 2p13 (anti EGFR humanized Ab)	Melanomamelanoma
Center of Molecular Immunology	her c3 (murine MAb colorectal) for radioimmunotherapy	Colorectal
Genentech Biotechnology/ Calera	BAB3 (bispecific antibody binding site)	Breast cancer
ImClone Systems/Chugai	PLK-2 (monoclonal antibody to focal liver kinase-2 (PLK-2))	Tumor-associated angiogenesis
Immunocore, Inc.	Humanized MAb anti-drug conjugate	Small-cell lung
Medarex, Inc.	MDX-260 bispecific, targets CD3	Melanoma, glioma

Procyon Biopharma, Inc.	ANA Ab	neuroblastoma
Protein Design Lab	SMART ID18 Ab	Cancer
Protein Design Lab/Novartis	SMART ABC184 Ab	B-cell lymphoma
Immunomedics, Inc.	ImmunAIP-CBA	Breast, lung, colon
		Colorectal

Yet other types of chemotherapeutic agents which can be used according to the

invention include Aminoglutethimide, Asparaginase, Busulfan, Carboplatin, Chlorambucil, Cytarabine HCl, Daunorubicin HCl, Etoposide (VP16-213), Flutamide, Hydroxyurea (hydroxycarbamide), Ifosfamide, Interferon Alfa-2a, Alfa-2b, Leuprolide acetate (LHRH-releasing factor analogue), Lomustine (CCNU), Mechlorethamine HCl (nitrogen mustard), Mercaptopurine, Mesna, Mitomycin (o,p'-DDD), Mitoxantrone HCl, Oestradiol, Plicamycin, Procarbazine HCl, Streptozocin, Tamoxifen citrate, Thioguanine, Thiotepa, Vinblastine sulfate, Vincristine (m-AMSA), Azacitidine, Ertropoietin, Ifexmethylnelamine (HMM), Interleukin 2, Mitoguerzone (methyl-GAG; methyl glyoxal bis-guanylhydrazones; MGBG), Penicistatin (2'-deoxycoformycin), Semustine (methyl-CCNU), Teoposide (VM-26) and Vinorelbine sulfate.

Cancer vaccines are medicaments which are intended to stimulate an endogenous immune response against cancer cells. Currently produced vaccines predominantly activate the humoral immune system (i.e., the antibody dependent immune response). Other vaccines currently in development are focused on activating the cell-mediated immune system including cytotoxic T lymphocytes which are capable of killing tumor cells. Cancer vaccines generally enhance the presentation of cancer antigens to both antigen presenting cells (e.g., macrophages and dendritic cells) and/or to other immune cells such as T cells, B cells, and NK cells.

Although cancer vaccines may take one of several forms, as discussed infra, their purpose is to deliver cancer antigens and/or cancer associated antigens to antigen presenting cells (APC) in order to facilitate the endogenous processing of such antigens by APC and the ultimate presentation of antigen presentation on the cell surface in the context of MHC class I molecules. One form of cancer vaccine is a whole cell vaccine which is a preparation of cancer cells which have been removed from a subject, treated *ex vivo* and then reintroduced as whole cells in the subject. Lysates of tumor cells can

also be used as cancer vaccines to elicit an immune response. Another form cancer vaccine is a peptide vaccine which uses cancer-specific or cancer-associated small proteins to activate T cells. Cancer-associated proteins are proteins which are not exclusively expressed by cancer cells (i.e., other normal cells may still express these antigens). However, the expression of cancer-associated antigens is generally

consistently upregulated with cancers of a particular type. Yet another form of cancer vaccine is a dendritic cell vaccine which includes whole dendritic cells which have been exposed to a cancer antigen or a cancer-associated antigen *in vitro*. Lysates or membrane fractions of dendritic cells may also be used as cancer vaccines. Dendritic cell vaccines are able to activate antigen-presenting cells directly. Other cancer vaccines include ganglioside vaccines, heat-shock protein vaccines, viral and bacterial vaccines, and nucleic acid vaccines.

The use of immunostimulatory nucleic acids in conjunction with cancer vaccines provides an improved antigen-specific humoral and cell mediated immune response, in addition to activating NK cells and endogenous dendritic cells, and increasing IFN α levels. This enhancement allows a vaccine with a reduced antigen dose to be used to achieve the same beneficial effect. In some instances, cancer vaccines may be used along with adjuvants, such as those described above.

As used herein, the terms "cancer antigen" and "tumor antigen" are used interchangeably to refer to antigens which are differentially expressed by cancer cells and can thereby be exploited in order to target cancer cells. Cancer antigens are antigens which can potentially stimulate apparently tumor-specific immune responses. Some of these antigens are encoded, although not necessarily expressed, by normal cells. These antigens can be characterized as those which are normally silent (i.e., not expressed) in normal cells, those that are expressed only at certain stages of differentiation and those that are temporally expressed such as embryonic and fetal antigens. Other cancer antigens are encoded by mutant cellular genes, such as oncogenes (e.g., activated ras oncogene), suppressor genes (e.g., mutant p53), fusion proteins resulting from internal deletions or chromosomal translocations. Still other cancer antigens can be encoded by viral genes such as those carried on RNA and DNA tumor viruses.

Other vaccines take the form of dendritic cells which have been exposed to cancer antigens *in vitro*, have processed the antigens and are able to express the cancer

antigens at their cell surface in the context of MHC molecules for effective antigen presentation to other immune system cells.

The immunostimulatory molecule acids are used in one aspect of the invention in conjunction with cancer vaccines which are dendritic cell based. A dendritic cell is a professional antigen presenting cell. Dendritic cells form the link between the innate and the acquired immune system by presenting antigens and through their expression of pattern recognition receptors which detect microbial molecules like LPS in their local environment. Dendritic cells efficiently internalize, process, and present soluble specific antigen to which it is exposed. The process of internalizing and presenting antigen causes rapid upregulation of the expression of major histocompatibility complex (MHC) and costimulatory molecules, the production of cytokines, and migration toward lymphatic organs where they are believed to be involved in the activation of T cells.

Table D lists a variety of cancer vaccines which are either currently being used or are in development.

Table D

MANUFACTURER	Cancer Vaccine in Development or on the Market	BRAND NAME (GENERIC NAME)	INDICATION
Center of Molecular Immunology		BDP	Cancer
Center of Molecular Immunology			Benign prostatic cancer vaccine
Center of Molecular Immunology		Anti-Hitropro	Cancer vaccine
ImCana Systems/Metastasis		Gp130 antigen	Melanoma
Shen-Kowling Cancer Center		Anti-Hitropro Ab	Cancer vaccine
ImCana Systems/Metastasis			
Shen-Kowling Cancer Center			
Progenics Pharmaceuticals, Inc.		GSK melanoma vaccine	Melanoma
Progenics Pharmaceuticals, Inc.		MDV granulosa embryonic vaccine	Lymphoma, colorectal, lung
Certa		H22/100	Breast, ovarian
Abdell		Dysent	Ovarian
AVAX Technologies Inc.		H-Vac, autologous whole cell	Melanoma
AVAX Technologies Inc.		O-Vac, autologous whole cell	Ovarian
AVAX Technologies Inc.		L-Vac, autologous whole cell	Lymphoma-AML
Bionika Inc./Certa		Therapex, F10-K11	Breast, Colorectal

Bionika Inc.	BLP23, MUC-1 peptide vaccine encapsulated in liposomal delivery system	Lung
Bionika Inc.	BLP23, MUC-1 peptide vaccine encapsulated in liposomal delivery system + Liposomal IL-2	Lung
Bionika Inc.	Liposomal Hitropro vaccine	Lymphoma B-cell malignancies
Bion Immunodex	Melanoma, cell lysate	Melanoma
Certa	Peptide antigens, microsphere delivery system and LAMP adjuvant	Breast
Certa	Peptide antigens, microsphere delivery system and LAMP adjuvant	Prostate
Certa	Peptide antigens, microsphere delivery system and LAMP adjuvant	Ovarian
Certa	Peptide antigens, microsphere delivery system and LAMP adjuvant	Lymphoma
Certa	Peptide antigens, microsphere delivery system and LAMP adjuvant	Lung
Virus Research Institute	Toxin/antigen recombinant delivery system	All cancers
Apollon Inc.	Gastric-TCR	T-cell lymphoma
Bavarian Nordic Research Institute AS	MVA-based (vaccine virus) vaccine	Melanoma
BioCana Pharma/BioCana Vaccine	PACIS, BCG vaccine	Bladder
Camba Pharmaceuticals	TA-HPV	Cervical
Camba Pharmaceuticals	TA-CN	Cervical
Camba Pharmaceuticals	DISC-Virus, immunotherapy	Cancer
Pastor Marican Consultants	ImmuCytob/TherCytob - BCG Immunotherapeutic (Bacillus Calmette-Guérin/Conseguat), for intravesical treatment of superficial bladder cancer	Bladder

As used herein, chemotherapeutic agents enhance all other forms of cancer medications which do not fall into the categories of immunotherapeutic agents or cancer vaccines. Chemotherapeutic agents as used herein encompass both chemical and biological agents. These agents function to inhibit a cellular activity which the cancer cell is dependent upon for continued survival. Categories of chemotherapeutic agents include alkylating/alkaloid agents, antineoplastic, hormones or hormone analogs, and miscellaneous antineoplastic drugs. Most if not all of these agents are directly toxic to cancer cells and do not require immune stimulation. Combination chemotherapy and

Johnson, E.	Lumbia	Cheshiba	Cancer, Breast Cancer, Hairy Cell Leukemia
Johnson	Pearce	Pearlizer	Kaposi Sarcoma
Ivaz	Drell	Doutchick, L. Pennant	K&C Cancer
Sequias	Coxley	Doutchick, L. Pennant	K&C Cancer
Sequias	Pinck	Pinck	Leukemia
Shelving, A.J.	Pharmachia	Pharmachia	Lung/Breast Cancer
Pharmachia, E.			
Upham	Deyo, C.T.	Deyo, C.T.	Neoplastic Meningitis
Upham	ZD 1103	ZD 1103	New Small Cell Lung Cancer
Zacca			Cancer, Pancreatic Cancer
BASF	LI 79533	Bi-Naphtalimide	Oncology
BASF	LI 103793	Dolamine	Ovarian/Breast Cancer
Shelving, Philip	Coxley	Doutchick, L. Pennant	Pancreatic Cancer, New Small Cell Lung Cancer, Breast, Bladder and Ovarian
Shelving, Philip	Guzzo	Genschick	Platinum based NSCL, ovarian etc.
Zacca	ZD 0473/Anomized	ZD 0473/Anomized	
Yanowitch	YM 116	YM 116	Prostate Cancer
Yanowitch	Second, 125 Rapid 86	Lodine Small	Prostate Cancer
Yanowitch			
Asenblum			
Agurum	C684/C622 Inhibitors	c684/c622 Inhibitors	Solid Tumors
Agurum	PAP Inhibitors	PAP Inhibitors	Solid Tumors
Chiriacenco	D4109	Dextamido	Solid Tumors
British Myers	UPT (regular/Anom)	UPT (regular/Anom)	Solid Tumors
British Myers			
Sakyo	Kashin	Kashin	Solid Tumors
Van Medina	182/Anom	182/Anom	Solid Tumors
British Myers	182/Anom	182/Anom	Solid Tumors
British Myers			
British Myers	Vanom	Vanopende	Solid Tumors
British Myers			
British Myers	Vanopende	Carboplatin	Solid Tumors
British Myers			
British Myers	Paranoid	Carboplatin, Small	Solid Tumors
British Myers			
British Myers	Paranoid	Capitain	Solid Tumors
British Myers			
British Myers	Vopende	Bespande	Solid Tumors, Metastases
British Myers			
Zacca	ZD 9331	ZD 9331	Solid Tumors, Metastases
Chapel			Colorectal
Russo, Thomas	1-tocoxen	1-tocoxen	Solid Tumors, Breast Cancer
Gino, Weldon	1-tocoxen	1-tocoxen	Solid Tumors, Breast Cancer
Gino, Weldon	Producing of granules	Producing of granules	1 Cell Tumors, lymphomas
British Myers	metastasis	metastasis	1 Cell, lymphoma
British Myers	Tocoxen Analogs	Tocoxen Analogs	Tumor follow up

- 114 -

The *in vitro* assay also includes a method for inducing antigen non-specific innate immune activation and broad spectrum resistance to infectious challenge using the immunostimulatory nucleic acids. The term antigen non-specific innate immune activation as used herein refers to the activation of immune cells other than B cells and for instance can include the activation of NK cells, T cells or other immune cells that can respond in an antigen independent fashion or some combination of these cells. A broad spectrum resistance to infectious challenge is induced because the immune cells are in active form and are primed to respond to any invading compound or microorganism. The cells do not have to be specifically primed against a particular antigen. This is particularly useful in biodefense, and the other circumstances described above such as travellers.

Immunostimulatory nucleic acids are effective in non-rodent vertebrates.

30 the same class of immunostimulatory nucleic acids, sometimes referred to as human specific immunostimulatory nucleic acids. Rodents, however, respond to different nucleic acids. As shown herein an immunostimulatory nucleic acid causing optimal

stimulation in humans may not generally cause optimal stimulation in a mouse and vice versa. An immunostimulatory nucleic acid causing optimal stimulation in humans often does, however, cause optimal stimulation in other animals such as cow, horses, sheep, etc. One of skill in the art can identify the optimal nucleic acid sequences useful for a particular species of interest using routine assays described herein and/or known in the art, using the guidance supplied herein.

The immunostimulatory nucleic acids may be directly administered to the subject or may be administered in conjunction with a nucleic acid delivery complex. A nucleic acid delivery complex shall mean a nucleic acid molecule associated with (e.g. ionically or covalently bound to; or encapsulated within) a targeting means (e.g. a molecule that results in higher affinity binding to target cell (e.g., B cell surfaces and/or increased cellular uptake by target cells). Examples of nucleic acid delivery complexes include nucleic acids associated with a sterol (e.g. cholesterol), a lipid (e.g. a cationic lipid, virosome or liposome), or a target cell specific binding agent (e.g. a ligand recognized by target cell specific receptor). Preferred complexes may be sufficiently stable *in vivo* to prevent significant uncoupling prior to internalization by the target cell. However, the complex can be cleavable under appropriate conditions within the cell so that the nucleic acid is released in a functional form.

Delivery vehicles or delivery devices for delivering antigen and nucleic acids to surfaces have been described. The immunostimulatory nucleic acid and/or the antigen and/or other therapeutics may be administered alone (e.g., in saline or buffer) or using any delivery vehicles known in the art. For instance the following delivery vehicles have been described: Cocllestes (Gould-Fogarty et al., 1994, 1996); Emulsomes (Vancott et al., 1998, Lowell et al., 1997); ISCOMs (Morset et al., 1993, Carlsson et al., 1991, Hu et al., 1998, Morein et al., 1999); Liposomes (Childers et al., 1999, Michalek et al., 1989, 1992, de Haan 1995a, 1995b); Live bacterial vectors (e.g., *Salmonella*, *Escherichia coli*, *Bacillus edwards-guerin*, *Shigella*, *Lactobacillus*) (Hesse et al., 1996, Pourwela et al., 1998, Chutfield et al., 1993, Stover et al., 1991, Nugent et al., 1998); Live viral vectors (e.g., Vaccinia, adenovirus, Herpes Simplex) (Gallichan et al., 1993, 1995, Mass et al., 1996, Nugent et al., 1998, Flexner et al., 1988, Morrow et al., 1999); Microspheres (Quin et al., 1998, Jones et al., 1996, Maloy et al., 1994, Moore et al., 1995, O'Hagan et al., 1994, Eldridge et al., 1989); Nucleic acid vaccines (Fyans et al., 1993, Kuklin et al.,

1997, Sasaki et al., 1998, Okada et al., 1997, Ishii et al., 1997); Polymers (e.g. carboxymethylcellulose, chitosan) (Hamejima et al., 1998, Jabbel-Gill et al., 1998); Polymer rings (Wyatt et al., 1998); Protosomes (Vancott et al., 1998, Lowell et al., 1998, 1996, 1997); Sodium Fluoride (Hsieh et al., 1998); Transgenic plants (Tacket et al., 1998, Mason et al., 1998, Haq et al., 1995); Virosomes (Gluck et al., 1992, Mangardi et al., 1995, Cysz et al., 1998); Virus-like particles (Jiang et al., 1999, Leibl et al., 1998). Other delivery vehicles are known in the art and some additional examples are provided below in the discussion of vectors.

The term effective amount of a immunostimulatory nucleic acid refers to the amount necessary or sufficient to realize a desired biologic effect. For example, an effective amount of a immunostimulatory nucleic acid for inducing mucosal immunity is that amount necessary to cause the development of IgA in response to an antigen upon exposure to the antigen, whereas that amount required for inducing systemic immunity is that amount necessary to cause the development of IgG in response to an antigen upon exposure to the antigen. Combined with the teachings provided herein, by choosing among the various active compounds and weighting factors such as potency, relative bioavailability, patient body weight, severity of adverse side-effects and preferred mode of administration, an effective prophylactic or therapeutic treatment regimen can be planned which does not cause substantial toxicity and yet is entirely effective to treat the particular subject. The effective amount for any particular application can vary depending on such factors as the disease or condition being treated, the particular immunostimulatory nucleic acid being administered, the antigen, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art can empirically determine the effective amount of a particular immunostimulatory nucleic acid and/or antigen and/or other therapeutic agent without necessitating undue experimentation.

Subject doses of the compounds described herein for mucosal or local delivery typically range from about 0.1 µg to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween. More typically mucosal or local doses range from about 10 µg to 5 mg per administration, and most typically from about 100 µg to 1 mg, with 2 - 4 administrations being spaced days or weeks apart. More typically, immune stimulant

5 doses range from 1 µg to 10 mg per administration, and most typically 10µg to 1 mg, with daily or weekly administrations. Subject doses of the compounds described herein for parenteral delivery for the purpose of inducing an antigen-specific immune response, wherein the compounds are delivered with an antigen but not another therapeutic agent are typically 5 to 10,000 times higher than the effective mucosal dose for vaccine adjuvant or immune stimulant applications, and more typically 10 to 1,000 times higher, and most typically 20 to 100 times higher. Doses of the compounds described herein for parenteral delivery for the purpose of inducing an innate immune response or for increasing ADCC or for inducing an antigen specific immune response when the immunostimulatory nucleic acids are administered in combination with other therapeutic agents or in specialized delivery vehicles typically range from about 0.1 µg to 10 mg per administration, which depending on the application could be given daily, weekly, or monthly and any other amount of time therebetween. More typically parenteral doses for these purposes range from about 10 µg to 5 mg per administration, and most typically from about 100 µg to 1 mg, with 2 - 4 administrations being spaced days or weeks apart. In some embodiments, however, parenteral doses for these purposes may be used in a range of 5 to 10,000 times higher than the typical doses described above.

For any compound described herein the therapeutically effective amount can be initially determined from animal models. A therapeutically effective dose can also be determined from human data for CpG oligonucleotides which have been tested in humans (human clinical trials have been initiated) and for compounds which are known to exhibit similar pharmacological activities, such as other mucosal adjuvants, e.g., LT and other adjuvants for vaccination purposes, for the mucosal or local administration. Higher doses are required for parenteral administration. The applied dose can be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other methods as are well-known in the art is well within the capabilities of the ordinarily skilled artisan.

The formulations of the invention are administered in pharmaceutically acceptable solutions, which may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, adjuvants, and optionally other therapeutic ingredients.

For use in therapy, an effective amount of the immunostimulatory nucleic acid can be administered to a subject by any mode that delivers the nucleic acid to the desired surface, e.g., mucosal, systemic. Administering the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan.

Preferred routes of administration include but are not limited to oral, parenteral, intranasal, intranasal, intratracheal, inhalation, ocular, vaginal, and rectal.

For oral administration, the compounds (i.e., immunostimulatory nucleic acids, antigens and other therapeutic agents) can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. Pharmaceutical preparations for oral use can be obtained as solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable excipients, if desired, to obtain tablets or dragee cores.

Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginate acid or a salt thereof such as sodium alginate. Optionally the oral formulations may also be formulated in saline or buffers for neutralizing internal acid conditions or may be administered without any carriers.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as

tal or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.

Microspheres formulated for oral administration may also be used. Such microspheres have been well defined in the art. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds, when it is desirable to deliver them systemically, may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions.

Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active compounds may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

Suitable liquid or solid pharmaceutical preparation forms are, for example, aqueous or saline solutions for inhalation, microencapsulated, emulsified, coated onto microscopic gold particles, contained in liposomes, nebulized, aerosols, pellets for implantation into the skin, or dried onto a sharp object to be scratched into the skin. The pharmaceutical compositions also include granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, drops or preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of methods for drug delivery, see Langer, *Science* 249:1527-1533, 1990, which is incorporated herein by reference.

The immunostimulatory nucleic acids and optionally other therapeutics and/or antigens may be administered *per se* (nude) or in the form of a pharmaceutically acceptable salt. When used in medicine the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically acceptable salts thereof. Such salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulphuric, nitric,

- 121 -

phosphoric, maleic, acetic, salicylic, p-toluenesulphonic, tartaric, citric, methanesulphonic, formic, malonic, succinic, naphthalene-2-sulphonic, and hexazene sulphonic. Also, such salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group.

Stable buffering agents include: acetic acid and a salt (1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.5-2% w/v). Stable preservatives include benzalkonium chloride (0.003-0.03% w/v), chlorobutanol (0.3-0.9% w/v), parabens (0.01-0.25% w/v) and thimerosal (0.004-0.02% w/v).

10 The pharmaceutical compositions of the invention contain an effective amount of an immunostimulatory nucleic acid and optionally antigens and/or other therapeutic agents optionally included in a pharmaceutically-acceptable carrier. The term

pharmaceutically-acceptable carrier means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration to a human or other vertebrate animal. The term carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being commingled with the compounds of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutic efficiency.

20 The immunostimulatory nucleic acids useful in the invention may be delivered in mixtures with additional adjuvant(s), other therapeutics, or antigen(s). A mixture may consist of several adjuvants in addition to the immunostimulatory nucleic acid or several antigen or other therapeutics.

25 A variety of administration routes are available. The particular mode selected will depend, of course, upon the particular adjuvants or antigen selected, the particular condition being treated and the dosage required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of an immune response without causing clinically unacceptable adverse effects. Preferred modes of administration are discussed above.

- 122 -

5 The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the compounds into association with a carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately bringing the compounds into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product. Liquid dose units are vials or ampoules. Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, nature and severity of the disorder, age and body weight of the patient, different doses may be necessary. The administration of a given dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units. Multiple administration of doses at specific intervals of weeks or months apart is usual for boosting the antigen-specific response.

15 Other delivery systems can include time-release, delayed release or sustained release delivery systems. Such systems can avoid repeated administrations of the compounds, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. They include polymer base systems such as poly(lactide-glycolide), copolyoxalates, poly(vinylacetate), polycaprolactones, polycaprolactams, poly(hydroxybutyric acid), and poly(anhydrides). Microcapsules of the foregoing polymers containing drugs are described in, for example, U.S. Patent 5,075,109. Delivery systems also include non-polymer systems that are: lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono-di- and tri-glycerides; hydrogel release systems; gelastic systems; peptide based systems; wax coatings; compressed tablets using conventional binders and excipients; partially fused implants; and the like. Specific examples include, but are not limited to: (a) ocudonal systems in which an agent of the invention is contained in a form within a matrix such as those described in U.S. Patent Nos. 4,452,775, 4,675,189, and 5,736,152, and (b) diffusional systems in which an active component permeates at a controlled rate from a polymer such as described in U.S. Patent Nos. 3,854,480, 5,133,974 and 5,407,686. In addition, pump-based hardware delivery systems can be used, some of which are adapted for implantation.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

Examples

Materials and Methods

Oligodeoxynucleotides: Native phosphodiester and phosphorothioate-modified ODN were purchased from Operon Technologies (Alameda, CA) and Hydriodon Specialty Products (Milton, MA). ODN were tested for endotoxin using the LAL-assay (LAL-assay BioWhittaker, Walkersville, MD; lower detection limit 0.1 EU/ml). For *in vitro* assays, ODN were diluted in TE-buffer (10 mM Tris, pH 7.0, 1 mM EDTA), and stored at -20° C. For *in vivo* use, ODN were diluted in phosphate buffered saline (0.1 M PBS, pH 7.3) and stored at 4°C. All dilutions were carried out using pyrogen-free reagents.

Isolation of human PBMC and cell culture: Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood of healthy volunteers by Ficoll-Paque density gradient centrifugation (Histopaque-1077, Sigma Chemical Co., St. Louis, MO) as described (Hartmann et al., 1999 Proc. Natl. Acad. Sci USA 96:9305-10). Cells were suspended in RPMI 1640 culture medium supplemented with 10% (v/v) heat-inactivated (56°C, 1 h) FCS (HyClone, Logan, UT), 1.5 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (all from Gibco BRL, Grand Island, NY) (complete medium). Cells (final concentration 1×10^6 cells/ml) were cultured in complete medium in a 5% CO₂ humidified incubator at 37°C. ODN and LPS (from *Salmonella typhimurium*, Sigma Chemical Co., St. Louis, MO) or anti-IgM were used as stimuli. For measurement of human NK lytic activity, PBMC were incubated at 5×10^6 /well in 24-well plates. Cultures were harvested after 24 hours, and cells were used as effectors in a standard 4 hours ⁵¹Cr-release assay against K562 target cells as previously described (Ballas et al., 1996 J. Immunol. 157:1840-1845). For B cell proliferation, 1 µCi of ³H thymidine was added 18 hours before harvest, and the amount of ³H thymidine incorporation was determined by scintillation counting at day 5. Standard deviations of the triplicate wells were < 5%.

Flow cytometry on human PBMC: Surface antigens on primary PBMC were stained as previously described (Hartmann et al., 1998 J. Pharmacol. Exp. Ther. 285:920-928). Monoclonal antibodies to CD3 (UCHL1), CD14 (M5E2), CD19 (B43), CD56 (B159), CD69 (FN50) and CD86 (2331 [FUN-1]) were purchased from Pharmingen, San Diego, CA. IgG1,k (MOPC-21) and IgG2a,k (Hartmann et al., 1999 Proc. Natl. Acad. Sci USA 96:9305-10) were used to control for non-specific staining. NK cells were identified by CD56 expression on CD3, CD14 and CD19 negative cells, whereas B cells were identified by expression of CD19. Flow cytometric data of 10000 cells per sample were acquired on a FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA). The viability of cells within the FSC/SSC gate used for analysis was examined by propidium iodide staining (2 µg/ml) and found to be higher than 98%. Data were analyzed using the computer program FlowJo (version 2.5.1, Tree Star, Inc., Stanford, CA).

Results:

Example 1: CpG-dependent stimulation of human B cells depends on methylation and ODN length

Human PBMC were obtained from normal donors and cultured for five days at 2×10^6 cells/well with the indicated concentrations of the indicated ODN sequences. As shown in Table F, human PBMCs proliferate above the background when cultured with a variety of different CpG ODN, but also show some proliferation even with ODN that do not contain any CpG motifs. The importance of unmethylated CpG motifs in providing optimal immune stimulation with these ODN is demonstrated by the fact that ODN 1840 (SEQ ID NO. 83) induces 56,603 counts of ³H-thymidine incorporation whereas the same T-rich ODN with the CpG motifs methylated (non-CpG), 1979 (SEQ ID NO. 222), induces lower, but still increased over background, activity (only 18,618 counts) at the same concentration of 0.6 µg/ml. The reduced proliferation at higher ODN concentrations may be an artifact of the cells becoming exhausted under these experimental conditions or could reflect some toxicity of the higher ODN concentrations. Interestingly, shorter ODN containing CpG motifs, such as the 13-14mers 2015 and 2016, are less stimulatory despite the fact that their molar concentration would actually be higher since the ODNs were added on the basis of mass rather than molarity. This demonstrates that ODN length may also be an important determinant in the immune

effects of the ODN. A non-CpG ODN but slight T-rich ODN (about 30% T), 1982 (SEQ ID NO. 225), caused only a small amount of background cell proliferation.

Table F

Oligo Concentration			
ODN#	0.15 µg/ml	0.6 µg/ml	2 µg/ml
Cues only	648	837	799
1840 (SEQ ID NO. 83)	5744	56,603	31,787
2016 (SEQ ID NO. 256)	768	4607	20,497
1979 (SEQ ID NO. 222)	971	18,618	29,246
1892 (SEQ ID NO. 135)	787	10,078	22,850
2010 (SEQ ID NO. 250)	849	20,741	8,054
2012 (SEQ ID NO. 252)	2586	62,955	52,462
2013 (SEQ ID NO. 253)	1043	47,960	47,231
2014 (SEQ ID NO. 254)	2700	50,708	46,625
2015 (SEQ ID NO. 255)	1059	23,239	36,119

Numbers represent cpm of ³H-thymidine incorporation for cultures of human PBMCs set up as described above.

Example 2. Concentration-dependent activation of human NK cell activity with thymidine-rich ODN.

Human PBMCs were cultured for 24 hours with a panel of different CpG or non-CpG ODN at two different concentrations, and then tested for their ability to kill NK target cells as described previously (Gallus et al., 1996 J. Immunol. 157:1840-1845). Killing is measured as lytic units, or L.U. The human donor used in this experiment had a background level of 3.69 L.U. which increased to 180.36 L.U. using the positive control, IL-2. A CpG oligo, 2006 (SEQ ID NO. 246), induced high levels of NK lytic function at a low concentration of 0.6, and a lower level at a concentration of 6.0. Surprisingly, a T-rich ODN in which the CpG motifs of 2006 were methylated (ODN at 2117 (SEQ ID NO. 358)) or inverted to GpCs (ODN 2137 (SEQ ID NO. 886)) retained strong immune stimulatory function at the higher ODN concentrations, as shown in Table G. These concentration-dependent immune stimulatory effects are not a general property of the phosphorothioate backbone since the experiments described below demonstrate that a poly-A ODN, is nonstimulatory above background levels. Some stimulation is seen with a 24-base long ODN in which all of the base positions are randomized so that A, C, G, and T will occur at a frequency of 25% in each of the base positions (ODN 2182 (SEQ ID NO. 432)). However, the stimulatory effect of such a 24-base ODN is greatly enhanced if it is pure poly-T, in which case stimulation is also seen at the lowest concentration of 0.6 µg/ml (ODN 2183 (SEQ ID NO. 433)). In fact, the stimulatory activity of ODN SEQ ID NO. 433 at this low concentration is higher than that of any other ODN tested at this low concentration, aside from the optimal human immune stimulatory ODN of SEQ ID NO. 246. In fact, the higher concentration of ODN SEQ ID NO. 433 stimulated more NK activity than any other phosphorothioate ODN except for the strong CpG ODN 2142 (SEQ ID NO. 890), which was marginally higher. If the G content of ODN SEQ ID NO. 246 is increased relative to the T content by addition of more Gs, thus resulting in a decrease in the proportion of T nucleotides the immune stimulatory effect of the ODN is reduced (see ODN 2132 (SEQ ID NO. 373)). Thus, the T content of an ODN is an important determinant of its immune stimulatory effect. Although a poly-T ODN is the most stimulatory of the non-CpG ODN, other bases are also important in determining the immune stimulatory effect of a non-CpG ODN. ODN 2131 (SEQ ID NO. 372), in which slightly more than half of the bases are T and in which there are no Gs, is immune stimulatory at a concentration of 6 µg/ml but has less activity than other T-rich ODN. If the 6 A's in ODN 2131 (SEQ ID NO. 372)

are replaced by 6 Gs, the immune stimulatory effect of the ODN can be increased (see ODN 2130 (SEQ ID NO. 371)).

Table G

HUMAN PBL CULTURED OVERNIGHT WITH OLIGOS

MR	3605																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				</
----	------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	----

- 129 -

+ 2131 (6.0 ug/ml)	2.29	6.73	7.30	18.02	32.73	49.06	5.08
+ 2136 (0.3 ug/ml)	2.50	5.26	8.20	15.95	26.64	33.07	2.31
+ 2136 (1.0 ug/ml)	5.91	10.99	17.31	26.97	50.64	63.78	10.84
+ 2137 (0.3 ug/ml)	2.36	4.00	6.65	12.94	24.13	38.86	2.58
+ 2137 (1.0 ug/ml)	3.72	9.55	17.15	34.55	52.27	65.33	11.58
+ 2158 (0.3 ug/ml)	1.25	2.36	6.90	16.39	15.63	29.82	1.17
+ 2158 (1.0 ug/ml)	4.73	7.26	11.07	15.55	30.80	43.71	4.16
+ 2118 (0.6 ug/ml)	1.55	3.38	6.85	13.36	20.15	27.71	1.13
+ 2118 (6.0 ug/ml)	2.65	3.88	9.29	12.19	22.47	28.99	1.34

Example 3: Induction of B cell proliferation by T-rich non-CpG ODN.

To assess the ability of T-rich ODN to activate B cell proliferation, human PBMCs were stained with the cytoplasmic dye CFSE2, incubated with five days with the indicated ODN at either 0.15 or 0.3 ug/ml, and then analyzed by flow cytometry. B cells were identified by gating on cells positive for the lineage marker CD19. CpG ODN 2006 was a strong inducer of B cell proliferation, and this effect was reduced if the CpG motifs were methylated or inverted to GpC as shown in Figure 1 at an ODN concentration of 0.3 ug/ml. The base composition of the ODN appears to be important in determining the immune stimulatory effect. Reducing the T content of an ODN substantially reduces immune stimulatory effect, as exemplified by ODN 2177 (SEQ ID NO. 427) in which 6 of the Ts present in ODN 2137 (SEQ ID NO. 886) have been switched to A's, resulting in a greatly reduced immune stimulatory effect. The importance of T's in the immune stimulatory effect of an ODN is also shown by comparison of ODN 2116 (SEQ ID NO. 357) and 2181 (SEQ ID NO. 431), which differ in the 3' end of the ODN. ODN 2181, in which the 3' end is poly-T is more stimulatory

- 130 -

than ODN 2116, in which the 3' end is poly-C, despite the fact that both ODN have a TCGTCG at the 5' end.

Example 4: B Cell Proliferation Induced by TG Oligonucleotides

The stimulatory effects of TG motifs are shown in Figure 2. ODN 2137 has the identical base composition as ODN 2006, but the CG motifs have all been inverted to GC's resulting in a CG-A-free nucleic acid. ODN does however contain 6 TG dinucleotides. In ODN 2177, all the TG dinucleotides of ODN 2137 have been changed to AG. Although ODN 2177 contains only 6 adenines, it is virtually nonstimulatory at a concentration of 0.2 ug/ml. For comparison, an ODN 24 bases in length in which each position is randomized to be any of the four bases (ODN 2182) induces > 12% of B cells to proliferate at a concentration of 0.2 ug/ml. These results indicate that the stimulatory effects of ODN 2137 are not simply those of a phosphorothioate backbone, but relate to the presence of TG dinucleotides.

In order to determine the effect of varying the number of TG dinucleotide motifs, ODN 2200 and ODN 2202 were compared, as shown in Figure 2. Both ODN contain 18 Ts and 6 Gs, but in ODN 2200 all of the Gs are consecutive, so that there is only one TG dinucleotide, whereas in ODN 2202, the Gs are split up as CG dinucleotides throughout the ODN so that there are three TGs. ODN 2202 is significantly more stimulatory than ODN 2200, consistent with the model that at least three TG motifs in an ODN are required for optimal stimulatory activity. It is likely that even higher levels of stimulation could be achieved if the TG motifs had been optimized as taught herein.

Example 5: Effects of TTG versus TTG motif.

Figure 3 shows the results of experiments conducted to study TG content in terms of the relative levels of Ts versus Gs as it relates to the stimulatory effect of an ODN. The Figure shows that an ODN in which all of the bases are randomized to be either T or G (ODN 2188 (SEQ ID NO. 905)) is nonstimulatory at a concentration of 0.2 ug/ml, similar to an ODN in which all of the bases are randomized to be either A or G (ODN 2189 (SEQ ID NO. 906)). However, at the higher concentration of 2 ug/ml, the randomized TTG ODN 2188 is significantly more stimulatory. This latter level of stimulation is still lower than that which occurs with a totally randomized ODN (ODN 2182 (SEQ ID NO. 432)). The highest stimulation at low concentrations is seen with an

CpG ODN 2006 (SEQ ID NO.: 246). PBMC (2×10^6 cells/ml) of a blood donor ($n=2$) were incubated with the indicated concentrations of ODNs 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 5126 (SEQ ID NO.: 1058), and 5162 (SEQ ID NO.: 1094). Cells were incubated for 48h at 37°C as described above and stained with mAb for CD19 (B cell marker) and CD86 (B cell activation marker, B7-2). Expression was measured by flow cytometry.

Using different concentrations of ODNs, we showed (Fig. 4) that T-rich ODNs without a CpG motif can induce stimulation of human B cells. ODN 5126 (SEQ ID NO.: 1058) which contains only a single poly-T sequence but is greater than 50% T, caused high levels of human B cell activation. Although there are some similarities to SEQ ID NO.: 246 (e.g. more than 80% T/G content), this ODN clearly lacks any known immunostimulatory CpG motif. Surprisingly, for all tested T-rich ODNs, the highest stimulatory index was obtained at concentrations between 3 and 10 μ g/ml. The highest stimulatory index of the tested ODNs was achieved by CpG/T-rich ODN SEQ ID NO.: 246 at 0.4 μ g/ml. Interestingly, the activity decreased at high concentrations.

Poly A, Poly C and Poly T sequences were synthesized and tested for biological activity. PBMC (2×10^6 cells/ml) of one representative donor ($n=3$) were stimulated as described above by 0.4 μ g/ml, 1.0 μ g/ml or 10.0 μ g/ml of the following ODNs: 2006 (SEQ ID NO.: 246), 2196 (SEQ ID NO.: 913) (Poly T, 18 bases), 2194 (SEQ ID NO.: 911) (Poly T, 27 bases), 5162 (SEQ ID NO.: 1094) (Poly T, 30 bases), 5163 (SEQ ID NO.: 1095) (Poly A, 30 bases), 5168 (SEQ ID NO.: 1096) (Poly C, 30 bases) and 5169 (SEQ ID NO.: 1097) (Poly C, 30 bases). Expression of the activation marker CD86 (B7-2) on CD19-positive B cells was measured by flow cytometry.

Fig. 5 demonstrates that the length of the sequence, at least for Poly T ODNs, has an important impact on its activity. A Poly T sequence containing only 18 bases (SEQ ID NO.: 913) was shown to be less stimulatory than one with 27 bases (SEQ ID NO.: 911) or one with 30 bases (SEQ ID NO.: 1094) with a clear rank of stimulation: SEQ ID NO.: 1094 > SEQ ID NO.: 911 > SEQ ID NO.: 913. Poly A (SEQ ID NO.: 1095) or Poly C (SEQ ID NO.: 1097) sequences, in contrast, do not induce activation of human B cells. Surprisingly it was also discovered that Poly C sequences (SEQ ID NO.: 1096) can activate human B cells at least at high concentrations (10 μ g/ml) (Fig. 5).

Two other T-rich ODNs, namely 1982 (SEQ ID NO.: 225) and 2041 (SEQ ID NO.: 282) lacking CpG motifs were tested for their effect on human B cells. PBMC ($n=2$) were incubated with the indicated concentrations of ODN 2006 (SEQ ID NO.: 246), 1982 (SEQ ID NO.: 225) and 2041 (SEQ ID NO.: 282) as described above. B cell activation (expression of the activation marker CD86) was measured by flow cytometry.

Fig. 6 demonstrates that T-rich non-CpG ODN are immunostimulatory at concentrations higher than 1 μ g/ml. Incorporation of a CpG motif into 1982 enhanced the immunostimulatory activity. Elongation with a Poly T sequence did not enhance the immunostimulatory activity of this already T-rich ODN but rather, decreased the activation potential slightly.

Example 7: Immunostimulation of non-CpG ODNs is reflected in the enhancement of NK activation, NK cytotoxicity and monocyte activation

NK cells as well as monocytes were tested for their response to non-CpG ODNs. PBMC (2×10^6 cells/ml) were incubated with 6 μ g/ml of the following ODNs ($n=4$): 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 911) and 5126 (SEQ ID NO.: 1058). After 24h of cultivation at 37°C cells were harvested and stained with mAb for CD3 (T cell marker), CD56 (NK cell marker) and CD69 (early activation marker) as described above. Expression of CD69 on CD56-positive NK cells was measured by flow cytometry.

Fig. 7 shows that for Poly T ODNs similar effects can be observed as described in Fig. 5. The stimulation of NK cells, like B cells, may be influenced by the length of the ODN. ODN 2183 (SEQ ID NO.: 433) (21 bases) induced activation of NK cells but to a lesser extent than the longer ODN 2194 (SEQ ID NO.: 911) (27 bases), as measured by enhanced expression of the early activation marker CD69. ODN 5126 (SEQ ID NO.: 1058) was also demonstrated to activate human NK cells (Fig. 7).

It is believed that the anti-tumor activity of CpG ODNs can be assessed by the ability of the ODN to enhance NK-mediated cytotoxicity *in vitro*. ODNs containing at the 5' and 3' ends stretches of Poly G were shown to result in the highest induction of cytotoxicity (Ballas, Z. K., et al. 1996 *J. Immunol.* 157:1840). To investigate the influence of non-CpG T-rich ODN on NK cytotoxicity, we analyzed the effect of the

ODNs 2194 (SEQ ID NO.: 911) and 5126 (SEQ ID NO.: 1058) on NK-mediated lysis (Fig. 8). NK-mediated lysis of K-562 target cells was measured after overnight incubation of PBMC with 6µg/ml of the ODN 2006 (SEQ ID NO.: 246), SEQ ID NO.: 911 (SEQ ID NO.: 911) (Poly T, 27 bases) and 5126 (SEQ ID NO.: 1058) as described above. SEQ ID NO.: 1058 demonstrated small increases in lysis by human NK cells as compared to no ODN. SEQ ID NO.: 911 and SEQ ID NO.: 246 enhanced human NK cell cytotoxicity to an even higher extent.

Previous reports demonstrated that not only NK cells but also NKT cells are mediators of cytotoxic responses to tumor cells (14). We, therefore, looked at the potential activation of human NKT cells by T-rich non-CpG ODN. PBMC of one representative donor (n=2) were incubated with 6µg/ml ODN 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 913) and 5126 (SEQ ID NO.: 1058) for 24h as described above. Activation of NKT cells was measured by flow cytometry after staining of cells with mAb for CD3 (T cell marker), CD56 (NK cell marker) and CD69 (early activation marker). Shown is the expression of CD69 on CD3 and CD56 double-positive cells (NKT cells).

In Fig. 9, SEQ ID NO.: 911 as well as SEQ ID NO.: 1058 were found to stimulate NKT cells. Similar to NK cells SEQ ID NO.: 911 (Poly T) was more active than SEQ ID NO. 1058. In addition, as described above for B cells and NK cells, the length of the ODN has some influence on the immunostimulatory potential, with the longer ODN having stronger effects on NKT cells. Similar results were observed for human T cells.

Another type of cell of the immune system involved in fighting infectious is the monocytes. These cells release upon activation a variety of cytokines and can mature into dendritic cells (DC), professional antigen-presenting cells (Reitt, L., J. Brostoff, and D. Males, 1998, *Immunology*, Mosby, London). Fig. 10 shows activation of human monocytes after culturing of PBMC with different ODNs. PBMC (2x10⁶ cells/ml) were incubated with 6µg/ml 2006 (SEQ ID NO.: 246), 2117 (SEQ ID NO.: 358), 2137 (SEQ ID NO.: 886), 2178 (SEQ ID NO.: 1096), 2183 (SEQ ID NO.: 433), 2194 (SEQ ID NO.: 911), 5126 (SEQ ID NO.: 1058) and 5163 (SEQ ID NO.: 1095) overnight at 37°C as

described above (n=3). Cells were harvested and stained for CD14 (monocyte marker) and CD80 (B7-1, activation marker). Expression was measured by flow cytometry.

As demonstrated above for NK and B cells, T-rich sequences (e.g., SEQ ID NO.: 433, SEQ ID NO.: 911) of different length induce monocyte stimulation but have different levels of activity e.g., SEQ ID NO.: 433> SEQ ID NO.: 911. Poly A (SEQ ID NO.: 1095) as well as Poly C (SEQ ID NO.: 1096 (2178) sequences, in contrast, did not lead to activation of monocytes (measured by the upregulation of CD80 at a concentration of 6µg/ml ODN).

Example 8: Induction of cytokine release by non-CpG ODNs

Next the ability of different T-rich ODNs to influence the cytokine milieu was examined. PBMC (3x10⁶ cells/ml) were cultured for 24h with or without 6µg/ml of the indicated ODNs or 1µg/ml LPS as positive control (n=2). After incubation supernatants were collected and TNFα measured by ELISA as described above and the results are shown in Fig. 11. PBMC were cultured with the indicated ODNs (1.0µg/ml) as described in Fig. 11 and IL-6 was measured in the supernatants by ELISA and the results are shown in Fig. 12.

Fig. 11 and 12 demonstrate that T-rich non-CpG and T-rich/CpG ODNs can induce the secretion of the pro-inflammatory cytokines TNFα and IL-6. For both cytokines, ODN 5126 (SEQ ID NO.: 1058) was found in most assays to be as potent as ODN 2194 (SEQ ID NO.: 911). It is known that CpG ODNs influence the Th1/Th2 balance by preferentially inducing Th1 cytokines (Krieg, A. M. 1999 *Biochemistry et Biophysics Acta* 932:1-1). To test whether T-rich ODN caused a similar shift to Th1 cytokines, IFNγ production in PBMC was measured. In a first set of experiments, it was demonstrated that, as described for IL-6 and TNFα, ODNs SEQ ID NO.: 1058 and SEQ ID NO.: 911 induced the release of comparable amounts of this Th1 cytokine IFNγ. In addition, it was demonstrated that another pro-inflammatory cytokine, IL-1β, was released upon culture of PBMC with these two ODNs. Although the amount of these cytokines induced by the T-rich ODN lacking CpG motifs was less than when CpG ODN SEQ ID NO.: 246 was used the amounts induced by T-rich ODN were significantly higher than the control.

Example 3.11**Introduction:**

- An optimal CpG motif for immune system activation in non-rodent vertebrates is described herein. A phosphodiester oligonucleotide containing this motif was found to strongly stimulate CD86, CD40, CD54 and MHC II expression, IL-6 synthesis and proliferation of primary human B-cells. These effects required internalisation of the oligonucleotide and endosomal maturation. This CpG motif was associated with the sustained induction of the NF- κ B p50/p65 heterodimer and of the transcription factor complex activating protein-1 (AP-1). Transcription factor activation by CpG DNA was preceded by increased phosphorylation of the stress kinases c-jun NH $_2$ terminal kinase (JNK) and p38, and of activating transcription factor-2 (ATF-2). In contrast to CpG, signaling through the B-cell receptor led to activation of extracellular receptor kinase (ERK) and to phosphorylation of a different set of JNK.

Materials and Methods:

- 15 **Oligodeoxynucleotides:** Unmodified (phosphodiester, PS) and modified nucleoside-resistant (phosphorothioate, PS) ODN were purchased from Operon Technologies (Alameda, CA) and Hydrion Specialty Products (Mallford, MA). The sequences used are provided in Table II. B. cell DNA and calf thymus DNA were purchased from Sigma Chemical Co., St. Louis, MO. Genomic DNA samples were purified by extraction with phenol-chloroform-isoamyl alcohol (25/24/1) and ethanol precipitation. DNA was purified from endotoxin by repeated extraction with tition x-114 (Sigma Chemical Co., St. Louis, MO) and tested for endotoxin using the LAL-assay (LAL-assay BioWhittaker, Walkersville, MD; lower detection limit 0.1 EU/ml) and the high sensitivity assay for endotoxin described earlier (lower detection limit 0.0014 EU/ml) (Hartmann G., and Kriegl A. M. 1999. CpG DNA and LPS induce distinct patterns of activation in human monocytes. *Gene Therapy* 6:893). Endotoxin content of DNA samples was below 0.0014 U/ml. B. cell and calf thymus DNA were made single stranded before use by boiling for 10 minutes, followed by cooling on ice for 5 minutes. DNA samples were diluted in TE-buffer using pyrogen-free reagents.

30

Table II: Oligonucleotide panel used¹

	Name (SEQ ID NO)	Sequence 5' to 3'
Starting sequence	PE 2079 (320)	TCG ACG TTC CCC CCC CCC CC
Middle base	PE 2100 (341)	TCG GCG TTC CCC CCC CCC CC
	PE 2082 (323)	TCG CCG TTC CCC CCC CCC CC
Human CpG motif	PE 2080 (321)	TCG TCG TTC CCC CCC CCC CC
5' flanking base	PE 2105 (346)	GCG TCG TTC CCC CCC CCC CC
	PE 2107 (348)	ACG TCG TTC CCC CCC CCC CC
	PE 2104 (345)	CCG TCG TTC CCC CCC CCC CC
3' flanking base	PE 2098 (339)	TCG TCG CTC CCC CCC CCC CC
	PE 2099 (340)	TCG TCG GTC CCC CCC CCC CC
	PE 2083 (324)	TCG TCG ATC CCC CCC CCC CC
First CpG deleted	PE 2108 (349)	CTG TCG TTC CCC CCC CCC CC
Second CpG deleted	PE 2106 (347)	TCG TCA TTC CCC CCC CCC CC
Methylation	PE 2095 (336)	TZG TZG TTC CCC CCC CCC CC
	PE 2094 (335)	TCG TCG TTC CCC CCC ZCC CC
Non-CpG control of 2080	PE 2078 (319)	TGC TGC TTC CCC CCC CCC CC
	PE 2101 (342)	GGC CTT TTC CCC CCC CCC CC
PS form of 2080	PS 2116 (357)	TCG TCG TTC CCC CCC CCC CC
Additional CpG motifs	PE 2059 (300)	TCG TCG TTC TGT GGT TTT GTG GTT
Best PS	PS 2006 (246)	TCG TCG TTC TGT GGT TTT GTG GTT
Methylated 2006	PS 2117 (358)	TZG TZG TTC TGT ZGT TTT GTZ GTT

¹PE, phosphodiester; PS, phosphorothioate; bold, base exchange; bold Z, methylated cytidine; underlined, CpG dinucleotides.

Cell preparation and cell cultures: Human peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood of healthy volunteers by Ficoll-Paque density gradient centrifugation (Histopaque-1077, Sigma Chemical Co., St. Louis, MO) as described (Hartmann G., et al 1996 *Antisense Nucleic Acid Drug Dev* 6:291). Cells were suspended in RPMI 1640 culture medium supplemented with 10 % (v/v) heat-inactivated (56°C, 1 h) FCS (HyClone, Logan, UT), 1.5 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (all from Gibco BRL, Grand Island, NY) (complete medium). All compounds were purchased endotoxin-tested. Viability was determined before and after incubation with ODN by trypan blue exclusion (conventional microscopy) or by propidium iodide exclusion (flow cytometric analysis). In all experiments, 96 % to 99 % of PBMC were viable. Cells (final concentration 1 x 10⁶ cells/ml) were cultured in complete medium in a 5 % CO₂ humidified incubator at 37°C. Different oligonucleotides (see table I, concentration as indicated in the figure legends), LPS (from salmonella typhimurium, Sigma Chemical Co., St. Louis, MO) or anti-IgM were used as stimuli. Chloroquine (5 µg/ml; Sigma Chemical Co., St. Louis, MO) was used to block endosomal maturation/acidification. At the indicated time points, cells were harvested for flow cytometry as described below.

For signal transduction studies, human primary B-cells were isolated by immunomagnetic cell sorting using the VARIOMACS technique (Miltenyi Biotec Inc., Auburn, CA) as described by the manufacturer. In brief, PBMC obtained from buffy coats of healthy blood donors (Elmer L. DeGowin Blood Center, University of Iowa) were incubated with a microbeads-conjugated antibody to CD19 and passed over a positive selection column. Purity of B-cells was higher than 95%. After stimulation, whole cellular extracts (Western blot) and nuclear extracts (EMSA) for signal transduction studies were prepared.

For CpG binding protein studies, Ramos cells (human Burkitt lymphoma B cell line, ATCC CRL-1923 or CRL-1596; Intervirology 5: 319-334, 1975) were grown in complete medium. Untreated cells were harvested and cytosolic protein extracts were prepared and analyzed for the presence of CpG oligonucleotide binding proteins by EMSA and UV-crosslink as described below.

Flow cytometry: Staining of surface antigens was performed as previously described (Hartmann G. et al. 1998 *J Pharmacol Exp Ther* 285:920). Monoclonal

antibodies to HLA-DR were purchased from Immunotech, Marseille, France. All other antibodies were purchased from Pharmingen, San Diego, CA: mAbs to CD19 (B43), CD40 (5C3), CD54 (HA58), CD86 (2331 (FUN-1)), IgG₁ (MOFC-21) and IgG_{2b} were used to control for specific staining. Intracellular cytokine staining for IL-6 was performed as described (Hartmann G., and Krieg A. M. 1999. CpG DNA and LPS induce distinct patterns of activation in human monocytes. *Gene Therapy* 6:893). In brief, PBMC (final concentration 1 x 10⁶ cells/ml) were incubated in the presence of brefeldin A (final concentration 1 µg/ml, Sigma Chemical Co., St. Louis, MO). After incubation, cells were harvested and stained using a FITC-labeled mAb to CD19 (B43), a PE-labeled rat anti-human IL-6 mAb (MQ2-6A3, Pharmingen) and the Fix and Perm Kit (Caltag Laboratories, Burlingame, CA). Flow cytometric data of 5000 cells per sample were acquired on a FACScan (Beckton Dickinson Immunocytometry Systems, San Jose, CA). Non-viable cells were excluded from analysis by propidium iodide staining (2 µg/ml). Data were analyzed using the computer program FlowJo (version 2.5.1, Tree Star, Inc., Stamford, CA).

Proliferation assay: CFSE (5-(and-6-) carboxyfluorescein diacetate succinimidyl ester, Molecular Probes, USA) is a fluorescein-derived intracellular fluorescent label which is divided equally between daughter cells upon cell division. Staining of cells with CFSE allows both quantification and immunophenotyping (Glycoerythrin-labeled antibodies) of proliferating cells in a mixed cell suspension. Briefly, PBMC were washed twice in PBS, resuspended in PBS containing CFSE at a final concentration of 5 µM, and incubated at 37°C for 10 minutes. Cells were washed three times with PBS and incubated for five days as indicated in the figure legends. Proliferating CD19-positive B-cells were identified by decreased CFSE content using flow cytometry.

Preparation of whole cell, nuclear and cytosolic protein extracts: For Western blot analysis, whole cell extracts were prepared. Primary B-cells were treated with medium, the phosphodiester oligonucleotides 2080 (SEQ ID NO.: 321) or 2078 (SEQ ID NO.: 319) at 30 µg/ml, or anti-IgM (10 µg/ml). Cells were harvested, washed twice with ice-cold PBS containing 1 mM Na₂VO₄, resuspended in lysis buffer (150 mM NaCl, 10 mM TRIS pH 7.4, 1 % NP40, 1 mM Na₂VO₄, 50 mM NaF, 30 mg/ml leupeptin, 50 mg/ml aprotinin, 5 mg/ml aprotinin, 5 mg/ml pepstatin, 50 µg/ml

- 141 -

phenylmethylsulfonylfluoride (PMSF). Incubated for 15 min on ice and spun at 14000 rpm for 10 min. The supernatant was frozen at -80°C. For the preparation of nuclear extracts, primary B-cells were resuspended in hypotonic buffer (10 mM HEPES/KOH (pH 7.9), 10 mM KCl, 0.05 % NP40, 1.5 mM MgCl₂, 0.5 mM dithiothreitol (DTT), 0.5 mM PMSF, 30 mg/ml leupeptin, 50 mg/ml aprotinin, 5 mg/ml anti-pa, 5 mg/ml pepstatin). After 15 minutes incubation on ice, the suspension was centrifuged at 1000 x g for 5 minutes. The pelleted nuclei were resuspended in extraction buffer (20 mM HEPES (pH 7.9), 450 mM NaCl, 50 mM NaF, 20% glycerol, 1 mM EDTA, 1 mM BDTA, 1 mM DTT, 1 mM PMSF, 30 mg/ml leupeptin, 50 mg/ml aprotinin, 5 mg/ml anti-pa, 5 mg/ml pepstatin) and incubated on ice for one hour. The nuclear suspension was centrifuged for 10 minutes at 16,000 g at 4°C. Supernatant was collected and stored at -80°C. Cytosolic extracts for the Cpg binding protein studies were prepared from unstimulated Ramos cells, which were lysed with hypotonic buffer as described for the preparation of the nuclear extract. After centrifugation, the supernatant was removed as cytoplasmic fraction and stored at -80°C. Protein concentrations were measured using a Bradford protein assay (Bio-Rad, Hercules, CA) according to the manufacturer.

Western blot analysis: Equal concentrations of whole cell protein extracts (25 µg/lane) were boiled in SDS sample buffer (50 mM Tris-Cl, pH 6.8; 1% p-mercaptoethanol; 2% SDS; 0.1% bromophenolblue; 10% glycerol) for 4 min before being subjected to electrophoresis on a 10 % polyacrylamide gel containing 0.1 % SDS (SDS-PAGE). After electrophoresis, proteins were transferred to Immobilon-P transfer membranes (Millipore Corp, Bedford, MA). Blots were blocked with 5 % nonfat dry milk. Specific antibodies against the phosphorylated form of extracellular receptor kinase (ERK), c-Jun NH2-terminal kinase (JNK), p38 and activating transcription factor-2 (ATF-2) were used (New England Biolabs, Beverly, MA). Blots were developed in enhanced chemiluminescence reagent (ECL; Amersham International, Aylesbury, UK) according to the manufacturer's recommended procedure.

Electrophoretic mobility shift assay (EMSA): To detect the DNA-binding activity of the transcription factor activator protein-1 (AP-1) and NF-κB, nuclear extracts (1 µg/lane) were analyzed by EMSA using the dsODNs 5' GAT CTA GTG AATG AGT CAG CCG GAT C 3' (SEQ ID NO.: 838) containing the AP-1 binding sequence, and the NF-κB URE from the c-myc promoter region 5' TCC AAG AAG TCC GGG TTT TCC

- 142 -

CCA ACC CCC C 3' (SEQ ID NO.: 1142), as probes. ODNs were end labeled with T4 polynucleotide kinase (New England Biolabs) and (³²P) ATP (Amersham, Arlington Heights, IL). Binding reactions were performed with 1 µg nuclear protein extract in DNA-binding buffer (10 mM Tris-HCl (pH 7.5), 40 mM MgCl₂, 20 mM EDTA, 1 mM dithiothreitol, 8% glycerol and 100 - 400 µg of poly (dI-dC) with 20,000 - 40,000 cpm labeled ODN in 10 µl total volume. Specificity of the NF-κB bands was confirmed by competition studies with cold oligonucleotides from unrelated transcription factor binding sites (10 - 100 ng). For the supershift assay, 2 µg of specific antibodies for c-Rel, p50 and p65 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) were added into the reaction mixture for 30 min before the radiolabeled probe was added. Following incubation for 30 minutes at room temperature loading buffer was added and the probes were electrophoresed on a 6 % polyacrylamide gel in Tris-borate-EDTA running buffer (90 mM Tris, 90 mM boric acid, 2 mM EDTA, pH 8.0). Gels were dried and then autoradiographed.

UV-crosslinking and denaturing protein electrophoresis: Nuclear extracts were incubated with labeled phosphodiester oligonucleotide as described for the EMSA. DNA-protein complexes were crosslinked with UV-light in a Stratalinker (Stratagene) for 10 minutes. Probes were mixed with SDS-sample buffer, boiled for 10 minutes and loaded on a 7.5% SDS-PAGE. The gel was dried on Whatman paper and autoradiographed. Plotting the distance against the molecular weight of the marker proteins yielded a standard curve which was used to calculate the approximate molecular weight of the crosslinked protein-ODN complexes. The molecular weight of the oligonucleotide was subtracted from this value to give the size.

Example 9: Identification of an Optimal Cpg motif for use alone or in combination with a T-rich ODN

Phosphorothioate oligonucleotides containing the murine Cpg motif GACGTT (SEQ ID NO.: 1143) (for example 1826 (SEQ ID NO.: 69)) and used at concentrations which are active in murine B-cells (Yi A. K., Chang M., Pecham D. W., Krig A. M., and Ashman R. F. 1998. CpG oligodeoxynucleotides induce mature spleen B cells from spontaneous sporadic and promote cell cycle entry. *J Immunol* 160:5983) have showed little or no immunostimulatory activity on human immune cells. At higher

concentrations this ODN was found to demonstrate some stimulatory effect on human B cells.

In earlier studies on B-cell activation in mice, it was found that a CpG dinucleotide flanked by two 5' purines and two 3' pyrimidines and preferably the 6mer motif 5' GACGTT 3' (SEQ ID NO:1143) was optimal for a phosphodiester oligonucleotide to be active (Krieg A. M., et al. 1995 *Nature* 374:546, Yi A. K., Chang M., et al., 1998 *J Immunol* 160:4898).

In order to identify an optimal motif for stimulation of an immune response in humans and non-rodent vertebrates we designed a series of ODN and tested their activity. First we designed a 20 mer phosphodiester oligonucleotide with a TC dinucleotide at the 5' end preceding the optimal murine CpG motif 5' GACGTT 3' (SEQ ID NO: 1143) and followed by a poly C tail (2079: 5' TCG ACG TTC CCC CCC CCC 3' (SEQ ID NO.: 320)). This oligonucleotide if added to human primary B-cells under the same conditions as found to be optimal for E. coli DNA (repeated addition at 0 hours, 4 hours and 18 hours, 30 µg/ml for each time point) stimulated high levels of CD86 expression on human primary B-cells after two days. To determine the structure-function relationship of the CpG motifs, we replaced the bases adjacent to the CpG dinucleotides while maintaining the two CpG dinucleotides within the sequence.

Exchange of the adenine located between both CpG dinucleotides by thymidine (2080 (SEQ ID NO.: 321)) resulted in slightly higher activity. Replacement by guanosine (2100 (SEQ ID NO.: 341)) or cytidine (2082 (SEQ ID NO.: 323)) at this position showed no major changes compared to 2079 (SEQ ID NO.: 320). In contrast, replacement of the thymidine 3' to the second CpG dinucleotide by the purines guanosine (2099 (SEQ ID NO.: 340)) or adenine (2083 (SEQ ID NO.: 324)) resulted in a major drop in activity of the oligonucleotide, while the pyrimidine cytidine caused only a minor decrease. The thymidine immediately 5' to the first CpG dinucleotide was also important.

Replacement of the thymidine by any other base (2105 (SEQ ID NO.: 346), guanosine; 2107 (SEQ ID NO.: 348), adenine; 2104 (SEQ ID NO.: 345), cytidine) led to a marked decrease in activity of the oligonucleotide. Elimination of the first (2108 (SEQ ID NO.: 349)) or the second (2106 (SEQ ID NO.: 347)) CpG dinucleotide also partially reduced the activity.

The addition of more 5' GTCGTT 3' (SEQ ID NO.: 1144) CpG motifs to the phosphodiester oligonucleotide containing the 6mer duplex CpG motif 5' TCGTCGTT 3' (SEQ ID NO:1149), 2080 (SEQ ID NO.: 321)) did not further enhance CD86 expression on B-cells (2059 (SEQ ID NO.: 300)). An oligonucleotide with the same

sequence as 2080 (SEQ ID NO.: 321) but with a phosphorothioate backbone showed no activity above background (2116 (SEQ ID NO.: 357)). This was surprising since the phosphorothioate backbone has been reported to greatly stabilize oligonucleotides and enhance CpG-induced stimulation (Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Korenzky G. A., and Kliman D. M. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature* 374:546). We therefore performed further structure-function analysis of phosphorothioate oligonucleotides containing the 5' GTCGTT 3' (SEQ ID NO:1144) and 5' TCGTCGTT 3' (SEQ ID NO:1149) motifs, which showed that additional CpG motifs (2006 (SEQ ID NO.: 246)) tended to increase the activity of phosphorothioate oligonucleotides.

Purified B-cells isolated from peripheral blood by immunomagnetic cell sorting were activated by CpG DNA to the same extent as unpurified B-cells within PBMC. Thus, activation of B-cells is a primary response and not a secondary effect caused by cytokines secreted by other cells.

In addition to the co-stimulatory molecule CD86, the functional stage of B-cells is characterized by other surface markers. For example, activated T helper cells stimulate B-cells by CD40 ligation, the intercellular adhesion molecule-1 (ICAM-1, CD54) mediates binding to other immune cells, and major histocompatibility complex II (MHC II) is responsible for antigen presentation. We found that B cell expression of CD40, CD54 and MHC II was upregulated by the CpG oligonucleotide 2080 (SEQ ID NO.: 321). The non-CpG control oligonucleotide 2078 (SEQ ID NO.: 319) showed no activity compared to medium alone.

When PBMC were incubated for 5 days in the presence of 2080 (SEQ ID NO.: 321) (added at 0 hours, 4 hours, 18 hours and every subsequent morning), it was intriguing that a subpopulation of lymphocytes increased in cell size (FSC) and became more granular (SSC). To examine if this subpopulation represented proliferating B-cells, we stained freshly isolated PBMC with CFSE (5-(and-6-) carboxyfluorescein diacetate succinimidyl ester) at day 0 and incubated them for 5 days with 2080 (SEQ ID NO.: 321)

as above. CFSE is a fluorescent molecule that binds irreversibly to cell proteins. Each cell division decreases CFSE stain by 50 %. Cells staining low with CFSE (proliferating cells) were found to be mainly CD19-positive B-cells. The oligonucleotide 2080 (SEQ ID NO.: 321) induced 60 to 70 % of CD19 positive B-cells to proliferate within 5 days.

The control oligonucleotide 2078 (SEQ ID NO.: 319) induced less than 5 % of B-cells to proliferate. Proliferating B-cells (CFSE low) showed a larger cell size (FS-C) and higher granularity.

Proliferating B-cells expressed higher levels of CD86 than non-proliferating cells (not shown). In agreement with this finding, the oligonucleotide panel tested above for induction of CD86 expression resulted in an almost identical pattern of B-cell proliferation. Replacement of the 3' thymidine reduced activity more than changing the thymidine in the middle position.

Example 10: B-cell activation requires endosomal maturation/acidification

It has previously been shown that chloroquine, an inhibitor of endosomal acidification, blocks CpG-mediated stimulation of murine antigen presenting cells and B-cells, while not influencing LPS-mediated effects (Hacker H., et al 1998 *Embo J* 17:6230, Yl A. K. et al 1998 *J Immunol* 160:4735, Macchiarelli D. E., and Manzoni L. 1998 *J Immunol* 160:1122). We found that the addition of 5 µg/ml chloroquine completely blocked CpG DNA-mediated induction of CD86 expression on primary B-cells (MFI CD86: 2006 (SEQ ID NO.: 246), 4.7 vs 1.4; B. cell DNA, 3.4 vs. 1.4; medium only, 0.9; *n*=4). Furthermore, chloroquine completely inhibited the induction of B-cell proliferation by the phosphorothioate oligonucleotide 2006 (SEQ ID NO.: 246) measured with the CFSE proliferation assay as well as with the standard. These results suggest that as with murine cells, activation of human B-cells by CpG DNA requires the uptake of DNA in endosomes and subsequent endosomal acidification.

Example 11: Analysis of sub-cellular events resulting upon human B cell stimulation with optimal human ODN.

Since the CpG motif requirement for maximal B-cell activation is substantially different between mouse (GACGTT) (SEQ ID NO.:143) and humans (TCGTCGCTT) (SEQ ID NO.:145), we were interested if the basic intracellular signaling events are

comparable. Rapid induction of NF- κ B binding activity has been found earlier in murine B-cells and macrophages (Shaoxy K. J., et al 1996 *J Immunol* 157:2116, Yl A. K. et al 1998 *J Immunol* 160:4735). To investigate the NF- κ B response to CpG DNA in humans, human primary B-cells were isolated from peripheral blood by immunomagnetic cell sorting and incubated with the CpG oligonucleotide 2080 (SEQ ID NO.: 321), the non-CpG control oligonucleotide 2078 (SEQ ID NO.: 319), or medium. At the indicated time points, cells were harvested and nuclear extracts were prepared. In the presence of CpG oligonucleotide, NF- κ B binding activity was increased within one hour and maintained up to 18 hours (latest time point examined). The non-CpG control oligonucleotide 2078 (SEQ ID NO.: 319) did not show enhanced NF- κ B activity compared to cells incubated with medium only. The NF- κ B band was identified by cold competition, and shown to consist of p50 and p65 subunits by supershift assay.

The activating protein-1 (AP-1) transcription factor is involved in the regulation of immediate early genes and cytokine expression (Karin M. 1995. The regulation of AP-1 activity by mitogen-activated protein kinases. *J Biol Chem* 270:16483). In murine B-cells, AP-1 binding activity is induced in response to CpG DNA (Yl A. K., and Kiegl A. M. 1998. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. *J Immunol* 161:4493). To determine whether this transcription factor would also be induced by CpG DNA in humans, we examined AP-1 DNA binding activity in human primary B-cells. Cells were incubated with the CpG oligonucleotide 2080 (SEQ ID NO.: 321) or the control oligonucleotide 2078 (SEQ ID NO.: 319). Nuclear extracts were prepared and the AP-1 binding activity was analyzed by EMSA. AP-1 binding activity was enhanced within one hour, and increased up to 18 hours (latest time point examined), showing a sustained response.

Since AP-1 activity is induced by many stimuli (Angel P., and Karin M. 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. *Biochim Biophys Acta* 1072:129), we were interested in signal transduction pathways upstream of AP-1. The AP-1 transcription factor complex integrates different mitogen activated protein kinase (MAPK) pathways (Karin M. 1995. The regulation of AP-1 activity by mitogen-activated protein kinases. *J Biol Chem* 270:16483). Western blots were performed using whole cell extracts from primary B-cells incubated with the CpG oligonucleotide 2080 (SEQ ID NO.: 321), the control 2078 (SEQ ID NO.: 319), or

medium only. Specific antibodies to the phosphorylated form of JNK, p38, ATF-2 and ERK were used. Strong induction of JNK phosphorylation was found 30 min and 60 min after exposure to CpG-DNA, while the non-CpG oligonucleotide showed no activity above background. The protein kinase p38, another stress activated protein kinase (SAPK), was also phosphorylated in response to CpG DNA within 60 min. ATF-2, a substrate of both p38 and JNK (Gupta S., Campbell D., Derjard B., and Davis R. J. 1995. Transcription factor ATF2 regulation by the JNK signal transduction pathway. *Science* 267:389) and a component of the AP-1 complex, showed weak phosphorylation after 30 min which increased after 60 min. CpG DNA failed to induce substantial phosphorylation of ERK. In contrast, anti-IgM, stimulating the B-cell receptor, did trigger phosphorylation of ERK. Anti-IgM activated different isoforms of JNK than CpG DNA.

Example 12: Assay for *in vivo* adjuvant activity.

An *in vitro* screening assay to identify ODN useful as an adjuvant *in vivo* in humans and other non-rodent animals was developed. Since we saw not only quantitative but also qualitative differences in activities of different CpG ODN in mice, we first screened a panel of CpG and non-CpG control ODN on mouse cells to find *in vitro* assays with reliable and strong correlation to *in vivo* adjuvant activity with hepatitis B surface antigen (HBsAg). We then systematically tested a panel of more than 250 ODN in corresponding human assays to identify sequences with *in vitro* immunostimulatory activity. We next examined if the ODN with the highest activity in these human assays also activate B cell proliferation in chimpanzees and monkeys, and finally, if they are active as adjuvants with HBsAg in chimpanzees and cynomolgus monkeys *in vivo*. These studies revealed that the sequence, number and spacing of individual CpG motifs contribute to the immunostimulatory activity of a CpG phosphorothioate ODN. An ODN with a TC dinucleotide at the 5' end followed by three 6mer CpG motifs (5' GTCGTT 3') separated by TT dinucleotides consistently showed the highest activity for human, chimpanzees, and rhesus monkey leukocytes. Chimpanzees or monkeys vaccinated once against hepatitis B with this CpG ODN adjuvant developed 15 times higher anti-HBe antibody titers than those receiving vaccine alone.

Materials and Methods

Oligonucleosides: Phosphorothioate-modified ODN were purchased from Operon Technologies (Alameda, CA) and Hybridon Specialty Products (Milford, MA). ODN were tested for endotoxin using the LAL-assay (LAL-assay BioWhittaker, Walkersville, MD; lower detection limit 0.1 EU/ml). For *in vitro* assays, ODN were diluted in TE-buffer (10 mM Tris, pH 7.0, 1 mM EDTA), and stored at -20° C. For *in vivo* use, ODN were diluted in phosphate buffered saline (0.1 M PBS, pH 7.3) and stored at 4° C. All dilutions were carried out using pyrogen-free reagents.

Mouse spleen cell cultures: Spleens were removed from 6-12 week old female BALB/c (The Jackson Laboratory), 2 x 10⁶ splenocytes were cultured with 0.2 µM ODN for 4 hours (TNF-α) or 24 hours (IL-6, IFN-γ, IL-12), and cytokines were detected by ELISA as previously described (Yi A. K., Klinman D. M., Martin T. L., Matsen S., and Krieg A. M. 1996. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. *J Immunol* 157:5394). To evaluate CpG-induced B cell proliferation, spleen cells were depleted of T cells with anti-Thy-1.2 and complement and centrifugation over lymphocyte M^c (Cedarlane Laboratories, Hornby, ON, Canada), cultured for 44 hours with the indicated ODN, and then pulsed for 4 hours with 1 µCi of ³H thymidine as described previously (Krieg A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R., Koretzky G. A., and Klinman D. M. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature* 374:546). To examine NK cell lytic activity murine spleen cells were depleted of B cells using magnetic beads coated with goat anti-mouse Ig as previously detailed (Ballas Z. K., and Rasmussen W. 1993. Lymphokine-activated killer cells. VIL IL-4 induces an NK1.1⁺CD8 αβ⁺ TCR-αβ B220⁺ lymphokine-activated killer subset. *J Immunol* 150:17). Cells were cultured at 5 x 10⁶/well in 24-well plates and harvested at 18 hours for use as effector cells in a standard 4 hour ⁵¹Cr-release assay against YAC-1 target cells. One unit (LU) was defined as the number of cells needed to effect 30 % specific lysis.

Immunization of mice against HBsAg and evaluation of the humoral response: Groups of 6-8 week old female BALB/c mice (n = 5 or 10, Charles River, Montreal, QC) were immunized against HBsAg as previously described (Davis H. L., et

- 149 -

at 1998 *J Immunol* 160:870). In brief, each mouse received a single IM injection of 50 μ l PBS containing 1 μ g recombinant HBsAg (Medix Biotech, Foster City, CA) and 10 μ g of CpG ODN or non-CpG ODN as a sole adjuvant or combined with alum (Allydrolgel "85", Superfos Biosector, Vedbaek, Denmark; 25 mg Al³⁺/mg HBsAg).

Control mice were immunized with HBsAg without adjuvant or with alum. Plasma was recovered from mice at various times after immunization and Abx specific to HBsAg (anti-HBx) were quantified by end-point dilution ELISA assay (in triplicate) as described previously (Davis H. L. et al 1998 *J Immunol* 160:870). End-point titer was defined as the highest plasma dilution that resulted in an absorbance value (OD450) two times higher than that of non-immune plasma with a cut-off value of 0.05.

Isolation of primate PBMC and cell culture: Peripheral blood mononuclear cells (PBMC) were isolated from peripheral blood of healthy volunteers, chimpanzees or rhesus or cynomolgus monkeys by Ficoll-hypaque density gradient centrifugation (Histopaque-1077, Sigma Chemical Co., St. Louis, MO) as described (Hartmann G., et al 1996 *Antisense Nucleic Acid Drug Dev* 6:291). Cells were suspended in RPMI 1640 culture medium supplemented with 10 % (v/v) heat-inactivated (56°C, 1 h) FCS (HyClone, Logan, UT), 1.5 mM L-glutamine, 100 U/ml penicillin and 100 μ g/ml streptomycin (all from Gibco BRL, Grand Island, NY) (complete medium). Cells (final concentration 1×10^6 cells/ml) were cultured in complete medium in a 5 % CO₂ humidified incubator at 37°C. ODN and LPS (from *Salmonella dysenteriae*, Sigma Chemical Co., St. Louis, MO) or anti-IgM were used as stimuli. For measurement of human NK lytic activity, PBMC were incubated at 5×10^6 /well in 24-well plates. Cultures were harvested after 24 hours, and cells were used as effectors in a standard 4 hours ⁵¹Cr-release assay against K562 target cells as previously described (Ballas Z. K., Rasmussen W. L., and Kriegl A. M. 1996. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. *J Immunol* 157:1840; Ballas Z. K., and Rasmussen W. 1993. Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1⁺CD8 α^+ β^+ TCR- $\alpha\beta$ B220⁺ lymphokine-activated killer subset. *J Immunol* 150:17). For B cell proliferation, 1 μ Cl of ³H thymidine was added 18 hours before harvest, and the amount of ³H thymidine incorporation was determined by scintillation counting at day 5. Standard deviations of the triplicate wells were < 5%.

- 150 -

Flow cytometry on primate PBMC: Surface antigens on primate PBMC were stained as previously described (Hartmann G et al 1998 *J Pharmacol Exp Ther* 285:920). Monoclonal antibodies to CD3 (UCHL1), CD14 (M5E2), CD19 (B43), CD56 (B159), CD69 (FN50) and CD86 (231) (TUN-1) were purchased from Pharmingen, San Diego, CA. IgG₁ (MOPC-21) and IgG_{2a} (Hartmann G et al 1999 *PNAS* 96:9305) were used to control for non-specific staining. NK cells were identified by CD56 expression on CD3, CD14 and CD19 negative cells, whereas B cells were identified by expression of CD19. Flow cytometric data from 10000 cells per sample were acquired on a FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA). The viability of cells within the FSC/SSC gate used for analysis was examined by propidium iodide staining (2 μ g/ml) and found to be higher than 98 %. Data were analyzed using the computer program FlowJo (version 2.5.1, Tree Star, Inc., Stanford, CA).

Immunization of chimpanzees and cynomolgus monkeys against HBsAg and evaluation of the humoral response: Fourteen cynomolgus monkeys (2.0-3.5 kg) were immunized with a pediatric dose of Engix-B (SmithKline Beecham Biologicals, Rixensart, BE) containing 10 μ g HBsAg adsorbed to alum (25 mg Al³⁺/mg HBsAg). This was administered alone (n=5), or combined with CpG ODN 1968 (n=5, 500 μ g) or CpG ODN 2006 (SEQ ID NO.: 246) (n=4, 150 μ g). Four chimpanzees (10-20 kg) were immunized in the same fashion with two receiving control vaccine (Engix-B only) and two receiving experimental vaccine (Engix-B plus 1 mg CpG ODN 2006). All vaccines were administered IM in the right anterior thigh in a total volume of 1 ml. Monkeys were maintained in the national facility of the Primate Research Center (Boyer, Indonesia) and chimpanzees were housed at Bioparc (Rockville, MD). Animals were monitored daily by animal care specialists. No symptoms of general ill health or local adverse reactions at the injection site were noted. Plasma was recovered by IV puncture prior to and at various times after immunization and was stored frozen (-20°C) until assayed for antibodies. Anti-HBs antibodies were detected using a commercial ELISA kit (Monoclonal Anti-HBs; Sanofi-Pasteur, Montreal, QC) and then were expressed in mIU/ml based on comparison with WHO defined standards (Monoclonal Anti-HBs Standard, Sanofi-Pasteur).

Results

Identification of CpG ODN with different profiles of *in vitro* immune activities:

Our studies showed that the precise bases on the 5' and 3' sides of a CpG dinucleotide within a CpG motif may have an impact on the level of immune activation of a synthetic ODN, but it has been unclear whether different CpG motifs might display different

immune effects. To evaluate this possibility, we tested a panel of CpG ODN for their ability to induce NK lytic activity, B cell proliferation, and to stimulate synthesis of TNF- α , IL-6, IFN- γ and IL-12 in murine spleen cells. Immunostimulatory activity of ODN without CpG motifs (ODN 1882 (SEQ ID NO.: 225), ODN 1983 (SEQ ID NO.: 226)) was negative or weak compared to CpG ODN. ODN with non optimal CpG motifs (ODN 1628 (SEQ ID NO.: 767), ODN 1758 (SEQ ID NO.: 1)) were less active than ODN containing CpG motifs flanked by two 5' pyrimidines and two 3' pyrimidines (ODN 1760 (SEQ ID NO.: 3), ODN 1826 (SEQ ID NO.: 69), ODN 1841 (SEQ ID NO.: 84)). ODN 1826 containing two optimal murine CpG motifs (5' GACGTT 3') (SEQ ID NO.: 1143) had the highest activity for 5 of 6 measured endpoints. Except for ODN 1628, all ODN showed a generally similar pattern of activity (NK cell-mediated lysis, B cell proliferation, IL-12, IL-6, TNF- α , IFN- γ). Of note, ODN 1628, which was unique in this panel for containing two G-rich regions, showed preferential induction of IFN- γ synthesis but relatively low stimulation of the other activities.

Identification of *in vitro* assays which correlate with *in vivo* adjuvant activity:

Since adjuvant activity is an *in vivo* endpoint, we were interested in identifying *in vitro* assays that would predict the adjuvant activity of a CpG ODN *in vivo*. The same ODN used for *in vitro* endpoints therefore were tested for their adjuvant activity to immunize mice against HBsAg. This was carried out both with ODN alone and with ODN combined with alum, since earlier studies had shown strong synergy for CpG ODN and alum adjuvants (PCT Published Patent Application WO98/40100).

BALB/c mice immunized with HBsAg without adjuvant attained only low titers of anti-HBs by 4 weeks, and this was not affected by addition of control ODN. In contrast, addition of CpG ODN raised anti-HBs titers by 5 to 40 fold, depending on the sequence used. When alum was added, titers of anti HBs were approximately 6 times higher than with HBsAg alone. Specifically, control ODN had no effect and the various CpG ODN augmented these titers 2 to 36 fold. Results obtained with the different ODN

alone correlated very strongly ($r = 0.96$) with those obtained using the same ODN plus alum. When linear regression was performed, a very high degree of correlation was found between certain *in vitro* assays and *in vivo* augmentation of anti-HBs titers. Of all the *in vitro* endpoints examined, the induction of NK lytic activity showed the best correlation to *in vivo* adjuvant activity (without alum, $r = 0.98$; with alum, $r = 0.95$; $p < 0.0001$). A good correlation regarding adjuvant activity was also obtained for B-cell stimulation ($r = 0.84$ and 0.7), as well as secretion of TNF- α ($r = 0.9$ and 0.88), IL-12 ($r = 0.88$ and 0.86) and IL-6 ($r = 0.85$ and 0.91). The one *in vitro* assay that did not correlate well with the *in vivo* results was IFN- γ secretion ($r = 0.57$ and 0.68). These data demonstrate that *in vitro* assays for NK lytic activity, B cell activation and production of TNF- α , IL-6 and IL-12 provide valuable information *in vitro* to predict the adjuvant activity of a given ODN *in vivo*.

Screening of a phosphorothioate ODN panel to activate human NK cells: In previous studies we found that synthesis of inflammatory cytokines by human PBMC is induced by extremely low amounts of endotoxin (induced TNF- α secretion is detectable with just 6 pg/ml endotoxin, 2 logs more sensitive than murine immune cells). In contrast, activation of human B cells and induction of human NK cell lytic activity with endotoxin is low even at high endotoxin concentrations. Based on these results we selected activation of NK cells (lytic activity and CD59 expression) and B cells (proliferation and CD86 expression) as the most highly specific and reproducible assays with low inter-subject variability and used these assays for *in vitro* screening of a pool of ODN.

First we studied the effect of phosphorothioate ODN containing various combinations and permutations of CpG motifs on NK cell-mediated lysis of target cells. For clarity and ease of presentation, only data with selected representative CpG and control ODN are shown. Human PBMC were incubated with different phosphorothioate ODN (6 μ g/ml) for 24 hours and tested for their ability to lyse 51 Cr-labeled K562 cells. ODN with two 6-mer CpG motifs (either 5' GACGTT 3' (SEQ ID NO.: 1143) or 5' GTGCTT 3' (SEQ ID NO.: 1144)) in combination with a T γ C at the 5' end of the ODN (ODN 1840 5' TCCATGTGCTTCCTGCTGCTT 3' (SEQ ID NO.: 83), ODN 1851 5' TCCGTGACGTTCTCTGACGTT 3' (SEQ ID NO.: 94) or with at least three 6-mer motifs without a T γ C at the 5' end (ODN 2013 (SEQ ID NO.: 253)) show intermediate activity.

High activity was found when the 5' Tpc directly preceded a 6-mer human CpG motif (5' TCGTCGTT 3' (SEQ ID NO.: 1145)) and was followed by two 6-mer motifs (ODN 2005 (SEQ ID NO.: 245), ODN 2006 (SEQ ID NO.: 246) and ODN 2007 (SEQ ID NO.: 247)). The best results were obtained when the 6-mer CpG motifs were separated from each other and from the 5' 8-mer CpG motif by Tpt (ODN 2006 (SEQ ID NO.: 246)).

Expression of the activation marker CD69 is rapidly upregulated on the surface of NK cells subsequent to stimulation. To confirm the results from the NK cell lysate assay, PBMC were incubated for 18 hours with ODN (2 µg/ml). CD69 expression was examined on CD56 positive NK cells (CD3, CD14 and CD19 negative). Although

induction of CD69 expression was less sequence restricted than stimulation of NK cell functional activity, control ODN (ODN 1982, ODN 2116, ODN 2117, ODN 2010)

showed only low activity similar to background levels. ODN with two human CpG motifs separated by 5' TTTT 3' (ODN 1965 (SEQ ID NO.: 208)) or four human CpG motifs without spacing (ODN 2013 (SEQ ID NO.: 253)) were relatively more active at

inducing CD69 expression than at stimulating NK cell lytic activity. Optimal NK cell functional activity, as well as CD69 expression, was obtained with ODNs containing a Tpc dinucleotide preceding the human CpG motif, and additional human motifs within the sequence (ODN 2006 (SEQ ID NO.: 246), ODN 2007 (SEQ ID NO.: 247)).

Activity of phosphorothioate ODN for stimulating human B cells: In preliminary experiments we found that the percentage of proliferating B cells (CFSE assay, see methods section) correlated with the surface expression of the co-stimulatory CD86 on B cells, as measured by flow cytometry. Thus we used CD86 expression on B cells to screen a panel of ODN for their immunostimulatory activity. PBMC were incubated with 0.6 µg/ml ODN. Expression of CD86 (mean fluorescence intensity, MFI) was examined on CD19 positive B cells. A poly C ODN (ODN 2017 (SEQ ID NO.: 257)) or ODN without CpG dinucleotides (ODN 1982 (SEQ ID NO.: 225)) failed to stimulate human B cells under these experimental conditions. A phosphorothioate ODN (ODN 2116 (SEQ ID NO.: 256)) with one optimal human CpG motif preceded by a Tpc (5' TCGTCGTT 3' (SEQ ID NO.: 1145)) had low activity. The presence of one human 6-mer CpG motif (5' GTCGTT 3' (SEQ ID NO.: 1144)) had no activating effect. Two of these CpG motifs within the sequence showed no (ODN 1960 (SEQ ID NO.: 203), ODN 2016 (SEQ ID NO.: 250)) or intermediate (ODN 1965 (SEQ ID NO.: 208)) activity dependent on the

sequence context. If the ODN was composed of three or four copies of this motif (ODN 2012 (SEQ ID NO.: 252), ODN 2013 (SEQ ID NO.: 253), ODN 2014 (SEQ ID NO.: 254)), intermediate activity on B cells could be detected. The combination of the human 8-mer CpG motif on the 5' end of the ODN with two 6-mer CpG motifs (ODN 2005 (SEQ ID NO.: 245), ODN 2006 (SEQ ID NO.: 246), ODN 2007 (SEQ ID NO.: 247), ODN 2102 (SEQ ID NO.: 343), ODN 2103 (SEQ ID NO.: 344)) led to a considerable increase in the ability of the ODN to stimulate B cells. The spacing between the single motifs was critical. The separation of CpG motifs by Tpt was preferable (ODN 2006 (SEQ ID NO.: 246)) compared to unspaced CpG motifs (ODN 2005 (SEQ ID NO.: 245)) also compare ODN 1965 (SEQ ID NO.: 208) to ODN 1960 (SEQ ID NO.: 203)). The human 6-mer CpG motif (5' GTCGTT 3') was better than the optimal mouse 6-mer CpG motif (5' GACGTT 3' (SEQ ID NO.: 246)) when combined with the human 8-mer CpG motif on the 5' end (ODN 2006 vs. ODN 2102 (SEQ ID NO.: 343) and ODN 2103 (SEQ ID NO.: 344)). A (TCG)_{poly} ODN was inactive or only weakly active, as were ODNs containing CpG dinucleotides flanked by guanines or other CpG dinucleotides (ODN 2010 (SEQ ID NO.: 250)). Taken together, the findings for NK cells and B cells showed consistently that of the ODN tested, ODN 2006 (SEQ ID NO.: 246) has the highest immunostimulatory activity on human immune cells.

Comparative analysis of potency of CpG phosphorothioate ODNs in different primates: Different CpG motifs are optimal to activate murine and human immune cells. Furthermore, the number and location of CpG motifs within an active phosphorothioate ODN is different in mice and humans. We were interested to know if CpG phosphorothioate ODN show a similar activity among different species of primates. We compared a panel of CpG ODN for their ability to induce B cell proliferation in humans, chimpanzees and rhesus or cynomolgus monkeys. The capability of ODN to stimulate human B cell proliferation (Table 3) correlated well with their ability to induce CD86 expression on B cells. ODN 2006 (SEQ ID NO.: 246), which showed the highest activity in human B cells and NK cells, was also the most active in stimulating chimpanzees and rhesus monkey B cell proliferation (Table 3). ODN 1968 (SEQ ID NO.: 211) and ODN 2006 (SEQ ID NO.: 246) gave the highest activation of cynomolgus monkey B-cells *in vitro* (SI of 25 and 29 respectively at 6 µg ODN/ml). Surprisingly, CpG ODN 2007 (SEQ ID NO.: 247), which displayed similarly high activity as the optimal ODN 2006

(SEQ ID NO.: 246) in human cells, did not stimulate Rhesus monkey or chimpanzee B cell proliferation, and the ODN 1968 (SEQ ID NO.: 211) showed low activity. CpG ODN originally identified with high activity in mice (ODN 1760 (SEQ ID NO.: 3), ODN 1826 (SEQ ID NO.: 69)) showed little activity in monkeys (Table J).

Table J: Proliferative response of PBMC to phosphorothioate CpG ODN in primates

	Humans	Chimpanzee	Rhesus monkey
No addition	0.5 \pm 0.1	0.5 \pm 0.1	0.5 \pm 0.0
ODN 1760 (SEQ ID NO.: 3)	23 \pm 7	0.3 \pm 0.1	0.5 \pm 0.3
ODN 1826 (SEQ ID NO.: 69)	0.8 \pm 0.1	0.4 \pm 0.1	0.6 \pm 0.1
ODN 1968 (SEQ ID NO.: 211)	35 \pm 9	20.0 \pm 3.8	1.9 \pm 0.7
ODN 1982 (SEQ ID NO.: 225)	9.7 \pm 1.1	2.5 \pm 1.1	0.7 \pm 0.1
ODN 2006 (SEQ ID NO.: 246)	59 \pm 8	27.4 \pm 8.9	6.3 \pm 3.3
ODN 2007 (SEQ ID NO.: 247)	47 \pm 11	0.5 \pm 0.1	0.4 \pm 0.2

PBMC were prepared from peripheral blood and incubated with ODN (0.6 μ g/ml) as indicated for five days. Proliferation was measured by uptake of 3 H-thymidine (cpm/1000) during the last 18 hours. More than 95 % of proliferating cells were B-cells as determined using the CFSE assay. Four human probands, six chimpanzees and two rhesus monkeys were tested.

In vivo adjuvant activity of CpG ODN in chimpanzees and cynomolgus monkeys: In order to evaluate whether CpG ODN with strong *in vitro* stimulatory effects on primate cells had detectable adjuvant activity *in vivo*, Cynomolgus monkeys and chimpanzees were immunized with Egerix B, which comprises HBsAg adsorbed to

alum, alone or with added ODN 1968 (500 μ g) or ODN 2006 (SEQ ID NO.: 246) (1 mg) respectively. Compared to controls not receiving CpG ODN, anti-HBs titers at 4 weeks post-prime and 2 weeks post-boost were 66- and 16-fold higher respectively in the monkeys, and 15- and 3-fold higher in the chimpanzees (Table K). Thus a clear adjuvant effect of CpG ODN was seen, and this was particularly striking after a single immunization.

Table K: Anti-HBs responses in primates immunized against HBsAg with CpG ODN¹

Primate species	n	CpG ODN	4 wks post-prime	2 wks post-boost
Cynomolgus monkey	5	None	15 \pm 44	4880 \pm 13113
	5	ODN 1968 (500 μ g) (SEQ ID NO. 211)	995 \pm 1309	76449 \pm 42094
Chimpanzee	2	None	6, 11	3712, 4706
	2	ODN 2006 (1 mg) (SEQ ID NO. 246)	125, 135	5640, 16800

¹Animals were immunized by IM injection of Egerix B containing 10 μ g HBsAg adsorbed to alum, alone or with added CpG ODN. Cynomolgus monkeys were boosted at 10 wks and chimpanzees were boosted at 4 wks post-prime. Anti-HBs was determined by ELISA assay; values for monkeys are GMT \pm SEM (n=5) whereas individual values for the two chimpanzees in each group are provided.

1 claim:

- 157 -

CLAIMS

1. A method of stimulating an immune response, comprising administering an immunostimulatory nucleic acid selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid, to a non-tolerant subject in an amount effective to induce an immune response in the non-tolerant subject.
2. The method of claim 1, wherein the immunostimulatory nucleic acid is a T-rich nucleic acid.
3. The method of claim 2, wherein the T-rich immunostimulatory nucleic acid is a poly T nucleic acid comprising
5' TTTT 3'.
4. The method of claim 3, wherein the poly T nucleic acid comprises
5' X₁ X₂TTT X₃ 3'
wherein X₁, X₂, X₃ and X₄ are nucleotides.
5. The method of claim 3, wherein the T-rich immunostimulatory nucleic acid comprises a plurality of poly T nucleic acid motifs.
6. The method of claim 4, wherein X₁X₂ is TT.
7. The method of claim 4, wherein X₃X₄ is TT.
8. The method of claim 4, wherein X₁X₂ is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, GT, GG, GA, and GC.
9. The method of claim 4, wherein X₃X₄ is selected from the group consisting of TA, TG, TC, AT, AA, AG, AC, CT, CC, CA, GT, GG, GA, and GC.
10. The method of claim 3, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 25% T.
11. The method of claim 1, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 33% T.

- 158 -

12. The method of claim 1, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 40% T.
13. The method of claim 1, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 50% T.
14. The method of claim 1, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 60% T.
15. The method of claim 1, wherein the T-rich immunostimulatory nucleic acid comprises a nucleotide composition of greater than 80% T.
16. The method of claim 1, wherein the immunostimulatory nucleic acid comprises at least 20 nucleotides.
17. The method of claim 1, wherein the immunostimulatory nucleic acid comprises at least 24 nucleotides.
18. The method of claim 1, wherein the immunostimulatory nucleic acid has a nucleotide backbone which includes at least one backbone modification.
19. The method of claim 18, wherein the backbone modification is a phosphorothioate modification.
20. The method of claim 18, wherein the nucleotide backbone is oligonucleic.
21. The method of claim 18, wherein the nucleotide backbone is entirely modified.
22. The method of claim 1, wherein the immunostimulatory nucleic acid is free of CpG dinucleotides.
23. The method of claim 1, wherein the immunostimulatory nucleic acid is free of unmethylated CpG dinucleotides.
24. The method of claim 1, wherein the immunostimulatory nucleic acid is free of methylated CpG dinucleotides.

25. The method of claim 1, wherein the immunostimulatory nucleic acid is free of poly-C sequences.

26. The method of claim 1, wherein the immunostimulatory nucleic acid includes a poly-A sequence.

27. The method of claim 20, wherein the immunostimulatory nucleic acid includes a poly-Q sequence.

28. The method of claim 1, wherein the immunostimulatory nucleic acid comprises a nucleotide composition of greater than 25% C.

29. The method of claim 1, wherein the immunostimulatory nucleic acid comprises a nucleotide composition of greater than 25% A.

30. The method of claim 1, wherein the immunostimulatory nucleic acid is administered orally.

31. The method of claim 1, wherein the immunostimulatory nucleic acid is administered locally.

32. The method of claim 1, wherein the immunostimulatory nucleic acid is administered in a sustained release device.

33. The method of claim 1, wherein the immunostimulatory nucleic acid is administered mucosally to a mucosal surface.

34. The method of claim 33, wherein the immune response is a mucosal immune response.

35. The method of claim 33, wherein the immune response is a systemic immune response.

36. The method of claim 33, wherein the mucosal surface is selected from the group consisting of an oral, nasal, rectal, vaginal, and ocular surface.

37. The method of claim 1, further comprising exposing the subject to an antigen and wherein the immune response is an antigen-specific immune response.

38. The method of claim 37, wherein a nucleic acid vector which encodes the antigen is administered to the subject, and wherein the nucleic acid vector is separate from the immunostimulatory nucleic acid.

39. The method of claim 37, wherein the antigen is a peptide antigen.

40. The method of claim 1, further comprising isolating an immune cell from the subject, contacting the immune cell with an effective amount to activate the immune cell of the immunostimulatory nucleic acid and re-administering the activated immune cell to the subject.

41. The method of claim 40, wherein the immune cell is a leukocyte.

42. The method of claim 41, further comprising contacting the immune cell with an antigen.

43. The method of claim 40, wherein the antigen is selected from the group consisting of a tumor antigen, a viral antigen, a bacterial antigen, and a parasitic antigen.

44. The method of claim 40, wherein the immune cell is a dendritic cell.

45. The method of claim 1, wherein the subject has or is at risk of developing asthma and the method is a method of treating or preventing asthma in the subject.

46. The method of claim 1, wherein the subject has or is at risk of developing allergy and the method is a method of treating or preventing allergy.

47. The method of claim 1, wherein the subject has cancer and the method is a method of treating the cancer.

48. The method of claim 47, wherein the cancer is selected from the group consisting of biliary tract cancer; brain cancer; breast cancer; cervical cancer; choriocarcinoma; CNS cancer; colon cancer; connective tissue cancer; endometrial cancer; eye cancer; gastric cancer; intraepithelial neoplasms; larynx cancer; lymphomas; Hodgkin's lymphoma; liver cancer; lung cancer (e.g. small cell and non-small cell); melanoma; neuroblastoma; oral cancer; oral cavity cancer; ovarian cancer; pancreas

- 161 -

cancer, prostate cancer, rectal cancer, sarcomas, thyroid cancer, and renal cancer, as well as other carcinomas and sarcomas.

49. The method of claim 1, wherein the cancer is selected from the group consisting of bone cancer, brain and CNS cancer, connective tissue cancer, esophageal cancer, eye cancer, Hodgkin's lymphoma, larynx cancer, oral cavity cancer, skin cancer, and testicular cancer.

50. The method of claim 47, further comprising administering an anti-cancer therapy.

51. The method of claim 50, wherein the anti-cancer therapy is an antibody.

52. The method of claim 47, wherein the subject is a human.

53. The method of claim 47, wherein the subject is selected from the group consisting of a dog, a cat, and a horse.

54. The method of claim 1, further comprising administering an antibody specific for a cell surface antigen, and wherein the immune response results in antigen dependent cellular cytotoxicity (ADCC).

55. The method of claim 1, wherein the subject has or is at risk of developing an infectious disease and wherein the method is a method for treating or preventing the infectious disease.

56. The method of claim 54, wherein the subject is a human.

57. The method of claim 54, further comprising administering an antigen to the subject.

58. The method of claim 57, wherein the antigen is selected from the group consisting of a bacterial antigen, a viral antigen, a parasitic antigen, and a fungal antigen.

59. The method of claim 56, wherein the subject is selected from the group consisting of a dog, cat, horse, cow, pig, sheep, goat, chicken, monkey, and fish.

60. The method of claim 59, further comprising administering an antigen to the subject.

- 162 -


61. The method of claim 59, wherein the antigen is derived from a microorganism selected from the group consisting of herpesviridae, reoviridae, orthomyxoviridae, toxoplasma, bacterophila, campylobacter, chlamidia, Rickettsia, and streptococcus.

62. The method of claim 1, wherein the immunostimulatory nucleic acid is a TG nucleic acid.

63. The method of claim 62, wherein the TG nucleic acid comprises



64. The method of claim 62, wherein the TG nucleic acid comprises



65. The method of claim 63, wherein N_1 is a nucleic acid sequence composed of a number of nucleotides ranging from (11-N₂) to (21-N₂).

66. The method of claim 63, wherein N_2 is a nucleic acid sequence composed of a number of nucleotides ranging from (11-N₁) to (21-N₁).

67. The method of claim 64, wherein N_1 is a nucleic acid sequence composed of a number of nucleotides ranging from (9-N₂) to (19-N₂).

68. The method of claim 64, wherein N_2 is a nucleic acid sequence composed of a number of nucleotides ranging from (9-N₁) to (19-N₁).

69. The method of claim 63, wherein X_2 is thymidine.

70. The method of claim 64, wherein X_3 is thymidine.

71. The method of claim 64, wherein X_1X_2 are nucleotides selected from the group consisting of GT, GQ, GA, AA, AT, AG, CT, CA, CQ, TA and TT.

72. The method of claim 64, wherein X_3X_4 are nucleotides selected from the group consisting of TT, CT, AT, AG, CQ, TC, AC, CG, TA, AA, and CA.

73. The method of claim 63, wherein X_1X_2 are nucleotides selected from the group consisting of TT, TC, TA and TG.

74. The method of claim 1, wherein the subject is at risk of developing cancer and the method is a method of preventing the cancer.

75. The method of claim 50, wherein the anti-cancer therapy is selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent and a cancer vaccine.

76. A method for preventing disease in a subject, comprising:

administering to the subject an immunostimulatory nucleic acid on a regular basis to prevent disease in the subject, wherein the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid.

77. A method for inducing an innate immune response, comprising

administering to the subject an immunostimulatory nucleic acid in an amount effective for activating an innate immune response, wherein the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid.

78. A composition comprising

a sustained release device including an immunostimulatory nucleic acid, wherein the immunostimulatory nucleic acid is free of unmethylated CpG motifs and is selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid.

79. The composition of claim 78, wherein the immunostimulatory nucleic acid has a phosphodiester backbone.

80. A composition of a nutritional supplement comprising

an immunostimulatory nucleic acid in a delivery device selected from the group consisting of a capsule, a pill, and a sublingual tablet, wherein the immunostimulatory nucleic acid is free of unmethylated CpG motifs and is selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid.

81. The composition of claim 80, wherein the immunostimulatory nucleic acid has a phosphorothioate backbone.

82. A composition comprising

an immunostimulatory nucleic acid and an antigen, wherein the

immunostimulatory nucleic acid is free of unmethylated CpG motifs and is selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid.

83. A composition comprising

an immunostimulatory nucleic acid and an anti-microbial agent, wherein the immunostimulatory nucleic acid is free of unmethylated CpG motifs and is selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid.

84. The composition of claim 83, wherein the anti-microbial agent is selected from the group consisting of an anti-viral agent, an anti-fungal agent, an anti-parasitic agent, and an anti-bacterial agent.

85. The method of claim 5, wherein the immunostimulatory nucleic acid comprises at least 3, at least 4, at least 5, at least 6, at least 7, or at least 8 T motifs.

86. The method of claim 5, wherein at least 2 of the plurality of poly T motifs each comprises at least three contiguous T nucleotide residues.

87. The method of claim 5, wherein at least two of the poly T motifs each comprises at least four contiguous T nucleotide residues.

88. The method of claim 5, wherein the plurality of poly T motifs is at least 3 motifs and wherein at least 3 motifs each comprises at least 3 contiguous T nucleotide residues.

89. The method of claim 5, wherein the plurality of poly T motifs is at least 4 motifs and wherein the at least 4 motifs each comprises at least 3 contiguous T nucleotide residues.

90. The method of claim 5, wherein at least one of the plurality of poly T motifs comprises at least 5, at least 6, at least 7, or at least 8 contiguous nucleotide residues.

- 165 -

91. The method of claim 1, wherein the immunostimulatory nucleic acid is free of two CpG dinucleotides.

92. The method of claim 1, wherein the immunostimulatory nucleic acid is free of three CpG dinucleotides.

93. The method of claim 1, wherein the immunostimulatory nucleic acid includes at least two poly C sequences of at least 3 contiguous C nucleotide residues.

94. The method of claim 1, wherein the immunostimulatory nucleic acid is free of two poly A sequences of at least 3 contiguous A nucleotide residues.

95. A pharmaceutical composition comprising an effective amount for stimulating an immune response of an isolated immunostimulatory nucleic acid of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 40, 41, 64, 65, 66, 67, 68, 69, 70, 71, 72, 85, 86, 87, 88, 89, 90, 91, 92, 93, or 94 and a pharmaceutically acceptable carrier.

96. A composition of matter, comprising an isolated immunostimulatory nucleic acid of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 32, 40, 41, 64, 65, 66, 67, 68, 69, 70, 71, 72, 85, 86, 87, 88, 89, 90, 91, 92, 93, or 94 and a pharmaceutically acceptable carrier.

97. The method of claim 80 wherein the nucleic acid further comprises a plurality of CpG motifs, and wherein the plurality is at least 3 motifs, at least 4 motifs and wherein the at least 4 motifs each comprises at least 3 contiguous T nucleotide residues.

98. The method of claim 90 wherein the plurality of CpG motifs and poly T motifs are interrupted.

99. A composition, comprising:
an immunostimulatory nucleic acid and an anti-cancer therapy,
formulated in a pharmaceutically-acceptable carrier and in an effective amount to treat a cancer or to reduce the risk of developing a cancer, wherein the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid and a TG nucleic acid.

100. A composition, comprising:

- 166 -

an immunostimulatory nucleic acid and an asthma/allergy medication,
formulated in a pharmaceutically-acceptable carrier and in an effective amount for preventing or treating an immune response associated with exposure to a mediator of asthma or allergy, wherein the immunostimulatory nucleic acid is selected from the group consisting of a T-rich nucleic acid, a TG nucleic acid and a C-rich nucleic acid.

101. A composition comprising

an immunostimulatory nucleic acid selected from the group consisting of SEQ ID NO: 95-136, SEQ ID NO: 138-152, SEQ ID NO: 154-222, SEQ ID NO: 224-245, SEQ ID NO: 247-261, SEQ ID NO: 263-299, SEQ ID NO: 301, SEQ ID NO: 303-4109, SEQ ID NO: 414-420, SEQ ID NO: 424, SEQ ID NO: 426-947, SEQ ID NO: 959-1022, SEQ ID NO: 1024-1093, and a pharmaceutically acceptable carrier.

102. A composition comprising

an immunostimulatory nucleic acid consisting essentially of:

5' M₁TCGTCGTTM₂ 3'

wherein at least one of the C₁ is unmethylated, wherein M₁ is a nucleic acid having at least one nucleotide, wherein M₂ is a nucleic acid having between 0 and 50 nucleotides, and wherein the immunostimulatory nucleic acid has less than 100 nucleotides.

103. A pharmaceutical composition comprising
an immunostimulatory nucleic acid comprising:

5' TCGTCGTT 3'

wherein at least one of the C₁ is unmethylated, wherein the immunostimulatory nucleic acid has less than 100 nucleotides and a phosphodiester backbone, and

a sustained release device.

104. The pharmaceutical composition of claim 103 wherein the sustained release device is a microparticle.

105. The pharmaceutical composition of claim 103, further comprising an antigen.

1/10


2/10

STATISTICAL ANALYSIS

	MEAN	STD DEV	STD ERROR	NUMBER	MINIMUM	MAXIMUM	# MISSING
o1758	57.60	.71	.50	2	57.10	58.10	2
o1812	20.70	.57	.40	2	20.30	21.10	2
o2006	56.35	.35	.25	2	56.10	56.60	2
o2117	40.00	1.13	.80	2	39.20	40.80	2
o2137	47.60	3.39	2.40	2	45.20	50.00	2
o2178	21.00	.99	.70	2	20.30	21.70	2
o2182	37.75	.35	.25	2	37.50	38.00	2
o2183	35.30	1.84	1.30	2	34.00	36.60	2
o2177	25.00	.71	.50	2	24.50	25.50	2
o2143	34.70	.71	.50	2	34.20	35.20	2
o2116	24.35	.64	.45	2	23.90	24.80	2
o2181	44.25	3.18	2.25	2	42.00	46.50	2
o2180	45.90	5.94	4.20	2	41.70	50.10	2
o2179	50.70	6.93	4.90	2	45.80	55.60	2
o2133	53.75	4.31	3.05	2	50.70	56.80	2
o1965	56.20	3.82	2.70	2	53.50	58.90	2
o1968	49.35	1.91	1.35	2	48.00	50.70	2
o2159	46.80	7.92	5.60	2	41.20	52.40	2
o2140	53.25	4.74	3.35	2	49.90	56.60	2
o2141	47.40	4.10	2.90	2	44.50	50.30	2
o2142	23.20	.42	.30	2	22.90	23.50	2
o1840	33.50	1.13	.80	2	32.70	34.30	2
o1979	59.50	1.70	1.20	2	58.30	60.70	2
o2186	36.90	.14	.10	2	36.80	37.00	2
o2187	27.15	.78	.55	2	26.60	27.70	2
o2188	22.25	.21	.15	2	22.10	22.40	2
o2189	21.45	1.20	.85	2	20.60	22.30	2
o2190	22.95	1.20	.85	2	22.10	23.80	2
o2191	28.35	.49	.35	2	28.00	28.70	2
o2192	20.40	1.70	1.20	2	19.20	21.60	2
o2193	19.70	.57	.40	2	19.30	20.10	2
o2194	34.00	1.70	1.20	2	32.80	35.20	2
o2195	27.30	1.27	.90	2	26.40	28.20	2
o2196	22.45	2.76	1.95	2	20.50	24.40	2
NO ADDITION	20.90	2.77	1.38	4	18.60	24.90	0

Fig. 1B

Fig. 1A






Fig. 2




Fig. 3

WO 01/25972

PCT/US00/6383

5/10




Fig. 4

SUBSTITUTE SHEET (RULE 26)

WO 01/25972

PCT/US00/6383

6/10




Fig. 5

SUBSTITUTE SHEET (RULE 26)

7/10




Fig. 6

8/10




Fig. 7








Fig. 8



SEQUENCE LISTING

<110> University of Iowa Research Foundation
Coley Pharmaceutical Group GmbH

<120> Immunostimulatory Nucleic Acids

<130> C1039/7039M0 (HCL/NAV)

<150> US 60/156,113

<151> 1998-09-25

<150> US 60/156,135

<151> 1998-09-27

<150> US 60/227,436

<151> 2000-08-23

<160> 1145

<170> FastSeq for Windows Version 3.0

<210> 1

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Sequence

<400> 1

ttctccagcgt tgcgcgat

18

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 2

atcatccagc ttgcacagag

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 3

atcatccagc ttgcacagag

20

<210> 4

<211> 18

<212> DNA

<213> Artificial Sequence

<400> 4

taccgcgtgac gcccctct

18

<210> 5

<211> 9

<212> DNA

<213> Artificial Sequence

<400> 5

gggggggggt

9

<210> 6

<211> 9

<212> DNA

<213> Artificial Sequence

<400> 6

gggggggggg

9

<210> 7

<211> 9

<212> DNA

<213> Artificial Sequence

<400> 7

ggcggggcgc

9

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (8)...(8)

<223> m5c

<400> 8

ttccatggtggt tccatgatgc

20

<210> 9

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (11)...(11)

<223> m5c

<400> 9

gtctactctg ngttga

15

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (8)...(8)

<223> m5c

<400> 10

ttccatggtggt tccatgatgc

20

<210> 11

<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (13)...(13)
<223> m5c
<400> 11
tccatgcgcgt tcntgatgct
<210> 12
<211> 15
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (7)...(7)
<223> m5c
<400> 12
gctagangtt agtct
<210> 13
<211> 19
<212> DNA
<213> Artificial Sequence
<400> 13
agctccatgag tgcctactg
<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 14
ccacgtgcgc cctacgcgcg
<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 15
gcacatgcgc ccgcgcgcg
<210> 16
<211> 19
<212> DNA
<213> Artificial Sequence
<400> 16
gtacactggt gacatgcg
<210> 17
<211> 25
<212> DNA
<213> Artificial Sequence

<400> 17
gttggtatcac ggcacgactt tgttg
<210> 18
<211> 25
<212> DNA
<213> Artificial Sequence
<400> 18
gcttcacactt ggcctcactt taggc
<210> 19
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 19
accatggagc aactgtttcc cctc
<210> 20
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 20
accatggagc agctgtttcc cctc
<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 21
accatggagc accgtgtttcc cctc
<210> 22
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 22
accatggagc tactgtttcc cctc
<210> 23
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 23
accatggagc gctcgtttcc cctc
<210> 24
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 24
accatggagc ttctgtttcc cctc
<210> 25

25

25

24

24

24

24

24

24

WU 01/29/72

5

PCVUS00/26383

<211> 25
<212> DNA
<213> Artificial Sequence

<400> 25
ccatccacat ccgcctgcctcc acaag

<210> 26
<211> 25
<212> DNA
<213> Artificial Sequence

<400> 26
actctccata gccacctctgctg tccag

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 27
tccatgcgtc tccctgcgtc

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (9)...(9)
<223> I

<221> modified_base
<222> (11)...(11)
<223> I

<221> modified_base
<222> (15)...(15)
<223> I

<400> 28
ggagagaggg agagagagcgc

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> I

<221> modified_base
<222> (13)...(13)
<223> I

<221> modified_base
<222> (18)...(18)
<223> I

WU 01/29/72

6

PCVUS00/26383

<400> 29
gggaatgcgt tcccgagcct

<210> 30
<211> 6
<212> DNA
<213> Artificial Sequence

<400> 30
aaaaaa

<210> 31
<211> 6
<212> DNA
<213> Artificial Sequence

<400> 31
ccccc

<210> 32
<211> 6
<212> DNA
<213> Artificial Sequence

<400> 32
cctgcac

<210> 33
<211> 6
<212> DNA
<213> Artificial Sequence

<400> 33
tcgtgag

<210> 34
<211> 6
<212> DNA
<213> Artificial Sequence

<400> 34
tcgtgag

<210> 35
<211> 6
<212> DNA
<213> Artificial Sequence

<400> 35
cgtgcgt

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 36
tccatgcgtc tccctgcgtc

<210> 37

20

8
20

tcacacacgt tcctgagttct
<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 45

20

tcacacacgt tcctgagttct
<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 46

20

tcacacacgt tcctgagttct
<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 47

20

tcacacacgt tcctgagttct
<210> 48
<211> 20
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 48

20

tcacacacgt tcctgagttct
<210> 49
<211> 39
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 49

20

tcacacacgt tcctgagttct
<210> 50
<211> 39
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 50

20

tcacacacgt tcctgagttct
<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 51

20

tcacacacgt tcctgagttct
<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 52

20

tcacacacgt tcctgagttct
<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 53

20

tcacacacgt tcctgagttct
<210> 54
<211> 20
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 54

20

tcacacacgt tcctgagttct
<210> 55
<211> 20
<212> DNA
<213> Artificial Sequence

20

tcacacacgt tcctgagttct
<400> 55

20

tcacacacgt tcctgagttct
<210> 56
<211> 20
<212> DNA
<213> Artificial Sequence

20

W0 01/29/72 PCT/US00/26383

9
20

cccccaagg atcagaagct
<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 52
agatagcaaa tccgtctgacg
<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 53
ggtccagcgg ctcattgctcg
<210> 54
<211> 18
<212> DNA
<213> Artificial Sequence

<400> 54
tctccagcg tgcgcacat
<210> 55
<211> 18
<212> DNA
<213> Artificial Sequence

<400> 55
tctccagcg tgcgcacat
<210> 56
<211> 18
<212> DNA
<213> Artificial Sequence

<400> 56
taccgctgcg gacacatct
<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 57
ataatccagcg ttgnaccag
<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 58
ataatccagcg ttccagcaag
<210> 59
<211> 20
<212> DNA

W0 01/29/72 PCT/US00/26383

10

<213> Artificial Sequence
<400> 59
tccatgactt tcccgatttc
<210> 60
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 60
ttgttttttc gtttttttgc ttct
<210> 61
<211> 22
<212> DNA
<213> Artificial Sequence

<400> 61
tttttttgcg tttttttgcg tt
<210> 62
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 62
tgcctgacttc gttcttttgc gctt
<210> 63
<211> 22
<212> DNA
<213> Artificial Sequence

<400> 63
tgcctgacttc gtttttttgc tt
<210> 64
<211> 23
<212> DNA
<213> Artificial Sequence

<400> 64
gcatcacca ggcggcgacg aat
<210> 65
<211> 23
<212> DNA
<213> Artificial Sequence

<400> 65
taccgagctt cgaagagatt tca
<210> 66
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 66
gcattgagctt gtagct
<210> 67
<211> 15

<212> DNA
<213> Artificial Sequence
<400> 82
gagggctgctctg tcaaggggg
<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 83
tccatggctgt tccctggctgt
<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 84
tccatggctgt tccctggctgt
<210> 85
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 85
tcgtggctgt ctcggctgt t
<210> 86
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 86
gcatggctgt gggct
<210> 87
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 87
tctccaggcg tggcgcatat
<210> 88
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 88
tctccaggcg tggcgcatat
<210> 89
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 89
tctccaggcg tggcgcatat
<210> 90
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 90
tctccaggcg tggcgcatat
<210> 91
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 91
tctccaggcg tggcgcatat
<210> 92
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 92
tctccaggcg tggcgcatat
<210> 93
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 93
gcatggctgt gggct
<210> 94
<211> 19
<212> DNA
<213> Artificial Sequence
<400> 94
tctggagctg cctggagctt
<210> 95
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 95
tctggagctg cctggagctt

tccatggctgt tccctggctgt
<210> 89
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 89
tccatggctgt tccctggctgt
<210> 90
<211> 16
<212> DNA
<213> Artificial Sequence
<400> 90
tccatggctgt tccctggctgt
<210> 91
<211> 18
<212> DNA
<213> Artificial Sequence
<400> 91
tccatggctgt tccctggctgt
<210> 92
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 92
tccatggctgt tccctggctgt
<210> 93
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 93
gcatggctgt gggct
<210> 94
<211> 19
<212> DNA
<213> Artificial Sequence
<400> 94
tctggagctg cctggagctt
<210> 95
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 95
tctggagctg cctggagctt

WO 01/23972	PCT/US00/26383	15	15	16	PCT/US00/26383
gcattgagctt gagct					
<210> 96					
<211> 15					
<212> DNA					
<213> Artificial Sequence					
<400> 96					
gcatttcag gagct					
<210> 97					
<211> 15					
<212> DNA					
<213> Artificial Sequence					
<400> 97					
gcattgagct gagct					
<210> 98					
<211> 20					
<212> DNA					
<213> Artificial Sequence					
<400> 98					
tcaggagct tctagtctt					
<210> 99					
<211> 20					
<212> DNA					
<213> Artificial Sequence					
<400> 99					
tcaggagct tctagtctt					
<210> 100					
<211> 20					
<212> DNA					
<213> Artificial Sequence					
<400> 100					
tcaggatgt tctagtctt					
<210> 101					
<211> 20					
<212> DNA					
<213> Artificial Sequence					
<400> 101					
tcagtcttag gctagtctt					
<210> 102					
<211> 20					
<212> DNA					
<213> Artificial Sequence					
<400> 102					
tcagttcga gctagtctt					
<210> 103					
<211> 15					
<212> DNA					
<213> Artificial Sequence					
<400> 103					
gcattgagctt gagct					
<210> 104					
<211> 15					
<212> DNA					
<213> Artificial Sequence					
<400> 104					
gcattgagctt gagct					
<210> 105					
<211> 15					
<212> DNA					
<213> Artificial Sequence					
<400> 105					
gcattgagctt gagct					
<210> 106					
<211> 15					
<212> DNA					
<213> Artificial Sequence					
<400> 106					
gcattgagctt cgttt					
<210> 107					
<211> 21					
<212> DNA					
<213> Artificial Sequence					
<400> 107					
tctccagag tgcgcata t					
<210> 108					
<211> 20					
<212> DNA					
<213> Artificial Sequence					
<400> 108					
tctccagag tgcgttat					
<210> 109					
<211> 20					
<212> DNA					
<213> Artificial Sequence					
<400> 109					
tctccctgag tgc					

WO 01/2972
17
PCT/US90/26383

<210> 111
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 111
tctctagcgt tgcgcacat

<210> 112
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 112
tctccacagc tgcgccttc

<210> 113
<211> 13
<212> DNA
<213> Artificial Sequence

<220> mlec_difference
<222> (5)...(5)
<223> n la a or g or c or t/a

<221> mlec_difference
<222> (6)...(6)
<223> d la a or g or t/oj not c

<221> mlec_difference
<222> (9)...(10)
<223> h la a or c or t/oj not g

<400> 113
gtctandogh agc

<210> 114
<211> 13
<212> DNA
<213> Artificial Sequence

<400> 114
tcttgagcgt ccc

<210> 115
<211> 13
<212> DNA
<213> Artificial Sequence

<400> 115
ggagagcgtt agc

<210> 116
<211> 13
<212> DNA
<213> Artificial Sequence

<400> 116
tcttgagcgtt agc

13

20

20

13

13

13

WO 01/2972
18
PCT/US90/26383

<210> 117
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 117
tcagacagc tgcgcggtg ttcctga

<210> 118
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 118
tcagacacac ccgaccagct gttctga

<210> 119
<211> 13
<212> DNA
<213> Artificial Sequence

<400> 119
gctagtcgct agc

<210> 120
<211> 13
<212> DNA
<213> Artificial Sequence

<400> 120
gctagtcgct agc

<210> 121
<211> 14
<212> DNA
<213> Artificial Sequence

<400> 121
gcttagcgtc tagc

<210> 122
<211> 14
<212> DNA
<213> Artificial Sequence

<400> 122
gcttagcgtc tagc

<210> 123
<211> 14
<212> DNA
<213> Artificial Sequence

<400> 123
gcttagcgtc aagc

<210> 124
<211> 14
<212> DNA
<213> Artificial Sequence

13

27

27

13

13

14

14

14

WO 01/22972	PCT/US00/23383	WO 01/22972	PCT/US00/23383
19	14	20	24
<400> 124 gctagcgtt tagc		<212> DNA <213> Artificial Sequence	
<210> 125 <211> 20 <212> DNA <213> Artificial Sequence		<400> 132 ccgcttcctc cagatgagct catg	
<400> 125 tcctatgact tcctgtgct		<210> 133 <211> 24 <212> DNA <213> Artificial Sequence	
<210> 126 <211> 14 <212> DNA <213> Artificial Sequence		<400> 133 catgagctca tcctgagcga gagg	
<400> 126 gctagcgtc tagc		<210> 134 <211> 24 <212> DNA <213> Artificial Sequence	
<210> 127 <211> 19 <212> DNA <213> Artificial Sequence		<400> 134 ccagatgagc tcctgggttt ctcac	
<400> 127 ggctatgtcg tctatgac		<210> 135 <211> 24 <212> DNA <213> Artificial Sequence	
<210> 128 <211> 19 <212> DNA <213> Artificial Sequence		<400> 135 ggagaacacc atgagctcat ctgg	
<400> 128 ggctatgtcg atctatgac		<210> 136 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 129 <211> 21 <212> DNA <213> Artificial Sequence		<400> 136 agcctcctgga agcactgga	
<400> 129 ctcctgggtt tctccaccac g		<210> 137 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 130 <211> 21 <212> DNA <213> Artificial Sequence		<400> 137 tccatgacgt tctctgacgtt	
<400> 130 cttgggtggc aabcccatga g		<210> 138 <211> 19 <212> DNA <213> Artificial Sequence	
<210> 131 <211> 20 <212> DNA <213> Artificial Sequence		<400> 138 gcgcgcgcgc gcgcgcgc	
<400> 131 tccatgacgt tctctgtct		<210> 139 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 132 <211> 24		<400> 139 ccgctctgctt ggcgcgcgcg	

WO 01/2972
21
PCT/US90/26383

<210> 140
<211> 43
<212> DNA
<213> Artificial Sequence

<400> 140
ttccacccag cccacccccc ttctggcccaca ccttcacact cca

<210> 141
<211> 43
<212> DNA
<213> Artificial Sequence

<400> 141
tggagggatga gggcggggcc agagcggggtg gggcgtgattg gaa

<210> 142
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 142
tcaatgtcgg gattttccca tgaatct

<210> 143
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 143
agactcatgg gaatatccca catttga

<210> 144
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 144
tgcacagtgc tgaatcacta ataaaga

<210> 145
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 145
tctttatagg tgaatcagca ctctgca

<210> 146
<211> 31
<212> DNA
<213> Artificial Sequence

<400> 146
tgcaggaagt ccgggttttc cccacccccc c

<210> 147
<211> 31
<212> DNA
<213> Artificial Sequence

31

WO 01/2972
22
PCT/US90/26383

<400> 147
ggggggttgg ggaatacccg gacttctgc a

<210> 148
<211> 38
<212> DNA
<213> Artificial Sequence

<400> 148
ggggaatttc cgtcgggggc ttccagggg gactttcc

<210> 149
<211> 45
<212> DNA
<213> Artificial Sequence

<400> 149
tccatggagct tctcttccat gacgttcttc tccatggagct tcttc

<210> 150
<211> 45
<212> DNA
<213> Artificial Sequence

<400> 150
ggagacagct atggagagga acgtcatgga ggagacagtc atcga

<210> 151
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 151
ataatagagc ttcacagagag

<210> 152
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 152
tccatggagct tccatggagct

<210> 153
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 153
tccatggagct tccatggagct

<210> 154
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 154
tccagagact tccatggagct

<210> 155

31

38

45

45

20

20

20

20

<213> Artificial Sequence
<400> 170
tcctgacgct gaagtc 15
<210> 171
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 171
tcctgacgct gaagtc 15
<210> 172
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 172
tcctgacgct gaagtc 15
<210> 173
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 173
gggggacgct ggagtc 15
<210> 174
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 174
tcctgacgct ccttc 15
<210> 175
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 175
tcctcagcgc agagagagcgc at 22
<210> 176
<211> 32
<212> DNA
<213> Artificial Sequence
<400> 176
tcctgacgct cccctggcggcg tcacctgtcg ct 32
<210> 177
<211> 28
<212> DNA
<213> Artificial Sequence
<400> 177
tcctgtcgct cctgtcgctc cttgtcgct 28

<210> 178
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 178
tcctggcggcg gaagtc 15
<210> 179
<211> 15
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (1)...(7)
<223> m5c
<400> 179
tcctgacgct gaagtc 15
<210> 180
<211> 15
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (3)...(3)
<223> m5c
<400> 180
tcctgacgct gaagtc 15
<210> 181
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 181
tcctgacgct gaagtc 15
<210> 182
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 182
tcctgacgct gaagtc 15
<210> 183
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 183
tcctgacggcg gaagtc 15
<210> 184
<211> 15
<212> DNA

<213> Artificial Sequence		
<400> 184	15	
tccgtgcgtt gacgt		
<210> 185		
<211> 27		
<212> DNA		
<213> Artificial Sequence		
<400> 185	27	
ggctcgggg aggaatttt tgcctat		
<210> 186		
<211> 27		
<212> DNA		
<213> Artificial Sequence		
<400> 186	27	
atagacaaa attcctccc cyggacc		
<210> 187		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<400> 187	21	
tccatgcgt tccggagtc t		
<210> 188		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<400> 188	21	
tccgtgcgt atcagcttct t		
<210> 189		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<400> 189	21	
tccgtgcgt ctcgcttct t		
<210> 190		
<211> 23		
<212> DNA		
<213> Artificial Sequence		
<400> 190	23	
tccgacatt gccatcatc ctg		
<210> 191		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<400> 191	20	
caattatgc atgtctcgc		
<210> 192		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<400> 192	20	
tccatgcgt tccgtgcg		
<210> 193		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<400> 193	20	
gcgatgcgt tccgtgcgt		
<210> 194		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<400> 194	20	
gcgatgcgt tccgtgcg		
<210> 195		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<400> 195	20	
tccatgcgt tccggcg		
<210> 196		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<400> 196	20	
tccatgcgt tccgtgcgt		
<210> 197		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<400> 197	20	
tccatgcgt tccgtgcgt		
<210> 198		
<211> 20		
<212> DNA		
<213> Artificial Sequence		
<400> 198	20	
gcggcgggg gcggcgccc		
<210> 199		
<211> 21		
<212> DNA		
<213> Artificial Sequence		
<400> 199	20	
caattatgc atgtctcgc		

<210> 222
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified base
<222> (8)... (8)
<223> m5c

<221> modified base
<222> (17)... (17)
<223> m5c

<400> 222
tccatgtngt tccgtngtt

<210> 223

<211> 20

<212> DNA
<213> Artificial Sequence

<400> 223
tccatgacgt tccgacgtt

<210> 224

<211> 20

<212> DNA
<213> Artificial Sequence

<400> 224
gggggttgcgt ttggggggg

<210> 225

<211> 20

<212> DNA
<213> Artificial Sequence

<400> 225
tccaggacgt cttcaggtt

<210> 226

<211> 20

<212> DNA
<213> Artificial Sequence

<400> 226
tttttttttt tttttttt

<210> 227

<211> 20

<212> DNA
<213> Artificial Sequence

<400> 227
tccatgacgt tccgacgtt

<210> 228

<211> 20

<212> DNA

<212> DNA
<213> Artificial Sequence

<400> 214
gggggtcgtc gtttggggg g

<210> 215

<211> 21

<212> DNA
<213> Artificial Sequence

<400> 215
gggggtcgtc gtttggggg g

<210> 216

<211> 15

<212> DNA
<213> Artificial Sequence

<400> 216
tccggacgtt gaaat

<210> 217

<211> 15

<212> DNA
<213> Artificial Sequence

<400> 217
tccggacgtt gaaat

<210> 218

<211> 15

<212> DNA
<213> Artificial Sequence

<400> 218
tccggacgtt gaaat

<210> 219

<211> 15

<212> DNA
<213> Artificial Sequence

<400> 219
tccggacgtt gaaat

<210> 220

<211> 15

<212> DNA
<213> Artificial Sequence

<400> 220
tccggacgtt gaaat

<210> 221

<211> 15

<212> DNA
<213> Artificial Sequence

<400> 221
tccggacgtt gaaat

<213> Artificial Sequence
<400> 228
tccatgcgcg gcctgcgcgg
20
<210> 229
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 229
tccatgcgcg tccctgcgcgt
20
<210> 230
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 230
tccatgcgcg tccctgcgcgg
20
<210> 231
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 231
tccatgcgcg tccctgcgtt
20
<210> 232
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 232
tccatgcgcg tccctgcgcgt
20
<210> 233
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 233
tccatgcgcg cgtgcgttct
20
<210> 234
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 234
tccatgcgtt gcgtgcgtt
20
<210> 235
<211> 30
<212> DNA
<213> Artificial Sequence
<220>
<215> ninc_feature
<225> (1)...(3)

<223> Biotin moiety attached at 5' end of sequence.
<400> 235
tccatccat tctagcgcg agctctccat
30
<210> 236
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 236
tccatgcgcg tccctgcgcgt
20
<210> 237
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 237
tccatgcgcg tccctgcgcgt
20
<210> 238
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 238
tccatgcgcg tccctgcgcgt
20
<210> 239
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 239
tccatgcgcg tccctgcgcgt
20
<210> 240
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 240
tccatgcgcg tccctgcgcgt
20
<210> 241
<211> 29
<212> DNA
<213> Artificial Sequence
<400> 241
tccatgcgtt tccctgcgcgt
29
<210> 242
<211> 29
<212> DNA
<213> Artificial Sequence
<400> 242
tccatgcgcg tccctgcgcgt
29

<210> modified base
<221> (10)...(10)
<223> m5c
<210> modified base
<221> (13)...(13)
<223> m5c
<400> 249
cnggcggcgg gggcgcgg
<210> 250
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 250
gcgcgcggcg gcgcgcgc
<210> 251
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (3)...(3)
<223> I
<221> modified base
<222> (6)...(6)
<223> I
<221> modified base
<222> (14)...(14)
<223> I
<400> 251
agncgcggca acgattcacc
<210> 252
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 252
tgtcgtttgt cgtttgtgt t
<210> 253
<211> 25
<212> DNA
<213> Artificial Sequence
<400> 253
tgtcgtgtgc grtcgcgttg tgcgt
<210> 254
<211> 25
<212> RNA
<213> Artificial Sequence

<210> 243
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 243
ggcgcgcggc ggcgcgcgg
<210> 244
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 244
tcacgcgcgt ttgcgcgtt
<210> 245
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 245
tcgtcgttgt cgttcgttgt
<210> 246
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 246
tcgtcgtttt grgcgtttgt cgtt
<210> 247
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 247
tcgtcgttgt cgttttgtgt tt
<210> 248
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 248
gcgtgcgttg tcgttgtgt t
<210> 249
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (2)...(2)
<223> m5c
<221> modified base
<222> (6)...(6)
<223> m5c

W0612372	W0612373	W0612374	W0612375	W0612376	W0612377	W0612378	W0612379	W0612380	W0612381	W0612382	W0612383	W0612384	W0612385	W0612386	W0612387	W0612388	W0612389	W0612390	W0612391	W0612392	W0612393	W0612394	W0612395	W0612396	W0612397	W0612398	W0612399	W0612400	W0612401	W0612402	W0612403	W0612404	W0612405	W0612406	W0612407	W0612408	W0612409	W0612410	W0612411	W0612412	W0612413	W0612414	W0612415	W0612416	W0612417	W0612418	W0612419	W0612420	W0612421	W0612422	W0612423	W0612424	W0612425	W0612426	W0612427	W0612428	W0612429	W0612430	W0612431	W0612432	W0612433	W0612434	W0612435	W0612436	W0612437	W0612438	W0612439	W0612440	W0612441	W0612442	W0612443	W0612444	W0612445	W0612446	W0612447	W0612448	W0612449	W0612450	W0612451	W0612452	W0612453	W0612454	W0612455	W0612456	W0612457	W0612458	W0612459	W0612460	W0612461	W0612462	W0612463	W0612464	W0612465	W0612466	W0612467	W0612468	W0612469	W0612470	W0612471	W0612472	W0612473	W0612474	W0612475	W0612476	W0612477	W0612478	W0612479	W0612480	W0612481	W0612482	W0612483	W0612484	W0612485	W0612486	W0612487	W0612488	W0612489	W0612490	W0612491	W0612492	W0612493	W0612494	W0612495	W0612496	W0612497	W0612498	W0612499	W0612500	W0612501	W0612502	W0612503	W0612504	W0612505	W0612506	W0612507	W0612508	W0612509	W0612510	W0612511	W0612512	W0612513	W0612514	W0612515	W0612516	W0612517	W0612518	W0612519	W0612520	W0612521	W0612522	W0612523	W0612524	W0612525	W0612526	W0612527	W0612528	W0612529	W0612530	W0612531	W0612532	W0612533	W0612534	W0612535	W0612536	W0612537	W0612538	W0612539	W0612540	W0612541	W0612542	W0612543	W0612544	W0612545	W0612546	W0612547	W0612548	W0612549	W0612550	W0612551	W0612552	W0612553	W0612554	W0612555	W0612556	W0612557	W0612558	W0612559	W0612560	W0612561	W0612562	W0612563	W0612564	W0612565	W0612566	W0612567	W0612568	W0612569	W0612570	W0612571	W0612572	W0612573	W0612574	W0612575	W0612576	W0612577	W0612578	W0612579	W0612580	W0612581	W0612582	W0612583	W0612584	W0612585	W0612586	W0612587	W0612588	W0612589	W0612590	W0612591	W0612592	W0612593	W0612594	W0612595	W0612596	W0612597	W0612598	W0612599	W0612600	W0612601	W0612602	W0612603	W0612604	W0612605	W0612606	W0612607	W0612608	W0612609	W0612610	W0612611	W0612612	W0612613	W0612614	W0612615	W0612616	W0612617	W0612618	W0612619	W0612620	W0612621	W0612622	W0612623	W0612624	W0612625	W0612626	W0612627	W0612628	W0612629	W0612630	W0612631	W0612632	W0612633	W0612634	W0612635	W0612636	W0612637	W0612638	W0612639	W0612640	W0612641	W0612642	W0612643	W0612644	W0612645	W0612646	W0612647	W0612648	W0612649	W0612650	W0612651	W0612652	W0612653	W0612654	W0612655	W0612656	W0612657	W0612658	W0612659	W0612660	W0612661	W0612662	W0612663
----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------	----------

WFO 01/29/72

38

<211> 24
<212> DNA
<213> Artificial Sequence

<400> 262
tcgcgttcgtt gtcgcgttcgtt cgtt

<210> 263
<211> 22
<212> DNA
<213> Artificial Sequence

<400> 263
tcgcgttcgtt cgttcgttcgtt tt

<210> 264
<211> 39
<212> DNA
<213> Artificial Sequence

<400> 264
gggggggggg gnaactctta aaattccccc agaatgtttt

<210> 265
<211> 39
<212> DNA
<213> Artificial Sequence

<400> 265
aaacattctg ggggaatttt aagaattccc tccctccccc

<210> 266
<211> 33
<212> DNA
<213> Artificial Sequence

<400> 266
atgtttacatt cttaaaattac cccagaattg ttt

<210> 267
<211> 32
<212> DNA
<213> Artificial Sequence

<400> 267
aaacattctg ggggaatttt aagaattcaa cct

<210> 268
<211> 33
<212> DNA
<213> Artificial Sequence

<400> 268
atgtttctaca gcaaaaattac cccagaattg ttt

<210> 269
<211> 33
<212> DNA
<213> Artificial Sequence

<400> 269

aaacattctg ggggaatttt gcttagtasa
33

<210> 270

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 270

aaatttgag ttttaaaaa

<210> 271

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 271

ccacttgac ttttccccc

<210> 272

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 272

tttttgttgt ttttgttgt

<210> 273

<211> 24

<212> DNA

<213> Artificial Sequence

<400> 273

tgtgtgtttt gctgttttgt cgtt

<210> 274

<211> 14

<212> DNA

<213> Artificial Sequence

<400> 274

ctgcgcctg ggc

<210> 275

<211> 25

<212> DNA

<213> Artificial Sequence

<400> 275

ccctgtgta attatagtas aaccc

<210> 276

<211> 21

<212> DNA

<213> Artificial Sequence

<400> 276

ggtaactctg gggactttgt g

<210> 277

<211> 18

<212> DNA
<213> Artificial Sequence

<400> 277

agacacgac gtgagcg

<210> 278

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 278

tccatgcgct tccgtgcggt

<210> 279

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 279

tccatgcgcy tccgtgcggt

<210> 280

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 280

tccatgcgcy tccgtgcggt

<210> 281

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 281

tccatgcgcy tccgtgcggt

<210> 282

<211> 24

<212> DNA

<213> Artificial Sequence

<400> 282

ctggctcttc tggttttttt ctgg

<210> 283

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 283

tccggggctg ggggaacctt

<210> 284

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<221> modified_base

WO 01/23972
<222> (8)...(8)
<223> m5c
<400> 284
tccatgaagtc tccatgaagtc
<210> 285
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 285
tccatgaagtc tccatgaagtc
<210> 286
<211> 26
<212> DNA
<213> Artificial Sequence
<400> 286
cccgaagttca ttccctctca mactgag
<210> 287
<211> 26
<212> DNA
<213> Artificial Sequence
<400> 287
ccaggttaag aggaatgac ttccgag
<210> 288
<211> 13
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (7)...(7)
<223> m5c
<400> 288
tccatgaagtc gaagtc
<210> 289
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (2)...(2)
<223> m5c
<221> modified base
<222> (3)...(3)
<223> m5c
<231> modified base
<232> (9)...(9)
<233> m5c

41

PCT/US00/26383

WO 01/23972
<221> modified base
<222> (12)...(12)
<223> m5c
<221> modified base
<222> (14)...(14)
<223> m5c
<221> modified base
<222> (16)...(16)
<223> m5c
<400> 289
gmgggggmg gmgmgccc
<210> 290
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 290
tccatgaagtc tccatgaagtc
<210> 291
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 291
tccatgaagtc tccatgaagtc
<210> 292
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 292
tccatgaagtc tccatgaagtc
<210> 293
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 293
tccatgaagtc tccatgaagtc
<210> 294
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 294
tccatgaagtc tccatgaagtc
<210> 295
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 295

42

PCT/US00/26383

tccagcagct tccagcagct		<213> Artificial Sequence	
<210> 286		<400> 303	20
<211> 286		tccagcagct ctcacagct	
<212> DNA		<210> 304	
<213> Artificial Sequence		<211> 304	
<400> 296	20	<212> DNA	
tccagcagct ctcagcagct		<213> Artificial Sequence	
<210> 297		<220>	
<211> 297		<221> modified base	
<212> DNA		<222> (2)... (2)	
<213> Artificial Sequence		<223> m5c	
<400> 297	15	<221> modified base	
tccagcagct gacgt		<222> (5)... (5)	
<210> 298		<223> m5c	
<211> 298		<221> modified base	
<212> DNA		<222> (13)... (13)	
<213> Artificial Sequence		<223> m5c	
<400> 298	15	<221> modified base	
tccagcagct gacgt		<222> (21)... (21)	
<210> 299		<223> m5c	
<211> 299		<400> 304	24
<212> DNA		tngtngtttt gtagttttgt nggt	
<213> Artificial Sequence		<210> 305	
<400> 299	15	<211> 29	
tccagcagct gacgt		<212> DNA	
<210> 300		<213> Artificial Sequence	
<211> 300		<220>	
<212> DNA		<221> misc feature	
<213> Artificial Sequence		<222> (1)... (1)	
<400> 300	24	<223> Biotin moiety attached at 5' end of sequence.	
tccagcagct gtagttttgt cgtt		<400> 305	29
<210> 301		tccagcagct gtagttttgt cgtttttt	
<211> 301		<210> 306	
<212> DNA		<211> 18	
<213> Artificial Sequence		<212> DNA	
<400> 301	24	<213> Artificial Sequence	
ctggtctcttc tggttttttt ctgg		<400> 306	18
<210> 302		gctatgagct tccagagg	
<211> 302		<210> 307	
<212> DNA		<211> 8	
<213> Artificial Sequence		<212> DNA	
<400> 302	20	<213> Artificial Sequence	
tccatgagct tccagcagct		<400> 307	8
<210> 303		tccagcagct	
<211> 303		<210> 308	
<212> DNA		<211> 20	

WO 01/2972
<212> DNA
<213> Artificial Sequence
<400> 308
tccagagcct tccctcaggt
<210> 309
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 309
ctctcgtctg gaccctctgg
<210> 310
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 310
cttccgcttg gaccctcggg
<210> 311
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 311
gtccgggcga gcccacagtc
<210> 312
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 312
gtccgggcga gcccacagtc
<210> 313
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 313
tccatgaggt tccctcaggt
<210> 314
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 314

45

PCT/US90/26383

WO 01/2972
ataagtcgac ataccacac
<210> 315
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 315
ataagtcgac atcccggggc
<210> 316
<211> 28
<212> DNA
<213> Artificial Sequence
<400> 316
<212> also difference
<222> (1)---(3)
<213> Protein moiety attached at 5' end of sequence.
ttttccatcg tgcctcctga tgcctttt
<210> 317
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 317
tccctgctgt gaagtttttt
<210> 318
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 318
gtctagctta gacctctaga gatt
<210> 319
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 319
tgcctgcttc cccccccccc
<210> 320
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 320
tgcagcttc cccccccccc
<210> 321
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 321

46

PCT/US90/26383

tctgtgttcc cccccccc	<210> 322	<213> Artificial Sequence	48	
	<211> 20			
	<212> DNA			15
	<213> Artificial Sequence			
tctgtgttcc cccccccc	<400> 322	<210> 330		
		<211> 21		
		<212> DNA		
		<213> Artificial Sequence		
tctgtgttcc cccccccc	<210> 323	<400> 330		21
	<211> 20	aaatctctgt cttttaaaaa n		
	<212> DNA	<210> 331		
	<213> Artificial Sequence	<211> 33		
		<212> DNA		
		<213> Artificial Sequence		
tctgtgttcc cccccccc	<400> 323	<400> 331		33
		gattccagttca cagtgcacgtg gcagatctg gat		
	<210> 324	<210> 332		
	<211> 20	<211> 33		
	<212> DNA	<212> DNA		
	<213> Artificial Sequence	<213> Artificial Sequence		
tctgtgttcc cccccccc	<400> 324	<400> 332		33
		gattccagtt cttgcacgtc actgtgactg gat		
	<210> 325	<210> 333		
	<211> 15	<211> 33		
	<212> DNA	<212> DNA		
	<213> Artificial Sequence	<213> Artificial Sequence		
tctgtgttcc cccccccc	<400> 325	<400> 333		33
		gattccagttca cagtgcacgtc gcagatctg gat		
	<210> 326	<210> 334		
	<211> 15	<211> 33		
	<212> DNA	<212> DNA		
	<213> Artificial Sequence	<213> Artificial Sequence		
tctgtgttcc cccccccc	<400> 326	<400> 334		33
		gattccagtt cttgcacgtc actgtgactg gat		
	<210> 327	<210> 335		
	<211> 15	<211> 20		
	<212> DNA	<212> DNA		
	<213> Artificial Sequence	<213> Artificial Sequence		
tctgtgttcc cccccccc	<400> 327	<220>		
		<221> modified base		
		<222> (16)...(16)		
		<223> m5c		
tctgtgttcc cccccccc	<210> 328	<400> 335		20
		tctgtgttcc cccccccc		
	<210> 329	<210> 336		
	<211> 15	<211> 20		
	<212> DNA	<212> DNA		

WO 01/2972
49
PCT/US90/24383

<213> Artificial Sequence
<220>
<221> modified base
<222> (2)...(2)
<223> m5c
<221> modified base
<222> (3)...(5)
<223> m5c
<400> 336
tngtngtgc cccccccc
20
<210> 337
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (2)...(2)
<223> m5c
<400> 337
tngtngtgc cccccccc
20
<210> 338
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (3)...(5)
<223> m5c
<400> 338
tngtngtgc cccccccc
20
<210> 339
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 339
tngtngtgc cccccccc
20
<210> 340
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 340
tngtngtgc cccccccc
20
<210> 341
<211> 20
<212> DNA
<213> Artificial Sequence

WO 01/2972
50
PCT/US90/24383

<400> 341
tcggcgctgc cccccccc
20
<210> 342
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 342
ggccatttgc cccccccc
20
<210> 343
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 343
tgctggttt gacgtttgt cgtc
24
<210> 344
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 344
tcgtggttt gacgtttga cgtc
24
<210> 345
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 345
ccgtggtgc cccccccc
20
<210> 346
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 346
ggctggtgc cccccccc
20
<210> 347
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 347
tcgtcatgc cccccccc
20
<210> 348
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 348
acgtggtgc cccccccc
20
<210> 349
<211> 20

WO 01/23972	PCT/US00/24383	51	52	PCT/US00/24383
<212> DNA				
<213> Artificial Sequence				
<400> 349				
ctgtgtgttt cccccccc				
<210> 350				
<211> 24				
<212> DNA				
<213> Artificial Sequence				
<220>				
<221> misc_feature				
<222> (1)...(3)				
<223> Biotin moiety attached at 3' end of sequence.				
<400> 350				
ttttgtgtgt tttccccccc cccc				
<210> 351				
<211> 20				
<212> DNA				
<213> Artificial Sequence				
<220>				
<221> misc_feature				
<222> (1)...(24)				
<223> Biotin moiety attached at 3' end of sequence.				
<400> 351				
tcgtgtgttt cccccccc				
<210> 352				
<211> 24				
<212> DNA				
<213> Artificial Sequence				
<220>				
<221> misc_feature				
<222> (2)...(24)				
<223> Biotin moiety attached at 3' end of sequence.				
<400> 352				
tcgtgtgttt gcgtgtttgt cgtt				
<210> 353				
<211> 20				
<212> DNA				
<213> Artificial Sequence				
<400> 353				
tcacgtttcct tcacgtgtct				
<210> 354				
<211> 24				
<212> DNA				
<213> Artificial Sequence				
<220>				
<221> modified_base				
<222> (2)...(2)				
<400> 354				
tcgtgtgttt gcgtgtttgt cgtt				
<210> 355				
<211> 15				
<212> DNA				
<213> Artificial Sequence				
<400> 355				
tcctggagggt gaagt				
<210> 356				
<211> 15				
<212> DNA				
<213> Artificial Sequence				
<400> 356				
tcctgaaag gaagt				
<210> 357				
<211> 17				
<212> DNA				
<213> Artificial Sequence				
<400> 357				
tcgtgtgttt ccccc				
<210> 358				
<211> 24				
<212> DNA				
<213> Artificial Sequence				
<220>				
<221> modified_base				
<222> (2)...(2)				
<223> misc				
<221> modified_base				
<222> (5)...(5)				
<223> misc				
<221> modified_base				
<222> (13)...(13)				
<223> misc				
<221> modified_base				
<222> (21)...(21)				
<223> misc				
<400> 358				
tcgtgtgttt gcgtgtttgt cgtt				
<210> 359				
<211> 20				
<212> DNA				
<213> Artificial Sequence				
<400> 359				
gggttcacgc ttggagggtgt				

W/O 01/25/97 53

<210> 360
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 360
tgcgtctcc ccccccccc

<210> 361
<211> 14
<212> DNA
<213> Artificial Sequence

<400> 361
tcgtgcgcgt cgct

<210> 362
<211> 14
<212> DNA
<213> Artificial Sequence

<400> 362
tcgtgcgcgt cgct

<210> 363
<211> 14
<212> DNA
<213> Artificial Sequence

<400> 363
tcgtgcgcgt cgct

<210> 364
<211> 8
<212> DNA
<213> Artificial Sequence

<400> 364
tcaacgctga

<210> 365
<211> 8
<212> DNA
<213> Artificial Sequence

<400> 365
tcaacgct

<210> 366
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 366
atagtttccc attttttac

<210> 367
<211> 20
<212> DNA
<213> Artificial Sequence

PCT/US90/26383

20

14

14

14

10

8

20

W/O 01/25/97 54

<400> 367
aatagtcgcg atccgcggag

<210> 368
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 368
aatagtcgcg atccgcggag

<210> 369
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 369
aatagtcgcg atcccccac

<210> 370
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 370
tgctgctttt gtcgtcttgc gctt

<210> 371
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 371
ctgtgcttcc tgcgtcttcc tgcg

<210> 372
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 372
ctaactcttc taatttttt ctaa

<210> 373
<211> 26
<212> DNA
<213> Artificial Sequence

<400> 373
tcgtgcttgc tgcgtcttgc gtcgtt

<210> 374
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 374
tcgtgcttgc tgcgtcttgc gctt

<210> 375

PCT/US90/26383

20

20

24

24

24

26

24

WO 01/23972	PCT/US00/26383	PCT/US00/26383	WO 01/23972
55		56	
<211> 24		<210> 383	
<212> DNA		<211> 20	
<213> Artificial Sequence		<212> DNA	
	24	<213> Artificial Sequence	
<400> 375		<400> 383	
accatggag agctgtttcc cctc		agacagacac gaacggccg	20
<210> 376		<210> 384	
<211> 20		<211> 20	
<212> DNA		<212> DNA	
<213> Artificial Sequence		<213> Artificial Sequence	
<400> 376	20	<400> 384	
tcgtcgtttt gctgcgttt		gtctgtccca tgatctcgaa	20
<210> 377		<210> 385	
<211> 20		<211> 20	
<212> DNA		<212> DNA	
<213> Artificial Sequence		<213> Artificial Sequence	
<400> 377	20	<400> 385	
ctgttaagta gcttggagag		gctggcagc ttactcccg	20
<210> 378		<210> 386	
<211> 18		<211> 21	
<212> DNA		<212> DNA	
<213> Artificial Sequence		<213> Artificial Sequence	
<400> 378	18	<400> 386	
gagacgctg gaattcc		ggggcctcta tacacctcg g	21
<210> 379		<210> 387	
<211> 20		<211> 18	
<212> DNA		<212> DNA	
<213> Artificial Sequence		<213> Artificial Sequence	
<400> 379	20	<400> 387	
cgggcgactc agtctatcgg		ggggctcccg agctgcg	18
<210> 380		<210> 388	
<211> 37		<211> 20	
<212> DNA		<212> DNA	
<213> Artificial Sequence		<213> Artificial Sequence	
<400> 380	37	<400> 388	
gtttcagat aagcggaac cagcacaga cacaga		gagacgctg gaattccat	20
<210> 381		<210> 389	
<211> 37		<211> 20	
<212> DNA		<212> DNA	
<213> Artificial Sequence		<213> Artificial Sequence	
<400> 381	37	<400> 389	
ttctgtgtc gtctcgtgtt cgtttttc tgaagac		tccatgtcgg tctgtatgct	20
<210> 382		<210> 390	
<211> 23		<211> 20	
<212> DNA		<212> DNA	
<213> Artificial Sequence			
<400> 382			

W/O 01/29/72	57	PC10/S00/26383	W/O 01/29/72	58	PC10/S00/26383
<213> Artificial Sequence			<210> 398		
<400> 390			<211> 20		
ctctctggac cggagagga	20		<212> DNA		
<210> 391			<213> Artificial Sequence		
<211> 20			<400> 398		
<212> DNA			ggcacacaaa ctgtccatg	20	
<213> Artificial Sequence			<210> 399		
<400> 391	20		<211> 20		
aggtacagcc agactacga			<212> DNA		
<210> 392			<213> Artificial Sequence		
<211> 24			<400> 399		
<212> DNA			gtccatggcg tggggagatga	20	
<213> Artificial Sequence			<210> 400		
<400> 392	24		<211> 19		
acctatggagc acctgttccc cctc			<212> DNA		
<210> 393			<213> Artificial Sequence		
<211> 24			<400> 400		
<212> DNA			cctctataca acctgggac	19	
<213> Artificial Sequence			<210> 401		
<400> 393	24		<211> 20		
acctatggatt accttttccc cctc			<212> DNA		
<210> 394			<213> Artificial Sequence		
<211> 20			<400> 401		
<212> DNA			cggcgacacc agtctatcgg	20	
<213> Artificial Sequence			<210> 402		
<400> 394	20		<211> 20		
atggaaagtc caagcttcttc			<212> DNA		
<210> 395			<213> Artificial Sequence		
<211> 20			<400> 402		
<212> DNA			ggactaacgg tagccctgagt	20	
<213> Artificial Sequence			<210> 403		
<400> 395	20		<211> 35		
agcatcagga ccgacatgga			<212> DNA		
<210> 396			<213> Artificial Sequence		
<211> 20			<400> 403		
<212> DNA			cgactggcga acagagatctc gttgtacagc acttgg	35	
<213> Artificial Sequence			<210> 404		
<400> 396	20		<211> 35		
ctctccaaagc tcaattacag			<212> DNA		
<210> 397			<213> Artificial Sequence		
<211> 21			<400> 404		
<212> DNA			ccagttgctga tcaaccagatat cctgtctggc agtccg	35	
<213> Artificial Sequence			<210> 405		
<400> 397	21		<211> 17		
tcacctggagc tgcctcacct c			<212> DNA		
			<213> Artificial Sequence		

WO 01/23571 60

<212> DNA
<213> Artificial Sequence
tcgtggtttt gtcgttttgc cgtt
<400> 413
<210> 414
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_difference
<222> (3)...(3)
<223> n is a or c or g or t/u
<221> misc_difference
<222> (8)...(8)
<223> n is a or c or g or t/u
<221> misc_difference
<222> (11)...(11)
<223> n is a or c or g or t/u
<221> misc_difference
<222> (16)...(16)
<223> n is a or c or g or t/u
<221> misc_difference
<222> (19)...(19)
<223> n is a or c or g or t/u
<221> misc_difference
<222> (24)...(24)
<223> n is a or c or g or t/u
<400> 414
tcgtggtttt ntgcgttttgc cgtt
<210> 415
<211> 17
<212> DNA
<213> Artificial Sequence
<400> 415
tctccacagc tgcacat
<210> 416
<211> 17
<212> DNA
<213> Artificial Sequence
<400> 416
tctccacatgc tgcacat
<210> 417
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 417

WO 01/23571 59

<400> 405
ccgggttgta tgcgcgc
<210> 406
<211> 18
<212> DNA
<213> Artificial Sequence
<400> 406
tctccacagc tgcacat
<210> 407
<211> 18
<212> DNA
<213> Artificial Sequence
<400> 407
tctccacagc tgcgtttt
<210> 408
<211> 18
<212> DNA
<213> Artificial Sequence
<400> 408
tctccacagc tgcgcacat
<210> 409
<211> 18
<212> DNA
<213> Artificial Sequence
<400> 409
tctccacagc tgcgcacat
<210> 410
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 410
atantgcagc tccacgcag
<210> 411
<211> 23
<212> DNA
<213> Artificial Sequence
<400> 411
tcgtggtttt gtcgttttgc cgt
<210> 412
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 412
tcgtggtttt gtcgttttgc cgtt
<210> 413
<211> 24

WO 01/2972	61	PCT/US90/26393	WO 01/2972	62	PCT/US90/26393
ataatcgttc gttcaagaaa g	21				
<210> 418			<213> Artificial Sequence		
<211> 20			<400> 425		19
<212> DNA			tccatgacgt tccctgaccc		
<213> Artificial Sequence			<210> 426 <211> 21 <212> DNA <213> Artificial Sequence		
<400> 418		20	<400> 426		21
ataatcgaag ttcacccccc			tgcctgcgtc tgcgcctctc t		
<210> 419			<210> 427		
<211> 20			<211> 24		
<212> DNA			<212> DNA		
<213> Artificial Sequence			<213> Artificial Sequence		
<400> 419		20	<400> 427		24
tctatcgaag ttcaagcaag			agacgctta gagctttaga gctt		
<210> 420			<210> 428		
<211> 14			<211> 24		
<212> DNA			<212> DNA		
<213> Artificial Sequence			<213> Artificial Sequence		
<400> 420		14	<400> 428		24
tccatgacgg gacg			ccccccccc ccccccccc cccc		
<210> 421			<210> 429		
<211> 19			<211> 32		
<212> DNA			<212> DNA		
<213> Artificial Sequence			<213> Artificial Sequence		
<400> 421		19	<400> 429		32
tccatgacgt tccctgaccc			tgcgcgtctc gtcgcgtctc gctttgcg tt		
<210> 422			<210> 430		
<211> 19			<211> 28		
<212> DNA			<212> DNA		
<213> Artificial Sequence			<213> Artificial Sequence		
<400> 422		19	<400> 430		28
tccatgacgt tccctgaccc			tgcctgtttc ttgcgtctc ttgcgtc		
<210> 423			<210> 431		
<211> 19			<211> 20		
<212> DNA			<212> DNA		
<213> Artificial Sequence			<213> Artificial Sequence		
<400> 423		19	<400> 431		20
tccatgacgt tccctgaccc			tgcctgtctc ttcttttttc		
<210> 424			<210> 432		
<211> 15			<211> 20		
<212> DNA			<212> DNA		
<213> Artificial Sequence			<213> Artificial Sequence		
<400> 424		15	<400> 432		20
tccctgacgtc gaaagt			tttttcaag ttgatttttc		
<210> 425					
<211> 19					
<212> DNA					

WO 01/2972	PCT/US00/26383	63	64	PCT/US00/26383
<210> 433 <211> 24 <212> DNA <213> Artificial Sequence				
tttttttttt tttttttttt tttt	24			
<400> 433 <210> 434 <211> 20 <212> DNA <213> Artificial Sequence				17
ggttgctctg ttttgggggg	20			
<400> 434 <210> 435 <211> 24 <212> DNA <213> Artificial Sequence				20
tcgtcgtttt gtcgtttttg gggg	24			
<400> 435 <210> 436 <211> 27 <212> DNA <213> Artificial Sequence				20
tcgtcgtctg ctccgtctctt tottgc	27			
<400> 436 <210> 437 <211> 15 <212> DNA <213> Artificial Sequence				21
tcgtcgtctg atccg	15			
<400> 437 <210> 438 <211> 20 <212> DNA <213> Artificial Sequence				20
ctgtcagtcg gcttggagag	20			
<400> 438 <210> 439 <211> 20 <212> DNA <213> Artificial Sequence				20
gagaaagctg gaatttcatt	20			
<400> 439 <210> 440 <211> 17 <212> DNA <213> Artificial Sequence				20
accacacga ggggaacgca				
<400> 440 <210> 441 <211> 17 <212> DNA <213> Artificial Sequence				17
ccaggttgta tagagc				
<400> 441 <210> 442 <211> 20 <212> DNA <213> Artificial Sequence				20
gtagacggtt agctcga				
<400> 442 <210> 443 <211> 20 <212> DNA <213> Artificial Sequence				20
ggagctcttc gaaagccata				
<400> 443 <210> 444 <211> 21 <212> DNA <213> Artificial Sequence				21
tctccatgat ggttttatcg				
<400> 444 <210> 445 <211> 20 <212> DNA <213> Artificial Sequence				20
aggttgggc agtctcagcg a				
<400> 445 <210> 446 <211> 20 <212> DNA <213> Artificial Sequence				20
atcggagagac tggcgcccg				
<400> 446 <210> 447 <211> 20 <212> DNA <213> Artificial Sequence				20
ttaggacaaag gtcctagggcg				
<400> 447 <210> 448 <211> 20				

<212> DNA
<213> Artificial Sequence
<400> 448
gacagcgcgag gacacgcgag
<210> 449
<211> 17
<212> DNA
<213> Artificial Sequence
<400> 449
gacattccaa tgcctgtt
<210> 450
<211> 17
<212> DNA
<213> Artificial Sequence
<400> 450
gctagacgct agcgtgga
<210> 451
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 451
gctcggagcg cctctgaagtg
<210> 452
<211> 12
<212> DNA
<213> Artificial Sequence
<400> 452
gtagacctcc ta
<210> 453
<211> 14
<212> DNA
<213> Artificial Sequence
<400> 453
cgttagacct cctca
<210> 454
<211> 16
<212> DNA
<213> Artificial Sequence
<400> 454
caagcttagc tctctta
<210> 455
<211> 18
<212> DNA
<213> Artificial Sequence
<400> 455
agacgcgtag cctctcta

<210> 456
<211> 18
<212> DNA
<213> Artificial Sequence
<400> 456
gacgcctgga ccttccat
<210> 457
<211> 10
<212> DNA
<213> Artificial Sequence
<400> 457
gaccttccat
<210> 458
<211> 12
<212> DNA
<213> Artificial Sequence
<400> 458
tggacctcca ac
<210> 459
<211> 14
<212> DNA
<213> Artificial Sequence
<400> 459
gctggacct ccat
<210> 460
<211> 16
<212> DNA
<213> Artificial Sequence
<400> 460
acgcctggacc ctcccat
<210> 461
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 461
taagctctgt caagccacg
<210> 462
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 462
ggagacgcctg gaccttccat gt
<210> 463
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 463 tccatgtcgg tccgtatgct	20	<211> 20 <212> DNA <213> Artificial Sequence	
<210> 464 <211> 21 <212> DNA <213> Artificial Sequence		<400> 471 tongctctgg tacttttcca	20
<400> 464 ttcatgctt gcaaatggc g	21	<210> 472 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 465 <211> 20 <212> DNA <213> Artificial Sequence		<400> 472 tggttacggt cgtcccatg	20
<400> 465 tgctagtctg gctgtacat		<210> 473 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 466 <211> 20 <212> DNA <213> Artificial Sequence	20	<400> 473 gtctatcgga ggaactgggc	20
<400> 466 agactcagga cagatctgga	20	<210> 474 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 467 <211> 22 <212> DNA <213> Artificial Sequence		<400> 474 cattttcagg gcgggcgggc	20
<400> 467 gaccttccat gtccgtctcg at	22	<210> 475 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 468 <211> 20 <212> DNA <213> Artificial Sequence		<400> 475 gaggagacca tttaacgggc	20
<400> 468 acacacaga gacggggac	20	<210> 476 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 469 <211> 20 <212> DNA <213> Artificial Sequence		<400> 476 tgtccagccg agggaccat	20
<400> 469 gaaacttcca tgcgttcag	20	<210> 477 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 470 <211> 20 <212> DNA <213> Artificial Sequence		<400> 477 cgggcttaac gggatgctg	20
<400> 470 caatcaatct gggagacac	20	<210> 478 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 471		<400> 478	

WO 01/2972 PCT/US00/26383

69

tggaacctct atgcgcgcgc

<210> 479
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 479

tgccacatgt tttagagacg

<210> 480
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 480

gtgtttacgg tctgcgcac

<210> 481
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 481

octcaaatgg aaagaccgcc

<210> 482
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 482

ttgtaccctc catgtatggt

<210> 483
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 483

ttccatgtcg ttccgcgcgg

<210> 484
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 484

gaactctcat gtcgcgcctg

<210> 485
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 485

gagagcgcgc gaactctcat

<210> 486
<211> 20
<212> DNA

WO 01/2972 PCT/US00/26383

70

<213> Artificial Sequence

<400> 486

ttgcaccata tttagagaac

<210> 487
<211> 18
<212> DNA
<213> Artificial Sequence

<400> 487

ttgaacctga gtttgggac

<210> 488
<211> 21
<212> DNA
<213> Artificial Sequence

<400> 488

ctatcgagag actggcgcgc c

<210> 489
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 489

cttggagggc ctccgcgcgg

<210> 490
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 490

gctgaacctc caatgcctgt

<210> 491
<211> 32
<212> DNA
<213> Artificial Sequence

<400> 491

tagaacaagc attctctctt taggcgcgc ca

<210> 492
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 492

agatggtctc caataaagc gga

<210> 493
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 493

ttccgcctta tttagagaac atct

WO 01/2973	PCT/US90/26383	72	PCT/US90/26383	71
<400> 501 gggggtttta acgttttgag ggggg		25	<210> 494 <211> 23 <212> DNA <213> Artificial Sequence	
<210> 502 <211> 20 <212> DNA <213> Artificial Sequence			<400> 494 gtcccaaggtt gtagagggc tgc	
<400> 502 ggttacggpta tgtcccatat		20	<210> 495 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 503 <211> 20 <212> DNA <213> Artificial Sequence			<400> 495 gcgcacggatcc tccgatagac	
<400> 503 ctgtcccatata tttttagaca		20	<210> 496 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 504 <211> 20 <212> DNA <213> Artificial Sequence			<400> 496 atcgggagggc tggggcgccg	
<400> 504 accatctctga ggcattccgg		20	<210> 497 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 505 <211> 23 <212> DNA <213> Artificial Sequence			<400> 497 ggctctgccc atatatttag	
<400> 505 cgtctctatcgg gcttctgtgt atg		23	<210> 498 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 506 <211> 21 <212> DNA <213> Artificial Sequence			<400> 498 tttttcaacg ttgagggggg	
<400> 506 ggcctatccca catgaaagt t		21	<210> 499 <211> 21 <212> DNA <213> Artificial Sequence	
<210> 507 <211> 22 <212> DNA <213> Artificial Sequence			<400> 499 tttttcaagc gttgatatttt t	
<400> 507 cctaatatcgy gtcgtcaagc ac		22	<210> 500 <211> 20 <212> DNA <213> Artificial Sequence	
<210> 508 <211> 23 <212> DNA <213> Artificial Sequence			<400> 500 gggggtcaacg tctattttt	
<400> 508 gtgcttgaca accgatattt gg		22	<210> 501 <211> 24 <212> DNA <213> Artificial Sequence	
<210> 509 <211> 26				

W/O 01/29/72

73

PCV1500/26383

<212> DNA
<213> Artificial Sequence

<400> 509
gtctgattca cagatctct gttcgg

<210> 510
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 510
gtccacattt caatttggga tggctctc

<210> 511
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 511
ttctggcgaa ttgctctcagg atgtttac

<210> 512
<211> 36
<212> DNA
<213> Artificial Sequence

<400> 512
tatagttcctt ggaatttggcc caattcttcca acaaac

<210> 513
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 513
ggaagctctca taaacatttgg gaatttga

<210> 514
<211> 22
<212> DNA
<213> Artificial Sequence

<400> 514
ctatcgaggg aacttgggac cg

<210> 515
<211> 21
<212> DNA
<213> Artificial Sequence

<400> 515
tatcgaggga ctggcgctgc g

<210> 516
<211> 21
<212> DNA
<213> Artificial Sequence

<400> 516
gattcgaggga ctggcgctgc g

26

27

27

36

27

27

22

21

21

W/O 01/29/72

74

PCV1500/26383

<210> 517
<211> 26
<212> DNA
<213> Artificial Sequence

<400> 517
cgaacaggga tatcggttgat caagac

<210> 518
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 518
ttttgggttc aacttggagg gggg

<210> 519
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 519
gggttcacag ttgagggggg

<210> 520
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 520
cggcgaggcg cggcgcgcg

<210> 521
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 521
ggggcaatgac gttcgggggg

<210> 522
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 522
ggggcatggc gttcaaaaaa

<210> 523
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 523
ggggcatggc cttcgggggg

<210> 524
<211> 20
<212> DNA
<213> Artificial Sequence

26

24

20

20

20

20

20

20

20

20

<211> 20
<212> DNA
<213> Artificial Sequence
20
gctgttaaat gaattggcgcg
<400> 532
<210> 533
<211> 20
<212> DNA
<213> Artificial Sequence
20
ttcggggcgga ctcttcatt
<400> 533
<210> 534
<211> 20
<212> DNA
<213> Artificial Sequence
20
tatgggcgcgc cggacttat
<400> 534
<210> 535
<211> 20
<212> DNA
<213> Artificial Sequence
20
gggggttaacg atcagggggg
<400> 535
<210> 536
<211> 20
<212> DNA
<213> Artificial Sequence
20
tttgagaagc ctggaccttc
<400> 536
<210> 537
<211> 20
<212> DNA
<213> Artificial Sequence
20
gctcgcgat ctatgctcgcg
<400> 537
<210> 538
<211> 20
<212> DNA
<213> Artificial Sequence
20
gtcgggtccgcg atgctgttcc
<400> 538
<210> 539
<211> 20
<212> DNA
<213> Artificial Sequence
20
<400> 539

<400> 524
ggggcattgac gttcggggggg
<210> 525
<211> 20
<212> DNA
<213> Artificial Sequence
20
aaaacattgac gttcaaaaaa
<400> 525
<210> 526
<211> 20
<212> DNA
<213> Artificial Sequence
20
aaaacattgac gttcgggggg
<400> 526
<210> 527
<211> 20
<212> DNA
<213> Artificial Sequence
20
ggggcattgac gttcaaaaaa
<400> 527
<210> 528
<211> 20
<212> DNA
<213> Artificial Sequence
24
accattgacg atctgtttcc octc
<400> 528
<210> 529
<211> 24
<212> DNA
<213> Artificial Sequence
24
gacattgacg aactgtttcc octc
<400> 529
<210> 530
<211> 20
<212> DNA
<213> Artificial Sequence
24
cccccccccc ccccccccc
<400> 530
<210> 531
<211> 20
<212> DNA
<213> Artificial Sequence
20
gggggggggg ggggggggg
<400> 531
<210> 532

WFO 01/23/97 77
 PCT/US90/26383

tcgtcgtccag ttgcgtcgtcg 20

<210> 540
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<400> 540

ctgcagcttc cagtcgcg 18

<210> 541
 <211> 17
 <212> DNA
 <213> Artificial Sequence

<400> 541

gacgcgtccag cgcgtcct 17

<210> 542
 <211> 16
 <212> DNA
 <213> Artificial Sequence

<400> 542

ctgcagcttc cagtcgc 16

<210> 543
 <211> 16
 <212> DNA
 <213> Artificial Sequence

<400> 543

cacgtcctcct cgtcga 16

<210> 544
 <211> 16
 <212> DNA
 <213> Artificial Sequence

<400> 544

cgcgtcagctt tccatcgtcg 20

<210> 545
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<400> 545

gctcagcttcag tgcgtcgtcg 20

<210> 546
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<400> 546

aacgcgttcag ctccatcgtc 20

<210> 547
 <211> 20
 <212> DNA

WFO 01/23/97 78
 PCT/US90/26383

<213> Artificial Sequence

<400> 547

ttgcagtcgcgt aacagcgtcct 20

<210> 548
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<400> 548

cttcacatcgt cgttcctcgtat 20

<210> 549
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<400> 549

taactccttcggt atccctcgtcg 20

<210> 550
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<400> 550

ttccatcgtcg gtcctcgtat 18

<210> 551
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<400> 551

ctgcagtcgc tccctcgtga 18

<210> 552
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<400> 552

ggcgttcattcc ctcgactcgcgc 20

<210> 553
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<400> 553

cttcacgttcgt atgcgcgcag ct 22

<210> 554
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<400> 554

gggttcacatcg atgcggggggg 20

WO 01/25772	PCT/US90/25353	WO 01/25772	PCT/US90/25353
79		80	
<210> 553 <211> 20 <212> DNA <213> Artificial Sequence		<400> 562 aaaasccccc cccccaaaa	20
<400> 555 ttggggggg cctccacatt	20	<210> 563 <211> 27 <212> DNA <213> Artificial Sequence	
<210> 556 <211> 20 <212> DNA <213> Artificial Sequence		<400> 563 tttgaattca ggcgcgtga ggttgag	27
<400> 556 ttttttttt ttttttttt	20	<210> 564 <211> 27 <212> DNA <213> Artificial Sequence	
<210> 557 <211> 20 <212> DNA <213> Artificial Sequence		<400> 564 tttgaattct cagcgcgttc cagtggc	27
<400> 557 ggggggtttt ttttggggg	20	<210> 565 <211> 45 <212> DNA <213> Artificial Sequence	
<210> 558 <211> 20 <212> DNA <213> Artificial Sequence		<400> 565 aattctctct cggggcttct gtcctgttg ctggttcgc tttat	45
<400> 558 ttttggggg ggggggtttt	20	<210> 566 <211> 45 <212> DNA <213> Artificial Sequence	
<210> 559 <211> 19 <212> DNA <213> Artificial Sequence		<400> 566 ctagataag cggacacagc acagacaca gagcccccga tagag	45
<400> 559 ggggggggg ggggggggt	19	<210> 567 <211> 28 <212> DNA <213> Artificial Sequence	
<210> 560 <211> 20 <212> DNA <213> Artificial Sequence		<400> 567 ttttctagag aggtcacaca tgctctg	28
<400> 560 aaaaaaaaa aaaaaaaaa	20	<210> 568 <211> 29 <212> DNA <213> Artificial Sequence	
<210> 561 <211> 20 <212> DNA <213> Artificial Sequence		<400> 568 tttgaattcc gtgtacagaa gcgcgaagc	29
<400> 561 cccccaaaa aaaaacccc	20	<210> 569 <211> 31 <212> DNA <213> Artificial Sequence	
<210> 562 <211> 20 <212> DNA <213> Artificial Sequence		<400> 569 tttgcgcg ctagacttaa cctgagcat a	31
		<210> 570 <211> 29	

WO 01/23972
<213> DNA
<213> Artificial Sequence
<400> 570
tttgggccc cgaagacag agacacttc
<210> 571
<211> 29
<212> DNA
<213> Artificial Sequence
<400> 571
tttgggccc cttctcgct cttgacacg
<210> 572
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 572
gagaaagctcg gaccttcacat
<210> 573
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 573
tcattgtccg tccatgatgct
<210> 574
<211> 6
<212> DNA
<213> Artificial Sequence
ctgtcgg
<400> 574
<210> 575
<211> 6
<212> DNA
<213> Artificial Sequence
tcgttga
<400> 575
<210> 576
<211> 6
<212> DNA
<213> Artificial Sequence
cgctcga
<400> 576
<210> 577
<211> 6
<212> DNA
<213> Artificial Sequence
agtgcct
<400> 577

81

PCVUS00/26383

WO 01/23972
<210> 578
<211> 6
<212> DNA
<213> Artificial Sequence
<400> 578
ctgtcgg
<210> 579
<211> 6
<212> DNA
<213> Artificial Sequence
<400> 579
agtgcct
<210> 580
<211> 6
<212> DNA
<213> Artificial Sequence
<400> 580
cgctcga
<210> 581
<211> 6
<212> DNA
<213> Artificial Sequence
<400> 581
tcgttga
<210> 582
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 582
gagaaagctcg cagcttcgct
<210> 583
<211> 7
<212> DNA
<213> Artificial Sequence
<400> 583
gcttagacgta agcgttga
<210> 584
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 584
gagaaagctcg gaccttcacat
<210> 585
<211> 21
<212> DNA
<213> Artificial Sequence

82

PCVUS00/26383

20

17

20

6

6

6

6

W0 01/29/72
85
PCYU/S90/26383

atggaagctc gacgtctctc
 <400> 599
 <210> 600
 <211> 6
 <212> DNA
 <213> Artificial Sequence
 <400> 600

tccctga
 <210> 601
 <211> 8
 <212> DNA
 <213> Artificial Sequence
 <400> 601

tcaagctt
 <210> 602
 <211> 8
 <212> DNA
 <213> Artificial Sequence
 <400> 602

aacgtt
 <210> 603
 <211> 8
 <212> DNA
 <213> Artificial Sequence
 <400> 603

aacgttga
 <210> 604
 <211> 17
 <212> DNA
 <213> Artificial Sequence
 <400> 604

tcaagctaac cctcagc
 <210> 605
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 605

ggaagctcgg gaccttgcac
 <210> 606
 <211> 14
 <212> DNA
 <213> Artificial Sequence
 <400> 606

gctggaacctt caat
 <210> 607

W0 01/29/72
86
PCYU/S90/26383

ggaagctcgg gaccttgcac at
 <210> 608
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <400> 607

ggaagctcgg gaccttgcac at
 <210> 608
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <400> 608

ggaagctcgg gaccttgcac cat
 <210> 609
 <211> 13
 <212> DNA
 <213> Artificial Sequence
 <400> 609

aacgttgcagg ggcac
 <210> 610
 <211> 15
 <212> DNA
 <213> Artificial Sequence
 <400> 610

atgcacctca aacgtt
 <210> 611
 <211> 10
 <212> DNA
 <213> Artificial Sequence
 <400> 611

tcaagcttga
 <210> 612
 <211> 14
 <212> DNA
 <213> Artificial Sequence
 <400> 612

gctggaacctt caat
 <210> 613
 <211> 7
 <212> DNA
 <213> Artificial Sequence
 <400> 613

caagctt
 <210> 614
 <211> 10
 <212> DNA
 <213> Artificial Sequence
 <400> 614

<211>
<212>

<210> 630
<211> 8
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)...(3)
<223> Blotting moiety attached at 5' end of sequence.
<400> 630
tcaagctt
<210> 631
<211> 8
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)...(3)
<223> F10C moiety attached at 5' end of sequence.
<400> 631
tcaagctt
<210> 632
<211> 8
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)...(3)
<223> F10C moiety attached at 5' end of sequence.
<400> 632
aaagctga
<210> 633
<211> 7
<212> DNA
<213> Artificial Sequence
<400> 633
tcaagctt
<210> 634
<211> 7
<212> DNA
<213> Artificial Sequence
<400> 634
aaagctg
<210> 635
<211> 6
<212> DNA
<213> Artificial Sequence
<400> 635

cgacga
<210> 636
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 636
tcaagctt
<210> 637
<211> 5
<212> DNA
<213> Artificial Sequence
<400> 637
tcgga
<210> 638
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 638
agaagctt
<210> 639
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 639
tcaacgat
<210> 640
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 640
tcaagctt
<210> 641
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 641
caagctt
<210> 642
<211> 6
<212> DNA
<213> Artificial Sequence
<400> 642
gttcga
<210> 643
<211> 6
<212> DNA

<210> 651
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 651
 onagagatgc tascacgac
 <210> 652
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 652
 accatcatmat agtctctgtgc
 <210> 653
 <211> 8
 <212> DNA
 <213> Artificial Sequence
 <400> 653
 ocatogtat
 <210> 654
 <211> 8
 <212> DNA
 <213> Artificial Sequence
 <400> 654
 tgcagctc
 <210> 655
 <211> 8
 <212> DNA
 <213> Artificial Sequence
 <400> 655
 cttagcgct
 <210> 656
 <211> 8
 <212> DNA
 <213> Artificial Sequence
 <400> 656
 taagcgct
 <210> 657
 <211> 13
 <212> DNA
 <213> Artificial Sequence
 <400> 657
 tgcgacattc gcy
 <210> 658
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<210> 644
 <211> 6
 <212> DNA
 <213> Artificial Sequence
 <400> 644
 ogttgt
 <210> 645
 <211> 6
 <212> DNA
 <213> Artificial Sequence
 <400> 645
 acgttgt
 <210> 646
 <211> 6
 <212> DNA
 <213> Artificial Sequence
 <400> 646
 cgttgg
 <210> 647
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 647
 ggcagagctg gacattcat
 <210> 648
 <211> 6
 <212> DNA
 <213> Artificial Sequence
 <400> 648
 cgcgta
 <210> 649
 <211> 6
 <212> DNA
 <213> Artificial Sequence
 <400> 649
 opttgc
 <210> 650
 <211> 8
 <212> DNA
 <213> Artificial Sequence
 <400> 650
 taccgggt

WO 01/2972
93
PCT/US00/26383

<100> 658
atggaaggct cagcttct
19
<210> 659
<211> 17
<212> DNA
<213> Artificial Sequence

<100> 659
actgaagctt agacttga
17
<210> 660
<211> 18
<212> DNA
<213> Artificial Sequence

<100> 660
cgccctgggac tggctctgg
18
<210> 661
<211> 18
<212> DNA
<213> Artificial Sequence

<100> 661
gtgtcggggc ctcggggc
18
<210> 662
<211> 18
<212> DNA
<213> Artificial Sequence

<100> 662
gtgcggggc ctcggggc
18
<210> 663
<211> 18
<212> DNA
<213> Artificial Sequence

<100> 663
cgccctgggac tggctctgg
18
<210> 664
<211> 21
<212> DNA
<213> Artificial Sequence

<100> 664
gaagtcacg ttgaaggca t
21
<210> 665
<211> 21
<212> DNA
<213> Artificial Sequence

<100> 665
atctgtggag ggaagcctat g
21
<210> 666
<211> 21

WO 01/2972
94
PCT/US00/26383

<212> DNA
<213> Artificial Sequence

<100> 666
gttgaaccc gagaactca t
21
<210> 667
<211> 8
<212> DNA
<213> Artificial Sequence

<100> 667
gcaacgct
8
<210> 668
<211> 8
<212> DNA
<213> Artificial Sequence

<100> 668
gtaacgct
8
<210> 669
<211> 8
<212> DNA
<213> Artificial Sequence

<100> 669
cgaacgct
8
<210> 670
<211> 8
<212> DNA
<213> Artificial Sequence

<100> 670
gaaacgct
8
<210> 671
<211> 8
<212> DNA
<213> Artificial Sequence

<100> 671
caaacgct
8
<210> 672
<211> 8
<212> DNA
<213> Artificial Sequence

<100> 672
ctaacgct
8
<210> 673
<211> 8
<212> DNA
<213> Artificial Sequence

<100> 673
gaaacgct
8
<210> 674
<211> 8
<212> DNA
<213> Artificial Sequence

WO 01/2572

95

PCT/US00/25333

<210> 674
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 674
tgaacgtt
<210> 675
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 675
acaacgtt
<210> 676
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 676
ttaacgtt
<210> 677
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 677
aaacgtt
<210> 678
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 678
ataacgtt
<210> 679
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 679
aacgttat
<210> 680
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 680
tcgaatcg
<210> 681
<211> 8
<212> DNA
<213> Artificial Sequence

WO 01/2572

96

PCT/US00/25333

<400> 681
tcgaatcg
<210> 682
<211> 17
<212> DNA
<213> Artificial Sequence
<400> 682
gctagaacgtt agaatga
<210> 683
<211> 25
<212> DNA
<213> Artificial Sequence
<400> 683
gagaacgtt gaaactatca tccat
<210> 684
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 684
gagaacgtt gaacttttat
<210> 685
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 685
actagaacgtt agtga
<210> 686
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 686
cacacacgttgc tcaatgtcac gt
<210> 687
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 687
ttctcatctct atgtttttat cg
<210> 688
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 688
cgaatggacat tccat
<210> 689

8

17

25

20

17

22

22

15

<211> 23
<212> DNA
<213> Artificial Sequence
<400> 689
cacacacttg gtcactctga cgt
<210> 690
<211> 17
<212> DNA
<213> Artificial Sequence
<400> 690
gtcagacggt agctgga
<210> 691
<211> 17
<212> DNA
<213> Artificial Sequence
<400> 691
atgagacgtg cagatcag
<210> 692
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 692
ttttggtttt gtggttttgt ggttc
<210> 693
<211> 23
<212> DNA
<213> Artificial Sequence
<400> 693
ttttggtttg tctgtttgtc gtt
<210> 694
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 694
ttttggtttt gtggttttgt ggttc
<210> 695
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 695
aacgacatgga ttctagggca
<210> 696
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 696

23

17

17

24

23

24

20

gtcagacggt agcgt
<210> 697
<211> 17
<212> DNA
<213> Artificial Sequence
<400> 697
aaagctggaa ctctcat
<210> 698
<211> 8
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (3)...(3)
<223> mc
<400> 698
tcgaagtt
<210> 699
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 699
cccttgat
<210> 700
<211> 17
<212> DNA
<213> Artificial Sequence
<400> 700
actagacggt agctgga
<210> 701
<211> 17
<212> DNA
<213> Artificial Sequence
<400> 701
gtcagaggtt agcgtga
<210> 702
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 702
atgagacttc cagcttctc
<210> 703
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 703

17

8

8

17

17

20

WO 01/2373

PCT/US00/26353

99

atcgactctc gagcgtttctc

20

<210> 704
<211> 13
<212> DNA
<213> Artificial Sequence

gctagacgtt agc

13

<400> 704
<210> 705
<211> 9
<212> DNA
<213> Artificial Sequence

gctagacgtt

9

<400> 705
<210> 706
<211> 17
<212> DNA
<213> Artificial Sequence

agtcgacgtc gagatcg

17

<400> 707
<210> 8
<211> 8
<212> DNA
<213> Artificial Sequence

<220> modified base
<221> (5)...(5)
<222> (5)...(5)
<223> m5c

tcagacgtt

8

<400> 708
<210> 18
<211> 18
<212> DNA
<213> Artificial Sequence

ctgattgtctc tctcgtga

18

<400> 709
<210> 8
<211> 8
<212> DNA
<213> Artificial Sequence

<220> modified base
<221> (2)...(2)
<222> (2)...(2)
<223> m5c

tnaacgtt

8

<210> 710

WO 01/2373

PCT/US00/26353

100

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified base
<222> (6)...(6)
<223> m5c

gagaaagctg gaccttcctc

20

<400> 710
<210> 711
<211> 17
<212> DNA
<213> Artificial Sequence

gctagacgtt agcgtga

17

<400> 711
<210> 712
<211> 14
<212> DNA
<213> Artificial Sequence

gctactctag gtag

14

<400> 712
<210> 713
<211> 15
<212> DNA
<213> Artificial Sequence

gctacacgttag cgtga

15

<400> 713
<210> 714
<211> 19
<212> DNA
<213> Artificial Sequence

atcgactctg agcgtttctc

19

<400> 714
<210> 715
<211> 20
<212> DNA
<213> Artificial Sequence

atgacactctg cagcgtttctc

20

<400> 715
<210> 716
<211> 20
<212> DNA
<213> Artificial Sequence

agtcgactctc cagcgtttctc

20

<210> 717

W0 01/29/72
101
PCT/US00/26383

<211> 17
<212> DNA
<213> Artificial Sequence

gcacagacgt agctgga
<400> 117
<210> 718
<211> 18
<212> DNA
<213> Artificial Sequence

atcgactcga gcttcttc
<400> 718
<210> 719
<211> 17
<212> DNA
<213> Artificial Sequence

atcgatcgag gcttcttc
<400> 719
<210> 720
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc. feature
<222> (1)...(3)
<223> Biotin moiety attached at 5' end of sequence.

ggagacgcgc gaacttcgat
<400> 720
<210> 721
<211> 17
<212> DNA
<213> Artificial Sequence

gctcagacgt agctgga
<400> 721
<210> 722
<211> 20
<212> DNA
<213> Artificial Sequence

atcgactcga gacttcttc
<400> 722
<210> 723
<211> 15
<212> DNA
<213> Artificial Sequence

tcagacgttgg cgttga
<400> 723
<210> 724

W0 01/29/72
102
PCT/US00/26383

<211> 18
<212> DNA
<213> Artificial Sequence

cgacttcga gcttcttc
<400> 724
<210> 725
<211> 21
<212> DNA
<213> Artificial Sequence

ggggtcgagcc tggagggggg g
<400> 725
<210> 726
<211> 16
<212> DNA
<213> Artificial Sequence

gctcagctta gcttga
<400> 726
<210> 727
<211> 9
<212> DNA
<213> Artificial Sequence

cgttcgtcgt
<400> 727
<210> 728
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified base
<222> (14)...(14)
<223> m5c

ggagacgcgt gaacttcgat
<400> 728
<210> 729
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified base
<222> (18)...(18)
<223> m5c

atcgacatac gctgccttnc
<400> 729
<210> 730
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (3)...(3)
<223> m5c

<400> 730
atgaactaa gtgcgtcttc

<210> 731
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (7)...(7)
<223> m5c

<400> 731
gttagangtt agcgt

<210> 732
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (14)...(14)
<223> m5c

<400> 732
.atcgactctc gagggtcttc

<210> 733
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 733
gggggtatgc atcagggggg

<210> 734
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 734
ggctgtatgc ctgactgccc

<210> 735
<211> 17
<212> DNA
<213> Artificial Sequence

<400> 735
ccatgtctaac ctctaga

<210> 736
<211> 17

<212> DNA
<213> Artificial Sequence

<400> 736
gctagatggt agcgtga

<210> 737
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 737
cgtaccttaac ggtga

<210> 738
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 738
tccatgtctgg tccgtgtgct

<210> 739
<211> 22
<212> DNA
<213> Artificial Sequence

<400> 739
atcgactctc tccagctctc to

<210> 740
<211> 17
<212> DNA
<213> Artificial Sequence

<400> 740
gctagatggt agcgtga

<210> 741
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 741
atcgactctc gactgtcttc

<210> 742
<211> 17
<212> DNA
<213> Artificial Sequence

<400> 742
aacgctctgac ctgcgat

<210> 743
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 743
ctcaacgctcy gacctccat

17

15

20

22

17

20

17

20

W/O 01/29/72
105
FCT/US00/26383

<210> 744
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 744
atcgaccatc gtcctcttc
20

<210> 745
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 745
gagatgctcg gacttcacat
20

<210> 746
<211> 17
<212> DNA
<213> Artificial Sequence

<400> 746
tcaagctcaac cctcggac
17

<210> 747
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<221> misc. feature
<222> (1)...(3)
<223> Nuclein moiety attached at 5' end of sequence.

<400> 747
gagacgctcg cagcctcgat
20

<210> 748
<211> 20
<212> DNA
<213> Artificial Sequence

<230>
<231> misc. feature
<232> (1)...(3)
<233> Nuclein moiety attached at 5' end of sequence.

<400> 748
gagacgctcg gacttcacat
20

<210> 749
<211> 18
<212> DNA
<213> Artificial Sequence

<400> 749
cgctagagcgt tgcctctga
18

<210> 750
<211> 15

W/O 01/29/72
106
FCT/US00/26383

<212> DNA
<213> Artificial Sequence

<400> 750
gctagagcgt aagct
15

<210> 751
<211> 19
<212> DNA
<213> Artificial Sequence

<400> 751
atggaagctc cagctcttc
19

<210> 752
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 752
gcttagagcgt aagct
15

<210> 753
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 753
gcttagagcgt aagct
15

<210> 754
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 754
tccatgagcgg tccctgatgct
20

<210> 755
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 755
tccatgagcgg tccctgatgct
20

<210> 756
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 756
gcttagagcgt aagct
15

<210> 757
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 757
gcttagagcgt aagct
15

20

<400> 763
tcctatgttg tctatgatgt
<210> 764
<211> 20
<212> DNA
<213> Artificial Sequence

20

<210> 759
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 758
tcctatgact tctatgatgt
<210> 759
<211> 20
<212> DNA
<213> Artificial Sequence

20

<220>
<221> modified base
<222> (3)...(3)
<223> m5c
<221> modified base
<222> (10)...(10)
<223> m5c
<221> modified base
<222> (14)...(14)
<223> m5c
<400> 764
ctnqactctn ggggtgtctc

20

<210> 765
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 765
atggaaggtc cagttgtctc

20

<210> 766
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 766
gcatgacgtt ggggt

15

<210> 767
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 767
gggttcacgc ttgcgggggg

20

<210> 768
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 768
gggttcacgc ttgcgggggg

20

<210> 769
<211> 20
<212> DNA
<213> Artificial Sequence

107

WO 01/22972

<210> 759
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 758
tcctatgact tctatgatgt

<210> 759
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 759
tcctatgact tctatgatgt

<210> 760
<211> 15
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (13)...(13)
<223> m5c
<400> 760
gtatgacgtt agtgt

15

<210> 761
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 761
gtatgacgtt agtgt

15

<210> 762
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (8)...(8)
<223> m5c
<400> 762
tcctatgttg tctatgatgt

20

<210> 763
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<221> modified base
<222> (12)...(12)
<223> m5c

WO 01/23572	PCT/US90/26383	WO 01/23572	PCT/US90/26383
111	112		
<222> (8)...(10)	<213> Artificial Sequence		
<223> F1TC moiety attached at 3' end of sequence.	<400> 789		
<400> 784	agttgcact		10
tcaatgctga			
<210> 785	<210> 790		
<211> 10	<211> 8		
<212> DNA	<212> DNA		
<213> Artificial Sequence	<213> Artificial Sequence		
<220>	<400> 790		8
<221> misc_feature	tcttcgaa		
<222> (8)...(10)	<210> 791		
<223> F1TC moiety attached at 3' end of sequence.	<211> 8		
<400> 785	<212> DNA		
tcaatgctga	<213> Artificial Sequence		
<210> 786	<400> 791		8
<211> 10	tcaacgpc		
<212> DNA			
<213> Artificial Sequence	<210> 792		
<220>	<211> 19		
<221> misc_feature	<212> DNA		
<222> (8)...(10)	<213> Artificial Sequence		
<223> Blotin moiety attached at 3' end of sequence.	<400> 792		19
<400> 786	ccatgtcggt cgtgtgct		
tcaacgptga			
<210> 787	<210> 793		
<211> 10	<211> 18		
<212> DNA	<212> DNA		
<213> Artificial Sequence	<213> Artificial Sequence		
<220>	<400> 793		18
<221> misc_feature	gttttttat atttggg		
<222> (8)...(10)	<210> 794		
<223> Blotin moiety attached at 3' end of sequence.	<211> 23		
<400> 787	<212> DNA		
gcattattgc	<213> Artificial Sequence		
<210> 788	<400> 794		23
<211> 10	tttttgttg tggtttgtc gtt		
<212> DNA	<210> 795		
<213> Artificial Sequence	<211> 12		
<220>	<212> DNA		
<221> misc_feature	<213> Artificial Sequence		
<222> (8)...(10)	<400> 795		12
<223> F1TC moiety attached at 3' end of sequence.	ttggggggggg tt		
<400> 788	<210> 796		
gcattattgc	<211> 13		
<210> 789	<212> DNA		
<211> 10	<213> Artificial Sequence		
<212> DNA	<400> 796		13
	gggggttgggg gtt		

W/O 01/29/97 113 PCT/US90/26383

<210> 797
 <211> 17
 <212> DNA
 <213> Artificial Sequence

<400> 797
 ggtgggtgag gtttcgg 17

<210> 798
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <222> (1)...(3)
 <223> Blottn moiety attached at 5' end of sequence.

<221> modified_base
 <222> (6)...(6)
 <223> n5c

<400> 798
 ggaagagtc gactctgat 20

<210> 799
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<400> 799
 tcaacgttaa cgttaacgtc 20

<210> 800
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <222> (1)...(3)
 <223> Blottn moiety attached at 5' end of sequence.

<221> modified_base
 <222> (8)...(8)
 <223> n5c

<400> 800
 ggaagagtc gactctgat 20

<210> 801
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> misc_feature
 <222> (1)...(3)
 <223> Blottn moiety attached at 5' end of sequence.

<221> modified_base

W/O 01/29/97 114 PCT/US90/26383

<222> (6)...(6)
 <223> n5c

<400> 801
 ggaagagtc cagactgat 20

<210> 802
 <211> 10
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> modified_base
 <222> (3)...(3)
 <223> n5c

<221> misc_feature
 <222> (8)...(10)
 <223> Blottn moiety attached at 3' end of sequence.

<400> 802
 tcaangtcga 10

<210> 803
 <211> 10
 <212> DNA
 <213> Artificial Sequence

<220>
 <221> modified_base
 <222> (2)...(2)
 <223> n5c

<221> misc_feature
 <222> (8)...(10)
 <223> Blottn moiety attached at 3' end of sequence.

<400> 803
 gnaacttcgc 10

<210> 804
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<400> 804
 tgcgtctttt gtcgttcgc gctt 24

<210> 805
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<400> 805
 ctgcpttcgc aaattacatg tg 22

<210> 806
 <211> 20
 <212> DNA
 <213> Artificial Sequence

WO 01/21971

PCT/US90/25393

115

<400> 806
tcactgagct tcttgatgct
<210> 807
<211> 28
<212> DNA
<213> Artificial Sequence
<400> 807
tgcatagcgt gatactgtaac acagctct
<210> 808
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 808
tgcatagcgt acacagctct
<210> 809
<211> 12
<212> DNA
<213> Artificial Sequence
<400> 809
tgcatagcgt ct
<210> 810
<211> DNA
<213> Artificial Sequence
<400> 810
tgcatagcct
<210> 811
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 811
ccccccccc ccccccccc
<210> 812
<211> 12
<212> DNA
<213> Artificial Sequence
<400> 812
cccccccccc cc
<210> 813
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 813
ccccccccc
<210> 814
<211> 12

WO 01/21971

PCT/US90/25393

116

<212> DNA
<213> Artificial Sequence
<400> 814
tgcatagcct ct
<210> 815
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 815
tgcatagcct acacagctct
<210> 816
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 816
gcgcacagctg gacattccat
<210> 817
<211> 32
<212> DNA
<213> Artificial Sequence
<400> 817
taccagcttaa cgttaacggtt acgcttaacg tt
<210> 818
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 818
gggcacagctc gacattccat
<210> 819
<211> 25
<212> DNA
<213> Artificial Sequence
<400> 819
gtcccaattt cccagcgag gaaat
<210> 820
<211> 25
<212> DNA
<213> Artificial Sequence
<400> 820
ctagagcgctg acgtatccaa gctag
<210> 821
<211> 25
<212> DNA
<213> Artificial Sequence
<400> 821
ctagcttgcg gacgtacgcc gctag

12

20

20

32

20

25

25

25

W/O 01/29/97

117

PCY1050/2533

<210> 822
<211> 16
<212> DNA
<213> Artificial Sequence
<400> 822
cggtgcagct catcaa
<210> 823
<211> 8
<212> DNA
<213> Artificial Sequence
<400> 823
ctgcagctg
<210> 824
<211> 10
<212> DNA
<213> Artificial Sequence
<400> 824
ctgcagctcat
<210> 825
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 825
attcgatcgg ggcggggcga g
<210> 826
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 826
ctgcgcgcgc ccgcacgcga t
<210> 827
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 827
gactgcagctc agcgt
<210> 828
<211> 26
<212> DNA
<213> Artificial Sequence
<400> 828
ctagcgctcg acgtcacaa gctcgc
<210> 829
<211> 26
<212> DNA
<213> Artificial Sequence

16
8
10
21
21
21
15
26

W/O 01/29/97

118

PCY1050/2533

<400> 829
ctagcttat gcgcgcagcc gctcgc
<210> 830
<211> 26
<212> DNA
<213> Artificial Sequence
<400> 830
ctagcgctcg agctcacaa gctcgc
<210> 831
<211> 25
<212> DNA
<213> Artificial Sequence
<400> 831
ctagcgctcg agctcacaa gctcgc
<210> 832
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 832
tccaccagct gctctatgct
<210> 833
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 833
gggaacgaaa gactctatcaa taag
<210> 834
<211> 26
<212> DNA
<213> Artificial Sequence
<400> 834
tctaaaac accatctctt aacct
<210> 835
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 835
agctaacgct catgc
<210> 836
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 836
ttaacgctcg tagcgctatc gctc
<210> 837

26
26
26
25
20
24
26
26
15
24

tcagacacacg tgcgcgcgcg ttcctcga

<210> 845
<211> 27
<212> DNA
<213> Artificial Sequence

tcaggacacacg cgcgcgcgcg ggtctcga

<400> 845
<210> 846
<211> 19
<212> DNA
<213> Artificial Sequence

catttcacacg atttccca

<400> 846
<210> 847
<211> 19
<212> DNA
<213> Artificial Sequence

ttcctctctcgc cgcgcgcgcg

<400> 847
<210> 848
<211> 19
<212> DNA
<213> Artificial Sequence

tgtctctctcgc tgcgcgcgcg

<400> 848
<210> 849
<211> 25
<212> DNA
<213> Artificial Sequence

ataagacacg actgcgcgcg gttc

<400> 849
<210> 850
<211> 25
<212> DNA
<213> Artificial Sequence

gcacatgcgc cgcgcgcgcg tttat

<400> 850
<210> 851
<211> 30
<212> DNA
<213> Artificial Sequence

tgccacacacg gcacatgcgc tttctacacg

<400> 851
<210> 852
<211> 30
<212> DNA

<211> 24
<212> DNA
<213> Artificial Sequence

tttagacacacg tgcgcgcgcg accg

<400> 837
<210> 838
<211> 25
<212> DNA
<213> Artificial Sequence

gcctctctcgc tgcgcgcgcg ggtc

<400> 838
<210> 839
<211> 25
<212> DNA
<213> Artificial Sequence

gcctctctcgc tgcgcgcgcg agtc

<400> 839
<210> 840
<211> 20
<212> DNA
<213> Artificial Sequence

tcacacacgc tgcgcgcgcg

<400> 840
<210> 841
<211> 20
<212> DNA
<213> Artificial Sequence

tcacacacgc tgcgcgcgcg

<400> 841
<210> 842
<211> 20
<212> DNA
<213> Artificial Sequence

tcacacacgc tgcgcgcgcg

<400> 842
<210> 843
<211> 17
<212> DNA
<213> Artificial Sequence

tcacacacgc tgcgcgcgcg

<400> 843
<210> 844
<211> 27
<212> DNA
<213> Artificial Sequence

tcacacacgc tgcgcgcgcg

W/O 01/29/77

121

PCT/US80/26383

<213> Artificial Sequence
<400> 852
ctgtatgaa caattcttc tcttggca
<210> 853
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 853
tttaggttg gtttaggtt
<210> 854
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 854
tccatgggt tcttggtct
<210> 855
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 855
aaacactgac gtccaaacaa
<210> 856
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 856
aaaacatgac gtccgggggg
<210> 857
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 857
ggggcatggg cttcgggggg
<210> 858
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 858
ctagatcgaac gtacacaaagc tagt
<210> 859
<211> 30
<212> DNA
<213> Artificial Sequence
<400> 859
tctgaagcaca tctgaacttg gttgaagttat

W/O 01/29/77

122

PCT/US80/26383

<210> 860
<211> 25
<212> DNA
<213> Artificial Sequence
<400> 860
ggatttagca ategatttag aagtt
<210> 861
<211> 30
<212> DNA
<213> Artificial Sequence
<400> 861
tttacccttc atcaaacataa ctcaaacataa
<210> 862
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 862
ggattttttt ttggg
<210> 863
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 863
atctctcaac aaacactcaa caaa
<210> 864
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 864
tctatcgaag gttggtctctg tttag
<210> 865
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)...(3)
<223> Biotin moiety attached at 5' end of sequence.
<400> 865
tccatggagtt tcttgatgct
<210> 866
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)...(3)

124
 <400> 871
 tcatgagct tcatgagct
 <210> 872
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <400> 872
 cttagcgccty cagtcacaa tctag
 <210> 873
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 873
 tgcctagctgt gcctgtacct
 <210> 874
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <400> 874
 atgctaaagc acgcaacatt gca
 <210> 875
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <400> 875
 tgcacatgca cgtccttttag cat
 <210> 876
 <211> 31
 <212> DNA
 <213> Artificial Sequence
 <400> 876
 gtaggggact ttcagagctc gagatcctat g
 <210> 877
 <211> 31
 <212> DNA
 <213> Artificial Sequence
 <400> 877
 outagagctct cagctctgga agtccctta c
 <210> 878
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <400> 878
 ctgtcagga ctcagggtaa gg
 <210> 879
 <211> 27

123
 <221> Biotin moiety attached at 5' end of sequence.
 <400> 866
 tcatgagct tcatgagct
 <210> 867
 <211> 13
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_feature
 <222> (11)...(13)
 <223> FTYC moiety attached at 3' end of sequence.
 <221> misc_feature
 <222> (0)...(0)
 <223> Bna phosphodiester backbone.
 <400> 867
 ttttttttt ttt
 <210> 868
 <211> 13
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_feature
 <222> (11)...(13)
 <223> Biotin moiety attached at 3' end of sequence.
 <221> misc_feature
 <222> (0)...(0)
 <223> Bna phosphorothioate and phosphodiester chimeric backbone with phosphodiester on 3' end.
 <400> 868
 ttttttttt ttt
 <210> 869
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <400> 869
 cttagcttcat gagctacacg cctag
 <210> 870
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <400> 870
 ttcagttgc ttgcgtctta gctaa
 <210> 871
 <211> 20
 <212> DNA
 <213> Artificial Sequence

W/O 01/29/72 125 PCT/US90/26383

<210> DNA
<213> Artificial Sequence

<400> 879
catatcactg gattattac tccctgcg

<210> 880
<211> 21
<212> DNA
<213> Artificial Sequence

<400> 880
ctccagctcc aagaaagaa g

<210> 881
<211> 21
<212> DNA
<213> Artificial Sequence

<400> 881
gaagttctcg gtaagctctc g

<210> 882
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 882
tcctgcctctt gtcgtcttcg gctt

<210> 883
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 883
tcgtgcctctt gtcgtcttcg gctt

<210> 884
<211> 23
<212> DNA
<213> Artificial Sequence

<400> 884
tcgtgccttcg tcgtcttcgc gctt

<210> 885
<211> 22
<212> DNA
<213> Artificial Sequence

<400> 885
tcctgacgctt cgcgcgcgcgc cc

<210> 886
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 886
tcgtgcctctt gtcgtcttcg gctt

W/O 01/29/72 126 PCT/US90/26383

<210> 887
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 887
tcctcagcgt tccctgcgctt

<210> 888
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 888
tcgtgccttc gtcgtcttcga cgtt

<210> 889
<211> 26
<212> DNA
<213> Artificial Sequence

<400> 889
tcgtgccttcg cgtgcgtcttc gtcgtt

<210> 890
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 890
tcgtgcgtcgt cttgcgtcgtc tcgactt

<210> 891
<211> 25
<212> DNA
<213> Artificial Sequence

<400> 891
ttcgcgtctt tcgtgccttcg tcgtt

<210> 892
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 892
tcctgcgcggg gaagc

<210> 893
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 893
tcctgcgcgcg gaagc

<210> 894
<211> 15
<212> DNA
<213> Artificial Sequence

<211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 902
 ggcgccttgcg gcgcgcgcgc
 <210> 903
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 903
 ggcgccttgcg gcgcgcgcgc
 <210> 904
 <211> 15
 <212> DNA
 <213> Artificial Sequence
 <400> 904
 tgcgccttgcg ctcgcg
 <210> 905
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 905
 tgcgccttgcg ctcgccttgcg
 <210> 906
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 906
 aggcgcgcgcgc aggcgcgcgcgc
 <210> 907
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <400> 907
 tgcgccttgcg tgcgccttgcg t
 <210> 908
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <400> 908
 ctcgccttgcg ctcgccttgcg ct
 <210> 909
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 909

<211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 902
 ggcgccttgcg gcgcgcgcgc
 <210> 903
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 903
 ggcgccttgcg gcgcgcgcgc
 <210> 904
 <211> 15
 <212> DNA
 <213> Artificial Sequence
 <400> 904
 tgcgccttgcg ctcgcg
 <210> 905
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 905
 tgcgccttgcg ctcgccttgcg
 <210> 906
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 906
 aggcgcgcgcgc aggcgcgcgcgc
 <210> 907
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 <400> 907
 tgcgccttgcg tgcgccttgcg t
 <210> 908
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <400> 908
 ctcgccttgcg ctcgccttgcg ct
 <210> 909
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <400> 909

WFO 01/23/71 PCT/US00/26383

129 20

gaggtcgagcgcgcagggggg

<210> 910
<211> 21
<212> DNA
<213> Artificial Sequence

<400> 910

atctctctct atctctctat atc

<210> 911
<211> 27
<212> DNA
<213> Artificial Sequence

<400> 911

cttttttttt tttttttt tttttt

<210> 912
<211> 21
<212> DNA
<213> Artificial Sequence

<400> 912

tttttttttt tttttttt c

<210> 913
<211> 18
<212> DNA
<213> Artificial Sequence

<400> 913

tttttttttt tttttttt

<210> 914
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 914

gctagagggg agggc

<210> 915
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 915

gctagagtc agggg

<210> 916
<211> 15
<212> DNA
<213> Artificial Sequence

<400> 916

gctagagggg gagct

<210> 917
<211> 20
<212> DNA

WFO 01/23/71 PCT/US00/26383

130 20

atggaagtc cagggggc

<210> 918
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 918

atggaagtc gagggggc

<210> 919
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 919

atggaagtc cagggggc

<210> 920
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 920

gaggaagggg gacctggat

<210> 921
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 921

gaggaagggg gacctcact

<210> 922
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 922

gaggaagggg cagcactgat

<210> 923
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 923

tccatgtggg gacctgatgct

<210> 924
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 924

tccatgggg gacctgatgct

WO 01/23971	PCT/US00/23393	131	WO 01/23971	PCT/US00/23393	132
<210> 925			<400> 932		
<211> 20			tcctatgagg tgggatgct		20
<212> DNA			<210> 933		
<213> Artificial Sequence			<211> 20		
<400> 925	20		<212> DNA		
tcctatgagg gctgctgct			<213> Artificial Sequence		
<210> 926			<400> 933		20
<211> 20			tcctatgagg tctgatgct		
<212> DNA			<210> 934		
<213> Artificial Sequence			<211> 20		
<400> 926	20		<212> DNA		
atggactctc cggggctctc			<213> Artificial Sequence		
<210> 927			<400> 934		20
<211> 20			tcctatgagg cctgatgct		
<212> DNA			<210> 935		
<213> Artificial Sequence			<211> 20		
<400> 927	20		<212> DNA		
atggagggtc cggggctctc			<213> Artificial Sequence		
<210> 928			<400> 935		20
<211> 20			tcctatgagg gctgatgct		
<212> DNA			<210> 936		
<213> Artificial Sequence			<211> 20		
<400> 928	20		<212> DNA		
atggactctc cggggctctc			<213> Artificial Sequence		
<210> 929			<400> 936		20
<211> 20			tcctatgagg tctgatgct		
<212> DNA			<210> 937		
<213> Artificial Sequence			<211> 20		
<400> 929	20		<212> DNA		
atggagggtc catgggctc			<213> Artificial Sequence		
<210> 930			<400> 937		20
<211> 20			tcctatgagg gctgatgct		
<212> DNA			<210> 938		
<213> Artificial Sequence			<211> 14		
<400> 930	20		<212> DNA		
atggactctg cggggctctc			<213> Artificial Sequence		
<210> 931			<400> 938		14
<211> 20			gctatagggga gctg		
<212> DNA			<210> 939		
<213> Artificial Sequence			<211> 18		
<400> 931	20		<212> DNA		
tcctatgagg tgggatgct			<213> Artificial Sequence		
<210> 932			<400> 939		18
<211> 20			tttttttttt ttttttt		
<212> DNA			<210> 940		
<213> Artificial Sequence			<211> 21		

WFO 01/29/72

133

PC70500/26383

<212> DNA
<213> Artificial Sequence
<220> misc difference
<221> (2) ... (2)
<222> m 1a a or c
<223> m 1a a or c
<231> misc difference
<232> (18) ... (18)
<233> m 1a a or c
<400> 940
gggtacacg ttgaggpav g
21
<210> 941
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 941
ggggagtcg ttgaggpav g
21
<210> 942
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 942
tcgtgcgttc ccccccoccc
20
<210> 943
<211> 25
<212> DNA
<213> Artificial Sequence
<400> 943
ttgggggggtc tttttttt tttt
25
<210> 944
<211> 23
<212> DNA
<213> Artificial Sequence
<400> 944
tttaaatct aaactaaa ata
23
<210> 945
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 945
ttgggttttt tgggttttt ttgg
24
<210> 946
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 946

WFO 01/29/72

134

PC70500/26383

ttccctcttc ccccttttc atc
24
<210> 947
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<221> misc difference
<222> (21) ... (21)
<223> a 1a g or c
<400> 947
gggggcacg atgaggpav g
21
<210> 948
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 948
tccatgacgt tccatgacgt
20
<210> 949
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 949
tccatgacgt tccatgacgt
20
<210> 950
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 950
tccatgacgt tccatgacgt
20
<210> 951
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 951
tccatgacgt tccatgacgt
20
<210> 952
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 952
tccatgacgt tccatgacgt
20
<210> 953
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 953

135 20

tcctatgagt taatgacgtt

<210> 954
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 954
 tccatgacgt tccgacgct
 <210> 955
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<400> 955
 tccatgagct tcatgagctt
 <210> 956
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<400> 956
tccatgaagct tccgaagctt

<210> 957
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 957
 tccatgacgt tccatgcgtt

 <210> 958
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<400> 938
 tccatgaagt tcttgacgtt

 <210> 939
 <211> 19
 <212> DNA
 <213> Artificial Sequence

```
<400> 859
gggggcagcat agtcggggg

<210> 960
<211> 20
<212> DNA
<213> Artificial Sequence
```

<400> 960
gggggttagta agacgggggg

<210> 961
<211> 24
<212> DNA

Use of a single sequence

[illegible]

<210> 963
<211> 24
<212> CMA
<213> Artificial Sequence

<400> 963

```

cccccccccc cccccccc cccc
<210> 964
<211> 24
<212> DNA
<213> Artificial Sequence

```

```
<400> 964
tqptqatitit gtqatitigt cgtt

<210> 965
<211> 24
<212> DNA
<213> Artificial Sequence
```

```
<400> 965
tqptgtttt gtagttttgt cgtt

<210> 966
<211> 24
<212> DNA
<213> Artificial Sequence
```

```

<40> 966
tgctgtttt gtcgttttgt cgtt

<210> 967
<211> 24
<212> DNA
<213> Artificial Sequence

```

```

<400> 957
tcgtcgtttt gcgcttttgt cgtt
      100
<210> 968
tcgtcgtttt gcgcttttgt cgtt
      100
<211> 20
tcgtcgtttt gcgcttttgt cgtt
      100
<212> 200A
tcgtcgtttt gcgcttttgt cgtt
      100
<213> Artificial Sequence

```

<10> 968
T T T T T T T T T T T T T T T T

WFO 01/23/72
137
PCT/US80/24383
<210> 969
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 969
gggtcagcg tctggggggg
<210> 970
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 970
gggtcagcg tctggggggg
<210> 971
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 971
tgcctctcc ccccccgc
<210> 972
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 972
gggtcagcg acgtggggg
<210> 973
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 973
gggtcagcg acgtggggg
<210> 974
<211> 24
<212> DNA
<213> Artificial Sequence
<400> 974
gggtcagcg tgcgtcggg gggg
<210> 975
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 975
gggtcagcg acgtggggg gg
<210> 976
<211> 19
<212> DNA
<213> Artificial Sequence

WFO 01/23/72
138
PCT/US80/24383
<400> 976
gggtcagcg cgtggggggg
<210> 977
<211> 19
<212> DNA
<213> Artificial Sequence
<400> 977
gggtcagcg tctggggggg
<210> 978
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 978
gggtcagcg acgtggggg gg
<210> 979
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 979
gggtcagcg gttggggggg
<210> 980
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 980
gggtcagcg gaacggggg gg
<210> 981
<211> 22
<212> DNA
<213> Artificial Sequence
<400> 981
gggtcagcg gaacggggg gg
<210> 982
<211> 10
<212> DNA
<213> Artificial Sequence
<400> 982
tcaactttga
<210> 983
<211> 10
<212> DNA
<213> Artificial Sequence
<400> 983
tcaagctga
<210> 984
<211> 12

WO 01/23572	PCT/US00/23583	WO 01/23572	PCT/US00/23583
139		140	
<212> DNA		<210> 992	
<213> Artificial Sequence		<211> 8	
<400> 984	12	<212> DNA	
tccagatgct ga		<213> Artificial Sequence	
<210> 985		<400> 992	8
<211> 12		tcaacgctt	
<212> DNA		<210> 993	
<213> Artificial Sequence		<211> 20	
<400> 985	12	<212> DNA	
tccagatgct ga		<213> Artificial Sequence	
<210> 986		<400> 993	20
<211> 20		tccatacgg tccatgctt	
<212> DNA		<210> 994	
<213> Artificial Sequence		<211> 20	
<400> 986	20	<212> DNA	
gggggagcat gctggggggg		<213> Artificial Sequence	
<210> 987		<400> 994	20
<211> 20		tccatacgg tccatgctt	
<212> DNA		<210> 995	
<213> Artificial Sequence		<211> 20	
<400> 987	20	<212> DNA	
gggggggggg gggggggggg		<213> Artificial Sequence	
<210> 988		<400> 995	20
<211> 22		gggggagcat cgtggggggg	
<212> DNA		<210> 996	
<213> Artificial Sequence		<211> 20	
<400> 988	22	<212> DNA	
gggggagcat atcgtggggg gg		<213> Artificial Sequence	
<210> 989		<400> 996	20
<211> 22		gggggagcat cgtggggggg	
<212> DNA		<210> 997	
<213> Artificial Sequence		<211> 21	
<400> 989	22	<212> DNA	
gggggagac gtcgtggggg gg		<213> Artificial Sequence	
<210> 990		<400> 997	21
<211> 22		gggggagca tctcggggg g	
<212> DNA		<210> 998	
<213> Artificial Sequence		<211> 21	
<400> 990	22	<212> DNA	
gggggagag ctcgtggggg gg		<213> Artificial Sequence	
<210> 991		<400> 998	21
<211> 20		gggggagcat cgtcggggg g	
<212> DNA		<210> 999	
<213> Artificial Sequence		<211> 12	
<400> 991	20	<212> DNA	
gggggagcta cgtcggggg		<213> Artificial Sequence	

W0 01/29/72
143
PCT/US90/26383

<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1014
cctgactgct atctggttag 20
<210> 1015
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1015
tataagcttc gccgcgactg 20
<210> 1016
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1016
catgtcggagc gaggctctata 20
<210> 1017
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1017
tcgtcgttggg gaggtaagctc 20
<210> 1018
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1018
gagctactacc cctacacaccca 20
<210> 1019
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1019
gacctggatc ttgcgttggga 20
<210> 1020
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1020
ttgactctacc tttagccgtct 20
<210> 1021
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1021

W0 01/29/72
144
PCT/US90/26383

atpctgtgac ccagcggctaaa 20
<210> 1022
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1022
accgattcac cggaaagctca 20
<210> 1023
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1023
tccatgtgacg tccgcgacgct 20
<210> 1024
<211> 24
<212> DNA
<213> Artificial Sequence

<400> 1024
ggagagaccc atpactctcat ctgg 24
<210> 1025
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1025
accacagagac agcagagcgaga 20
<210> 1026
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1026
gagcgtcgagc ttgcgcgagaga 20
<210> 1027
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1027
tcgtacacct tgcagcgcgctt 20
<210> 1028
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1028
ctggagacct agccaaagcat 20
<210> 1029
<211> 20
<212> DNA

145		146	
20	<213> Artificial Sequence	22	<210> 1037
	<400> 1029		<211> 22
	gcagctccat caccagcgt		<212> DNA
	<210> 1030		<213> Artificial Sequence
	<211> 21		<400> 1037
	<212> DNA		gggtcgttc gacgagggg gg
	<213> Artificial Sequence		<210> 1038
	<400> 1030		<211> 22
	ccggaagtae gacacggtg t		<212> DNA
	<210> 1031		<213> Artificial Sequence
21	<211> 21	22	<400> 1038
	<212> DNA		gggacgttc gacgtgggg gg
	<213> Artificial Sequence		<210> 1039
	<400> 1031		<211> 15
	ctgtgttacc tgcattacc c		<212> DNA
	<210> 1032		<213> Artificial Sequence
	<211> 21		<220>
	<212> DNA		<221> modified base
	<213> Artificial Sequence		<222> (9)...(9)
	<400> 1032		<223> n is 5-methylcytosine.
21	aattagcatt agtgcgtgg g	15	<400> 1039
	<210> 1033		tctggcggg gaagt
	<211> 21		<210> 1040
	<212> DNA		<211> 22
	<213> Artificial Sequence		<212> DNA
	<400> 1033		<213> Artificial Sequence
	acatctgggt cttcttcgg g		<400> 1040
	<210> 1034		ggggacagac gtcgtgggg gg
	<211> 23		<210> 1041
	<212> DNA		<211> 20
23	<213> Artificial Sequence	20	<212> DNA
	<400> 1034		<213> Artificial Sequence
	ataagtcata ttctgggac tac		<400> 1041
	<210> 1035		ggggacagta cgtcggggg
	<211> 21		<210> 1042
	<212> DNA		<211> 24
	<213> Artificial Sequence		<212> DNA
	<400> 1035		<213> Artificial Sequence
	cccatcac teaggtcatt t		<400> 1042
	<210> 1036		ggggacagta cgtcgttgg gggg
20	<211> 20	24	<210> 1043
	<212> DNA		<211> 20
	<213> Artificial Sequence		<212> DNA
	<400> 1036		<213> Artificial Sequence
	gggtcgtcg agagggggg		<400> 1043
			gggttcaccg gtaaggggg

WO 01/23972
147
PCT/US00/2583

<210> 1044
<211> 24
<212> RNA
<213> Artificial Sequence

<400> 1044
gggtcgagcgcg taactcgagg gggg

<210> 1045
<211> 22
<212> DNA
<213> Artificial Sequence

<400> 1045
ggggacccggt accggtcggg gg

<210> 1046
<211> 18
<212> DNA
<213> Artificial Sequence

<400> 1046
gggtcgagcgcg cggggggg

<210> 1047
<211> 18
<212> DNA
<213> Artificial Sequence

<400> 1047
gggtcgagcgcg tcgagggg

<210> 1048
<211> 22
<212> DNA
<213> Artificial Sequence

<400> 1048
ggggacccggt aacgttcggg gg

<210> 1049
<211> 19
<212> DNA
<213> Artificial Sequence

<400> 1049
ggggacccggt aacgttcggg

<210> 1050
<211> 34
<212> DNA
<213> Artificial Sequence

<400> 1050
ggactcttcg aagtcacagc cggacagctc tgaat

<210> 1051
<211> 32
<212> DNA
<213> Artificial Sequence

WO 01/23972
148
PCT/US00/2583

<400> 1051
cggactcttc atgagtcgtc tgcactctt gg

<210> 1052
<211> 35
<212> DNA
<213> Artificial Sequence

<400> 1052
cggactcttc atgaaagctc ttggacgctg tgaac

<210> 1053
<211> 13
<212> DNA
<213> Artificial Sequence

<400> 1053
tcctgcagct tgaagc

<210> 1054
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1054
gggggtcgcgt cgttcggggg

<210> 1055
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1055
gggggagtcgt tgcggggg

<210> 1056
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1056
gggggagtcgt ngttcggggg

<210> 1057
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 1057
gggggagtcgt gcttcggggg

<210> 1058

tccagggaatt ctctcagggtt tttt

<210> 1066
<211> 20
<212> DNA
<213> Artificial Sequence

tccaaaactt ctctcaaat

<400> 1066
<210> 1067
<211> 24
<212> DNA
<213> Artificial Sequence

tactactttt atacttttat acctt

<400> 1067
<210> 1068
<211> 24
<212> DNA
<213> Artificial Sequence

tgtgtgtgtg tgtgtgtgtg tgtg

<400> 1068
<210> 1069
<211> 25
<212> DNA
<213> Artificial Sequence

tgtgtgtgtg tgtgtgtgtg tgtgtg

<400> 1069
<210> 1070
<211> 27
<212> DNA
<213> Artificial Sequence

ggctccgggg agggaaatttt tgtctat

<400> 1070
<210> 1071
<211> 19
<212> DNA
<213> Artificial Sequence

ggggcgcgcg tcgggggggg

<400> 1071
<210> 1072
<211> 20
<212> DNA
<213> Artificial Sequence

gggtcgtcga cpaagggggggg

<400> 1072
<210> 1073
<211> 19
<212> DNA

gggtcttttg gtcattgtct

<211> 20
<212> DNA
<213> Artificial Sequence

gggtcttttg gtcattgtct

<400> 1058
<210> 1059
<211> 20
<212> DNA
<213> Artificial Sequence

gggtcttttg gtcattgtct

<400> 1059
<210> 1060
<211> 20
<212> DNA
<213> Artificial Sequence

gggtcttttg gtcattgtct

<400> 1060
<210> 1061
<211> 20
<212> DNA
<213> Artificial Sequence

gggtcttttg gtcattgtct

<400> 1061
<210> 1062
<211> 20
<212> DNA
<213> Artificial Sequence

gggtcttttg gtcattgtct

<400> 1062
<210> 1063
<211> 20
<212> DNA
<213> Artificial Sequence

gggtcttttg gtcattgtct

<400> 1063
<210> 1064
<211> 20
<212> DNA
<213> Artificial Sequence

gggtcttttg gtcattgtct

<400> 1064
<210> 1065
<211> 24
<212> DNA
<213> Artificial Sequence

gggtcttttg gtcattgtct

<400> 1065
<210> 1066
<211> 20
<212> DNA
<213> Artificial Sequence

W01/25972	PCT/US00/2583	W01/25972	PCT/US00/2583
151		152	
<213> Artificial Sequence		<210> 1081	
<400> 1073		<211> 15	
ggtcgtcgcgc ggcgcgcgcgc	19	<212> DNA	
<210> 1074		<213> Artificial Sequence	
<211> 20		<400> 1081	
<212> DNA		tcctgcgcgc gaaatc	15
<213> Artificial Sequence		<210> 1082	
<400> 1074		<211> 15	
gggtcgtcgtc cgtcgcgcgcgc	20	<212> DNA	
<210> 1075		<213> Artificial Sequence	
<211> 20		<400> 1082	
<212> DNA		tcctgcgcgc gaaatc	15
<213> Artificial Sequence		<210> 1083	
<400> 1075		<211> 15	
gggcgcgcgc gtcgcgcgcgc	20	<212> DNA	
<210> 1076		<213> Artificial Sequence	
<211> 20		<400> 1083	
<212> DNA		tcctgcgcgc gaaatc	15
<213> Artificial Sequence		<210> 1084	
<400> 1076		<211> 15	
gggcgcgcgc tcgtgcgcgcgc	20	<212> DNA	
<210> 1077		<213> Artificial Sequence	
<211> 27		<400> 1084	
<212> DNA		tcctgcgcgc caaatc	15
<213> Artificial Sequence		<210> 1085	
<400> 1077		<211> 15	
gggtcgcgcgc tcgcgcgcgcgc	27	<212> DNA	
<210> 1078		<213> Artificial Sequence	
<211> 21		<400> 1085	
<212> DNA		tcctgcgcgc taaatc	15
<213> Artificial Sequence		<210> 1086	
<400> 1078		<211> 15	
gggcgcgcgc ggtcgcgcgcgc	21	<212> DNA	
<210> 1079		<213> Artificial Sequence	
<211> 21		<400> 1086	
<212> DNA		tcctgcgcgc aaatc	15
<213> Artificial Sequence		<210> 1087	
<400> 1079		<211> 15	
gggcgcgcgc tcgtgcgcgcgc	21	<212> DNA	
<210> 1080		<213> Artificial Sequence	
<211> 23		<400> 1087	
<212> DNA		tcgcgcgcgc gaaatc	15
<213> Artificial Sequence		<210> 1088	
<400> 1080		<211> 15	
tcgtcgtcgtc cgtcgcgcgcgc	23	<212> DNA	
		<213> Artificial Sequence	

<400> 1088
tcgggggggg gaagt
<210> 1089
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 1089
tcgggggggg gaagt
<210> 1090
<211> 15
<212> DNA
<213> Artificial Sequence
<400> 1090
gggggggggt ggggg
<210> 1091
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 1091
gggggttttt ttgtggggg
<210> 1092
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 1092
gggggggggg cccggggggg
<210> 1093
<211> 21
<212> DNA
<213> Artificial Sequence
<400> 1093
gggggttgtg ttgtggggg g
<210> 1094
<211> 30
<212> DNA
<213> Artificial Sequence
<220> Synthetic Sequence
<400> 1094
tttttttttt tttttttttt tttttttt
<210> 1095
<211> 30
<212> DNA
<213> Artificial Sequence
<220> Synthetic Sequence

<400> 1095
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
<210> 1096
<211> 30
<212> DNA
<213> Artificial Sequence
<220> Synthetic Sequence
<400> 1096
ccccccccc ccccccccc ccccccccc
<210> 1097
<211> 30
<212> DNA
<213> Artificial Sequence
<220> Synthetic Sequence
<400> 1097
cgcgcgcgcg cgcgcgcgcg cgcgcgcgcg
<210> 1098
<211> 12
<212> DNA
<213> Artificial Sequence
<220> Synthetic Sequence
<400> 1098
gattttatcg tc
<210> 1099
<211> 12
<212> DNA
<213> Artificial Sequence
<400> 1099
tcgatttttc ga
<210> 1100
<211> 12
<212> DNA
<213> Artificial Sequence
<400> 1100
tcatttttat ga
<210> 1101
<211> 12
<212> DNA
<213> Artificial Sequence
<400> 1101
gttttttacy ac

<210> 1102	
<211> 12	
<212> DNA	
<213> Artificial Sequence	
<400> 1102	
tcatttttc ga	12
<210> 1103	
<211> 12	
<212> DNA	
<213> Artificial Sequence	
<400> 1103	
acgtttttac gc	12
<210> 1104	
<211> 12	
<212> DNA	
<213> Artificial Sequence	
<400> 1104	
tcgttttttc ga	12
<210> 1105	
<211> 16	
<212> DNA	
<213> Artificial Sequence	
<400> 1105	
tcgttttttc cgtcga	16
<210> 1106	
<211> 14	
<212> DNA	
<213> Artificial Sequence	
<400> 1106	
attttttttac cgtc	14
<210> 1107	
<211> 14	
<212> DNA	
<213> Artificial Sequence	
<400> 1107	
tcgttttttc aaga	14
<210> 1108	
<211> 14	
<212> DNA	
<213> Artificial Sequence	
<400> 1108	
acgttttttc acgt	14
<210> 1109	
<211> 13	
<212> DNA	
<213> Artificial Sequence	

<210> 1110	
<211> 12	
<212> DNA	
<213> Artificial Sequence	
<400> 1110	
tcatttttc ga	12
<210> 1111	
<211> 12	
<212> DNA	
<213> Artificial Sequence	
<400> 1111	
acgttttttc gc	12
<210> 1112	
<211> 12	
<212> DNA	
<213> Artificial Sequence	
<400> 1112	
tcgttttttc ga	12
<210> 1113	
<211> 16	
<212> DNA	
<213> Artificial Sequence	
<400> 1113	
tcgttttttc cgtcga	16
<210> 1114	
<211> 14	
<212> DNA	
<213> Artificial Sequence	
<400> 1114	
attttttttac cgtc	14
<210> 1115	
<211> 14	
<212> DNA	
<213> Artificial Sequence	
<400> 1115	
tcgttttttc aaga	14
<210> 1116	
<211> 14	
<212> DNA	
<213> Artificial Sequence	
<400> 1116	
acgttttttc acgt	14
<210> 1117	
<211> 13	
<212> DNA	
<213> Artificial Sequence	

502/26488

WO 01/2972	PCT/US00/26383	158	159	PCT/US00/26383
<210> 1125 <211> 10 <212> DNA <213> Artificial Sequence				
<400> 1125 actgtatcgt	10		<400> 1132 gacgatgctc tc	12
<210> 1126 <211> 10 <212> DNA <213> Artificial Sequence			<210> 1133 <211> 12 <212> DNA <213> Artificial Sequence	
<400> 1126 actgtatcgt			<400> 1133 gatgatgctc tc	12
<210> 1127 <211> 14 <212> DNA <213> Artificial Sequence			<210> 1134 <211> 10 <212> DNA <213> Artificial Sequence	
<400> 1127 tcgtgtatcgc tcga	10		<400> 1134 gatgtatcgtc	10
<210> 1128 <211> 12 <212> DNA <213> Artificial Sequence			<210> 1135 <211> 8 <212> DNA <213> Artificial Sequence	
<400> 1128 actgttatcgc tc	14		<400> 1135 atgtatcgt	8
<210> 1129 <211> 12 <212> DNA <213> Artificial Sequence			<210> 1136 <211> 12 <212> DNA <213> Artificial Sequence	
<400> 1129 tcgtgttatcgc ga	12		<400> 1136 aacgatgtcgc tt	12
<210> 1130 <211> 12 <212> DNA <213> Artificial Sequence			<210> 1137 <211> 10 <212> DNA <213> Artificial Sequence	
<400> 1130 actgtgttatcgc gt	12		<400> 1137 tcactgtgtgc	10
<210> 1131 <211> 11 <212> DNA <213> Artificial Sequence			<210> 1138 <211> 8 <212> DNA <213> Artificial Sequence	
<400> 1131 gatgtatcgt c	11		<400> 1138 tcgtatgc	8
<210> 1132 <211> 12 <212> DNA <213> Artificial Sequence			<210> 1139 <211> 12 <212> DNA <213> Artificial Sequence	
<400> 1132 actgtgtatcgc gt	12		<400> 1139 actgtgtatcgc gt	12
			<210> 1140	

W0 01/25/72

PCT/US90/2433

160

<21> 16
<22> DNA
<23> Artificial Sequence

topatgcgc optcga

16

<400> 1140
<210> 1141
<211> 10
<212> DNA
<213> Artificial Sequence

<400> 1141
acgatgcgcgc

10

<210> 1142
<211> 31
<212> DNA
<213> Artificial Sequence

<400> 1142
tgcagagagat ccaggtcttcc cccacccccc c

31

<210> 1143
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<221> Synthetic Sequence

<400> 1143
gcgcgc

6

<210> 1144
<211> 6
<212> DNA
<213> Artificial Sequence

<400> 1144
gcgcgc

6

<210> 1145
<211> 6
<212> DNA
<213> Artificial Sequence

<400> 1145
topcgcgc

8

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)